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 Antibiotics inhibit the growth or survival of bacteria by targeting their essential functions.1 
Due to weaknesses in traditional antibiotics and the increasing prevalence of antibiotic resistance 
genes, virulence factors are being targeted for therapeutic treatment of bacterial infection.2 We 
have developed an assay to quantify and observe type III secretion system (T3SS) activity. The 
type III secretion system (T3SS) is a virulence factor present in some Gram-negative pathogens 
including enteropathogenic and enterohemorrhagic E. coli (EPEC and EHEC, respectively),3 and 
xxiii 
 
others.4–9 The T3SS between EPEC and EHEC are highly conserved and share over 90% sequence 
identity with the mouse pathogen Citrobacter rodentium.3,10,11 Because of the high similarity 
between the pathophysiology of these organisms, C. rodentium is often used as the mouse model 
of EPEC and EHEC infection.12–14 We have developed a construct of C. rodentium to produce 
carboxypeptidase G2 (CPG2), a eukaryotic enzyme that selectively cleaves glutamate residues. 
We have tagged CPG2 on the N-terminus with an amino acid sequence to target the enzyme for 
type III secretion.15 The CPG2 reporter assay was used to screen natural products for their ability 
to inhibit the T3SS.16–26  
 We also completed a high throughput screening campaign for the identification of 
inhibitors of phage-related ribosomal protease Prp. This protease is essential for ribosomal 
assembly in bacteria and previously reported knockdown studies have indicated that bacteria 





ENTEROPATHOGENIC AND ENTEROHEMORRHAGIC ESHERICHIA COLI 
1.1 Clinical relevance of E. coli 
 E. coli is a common part of the commensal bacteria residing in the digestive tract of humans 
and other mammals and birds.27–29 Typically, E. coli is harmless, but some strains cause serious 
foodborne illnesses that result in an estimated 265,000 infections in the United States every 
year.30,31 Many diarrheal infections of E. coli go undiagnosed, as many patients do not seek medical 
treatment.32 Of the diagnosed gastrointestinal infections, 36% are caused by E. coli O157, which 
typically results in more severe disease outcomes.30 These include bloody diarrhea, hemolytic 
uremic syndrome (HUS) and kidney failure.33,34 The leading cause of HUS is gastrointestinal 
infection of Shiga toxin-producing E. coli (STEC).35–37 STEC is a designation that can refer to any 
variant of E. coli capable of producing Shiga toxin.38–40  
 Every year, waterborne diarrheal disease kills over 800,000 people, over 25% of whom are 
children under the age of 5.41 In addition, pathogenic E. coli outbreaks are common in developed 
nations.30 In 2011, an outbreak of STEC in Europe resulted in >4000 illnesses, and ~900 cases of 
HUS.39,42,43 The cause of the outbreak was contaminated bean sprouts that originated from a vendor 
in Egypt.44 A much smaller outbreak occurred in July 2018 in three elementary schools in 
Gyeongsangbuk-Do Province, South Korea.45 The illnesses were attributed to water supplies 
contaminated with non-Shiga toxin-producing E. coli that was used in food preparation for the 
school cafeterias. In another school-related incident in 1996, children in 47 elementary schools 
across two school districts were hospitalized after consuming uncooked white radish sprouts used 
in the preparation of their lunches.46 This outbreak resulted in almost 400 hospitalizations within 
a ten-day period. The radishes were contaminated with STEC. It was also reported that this 
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outbreak was one of sixteen total outbreaks (with >10 infected patients) in Japan between May and 
December of 1996.46 In total, ~7,900 cases were reported within that time period, 7,470 of which 
were children infected by school lunches.  
 
1.2 E. coli pathotypes 
 There are six pathotypes, or disease-causing variations of E. coli, including 
enterohemorrhagic E. coli (EHEC), also known as Verocytotoxin-producing E. coli (VTEC), 
enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), enteroaggregative E. coli 
(EAEC), enteroinvasive E. coli (EIEC) and diffusely adherent E. coli (DAEC).9,47,48 E. coli are 
often referred to by their pathotype followed by a serological classification (for example, EHEC 
O157:H7). This strain of E. coli belongs to the enterohemorrhagic pathotype. The “O” designation 
refers to the lipopolysaccharide antigen present for this strain,49 and the “H” designation refers to 
the flagellar antigen present.50 If the strain produces Shiga toxins, that may be included in the name 
as well (for example, EAEC strain STEC O104:H4).43 
 
1.3 Epidemiology, symptoms, treatment, and pathogenesis of EPEC and EHEC 
1.3.1 Enteropathogenic E. coli 
 The first description of EPEC was published in 1955 after an outbreak of infantile diarrhea 
in the 1940s and 1950s.51 EPEC is considered an attaching/effacing (A/E) pathogen due to its 
characteristic intimate adherence strategy during infection, which results in actin rearrangement 
and the formation of a pedestal and clearing of intestinal microvilli on epithelial cells.52,53 EPEC 
does not produce Shiga toxin, unlike A/E EHEC. Many strains carry an EPEC adherence factor 
(EAF) plasmid that encodes virulence factors including bundle-forming pili (BFP), but there are 
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also many strains that do not.54 Strains that harbor the EAF plasmid are classified as “typical 
EPEC” and those that do not are classified as “atypical EPEC” (aEPEC). Some aEPEC strains 
cannot be classified based on traditional O/H-serotyping because they do not carry the plasmid 
that encodes O-lipopolysaccharides or H-flagellar antigens.55 Genetic analysis of typical and 
atypical EPEC indicates that these two classes are vastly different, and aEPEC more closely 
resembles some EHEC serotypes.56 Proteomic and genomic analysis indicates that EHEC 
O157:H7 evolved from an ancestor of aEPEC O55:H7.57  
 Epidemiology. A 2017 report indicated that EPEC is associated with moderate to severe 
diarrhea in children under 2 years old in some developing nations, and is associated with increased 
risk of death in patients younger than 11 months.58 EPEC is typically transmitted through the fecal-
oral route from contaminated food and water supply and from infected people. The infectious dose 
of EPEC is estimated at 2 x 1010 colony forming units (CFU).59 
 Symptoms. Symptoms of an EPEC infection include diarrhea, fever, and vomiting 
resulting in dehydration.53 Onset of symptoms typically occurs within a few hours of exposure and 
lasts for a short time period, but persistence up to two weeks has been observed.58 Diagnosis can 
be made based on the presence or absence of virulence genes such as the EAF plasmid or the eae 
gene, which encodes a protein intimin, part of the T3SS.59,60 In addition, the fluorescent actin 
staining (FAS) test can be performed.61 This test involves visualization of fluorescently labeled 
actin rearrangement because of the A/E histopathology.  
 Treatment. Treatment of EPEC infection typically involves oral rehydration therapy and 
antibiotics may be administered if the infection persists; however, clinical isolates have indicated 
a high degree of antibiotic resistance. Strains have demonstrated resistance against penicillins, 
cephalosporins, and aminoglycosides. While no vaccine against EPEC infections is available 
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commercially, there is evidence that some mothers’ breast milk contains IgA antibodies against 
typical antigens, including T3SS-related proteins EspA, EspB, and intimin.62 The transfer of these 
antibodies may be responsible for conferring immunity to breastfed infants, and provides evidence 
that adaptive immunity may provide protection to older patients. This may explain why only 
extremely young children suffer from severe EPEC infections.62 
 Pathogenesis. A major virulence factor utilized by EPEC is the non-flagellar type III 
secretion system (T3SS), which is described in detail in section 1.4. The T3SS is also utilized by 
a diverse assortment of bacteria, including EPEC and EHEC,63,64 Citrobacter rodentium,65 
Salmonella enterica serovar Typhimurium,66,67 Yersinia pestis,68–70 Pseudomonas spp.,7 and 
Chlamydia spp.71 For EPEC, the T3SS is necessary for the attachment of bacteria to host cell 
surfaces and propagation of infection.9 This secretion system is evolutionarily related to flagella, 
and the bases of flagellar and non-flagellar T3SSs are structurally similar.66 Whereas flagella 
secrete proteins necessary for motility, the non-flagellar T3SS has evolved specifically for 
pathogenic interaction with eukaryotic cells and transports bacterial proteins (effectors) directly 
into the cytoplasm of intestinal epithelial cells. After secretion, these effectors perform a multitude 
of tasks within the host cells, including interference with cytoskeletal assembly, allowing for 
intimate attachment of the pathogen to the host cell or allowing endocytosis of the pathogen, and 
cell death.72  
 A characteristic symptom of a T3SS-mediated infection is the formation of 
attaching/effacing (A/E) lesions on the epithelial surface.73 Other A/E pathogens also rely on the 
T3SS as a virulence factor, including C. rodentium (a well-adopted mouse model for EPEC and 
EHEC infection),10 rabbit EPEC (REPEC),52 porcine EPEC (PEPEC),74 dog EPEC (DEPEC)75 and 
Escherichia albertii.76 The T3SS of A/E pathogens is encoded by a pathogenicity island called the 
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locus of enterocyte effacement (LEE).60,77 The LEE is a 35 kb region of chromosomal DNA present 
in EPEC and EHEC, as well as C. rodentium, a murine pathogen with similar symptoms as human 
E. coli infection.10,60 The sequence homology between the three organisms is >90%, suggesting 
that C. rodentium acquired the T3SS in a horizontal transfer.10 It is this high homology that allows 
for C. rodentium to act as a mouse model for E. coli infection.  
The formation of the characteristic A/E lesions of EPEC and EHEC infection are a result 
of the interactions between intimin and the translocated intimin receptor (Tir).78 The interaction 
between intimin and Tir is the most important in EHEC and EPEC intimate attachment to epithelia, 
and mutational studies confirm that changes to the receptor recognition domain on the C-terminus 
abolishes attachment capabilities.59 The relationship between intimin and Tir is unique, in that they 
are both encoded within the E. coli genome and are co-expressed.78 The genes for these proteins 
are located within the LEE.60,79 The T3SS is responsible for translocating Tir to the surface of the 
target cell, allowing for attachment, while intimin is secreted through the Sec pathway and 
presented on the surface of the bacterial cell.80 
Intimin is a 95-kDa protein consisting of three regions.81 The N-terminus encodes a signal 
peptide that allows for passage through the Sec pathway. This region is eventually anchored into 
the peptidoglycan layer. Residues 189 to 550 constitute the β-domain, which floats on the outer 
membrane, exposing the C-terminus to the surface.82 The C-terminal region is composed of four 
sub-domains, D1 through D4.83 Each of these immunoglobulin-like domains forms a rod 
responsible for interactions with Tir.84 Once Tir is translocated into the epithelial cell, it extends 
both terminal regions toward the cytosol, and forms a β-hairpin with the middle region on the 
extracellular surface to interact with intimin. 
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The presence of the intimin-encoding gene eae is often used as a characterization and 
classification tool for pathogenic E. coli and is associated with the A/E lesion phenotype. This 
gene indicates the presence of the T3SS and is therefore associated with more severe clinical 
outcomes. Studies have indicated that mice dosed with intimin developed a protective immune 
response to further challenge by C. rodentium.77 More recently, a chimeric vaccine consisting of 
T3SS protein EspA and intimin decreased intestinal colonization of EHEC O157:H7 in mice.85 
Both studies indicate that a vaccine containing intimin may efficiently protect susceptible patients 
from infection. 
The ~95 kb EAF plasmid, which is characteristic of typical EPEC, encodes 14 genes 
responsible for BFP formation.86 BFP is an adhesin that produces a localized adherence (LA) 
colonization pattern on epithelial cells. LA describes a pattern of growth of discrete clusters of 
bacteria on cultured mammalian cells. Each individual pilus of BFP is composed of many filaments 
aggregated together on the outer membrane of the bacterial cell. One pilus is 50 to 500 nm wide 
and 15 to 20 µM long. Their expression is induced by the presence of eukaryotic cells. When 
expressed, BFPs form a complex matrix of pili, intertwined with neighboring EPEC cells’ BFPs. 
This results in an interlocking system of E. coli and aids in the attachment of bacteria to epithelial 
cells. 
Three of the genes encoded by pEAF include the plasmid encoded regulator (perABC, also 
called bfpTVW) genes. These proteins are transcriptional regulators of multiple virulence factors, 
including BFP.87 The bfp operon consists of 14 genes (bfpABCUDEFPHIJKLM) that are all 
required for BFP formation.88 Before assembly of the major structural pilus, composed of protein 
BfpA, the monomers of BfpA must be processed by prepilin signal peptidase BfpP. Export of 
BfpA is dependent upon BfpB, a lipoprotein that also aids in assembly of the pilus. The remaining 
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functions of the pEAF-encoded genes are based on sequence homology with other known type IV 
pili of other bacterial species. bfpH also encodes a lipoprotein, as predicted due to a conserved N-
terminal cysteine lipid attachment site. BfpD shares homology with proteins responsible with type 
IV secretion system biogenesis and contains a nucleotide-binding motif. Sequence homology 
studies suggest that BfpD and E may be involved with DNA uptake and protein secretion. BfpF, 
like BfpD, contains a nucleotide-binding domain. BfpF is homologous with Pseudomonas 
aeruginosa protein PilT, which is responsible for pilus-mediated twitching motility, and may 
provide energy via ATP hydrolysis to power this movement. bpfI, J, and K encode minor type IV 
pili structural components that are incorporated within the bundle structure and provide structural 
integrity and aid in epithelial cell adhesion.89 Protein BpfL shares  no homology with other 
proteins, but sequence analysis predicts that the protein may form a β-sheet.88 
EPEC strain UMD880 (bfpA+ eae-) rapidly attached to the surface of Caco-2 cells, even 
though no intimin was expressed.90 This attachment to the brush border microvilli of the intestinal 
epithelia did not induce A/E lesion formation, but the extent of adhesion was similar to wild type. 
When EPEC strain EAV84 (ΔbfpU) was cultured with HeLa cells, colony formation was 85% as 
efficient as wild type.91 The introduction of a lipid disrupting agent MβCD, however, decreased 
the % adherence from 85% to 1%, indicating that lipid rafts within epithelial membranes are 
necessary for attachment in the absence of BFPs. 
 
1.3.2 Enterohemorrhagic E. coli  
 STEC O157:H7 was originally documented as a human pathogen in the 1980s after 
serotype analysis of samples obtained from patients suffering from an outbreak of hemorrhagic 
colitis revealed E. coli O157:H7 as the causative agent.92 E. coli O157:H7 is the representative 
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organism for the EHEC pathotype.93 O157:H7 produces Shiga toxin; therefore it is also considered 
an STEC. The presence of other virulence mechanisms, however, delegates that O157:H7 have a 
pathotype separate from other STECs.38 For that reason, all EHEC strains are also STEC strains, 
but not all STEC strains can be classified as EHEC.93  
 Epidemiology. This serotype has been implicated as a major cause of bloody diarrhea and 
HUS.30 While many patients recover spontaneously from STEC-HUS,36 some develop end-stage 
renal damage.94,95 This pathotype is non-invasive, so the bacterial cells do not cross through the 
epithelial cell lining; the damage done outside of the gastrointestinal tract can be attributed to 
release of Shiga toxin.38 The cohorts most affected by O157:H7 outbreaks are often children under 
the age of 5 and adults aged 65 and above, with lethality for these groups ranging from 2-7% and 
15-23%, respectively.92 Children who recover from O157:H7 infections have a significant risk of 
renal failure or residual organ damage that results in chronic and end-stage renal disease, renal 
hypertension, diabetes mellitus, and some neurological disorders.92 Transmission of O157:H7 is 
believed to occur through three major routes: contaminated food and contaminated drinking and 
swimming water, person-to-person contact, and animal contact. The infectious dose has been 
estimated as fewer than 50 organisms; reports from a 1996 outbreak of O157:H7 in fermented 
sausages reported a bacterial load of fewer than one cell per 10 g of contaminated food.92,96,97 
 Diagnostic procedures for O157:H7 include culture analysis of stool samples from infected 
patients via detection of Shiga toxins and the O157 antigen using enzyme-linked immunosorbent 
assay (ELISA) kits, and polymerase chain reaction (PCR) analysis of relevant genes.92,95 
Unfortunately, the presence of O157:H7 cells within the colon drops significantly after the first 
week of infection, while severe HUS symptoms may take 5-13 days to develop, lowering the odds 
of correct diagnosis to ~70% using stool sample analysis alone.95 Serological tests for the 
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identification of immunoglobulin M (IgM) response to the O157 lipopolysaccharide antigen have 
been developed with better prognostic ability.98,99 Up to 94% of patients with O157:H7 are 
correctly diagnosed using serology tests.95 This higher success rate may be attributable to the long 
serum life of patients’ IgM responses (5 days to 2 months post infection).95,99 While the serological 
presence of these antibodies is not sustained long enough to provide protection against future 
infection,99 the circulating concentration is sufficient as a diagnostic tool. 
 Pathogenesis. There are two major contributors to the pathogenesis of EHEC: Shiga toxins 
and the LEE-encoded T3SS. These two virulence factors contribute to the hallmark symptoms of 
EHEC infection, including the development of HUS and A/E lesions, respectively. 
 The Shiga toxin family is composed of Shiga toxin 1 and 2 (STX1 and STX2, 
respectively).33,35,100 Shiga toxin consists of one A subunit, which has RNA-glycohydrolase 
activity, and five B subunits that participate in toxin binding to glycolipid receptor Gb3 on 
eukaryotic epithelial cell membranes.100 After docking to the receptor, the toxin may be 
endocytosed and trafficked to the Golgi apparatus, then to the endoplasmic reticulum, and is 
ultimately released to the cytoplasm. Here, subunit A acts upon the ribosome as a glycohydrolase 
and inhibits protein production, killing the epithelial cell. Once the epithelial barrier is damaged, 
the toxin may pass into the blood stream and bind to platelets expressing Gb3 receptors. This 
results in the hallmark low-platelet count in STEC patients. The toxin may then be transported to 
the kidneys, which express high levels of Gb3 receptors, and cause acute renal damage and HUS.101 
 Shiga toxin is encoded as part of a bacteriophage that has been incorporated into the E. coli  
O157:H7 genome.101,102 Transcription of the bacteriophage is typically repressed due to binding 
of the repressor cI to one of two operons within the phage.103 When the SOS response is triggered 
by damage to DNA, the regulator protein RecA is activated. Activated RecA releases cI from the 
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phage operon, derepressing transcription. Phage is then produced, as is Shiga toxin, and bacteria 
are lysed, releasing the toxin.103 Because of this, strong consideration and care must be taken in 
choosing treatments for EHEC O157:H7.101,104–106 Treatment of O157:H7 by certain antibiotics 
upregulated production of Shiga toxin via activation of the SOS pathway.102,106–108 The subsequent 
release of Shiga toxin following bacterial cell lysis causes immense damage.37,109  
 It has been reported that treatment of O157:H7 infection with antibiotics that damage DNA, 
impair DNA replication, or arrest cell growth can increase a patients’ likelihood to develop HUS 
and other pathologies due to the increase in circulating Shiga toxin.107,110 For example, 
fluoroquinolones act by blocking DNA gyrase111 and trimethoprim interferes with purine and 
pyrimidine synthesis through inhibition of dihydrofolate reductase.112 Both induce the SOS 
response.107 β-lactam antibiotics induce the SOS response indirectly. The cell wall damage induced 
by β-lactam treatment stimulates a response from the two-component proteins DpiBA, which 
impair DNA replication.113,114 In general, antibiotic treatment of EHEC O157:H7 patients is not 
recommended.101 Patients are typically treated for symptom alleviation and renal protection with 
aggressive intra-venal rehydration. Dialysis has proven helpful in renal recovery from severe 
cases. Monitoring for neurological symptoms is necessary, and approximately 10% of patients 
experience stroke, seizures, or coma as a result of toxin exposure.101 Many toxin-conjugating 
therapeutics have been designed to neutralize Shiga toxin in vivo, but there are currently no 
therapeutics targeting Shiga toxin on the market.115  
 
1.4 The bacterial type III secretion system 
1.4.1 Structure of the T3SS 
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 The T3SS is composed of a base and a hollow, needle-like structure (Figure 1). The T3SS 
is often referred to as the injectosome, as its function in pathogenesis is injection of effectors into 
host cells. The anatomy of the T3SS varies slightly across bacterial species, but a common 
nomenclature exists based on the placement and function of proteins within the injectisome. The 









 The T3SS base consists of the ATPase and sorting platform, the cytoplasmic ring, the 
export apparatus, and the basal body. The sorting platform is composed of the ATPase (EscN), the 
central stalk protein (EscO), the structural stator protein (EscL), and a final structural protein 
(EscK). The ATPase (EscN) forms a homo-hexameric ring, which has conserved properties from 
other known rotary ATPases.116 The EscO central stalk protein stabilizes the oligomerization of 
the ATPase and helps prevent ATP-mediated dissociation. EscL mediates interactions between the 
EscN ATPase and the cytoplasmic ring.117,118 Pull-down studies indicate that EscL binds to a 
filamentous component of the translocon, EspA; data also suggest that EscL helps to stabilize 
EspA in the bacterial cytosol.119 The final component of the sorting platform, EscK, binds within 
the inner diameter of the cytoplasmic ring.118 While the function of EscK is thought to be only 
structural, functional analysis of an EscK knockout indicates that the presence of EscK is critical 
for secretion of effectors.118 The cytoplasmic ring is composed of EscQ, which is held in place by 
interactions with EscN and EscL, though the arrangement of these proteins is not well understood. 
 The export apparatus of the T3SS is located within the sorting platform and the inner 
membrane ring. The export apparatus is composed of a gate protein (EscV), an autoprotease 
(EscU), and inner membrane components (EscR, S, and T).120–123 Gate protein EscV is 
homologous with flagellar protein FlhA, which facilitates transport of sodium ions and protons.122 
EscV is proposed to function as a proton/protein antiporter.116  
 Self-cleavage of the autoprotease EscU is necessary for EPEC-mediated infection of HeLa 
cells.124 In addition, an absence of EscU cleavage resulted in decreased accumulation of chaperone 
CesT on the inner membrane. This suggests that the autoprotease activity of EscU contributes to 
successful docking of effector/chaperone complexes necessary for type III secretion.124 The related 
flagellar autoprotease (FlhB) contributes to substrate switching, an important process that 
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determines the  hierarchal order of protein secretion.123 It is believed that EscU participates in a 
similar fashion in substrate switching for non-flagellar type III secretion.125 
 The inner membrane components of the export apparatus are EscR, EscS, and EscT.121 
EscR is the central component of the export apparatus. Evidence suggests that EscR localizes 
within the bacterial inner membrane, oligomerizes, then initiates the assembly of the rest of the 
T3SS through interactions with other structural components. EscS is the smallest protein of the 
T3SS base, with only 81 amino acids and 2 putative transmembrane domains (PTMDs).120 When 
either of the PTMDs are replaced with random hydrophobic residues, the T3SS cannot function, 
suggesting that EscS plays a crucial role in T3SS activity. Studies suggest that the assembly of the 
base of the T3SS is not dependent on EscS, but that EscS may play a role in adjustments of protein 
orientation within the base. These adjustments are necessary for the proper arrangement of static 
and dynamic proteins within the base, which allows for efficient type III secretion. The role of 
EscT is not well understood, but it has been identified as a T3SS protein based on sequence 
homology with Yersinia T3SS protein YscT.11 
 The basal body of the T3SS consists of inner (IM, EscD, J and I) and outer membrane (OM, 
EscC) rings, a lytic glycosylase (EtgA), and the needle (EscF). IM protein EscD oligomerizes to 
form a ring around the export apparatus and spans the inner membrane.126 The oligomerization 
domain of EscD is found on the N-terminus. The C-terminal domain binds to OM protein EscC, 
promoting formation of the OM ring.126 EscJ belongs to a family of lipoproteins that are known to 
polymerize to form a 24-mer multi-ring structure in the periplasm.127 The IM ring components 
EscD and J are necessary for the assembly of the OM ring, as null mutations in those components 
results in decreased oligomerization of EscC. Oligomers of protein EscI form an inner rod structure 
that is essential to type III secretion.125 EscI interacts with OM secretin EscC and autoprotease 
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EscU in solution. These interactions, as well as characterization of similar proteins in other T3SSs 
suggest that EscI is located at the center of the T3SS apparatus and that EscI may be a signaling 
molecule in the substrate switching process.128  
 The OM ring is composed of EscC, a member of the secretin family of proteins.129 Secretins 
transport large proteins through the outer membrane, typically by forming a pore.130 Members of 
the secretin family are involved in protein transport through multiple secretion mechanisms not 
limited to the T3SS.131 Structural analysis of the Yersinia enterocolitica secretin YscC indicated 
that the OM ring formed by oligomerization consists of 13 subunits that form two stacked rings 
and a conical domain. While the structure of the rings formed by EscC in E. coli are not well 
understood, studies have shown that proper localization of the OM ring is dependent on EscV and 
EscN but not dependent on needle EscF formation.129  
 In order for the T3SS machinery to assemble within the peptidoglycan-rich periplasm, the 
lytic glycosylase EtgA is employed.132 EtgA and similar lytic glycosylases cleave the β-1,4 
glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine within the 
peptidoglycan layer. This cleavage allows T3SS proteins to arrange within the periplasm and 
oligomerize to form the base of the structure. Overexpression of EtgA results in cell lysis. Mutation 
in the catalytic glutamate residue results in attenuation of T3SS-mediated hemolytic activity and a 
reduction in EspA filamentation.132 
 The final component of the basal body is the needle, which is composed of oligomerized 
EscF.63,133 EscF was originally identified as the E. coli T3SS needle based on its sequence 
similarity with T3SS needle proteins MxiH and PrgI from Shigella and Salmonella, respectively.133 
Analysis of secreted protein concentrations indicated that EscF is required for secretion of 
translocator proteins EspA, EspB and EspD. EscF is transported to the T3SS by cochaperones 
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EscE and EscG, which form interactions with the bacterial membrane while in complex with 
EscF.134 These cochaperones also prevent premature polymerization of the needle. Null mutants 
of EscE and EscG do not secrete translocators EspA, EspB or EspD, further implementing EscF 
as a necessity for type III secretion. 
 The last structural component of the T3SS is the translocon. The translocon consists of E. 
coli secreted proteins EspA, EspB, and EspD.135 EspA monomers interact through a coiled-coil 
domain to form a homo-oligomer filamentous structure, which builds from interactions with the 
central rod, EscF.63,136,137 The EspA filament is hollow, with an interior diameter of ~25Å, which 
is only large enough to allow passage of linear or partially unfolded proteins.138 Deletion of EspA 
inhibits bacterial attachment to red blood cells (RBCs).139 Mutations in pore-forming protein EspD 
result in a truncated form of EspA that was able to lyse 40% of RBCs when contact between the 
cells was initiated with centrifugation. EspA spontaneously forms filamentous oligomers in 
solution, so cytosolic EspA binds to a chaperone protein CesA to prevent premature 
oligomerization before secretion.135,140  
 Upon interactions of EspA with the host cell membrane, the filament tip serves as a scaffold 
for pore formation by EspB and EspD.141 EspB coprecipitates with EspA, and imaging studies 
suggest that EspB localizes with EspA, indicating that EspB may form important interactions with 
the T3SS filament.142 EspB and EspD then form a hetero-oligomeric donut-shaped structure within 
the cytoplasmic membrane of eukaryotic host cells.143 The exterior diameter of the structure is 
between 55 and 65 nm wide. The pore is a funnel shape, with the diameter of the opening becoming 
smaller towards the cytoplasm of the eukaryotic cell. The minimum diameter of the pore is 
estimated at 2.5 nm.144 EspD is critical for lysis of red blood cells (RBCs), while E. coli lacking 
EspB is still capable of a basal level of hemolysis.139 In addition, analysis of membrane-associated 
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proteins confirmed membrane-association of EspD consistently after hemolysis. An amphipathic 
region consisting of residues 66-83 of EspD is responsible for conformational changes to the 
protein upon exposure to eukaryotic cell membranes.145 This natively-disordered protein, when 
inserted into the lipid bilayer of HeLa cells, formed a homodimer thought to increase pore 
formation. Deletion of residues 66-83 abolished dimerization. The pore formation of EspB and 
EspD is the final step in the construction of the E. coli T3SS. 
 
1.4.2 Mechanisms of action of secreted effectors 
 Once the T3SS is assembled, effector proteins are transported through the EscF/EspA 
needle and filament and are delivered into eukaryotic host cells through the EspB/EspD pore. The 
effectors then perform a collection of actions that promote infection by EPEC or EHEC. Some of 
these proteins are involved in cytoskeleton remodeling to allow for effacement of the intestinal 
microvilli and pedestal formation which ultimately leads to intimate attachment of the bacteria to 
the eukaryotic cell membrane. Some effectors interrupt eukaryotic cell trafficking or 
phosphorylation pathways, while others interfere with cell survival/death pathways. The process 
of the sustainment of an intestinal E. coli infection by T3SS-harboring EPEC or EHEC relies on 
the actions of these effectors to maintain an infection. 
 Cytoskeleton remodeling. Mutations in a particular protein have been implicated in a 
genetic disorder called Wiskott-Aldrich syndrome (WAS).146,147 The WAS protein (WASP) is 
expressed exclusively in hematopoietic cells. WASP has a ubiquitously expressed homolog with 
~50% aa identity that is most highly expressed in nerve cells (N-WASP). These proteins are similar 
in structure and contain many of the same functional domains, including the verprolin-homology, 
cofilin-homology, highly acidic (VCA) region.148,149 Together, this VCA binding domain is 
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essential for activation of the Arp2/3 complex and initiation of actin polymerization. The V region 
binds actin monomers directly, while the C and A regions bind the Arp2/3 complex.146,150,151 In 
the resting state, this process is regulated through autoinhibition of N-WASP.152 Activators of N-
WASP, including the Rho family153,154 of small GTPases (sGTPases) and the Src family155,156 of 
tyrosine kinases, interrupt the autoinhibited structure, exposing the VCA domain for Arp2/3 
binding and resulting in actin polymerization. 
 The Rho family of sGTPases modify a broad range of cellular mechanisms in a GTP-
dependent manner.153 The GDP-bound form is inactive, and the GTP-bound form is active. 
GTPase activating proteins (GAP) enhance the basal level phosphatase activity of GTPases by 
aiding in the conversion of GTP to GDP. Guanine-nucleotide exchange factors (GEFs) facilitate 
the exchange of GDP for GTP, accelerating turnover. The Rho sGTPases involved in N-WASP 
activation and cytoskeleton remodeling include Rac1 and Cdc42.157–160 
 Pathogenic E. coli have evolved an intricate mechanism for hijacking Rho GTPase 
regulation for the formation of cytoskeleton pedestals (Figure 2).161 This process involves multiple 
effector proteins (EspH, EspT, EspM2, EspW and Map). EspH binds to and inhibits Rho GEFs, 
while EspT, EspM2, and Map mimic specific GEFs. EspT activates Cdc42 and Rac1, EspM2 
activates RhoA and induces stress fiber formation. EspW activates Rac1,162 and Map activates 
Cdc42. Through these effectors, EPEC and EHEC shut off the eukaryotic cell’s mechanism of Rho 






Figure 2. Infection by attaching/effacing (AE) pathogens like E. coli and C. rodentium 
results in morphological changes to the surface of the epithelial cell. These changes result 
in the loss of extracellular microvilli and the formation of a pedestal on which the bacteria 
are attached. The intracellular mechanisms that result in this dramatic change are brought 
on by bacterial effector proteins (red) interfering with host actin and microtubule control 
mechanisms (blue).  
 
 Effectors EspG and EspG2 participate in cytoskeleton remodeling during the establishment 
of infection through multiple pathways.163–165 These effectors bind directly to tubulin, which 
causes localized microtubule disruption.164 Tubulin binding also results in increased actin stress 
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fiber polymerization. When C. rodentium with mutated espG was used to infect C57BL/6 mice, 
the bacteria showed a significantly reduced ability to colonize the gut epithelia compared to wt 
cells.163 Yeast producing recombinant EspG lost control of microtubule structure and function. 
 Another mechanism by which EspG interferes with cytoskeleton regulation is through 
interactions with Arf GAPs and p21-activated kinase (PAK).165,166 Arf GAPs activate Rac1, a Rho 
GTPase, to recruit and activate the Wave regulatory complex (WRC), a member of the WASP 
family.167 In addition, Arf GAPs consist of multiple membrane-binding domains, which anchors 
any Arf-containing complex to the plasma membrane. EspG interacts with Arf GAPs, which aids 
in downstream interactions with PAK.166 PAK participates in cytoskeleton remodeling through 
multiple mechanisms, including phosphorylation and activation of the Arp2/3 complex.168 After 
injection by the T3SS, EspG localizes in the plasma membrane by binding to Arf GAPs.165 The 
inactive PAK homodimer then binds to Rho GTPase, which also localizes PAK to the plasma 
membrane. PAK-Rho interactions expose the EspG binding site on PAK, allowing for PAK-Rho-
EspG complex formation and disassociation of the PAK homodimer, releasing the active PAK 
monomer. PAK is then free to phosphorylate and activate Arp2/3, stimulating cytoskeleton 
polymerization.  
 The characteristic pedestal formation following T3SS-mediated infection is dependent on 
the translocated intimin receptor Tir.169,170 Though actin polymerization is activated through 
multiple mechanisms, Tir serves as a direct connection between the bacterial cell surface and the 
eukaryotic cytoskeleton.171,172 Once Tir is translocated into the eukaryotic cell, it may be 
phosphorylated before localizing within the cell membrane to act as a receptor for intimin 
expressed on the bacterial outer membrane.171  
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 Phosphorylation is necessary for Tir-intimin interaction for EPEC, but it is not necessary 
for EHEC.169 After phosphorylation, EPEC Tir recruits N-WASP and Arp2/3 to initiate pedestal 
formation. The N-terminus of Tir also binds directly to α-actinin, which attaches Tir to the actin 
filament.173 Evidence suggests that Tir also interacts with talin and vinculin, other adhesion 
proteins172 and cytokeratin 18, an intermediate filament protein.174 Recruitment of N-WASP is 
mediated through direct interactions between Tir and Nck, a protein implicated in the attachment 
of phosphorylated receptors to the cytoskeleton.175 In EPEC, Tir-Nck interactions are required for 
subsequent recruitment of N-WASP and Arp2/3. In EHEC, recruitment of cytoskeleton modifiers 
and the anchoring of Tir to the actin cytoskeleton is mediated through TccP (also known as 
EspFU).
176 TccP is encoded by EHEC, and the amino acid sequence of TccP consists of a secretion 
signal necessary for translocation through the T3SS and a 47-amino acid (aa) repeat.177 A 17-aa 
motif within the repeat mimics the autoinhibitory fragment of N-WASP. Through competitive 
interactions with the autoinhibitory binding region on N-WASP, TccP binding exposes the VCA 
domain and allows N-WASP-Arp2/3 interactions. Since TccP encodes multiple repeats of this 
domain, multiple N-WASP particles can interact at the same time, resulting in an amplified actin 
polymerization response.177 
 In addition to its structural pore-forming activity, EspB inhibits Arp2/3-mediated actin 
polymerization.178 EspB enhances dimerization of α-catenin.179 The EspB/α-catenin complex 
outcompetes Arp2/3 for binding of actin filaments.178 Interactions between actin and the EspB/α-
catenin complex results in a bundling of the filaments. Accumulation of the EspB/α-catenin 
complex is observed beneath the pedestals formed with the development of A/E lesions, 
implicating them in attachment of bacteria to host cells during infection.179 
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 Avoiding phagocytosis. For E. coli to colonize the intestinal epithelia, the bacteria must 
get past front-line immune response mechanisms by the host. E. coli accomplishes this through the 
secretion of effectors that inhibit uptake of the bacteria into macrophages.180 Macrophages 
internalize particulate by depositing opsonins, including C3bi and IgG, onto the cell membranes 
of their targets.181,182 Phagocytic receptors expressed on the membrane of the macrophages bind 
to these opsonins. The receptors for C3bi and IgG are complement receptor 3 (CR3)181 and Fc 
gamma receptors (FcγR),182 respectively. Pathogenic E. coli can inhibit the phagocytic uptake of 
itself (cis-inhibition) and other opsonized cells (trans-inhibition) through the secretion of effectors 
EspJ and EspF (Figure 3).180  
 
  
Figure 3. Effectors (red) secreted into host macrophages are able to inhibit the uptake of 
the cell that secreted them (cis-inhibition). Other effectors inhibit the uptake of other 
bacterial cells (trans-inhibition). These effectors were identified by analysis of uptake of 
opsonized particles into macrophages in the presence of EHEC (cis-inhibition) or into 




 EspJ is capable of trans-inhibition of opsono-phagocytosis.180,183,184 EspJ is an adenosine 
diphosphate (ADP) ribosyltransferase that inhibits Src kinases.183 Src kinase is responsible for 
phosphorylation of Tir and FcγR. Inhibition of Src indirectly results in inhibition of Arp2/3-
dependent actin polymerization by inhibiting phosphorylation of Tir. Opsono-phagocytosis is also 
inhibited by downstream inhibition of FcγR. When J774.A1 macrophages were pre-incubated with 
EPEC or EHEC, they were incapable of internalizing RBCs that were pre-opsonized with C3bi or 
IgG.180 An active T3SS was necessary for inhibition, and mutation in the espJ gene abolished the 
protective phenotype. When Cos-7 cells were co-transfected to express EspJ and FcγR or CR3, 
EspJ appeared to inhibit uptake of IgG- and C3bi-opsonized RBC into the Cos-7 cells. This result 
implies that the presence of EspJ in macrophages may be sufficient in  protecting bacteria from 
phagocytosis. 
 EspF exhibits cis-inhibition of phagocytosis of EPEC and EHEC.180,185 This was 
demonstrated by incubation of J774.A1 macrophages with EHEC wt, ΔescN, and ΔescF.180 The wt 
strain was capable of inhibiting uptake, while the T3SS-inhibited ΔescN strain and the escF mutant 
showed similar, increased levels of phagocytosis. Mutation in the espF gene also resulted in 
decreased uptake of E. coli by M cells.185 EspF is believed to inhibit phosphatidyl inositol-3 (PI-
3) kinase-dependent manner, as inhibition of PI-3 kinase restored the protective phenotype to espF 
mutants.186 PI-3 kinase is required for FcγR-mediated phagocytosis.187 PI-3 kinase inhibition 
results in activation of Cdc42 and Rac1, which implicates EspF in actin reorganization, though 
this is most likely in reference to inhibition of phagocytosis rather than pedestal formation. 
 Cell trafficking and secretion. Eukaryotic immune response cells secrete signaling 
molecules such as cytokines and chemokines in response to infection by pathogens.188 This process 
is completed through a secretory pathway that includes intracellular trafficking of enzymes 
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between the endoplasmic reticulum (ER) and the Golgi apparatus.189 Major regulators of the 
essential ER-Golgi membrane trafficking process include Arf1190 and Rab GTPases191 and coat 
protein complexes I (COPI) and II (COPII).192 Arf1 is involved in membrane transport within the 
Golgi apparatus as well as Golgi-to-ER trafficking.190 Rab GTPases are responsible for the fusion 
of incoming compartments to the Golgi membrane190,191 as well as correct transport of ER-derived 
vesicles.191 COPII coat ER-derived vesicles and form complexes with transport protein particle 
(TRAPP). These complexes serve as GEFs to activate Rab proteins. COPI coat vesicles that are 
recycled back to the ER from the Golgi.193 
 
 
Figure 4. Secreted bacterial effectors (red) interfere with Golgi/ER trafficking by targeting 




 EspG forms an Arf1-EspG-Rab1 ternary complex.194 The formation of this complex results 
in the redirection of Arf1 activity to inhibit Rab1, significantly decreasing secretion of interleukin-
8 (IL-8). EspG stabilizes the active Arf1-GTP complex, inhibiting turnover.195 This results in the 
recruitment of Arf1-dependent tethering factors, which ultimately restricts vesicle movement. In 
addition, EspG acts as a Rab1-specific GAP. Inhibition of Rab1 results in the restriction of vesicle 
movement. These activities together result in halting of ER-Golgi transport. EspG also binds Arf6 
and Rab35, which results in disruption of recycling endosome function and accumulation of 
recycling cargo in the cytosol.196 
 The non-LEE-encoded (Nle) effector protein NleA, or EspI, destabilizes the COPII 
complex to inhibit its function.197 It is theorized that this interference results in inhibition of vesicle 
uncoating and fusion of the vesicles in ER-Golgi transport. The ability for C. rodentium to maintain 
an infection in mice is dependent on interactions with NleA and the Sec24 subunit of the COPII 
complex.197,198 NleF binds to a receptor for the COPI complex, Tmp21.193 Tmp21 serves to 
facilitate packing of cargo into COPI-coated vesicles in conjunction with Arf1. The activity of 
Tmp21 is imperative for the formation of COPI-coated vesicles and retrograde transport from the 
Golgi to the ER. Interference by NleF results in slowed intracellular trafficking.193 
 NF-κB and MAPK signaling pathway. The NF-κB and MAPK signaling cascades are 
highly complex pathways that result in global changes in gene transcription and inflammatory 
signaling in all cell types.199–202 A highly simplified explanation will be given to describe the 
influence of T3SS-dependent effectors on these signaling cascades. Transforming growth factor-
β-activated kinase 1 (TAK1) can be activated by a multitude of proteins, nod-like receptor proteins 
(NLRPs), kinases, and ubiquitin ligase tumor necrosis factor (TNF) receptor-associated factors 
(TRAFs).199 TAK1 is a complex consisting of  the TAK1 kinase and adaptors TAB1, TAB2, and 
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TAB3.203 TAB2/3 induce oligomerization and autophosphorylation of TAK1, which is essential 
for activity. TAK1 then activates inhibitory kappa B kinase (IKK), an activator of the NF-κB 
pathway. IKK breaks the inhibitory interactions of inhibitory kappa B (IκB) with NF-κB, which is 
then free to dimerize into functional units, cross into the nucleus, and bind the promoter regions 
of target genes to activate transcription.200 These genes produce an immune response through 
production of interleukin (IL) molecules or other cytokines specific to the pathogen type that 
initiated the signaling cascade. The mechanisms by which the specificity of the response is 
accomplished is not well understood. TAK1 may also activate the MAPK p38, JNK and the 
ERK1/2 pathways.199 The activated MAPK pathways then induce the downstream expression of 
inflammatory cytokines.201,202 
 At the initiation of infection, EPEC causes an increase in inflammatory signaling that later 
diminishes in the later stages of infection (Figure 5).204 The initial spike in inflammation is due to 
effector NleF, which is localized to the mitochondria upon secretion into epithelial cells. NleF 
causes increased translocation of NF-κB to the nucleus and subsequent upregulation of IL-8 
expression. Tir, the effector responsible for initiation of attachment and pedestal formation by 
interacting with the bacterial cell-surface protein intimin, also functions as an inhibitor of NF-κB 
signaling.205–207 The C-terminus of Tir mimics an immunoreceptor tyrosine-based inhibitory motif 
(ITIM) which binds to tyrosine phosphatases SHP-1 and SHP-2.207 The Tir-SHP1/2 interactions 
then recruit TAK1 and inhibit its phosphorylation.206,207 Binding to SHP-2 also leads to 





Figure 5. Secreted effectors (red) interfere with NFκB and MAPK signaling pathways 
(blue) through both activation and inhibition. 
 
 NleB, a glycosyltransferase, inhibits NF-κB signaling through modification of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). NleB acetylates GAPDH, which results in 
decreased polyubiquitination, which is necessary for GAPDH to act as a cofactor for TRAF2. 
NleB-mediated inhibition of this interaction results in a reduction of NF-κB activation. Mutations 
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in the nleB gene that remove glycosyltransferase activity attenuated infection of mouse intestines 
in vivo. Through a similar mechanism, NleB inhibits ubiquitination of TRAF3, which reduces 
production of IFN-β.208  
 The NF-κB functional units are Rel proteins, which dimerize to bind to specific nucleotide 
sequences at the promoter regions of their target genes.200 NleC is a zinc-dependent 
metalloprotease known to cleave multiple proteins related to inflammatory regulation,209 including 
p300,210 IκB,211 and Rel proteins p65 and p50.212–214 Cleavage of these proteins results in their 
deactivation and degradation. Mutational studies also suggest that NleC is an inhibitor of the 
MAPK pathway by inhibition of p38 MAPK phosphorylation.215 Another zinc-dependent 
metalloprotease, NleD, cleaves and inactivates MAP kinases JNK and p38, ultimately reducing 
the expression and secretion of IL-8.216–218 Cleavage an inactivation of JNK results in decreased 
cleavage of c-Jun, a subunit of AP-1, a transcriptional regulatory complex responsible for the 
expression of inflammatory genes.217 
 NleE methylates the active site cysteine on TAB2 and 3, impairing their ability to bind a 
ubiquitin chain.203 This directly inactivates the TAK1-TAB complex and results in inhibition of 
the NF-κB signaling pathway. NleH1 and NleH2 are similar effectors with 84% sequence 
homology.219 Both bind to ribosomal protein S3 (RPS3), which inhibits its activity as a guide for 
NF-κB in the nucleus.220 NleH1 and NleH2 interact with each other during infection, and NleH1 
directly inhibits IKKβ-mediated phosphorylation of RPS3.221 NleA inhibits IL-1β secretion by 
interacting with NLRP3, inhibiting inflammasome activation.222 
 EspT acts as a Rac1-specific GEF.223,224 EspT-mediated Rac1 activation induces the 
expression of immune response proteins IL-8 and IL-1β in macrophages by activating the JNK 
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and Erk pathways. Infection of mice with an espT mutant strain of C. rodentium results in 
decreased production and secretion of KC, the murine equivalent of IL-8. 
 Survival pathway/cell death. Programmed cell death, or apoptosis, occurs through two 
pathways. The intrinsic pathway is mediated by the mitochondria and the extrinsic pathway is 
mediated by receptors.225 Both pathways ultimately result in the activation of caspases which leads 
to cell death. The T3SS of pathogenic E. coli secretes effectors that modulate the apoptotic 
pathways.225 
 There are four major effectors that induce apoptosis during infection: Cif, Map, EspF, and 
EspH (Figure 6). Cif, or cell cycle inhibiting factor, is not a LEE-encoded effector.226 The cif gene 
is located on a lambdoid prophage that is present in most strains of EPEC and EHEC. Cif arrests 
cell cycle progression at the G2/M phase and causes the accumulation of inactive cyclin-dependent 
kinase Cdk1, an enzyme required for cell-cycle progression into the mitotic phase.226 Cif is 
targeted to the T3SS by a 16-aa N-terminal translocation signal, similar to other type III 
translocated proteins.227 Cif shares a catalytic triad with cysteine proteases and acetyltransferases, 
and mutation of the catalytic residues abolished the cell cycle arrest phenotype.228 Cif ultimately 
induces delayed apoptosis 48 hours after infection.229 When Cif was delivered to eukaryotic cells 
in the absence of bacteria, Cif induced accumulation of cleaved, activated caspase-3. This result 
was dependent on the active site cysteine residue, and mutation at that site resulted in decreased 





Figure 6. Throughout the infection, bacterial effector molecules (red) modulate intrinsic 
and extrinsic apoptotic pathways. 
 
 The mitochondria-associated protein (Map) is localized to the mitochondria after T3SS-
mediated translocation by a mitochondrial-targeting sequence.230,231 Once there, Map is 
responsible for morphological changes to the mitochondrial membrane.231,232 Map then disrupts 
the mitochondrial membrane potential (MMP), which results in the release of cytochrome c and 
induction of apoptosis.230–233  Like Map, EspF is targeted to the mitochondria through an N-
terminal sequence,234 where it destabilizes the MMP and induces cytochrome c release.234–236 A 
secondary mechanism of apoptosis induction has also been proposed.237 Interaction of EspF with 
ABC transporter family member Abcf1 is thought to result in Abcf1 degradation. Abcf1 activity 
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potentially results in the inhibition of caspase activation, so degradation of Abcf1 would result in 
increased accumulation of caspase-3 downstream.237 
 NleH plays a minor role in induction of apoptosis, which is normally counteracted by EspT 
and EspM2 at biologically relevant concentrations.161 Overexpression of NleH, the global RhoGEF 
inhibitor, in epithelial cells resulted in increased caspase-3 activation. This results in downstream 
activation of intrinsic apoptosis. The ability of effectors EspT and EspM2 to disrupt this activity 
indicates a built-in mechanism of self-modulation for the T3SS.161 
 NleF is a general inhibitor of apoptosis that acts during a late phase of cell death 
initiation.238,239 The C-terminal domain of NleF binds directly to the catalytic domain of caspases-
4, -8, and -9, inhibiting their protease activity.238 Mutations in the C-terminal domain of NleF 
abolished caspase binding and apoptotic signaling was regained.  
 The extrinsic induction of apoptosis is inhibited by two effectors, NleD and NleB1. 
Extrinsic apoptosis is triggered by the recognition of danger signals by cell surface death receptors, 
which results in the activation of signaling cascades that lead to cell death.240 Two of the death 
receptor cascades modulated by T3SS effectors are TNF receptor 1 (TNFR1) and Fas receptor.240 
Association of TNFα with TNFR1 results in the recruitment of TNFR1-associated death domain 
(DD) protein (TRADD), while association of Fas ligands to the Fas receptor recruits Fas-
associated DD protein (FADD).240 Downstream consequences of activation of these cascades 
include activation of caspase-8, which further activates executioner caspases, resulting in 
apoptosis. 
 NleD inhibits extrinsic apoptosis by cleaving JNK, which is activated downstream of 
TNFR.217,218 In addition, when active, JNK phosphorylates and activates the c-Jun subunit of 
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transcription factor AP-1.241 AP-1 activation then leads to transcription of apoptosis-related genes. 
Cleavage of JNK therefore decreases the expression of genes related to cell death.218,241 
 NleB1 is a glycosyltransferase with multiple cellular targets and roles in infection.242–244 In 
addition to modulating inflammatory responses, NleB acetylates arginine residues within the DDs 
of FADD, and TRADD,244 leading to inhibition of dimerization required for recruitment to death 
receptors. Downstream effects of this inhibition included reduced activation of caspase-8.243 The 
homolog of NleB1, NleB2, was incapable of eliciting the same effects. 
 Intrinsic apoptosis is directly mediated by the mitochondria.245,246 This pathway is activated 
by increased permeabilization of the mitochondrial membrane, which results in the release of 
cytochrome c into the cytosol.246 MMP is increased by intracellular protein Bax.246,247 Cytochrome 
c accumulation in the cytosol results in the formation of the apoptosome, a caspase-9 activator 
complex.248 Caspase-9 then activates executioner complexes including caspases-3 and -7. 
Effectors that inhibit intrinsic apoptosis include NleH1 and EspZ.225 
 NleH1 reduces disruption in MMP caused by Bax.219,249 Interactions between NleH1 and 
Bax inhibitor-1 (BI-1) promotes BI-1-mediated inhibition of Bax.249 This reduces the 
permeabilization of the mitochondrial membrane and reduces the accumulation of caspase-3 that 
is necessary to induce apoptosis.247 EspZ inhibits apoptosis through multiple mechanisms.225 EspZ 
localizes to the mitochondria and stabilizes the MMP by interacting with translocase of the inner 
mitochondrial membrane 17b (Tim17b).250 Tim17b is a voltage-gating component of protein 
transport to the mitochondria. EspZ is also theorized to act as a negative-regulator of T3SS 
activity.251 EspZ localizes to the cytosolic region of the plasma membrane and interacts with pore-
forming protein EspD. Heterologous overexpression of EspZ in HeLa cells prior to infection with 
T3SS-harboring EPEC decreased delivery of effector proteins into the HeLa cells.251 
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 Disruption of tight junctions. The stability and homeostasis of an epithelial cell 
membrane relies on the maintenance of tight junctions (TJ).252 TJs also function in determining 
the selective paracellular permeability by acting as a gate for ions and proteins to pass through.253 
Disruption of TJ stability results in increased permeability through epithelial membranes and 
decreased barrier function. The proteins that make up TJs are localized to paracellular regions.254 
These proteins include claudins, occludin, junctional adhesion molecules (JAMs), tricellulin and 
cytosolic scaffold proteins such as zonulae occludens (ZO) and cingulin (Figure 7).253–257 
Characteristics of a destabilized TJ include increased permeability and delocalization of the TJ 
proteins.252 Permeability of cell monolayers can be quantified by measuring the transepithelial 
electrical resistance (TEER) of the membrane.258 Decreased TEER indicates increased 
permeability of the monolayer and a disrupted TJ. 
 
 
Figure 7. Image of tight junctions. 
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 Pathogenic E. coli and C. rodentium secrete effectors to disrupt the stability of TJs for the 
purpose of infection.252 These effectors (NleA/EspI,198,259–261 EspF,262–264 Map,265 
EspG/G2,252,266,267 and EspM268) all serve other functions relating to actin rearrangement, 
microtubule interactions, interference with ER/Golgi trafficking, induction of inflammatory 
responses, and modulation of cell survival/death pathways. These primary functions all interfere 
in some way with TJ performance, and they disassemble TJs as secondary functions.252 Mutation 
of any of these effectors results in either decreased TEER measurements on a cell monolayer or 
delocalization of tagged TJ proteins to other regions of the cell, away from the paracellular space. 
 
1.4.3 Regulation 
 Chaperones of T3SS effectors. T3SS-specific chaperones are essential for the secretion 
of their concordant effectors, or substrates. Oftentimes, knockdown or mutations to these 
chaperones decreases secretory efficiency of their substrates, making chaperones essential for the 
propagation of T3SS-mediated infection.269,270 Some chaperones bind to only one substrate135 
while others bind to multiple (Table 1).271  
 
Table 1. Type III secretion system chaperones and their substrates. 
Chaperone Substrates 
CesT Tir,270–273 Map,270–272 EscJ,270,271 EscC,270,271 EspF,270,271  
NleA,270,271 NleG,270 NleH1,270 NleH2,270 NleF, EspH, EspZ, EspG 
CesF EspF274 
EscE EscF134 
EscG/CesA2 EscF,134 EspA135,275 
CesAB EspA,140 EspB140 







 Most chaperones function as dimers.269,279 Associations between a chaperone and its 
substrate are dependent on a specific aa sequence present on the N-terminus of the substrate called 
the chaperone binding domain (CBD).280,281 This region is composed of a secretion signal and a 
chaperone binding region and is typically 50-100 aa in length, and it binds by wrapping around 
the dimerized chaperone proteins in a mostly linearized manner that allows for the formation of 
secondary structures.279,280 The role of these chaperone-substrate complexes was originally 
hypothesized to be targeting of the effectors to the T3SS.282 Evidence in favor of that theory is 
presented in an ATPase-binding domain specific to EscN that is present on CesT, a promiscuous 
chaperone that binds Tir and other substrates. CesT can independently bind substrates and the 
ATPase, and a E142G mutant displayed a decrease in Tir secretion without inhibiting CesT-Tir 
interactions.271 
 In some cases, the entire effector substrate remains unfolded because of chaperone 
binding.135 This is true for EscE and EscG binding to EscF134 and EspA binding with chaperones 
CesA135 or CesAB.283 In a divergent example, substrates that bind to CesT are only linearized 
through the CBD.284 The remainder of their structure is fully formed and enzymatically active. 
Because the inner diameter of the T3SS needle is only 2-3 nm, these effectors must be unfolded 
prior to secretion. The ATPase of the Salmonella T3SS, InvC, has been implicated as an “unfold-
ase” that serves to linearize effectors in an ATP-dependent manner.285 The conserved structure of 
the T3SS family of ATPases suggests this may be a universal role for InvC homologs.66 The 
ATPase binding domain on CesT supports that claim.271  
 The unfolding activity of the ATPase appears to be substrate-dependent.269 When 
dihydrofolate reductase (DHFR) with a stable fold was fused to the secretion signal (but not the 
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full CBD) of YopE in Yersinia, the enzyme could not be secreted.286 When the entire CBD of 
YopE was included (residues 1-52), DHFR was successfully secreted, regardless of folding before 
secretion.286,287 This indicated that secretion of the enzyme may be dependent on the entire CBD 
of some effectors.  
 Chaperones of the T3SS effectors are instrumental in the efficient secretion of their 
substrates.271 Mutation or knock-down of chaperones results in decreased concentrations of 
secreted proteins. Chaperones associate with their substrates in a dimerized form, with the N-
terminal CBD wrapped around the dimer.279 In some cases, chaperones are necessary to keep the 
effectors linearized before secretion.135 When the effector is folded before secretion, chaperones 
work in conjunction with the ATPase located at the base of the T3SS complex to transport 
linearized peptides through the needle complex, allowing for propagation of infection.285  
 Regulation of expression of the T3SS. In AE pathogens, the T3SS is encoded by the LEE, 
a highly conserved pathogenicity island (Figure 8).288 The LEE is a chromosomally encoded 35 
kb region288 that contains 41 genes in seven operons (LEE1-7).11,289–292 The LEE encodes structural 
components of the T3SS, regulatory proteins, some secreted effectors and their chaperones, and 
proteins implicated in attachment. The LEE of EPEC and EHEC have 94% sequence identity and 
the operons are present in the same order,293 while the C. rodentium LEE shares lower 
homology.10,294 In addition, the operon LEE6 in C. rodentium is placed differently within the LEE 





Figure 8. The locus of enterocyte effacement (LEE) of EPEC and EHEC. 
 
 Regulation of LEE expression is complex and involves autoregulatory systems, 
environmental conditions, transcriptional and post-transcriptional regulation, and quorum 
sensing.295 The LEE encodes four transcriptional autoregulators: Ler, GrlA, GrlR, and CesL.289,296 
Ler is encoded by LEE1 and belongs to the H-NS-like protein family.289 H-NS, the prototype 
member of the family, binds and negatively regulates transcription of the LEE.297–299 Ler displaces 
H-NS, derepressing LEE expression and acting as a positive feedback loop.297,300 Ler is essential 
for expression of the LEE, while simultaneously acting as its own negative regulator through 
modulating expression of grlA and grlR.301,302 GrlA and GrlR are encoded by LEE7.296,303 GrlA 
binds directly to the LEE1 promoter region, activating transcription of Ler.303,304 Ler then activates 
LEE7 transcription, forming another positive feedback loop.291 GrlR represses LEE expression 
through an unknown mechanism.305,306 It is known, however, that GrlR binds to GrlA, indicating 
that GrlR may inhibit expression by sequestering available GrlA.304,306 
 There are also several pathotype-specific regulators of the LEE.3 CesL serves as both a 
chaperone and a transcriptional regulator of LEE expression in EHEC.307,308 CesL interacts with 
Ler, and overexpression leads to sequestration of Ler, resulting in repression of LEE expression.307 
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Typical EPEC encode a positive regulator of expression, PerC, on the EAF plasmid.87,309 EHEC 
encodes three PerC homologs, PchA, PchB, and PchC.310 
 Global transcriptional regulators that affect LEE expression include BipA, Cpx, Fis, GadE, 
Hha, H-NS, H-NST, IHF, RgdR, RpoN, SspA, FusK/R, EutR, LeuO, SdiA, KdpE, QseA, QseC, 
QseD, QseE, RcsB, RegA, and GlmY/GlmZ.79,311–313 To add to the complexity, these regulators 
may not affect transcription in the same way between organisms. For example, global epigenetic 
modifier Lrp upregulates T3SS activity in EPEC and EHEC while downregulating T3SS 
expression in C. rodentium.65,314,315 
 Hierarchal secretion. The hierarchy of secretion and assembly of T3SS components is 
important for function of the injectosome. This process is regulated through two molecular 
switches: EscP/EscU and SepL/SepD.311,316 These switches regulate the change of proteins 
secreted from early to middle and late stage substrates. Early stage substrates include structural 
components such as the inner rod the needle.317 Middle stage substrates include the translocon 
proteins EspA, EspB, and EspD. Translocation of the first effector, Tir, marks the initiation of late 
stage secretion.80,318 
 The first molecular switch is dependent on the interactions between sorting platform 
protein EscU and ruler protein EscP.319,320 EscP interacts with the C-terminal region of the 
autoprotease EscU, which in theory results in a conformational change responsible for a shift in 
substrate specificity. This shift is substrate specificity allows for middle stage proteins to be 
secreted.321 The EscU/EscP interactions are theorized to work in consort with the autoprotease 
activity of EscU, since a non-cleavable mutant of EscU decreases the secretion of middle and late-
stage substrates while decreasing membrane association of multi-effector chaperone CesT.124,322 
39 
 
 EscP is thought to associate with EscU in an “infrequent ruler model,” proposed by Moriya 
et al. for the flagellar system.323 In this model, EscP acts as a ruler for the assembly of the needle 
by oligomerization of EscF. Through direct interaction with EscF monomers, EscP moves through 
the interior of the needle complex, and secretion of EscF stops after the needle reaches the same 
length as EscP. EscP is occasionally secreted throughout the process of needle assembly, which 
temporarily halts the secretion of EscF. The pause in secretion allows for “measurement” of the 
needle length while subdomains of EscP interact with the inner diameter of the EscF super 
structure. When the needle length is equal to the length of EscP, these interactions are maximized, 
allowing time for interactions between EscU at the base of the needle and EscP. This interaction 
is then proposed to cause the conformational change in the EscU proteins responsible for changing 
the specificity of effector binding to allow secretion of middle and late stage effectors.323 
 The second molecular switch changes the secretion pattern from translocon-associated 
proteins to effectors through interactions between SepL and SepD. Null mutations in sepL result 
in abolishment of translocon secretion and increases effector secretion.296,324,325 This suggests that 
SepL plays a direct role in enhancing secretion of translocon proteins by inhibiting the secretion 
of effectors. In EPEC and EHEC, SepL binds to a protein SepD. Deletion of SepD results in the 
same secretion patterns as the mutant SepL, suggesting that SepL activity is dependent on 
interactions with SepD.324–326 These two proteins form a ternary SepD/SepL/CesL/Tir complex.327 
Evidence suggests that gate protein EscV may serve as a docking site for SepL-mediated secretion, 
though the exact mechanism for that is not well understood.327 It is hypothesized that SepL may 
be sequestered by competitive binding of EscD to the Tir binding site, resulting in Tir release and 




1.4.4 Inhibitors of the E. coli/C. rodentium T3SS 
Caminosides. The first inhibitor of the T3SS discovered was caminoside A (Figure 9).328 
The caminosides are glycolipids isolated from the marine sponge Caminus sphaeroconia found in 
the upper walls of Toucari Caves on the island of Dominica. Marine invertebrates were extracted 
repetitively with methanol before screening for T3SS inhibitory activity in EPEC. The isolation of 
caminoside A was a result of a bioassay guided fractionation approach using a protocol designed 
to screen for T3SS inhibitors using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and analyzing secretion of effector proteins. Samples having cytotoxic effects 
against EPEC were dropped from the study.328  
 
 
Figure 9. Structures of caminosides A (1) and B (2). 
 
Caminoside A decreased the secretion of EspB, but not EspC.328  The structure of 
caminoside A was elucidated and potency was characterized (IC50 = 20 μM), though details on the 
mechanism of action are still not well understood. Interestingly, though caminoside A has no 
cytotoxic effect against EPEC, it does have cytotoxic activity against Gram-positive methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (minimal 
inhibitory concentration, MIC = 12 μg/mL for each).  Since the discovery of the caminosides, full 
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syntheses of caminoside A and B have been published,329 detailing a synthetic process of 33 and 
25 steps, respectively. Despite the promising activity of the caminosides against EPEC, very little 
has been done since their discovery to further develop these natural products for use as T3SS 
inhibitors due to difficulties in production or synthesis of the compounds. 
Aurodox. Aurodox, a polyketide produced by Streptomyces goldiniensis, was originally 
isolated and characterized as having antibiotic activity against Gram-positive bacteria in 1973 
(Figure 10).330 Aurodox was originally named antibiotic X-5108 when its structure was elucidated 
and its antibiotic activity was discovered. Later, its molecular target was determined to be 
elongation factor-Tu (EF-Tu) and structure-activity relationship (SAR) studies were performed to 
characterize its pharmacophore.26 
 
 
Figure 10. Structure of aurodox (3). 
 
 Aurodox was identified as a T3SS inhibitor in 2011 as part of a screen for inhibitors of the 
T3SS using EPEC-mediated hemolysis.17,331 The molecular components of the translocon, EspB 
and EspD, typically form the end of the T3SS needle complex and allow for passage of effectors 
into the target host cell;15,73,326 however, they also form pores on the surface of RBCs.331,332 
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Formation of these pores results in leakage of hemoglobin into the extracellular space. The 
supernatant may then be separated from cellular components and the concentration of hemoglobin 
may be quantified by measuring the absorbance at 540-590 nm. The higher the hemoglobin 
concentration, the greater the T3SS activity. 
To discover aurodox, a hemolysis screen was performed on 13,300 biological extracts from 
actinomycetes, fungi, plants, and invertebrates.17 After extracts from Streptomyces sp. K06-0806 
showed potent inhibition of EPEC-mediated hemolysis without significantly affecting bacterial 
growth, a large culture of Streptomyces sp. K06-0806 was fermented and aurodox was purified. 
Further testing with purified compound determined the inhibitory potency of aurodox in the 
hemolysis assay. According to analysis by SDS-PAGE followed by Western blotting, aurodox 
reduces the amount of secreted proteins EspA, EspB, EspD, EspF and Map without significantly 
affecting overall protein levels. It was shown that T3SS inhibition (IC50 = 1.5 μg/mL) occurs at a 
concentration much lower than the concentration at which aurodox shows signs of toxicity against 
Gram-negative bacteria (~10 μg/mL).17 
Aurodox was later analyzed using an in vivo mouse model using C. rodentium to analyze 
the effectiveness of aurodox on mitigating infection.10 C. rodentium is a commonly used model of 
EPEC infection in mice, due to a high identity of sequence between the EPEC LEE and the LEE 
in C. rodentium.10,17 Mice were initially infected with C. rodentium, then treated either with 10% 
dimethyl sulfoxide (DMSO) as a control, a single dose of tetracycline (200 mg/kg), or aurodox (25 
mg/kg) every 24 hours for four days. All the mice that were treated with aurodox survived while 
none of those that were treated with tetracycline survived past day thirteen. These results show the 
power of T3SS inhibitors to protect against an otherwise lethal dose of pathogen.  
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 A recent study has been published investigating the mechanism of action of aurodox.25 
Aurodox decreased the secretion of effector proteins EspB and Tir via Western blotting. Aurodox 
was also shown to decrease infectability of epithelial cells by EHEC. Transcriptional analysis on 
gene expression revealed that aurodox downregulates over 100 genes cell-wide and downregulates 
25 of 41 genes related to the T3SS. This suggests that the inhibitory activity of aurodox is a result 
of a change in gene expression, and not a result of physical manipulation of the T3SS needle 
complex. One of the genes downregulated by aurodox is ler, a major activator of the LEE.272 In 
addition, aurodox downregulated the expression of EspG and NleB, which are non-LEE encoded 
effectors.25 Importantly, treatment with aurodox does not induce Shiga toxin production in EHEC, 
suggesting promise for the use of aurodox to treat EHEC infection. If the binding target of aurodox 
were identified, efforts could be made to strengthen that binding and increase the potency of 
aurodox further. 
 Guadinomines. The guadinomines were discovered using EPEC-mediated hemolysis to 
screen natural product extracts.333,334 Streptomyces sp. K01-0509 was found to produce potent 
inhibitors of hemolysis.331,332 Guadinomines A, B, C1, C2, and D were isolated from Streptomyces 
sp. K01-0509, purified and analyzed (Figure 11).333 Guadinomines A and B are the most potent 
natural product T3SS inhibitors with IC50 = 0.007 and 0.01 μg/mL, respectively. The mechanism 
of inhibition of the guadinomines are not well understood and yields of guadinomines from culture 
are low, making further research difficult. The lengthy total syntheses of guadinomine B and C2 
have been published, with 33 steps in the longest linear synthetic sequence.335 In 2012, a study on 
the biosynthetic pathway of guadinomine A was published.336 Notably, guadinomine D, having an 
acylated amine at R2 is 1000-fold less potent than guadinomine B. This shows the importance of 
the vicinal diamine to biological activity. The acyl group on guadinomine D may be installed by 
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enzymes apart from the guadinomine synthetase, since no obvious acylation enzyme is part of the 
gene cluster. While guadinomines do not appear to produce any antimicrobial activity, Ōmura 
found that guadinomine B is cytotoxic to Jukat cells at a concentration 100 times higher than the 




Figure 11. Structures of guadinomines A (4), B (5), C1 (6), C2 (7), and D (8). 
 
 Epigallocatechin-3-gallate (EGCG). EGCG is a polyphenolic flavonoid produced by 
green tea.337 EGCG is an anti-inflammatory compound that inhibits NF-κB activation and protein 
kinase C.338 EGCG is also being explored for its anticancer activity 339 and is a recognized inhibitor 
of epigenetic modifications such as DNA methylation and histone modification.340–342 The 
versatility of EGCG has been explored extensively and it is being reviewed for its potential as a 
treatment option for many conditions.343 Previous studies have indicated that at high 
concentrations, EGCG inhibits the T3SS of multiple organisms including EPEC and EHEC, S. 
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Typhimurium, and Y. pestis.344 This result was explored using ELISA quantification of secreted 
EspB as well as quantitative analysis of T3SS-mediated hemolytic activity in the presence and 
absence of 50 μg/mL EGCG. EGCG was also analyzed for its ability to inhibit adherence of EPEC 
to Hep-2 cells. In this assay, EPEC was cultured with the Hep-2 cells and incubated for 2 hours in 
the presence and absence of EGCG. The Hep-2 cells were then affixed to a microscope slide and 
stained with Giemsa. The number of adhered bacteria was then quantified. The presence of EGCG 
reduced adherence by ~50%. There are currently no works published indicating the potency of 
EGCG as a T3SS inhibitor for E. coli, and all published analysis has been performed at 
concentrations of 100 μM. 
 
 
Figure 12. Structure of epigallocatechin-3-gallate (EGCG, 9) 
 
 Regacin. Regacin reduces the expression of the C. rodentium T3SS by inhibiting binding 
of the transcriptional regulator RegA to its DNA substrates.16,345 The interaction between RegA 
and DNA typically enhances type III secretion. Western blot analysis of secreted protein showed 
that complete inhibition of RegA-DNA interaction resulted in partial, but not complete inhibition 





Figure 13. A) Structure of regacin (10). B) RegA binds to DNA, resulting in expedited 
activation of the T3SS. When RegA binding to DNA is inhibited by regacin, the T3SS is  
still partially active because LEE1 transcription and Ler expression are governed by 
multiple regulators. 
 
 Butyric acid. Initial studies relating to the biological effects of butyric acid predate 
knowledge of the T3SS (Figure 14).346 In the 1960s, the change in the infectious dose of S. 
enteritidis upon pretreatment of antibiotics was analyzed. The ED50 went from 106 to <10 cells 
when a single dose of streptomycin was administered 24 hours before infection. The authors noted 
that treatment with antibiotic increased the gut pH and identified that butyric acid and acetic acid 
were being produced by the gut bacteria. The authors attributed the ability of the mice to tolerate 
the pathogen to a low gut pH and not a specific inhibitory effect caused by butyric acid. Since 
these experiments were performed before the discovery of the T3SS, the authors were unaware 





Figure 14. Structure of butyric acid (11) 
 
 Butyric acid is classified as a short-chain fatty acid (SCFA) and is produced as a 
fermentation product by commensal Bacterioidetes species in mammals.347 In human intestines 
butyric acid is typically present at 10-20 mM.314,347,348 Butyric acid is a major energy source for 
colonocytes, and the ability of colonic cells to absorb and utilize sodium butyrate is seen as a sign 
of good health.348 Administration of butyric acid to the intestines of mice infected with C. 
rodentium results in decreased inflammation and increased mucus production from colonic cells. 
Butyric acid interacts with the epigenetic modifier Lrp, a major regulator of gene 
expression in bacteria.79,314,315,346–348 Lrp does not control the expression of genes in the same 
pattern from one organism to another. As a result, butyrate acts as a T3SS inhibitor for some 
organisms and as a T3SS activator in others.65,314,315,349 A notable example involves LEE-encoding 
bacteria EPEC and C. rodentium. Activation of Lrp upregulates expression of the LEE in EPEC, 
while activation of Lrp downregulates expression of the LEE in C. rodentium.65,314,315  
 Research into SCFAs as T3SS regulators has focused primarily on the effects of probiotics 
on infection.315,347,349 By increasing the concentration of SCFA-producing bacteria in the gut, 
concentrations of a variety of SCFAs are altered. Depending on the pathogen attempting to infect 
the gut, differing ratios of SCFAs could have dramatically different results, from improving to 
worsening infection. Given the prevalence and widespread use of probiotics, this area requires 
further investigation.  
48 
 
Small molecule inhibitors. There are multiple known small molecule inhibitors of the 
T3SS of E. coli or C. rodenium.350–352 For some of these compounds, the mechanism of action has 
yet to be elucidated, but with the improved structural characterization technology over the last 
decade, target-based drug design is becoming possible.353 A new class of small molecule inhibitor 
was discovered using a virtual screen for potential compounds to target the EscN ATPase.350 The 
screening campaign was conducted using the ATP binding site of EscN (PDB code: 2OMB) and 
compounds from the ZINC database. The initial 3000 compounds were filtered for predicted 
cytotoxicity, and the remaining top 70 compounds were purchased for ATP hydrolysis screening 
using recombinant EscN. Next, compounds were screened for their cytotoxicity toward HeLa cells. 
Finally, five compounds were screened for their ability to inhibit the T3SS based on the relative 
secretion of effector EspG1 according to Western blot results. Based on these data, analogs of one 
compound were designed based on predicted binding pose withing the EscN active site (Figure 
15). These compounds were named the WEN compounds. The most efficacious compound was 






Figure 15. Structures of WEN compounds. 
 
The salicyclidene acylhydrazides (SAs) are a well-characterized structural class of small 
molecule T3SS inhibitors (Figure 16). They were originally discovered as inhibitors of the T3SS 
of Y. pestis, but have since been indicated as T3SS inhibitors for a collection of pathogens, 
including Chlamydia spp.,6,12 S. Typhimurium,354 Shigella spp.,355 and EHEC.352 These 
compounds induce changes in growth rate of EHEC at 50 μM as a result of their effects on global 
transcription of genes.352 Addition of compounds at 20 μM decreased expression of Tir and EspD. 
The LEE-encoded regulators Ler, GrlA, and GrlR were also downregulated, while regulator genes 





Figure 16. Structures of SA derivatives that inhibit the T3SS in EHEC. 
 
In a recent screen of SA derivatives, the RCZ compounds (Figure 17), two compounds in 
particular were observed to interact directly with translocon protein EspD.351 Pull-down assays 
also indicated binding with EF-Tu and 2-oxoglutarate dehydrogenase. Secretion analysis was then 
performed on truncated versions of EspD to determine the region of RCZ12 and RCZ20 
interactions with the protein. Their results indicated that the coiled-coil domain of EspD is 
responsible for binding with the compounds. RCZ12 and RCZ20 maintain the ability to affect 
global gene transcription. To analyze the effect of EspD inhibition on the translation of the LEE, 
a ΔespD mutant was developed. In the absence of compounds, the EspD knockout showed no 
change in LEE expression. Introduction of RCZ12 and RCZ20 reinstated the downregulation of 
LEE transcription. This indicated that the regulatory activity of the inhibitors was independent of 
EspD interactions.351 Given the similarities between the observed mechanisms of inhibition of the 
RCZ compounds and aurodox, and given that they all bind to EF-Tu, this may indicate a connection 





Figure 17. Structures of RCZ12 (20) and RCZ20 (21). 
 
 Coiled-coil peptides It is common for the effectors transported through the T3SS to be 
composed of a coiled-coil domain, a structure composed of an amphipathic secondary α-helix. The 
residues within the coiled-coil domains typically consist of a seven-residue repeat. The presence 
of this domain is hypothesized to play a role in multimeric oligomerization, molecule recognition, 
and potentially interaction between bacterial and eukaryotic proteins upon translocation. The 
proteins responsible for forming the filament (EspA) and needle (EscF) have coiled-coil domains, 
as does the chaperone for EspA (CesA). To analyze potential inhibitory effects of these domains 
on T3SS function, coiled-coil mimetics were synthesized based on the aa sequences of EspA, EscF, 
and CesA (Table 2).  
 
Table 2. Sequences of effectors and synthesized coiled-coil peptides. Red residues were 
changed to increase solubility 
Name Sequence 
EspA KANNLTTTVNNSQLEIQQMSNTLNLLTSARSDMQSLQYRTISGI 
Coil A LTTTVNNSQLEIQQM 
Coil B MSNTLNLLTSARSDM 
Coil AB1 KMNNLTTKVNNLQLELQEMRNTLKRLKSAMRRMQ 
Coil AB2 KINNLTTKVNNLQLELQEMRNTLKRLKSAMRRMQ 
EscF LSDSVPELLNSTDLVNDPEKMLELQFAVQ 
Coil C LSDSVPELLNSTDLV 




Ces A1 IVSQTRNKELLDKKIRSEIEA 
Ces A2 IKKIIAEFDVVKESVNELSEK 
 
 The ability of these peptides to inhibit T3SS activity was quantified based on hemolysis of 
RBCs in the presence of EPEC.356 T3SS-mediated hemolysis was inhibited by 95% in the presence 
of Coil A or Coil B at 0.16 mM. Coil AB1 and Coil AB2 showed less potent inhibition of between 
10% and 20% at 0.14 mM. Coil B7.1 and Coil B7.2 were only capable of inhibiting the T3SS when 
they were combined. Coil C and Coil D did not exhibit inhibitory effects to a major extent. Ces 
A1 did not inhibit hemolysis, but Ces A2 inhibited hemolysis by ~50% at 0.23 mM. With the 
growing prevalence of peptide drugs approved by the FDA,357 and given that these coiled peptides 
target extracellular proteins, these peptides show promise for use as pharmaceutical agents. 
 Antibodies. Antibodies (Abs) targeting the T3SS have shown promise in inhibition of 
infection and cell adhesion for many T3SS-harboring pathogens.358 As the prominent pathogen for 
infantile diarrhea, Abs targeting the E. coli T3SS may have protective benefits as a pharmaceutical 
agent. Proof of this exists in the practice of mothers breastfeeding their children.359 Colostrum 
samples from breastfeeding mothers were obtained and their IgA content was characterized using 
Western blot analysis. The results indicated that the samples contained IgA that was reactive 
against intimin, EspA and EspB proteins from E. coli. In a similar study, serum from children in 
Brazil was tested for the presence of IgG protective against EHEC infection.360 Thirteen of the 
children had been diagnosed with HUS, while 54 healthy children were analyzed as controls. In 
both healthy children and children diagnosed with HUS, protective IgG against intimin, EspA, and 
EspB were present in comparable amounts. This indicates that secondary immunity may be a major 
contributing factor to the immunization of children against EHEC infection since prior exposure 
to the bacteria was not necessary for Abs to be present. In another study, rats and chickens were 
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immunized with recombinant EspA, EscF, or the C-terminal region of intimin.361 The rat antisera 
contained IgG Abs that could prevent adherence of EHEC to HeLa cells. Egg powders from the 
EspA- and intimin-immunized chickens produced IgY Abs that were also protective. While most 
of the literature on protective Abs target extracellular proteins such as EspA362,363 and EspB,363 or 
membrane-associated proteins such as intimin364 or Tir,363,365 vaccination of mice with NleA 
produces a strong IgG response.363 Collectively, the research on Ab production against E. coli 
T3SS components implies promise in orally administered Ab as a therapeutic immunization 
against EHEC infection. 
 Probiotics. The logic for the protective abilities of probiotics lies in the observation that 
healthy commensal colonization in the gut reduces the ability of a pathogen to begin an 
infection.366,367 Murine models of EPEC and EHEC infection have explored the protective abilities 
of lactobacillus strains, focusing on the ability of lactobacillus to ameliorate the inflammatory 
response and leaky tight junctions associated with E. coli infection of the colon. Since the 
mechanism of protective action in these cases are not clear, it is impossible to claim lactobacillus 
species may inhibit the T3SS. Alternatively, studies on Saccharomyces boulardii, a yeast strain 
that rapidly and ephemerally colonizes the gut of mice, indicate direct inhibition of type III 
secretion.368 Mice were treated twice daily with S. boulardii beginning two days post-infection 
with C. rodentium. Mice treated with S. boulardii regained the weight lost in the first two days 
post-infection. In addition, transmission electron micrographs of the colonic epithelium of treated 
mice showed decreased colonization by C. rodentium and decreased morphological changes to the 
microvilli. C. rodentium and S. boulardii were co-colonized to analyze the effects of the yeast on 
T3SS effector secretion in vitro. Western blot analysis of the secretome and the cell lysates 




 EPEC and EHEC are major pathogens that infect thousands of children every year in 
developing nations. These pathogens rely on the T3SS, a bacterial injectosome, to adhere to the 
colonic epithelium and propagate infection. The T3SS is a syringe-like megastructure encoded by 
the LEE pathogenicity island that connects the bacterial cytosol to the cytoplasm of the targeted 
eukaryotic host cell. Once attached, the bacteria secrete effector proteins through the T3SS into 
the epithelial cells. These effectors then alter host cell machinery and signaling pathways to better 
suit the bacteria for infection and evade host immune responses. While laboratory research on 
inhibition of the T3SS in E. coli and the mouse model pathogen C. rodentium has resulted in the 
identification of multiple natural product and small molecule inhibitors, there are currently no 
drugs on the market that target the T3SS directly. 
 This dissertation will describe the development of a novel assay for the analysis of T3SS 
activity in C. rodentium. This solution-based assay allows for more rapid screening of compounds 
than what is currently possible without relying on mammalian host cells. Here we will describe 
the development and optimization of this assay and deliver screening results for compounds 






DEVELOPMENT OF ASSAYS FOR MONITORING T3SS ACTIVITY 
2.1 Introduction 
 The T3SS is an attractive target for antivirulence treatment of bacterial infections. Many 
known inhibitors of the T3SS are natural products derived from plants, fungi, or other bacteria, 
originally produced to protect from bacterial invasion. With this understanding, we sought to 
develop an assay to screen for natural product inhibitors of the T3SS as a starting point for SAR 
analysis that may lead to a therapeutic. We were also interested in studying the relationships 
between the T3SS and other mechanisms present within bacterial pathogens. 
 Since the discovery of the T3SS in the 1990s, multiple assays have been employed for the 
purpose of analyzing T3SS activity. One strategy involves direct detection of native secreted 
proteins. Heterologous proteins chosen for the purpose of detection have also been used. Most 
assays rely on the successful translocation of effectors or attachment of bacteria to eukaryotic host 
cells. 
 
2.1.1 Western blotting and ELISAs.  
 The direct detection of secreted effector proteins has been performed using Western 
blotting or ELISA assays utilizing commercially available antibodies targeting relevant effector 
proteins. These protocols have been employed to reliably indicate the changes in expression or 
secretion of effector molecules after the bacteria have been treated with an inhibitor, though these 
are usually performed to further characterize compounds identified using another method. For 
example, aurodox was discovered through EPEC-mediated hemolysis of RBCs. When 
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characterizing aurodox as an inhibitor of the expression of the LEE, the accumulation of certain 
effectors within the bacteria was visualized by Western blotting. 
 Immunochemical methods are often employed to indicate changes in the levels of effector 
secretion. Regacin, an inhibitor of the T3SS of C. rodentium, is effective at abrogating infection 
in in vivo mouse models. Regacin competitively targets a regulator of LEE expression. While it 
was shown that regacin is efficacious enough to inhibit the propagation of infection, Western 
blotting analysis indicated that expression of the LEE is never entirely inhibited after treatment 
with this compound. This result was important in that it established that T3SS activity does not 
need to be entirely abolished for a treatment to be physiologically effective.  
 
2.1.2 Hemolysis of RBCs.  
 EPEC and EHEC can lyse RBCs as a result of the introduction of pore forming proteins 
EspB and EspD into the erythrocyte cell membrane. When the pore is formed, the cells are lysed, 
releasing hemoglobin into solution. The concentration of hemoglobin in solution can then be 
quantified by absorbance, indicating performance levels of the T3SS. This technique has been used 
to identify multiple inhibitors of the EPEC T3SS, including aurodox and guadinomines B and D.  
 While this method has shown to be effective in the discovery of inhibitors, its reliance on 
translocation of effectors gives no indication to the mechanism of inhibition. This assay also 
requires fresh red blood cells, since the erythrocyte will lyse much more easily after a few weeks. 
In addition, further analysis of any identified compounds is necessary. It is possible that iron-
chelation would result in a false-positive result, but controls of solubilized hemoglobin are rarely 




2.1.3 Adhesion assays.  
 The T3SS is a major contributor to the ability of bacterial cells to adhere to eukaryotic host 
cells. Some analysis into the ability of compounds to inhibit cellular adhesion have been performed 
to compliment screens of potential T3SS inhibitors. These assays typically involve fluorescence 
microscopy to visualize the adherence of the bacteria to the cell surface. Since EPEC, EHEC, and 
C. rodentium are AE pathogens, pedestal formation and changes in eukaryotic morphology may 
also be noted. These assays are not sufficient for stand-alone screening for T3SS inhibitors because 
they do not exclude other methods of bacterial adhesion to host cells as targets, so further 
exploration to determine the mechanism of inhibition is necessary. 
 
2.1.4 Translocation of detection molecules.  
 CyaA. Bordetella pertussis, the causative agent of whooping cough, produces an adenylate 
cyclase toxin, CyaA.369 This toxin is dependent on calmodulin, a component of eukaryotic cells, 
which increases turnover of CyaA by approximately 1000-fold. CyaA has been fused to effector 
proteins for T3SS-dependent translocation into host cells, where it increases cAMP levels. The 
concentration of cAMP can then be quantified as a measure of T3SS activity. This reporter system 
has been used to identify that the pore-forming protein EspB also enters the host cell cytoplasm, 
rather than remaining membrane-bound.370 It has also been used to identify the N-terminal 
secretion signal of Tir.371 
 Β-lactamase. A β-lactamase reporter system was developed to identify and to characterize 
the secretion signals necessary for type III-dependent secretion of Cif, an effector protein 
necessary for actin-rearrangement in bacterial attachment to host cells.227 In this method, host cells 
were incubated with a substrate of β-lactamase, CCF2/AM. CCF2/AM is cell-permeable, non-
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fluorescent esterified pro-substrate. Upon cell entry, native esterases cleave CCF2/AM and release 
the β-lactamase substrate CCF2. CCF2 consists of a cephalosporin linker connecting fluorescein 
and hydroxycoumarin and is often used in Förster resonance energy transfer (FRET) applications. 
When hydroxycoumarin is excited at 409 nm, the resulting fluorescent emission excites 
fluorescein. Fluorescein then emits a fluorescent signal at 520 nm. This result depends on their 
close proximity. In the bacterial cell, β-lactamase is expressed with an N-terminal secretion tag 
which allows the enzyme to be translocated into the host cell through the T3SS. β-lactamase then 
acts upon the CCF2 substrate, cleaving and separating the hydroxycoumarin and the fluorescein, 
ending their FRET interactions. Therefore, successful translocation of β-lactamase into the host 
cell can be monitored by decreases in the fluorescent signal at 520 nm. 
 Green fluorescent protein (GFP). There are two versions of the GFP translocation assay. 
In one version, the T3SS-harboring bacterial cell is made to express an effector-GFP conjugate. 
This fused protein is then translocated via the T3SS into a eukaryotic host cell, and accumulation 
of the effector can be monitored by fluorescence microscopy. This method has been used to 
determine localization points for specific effectors in regions of the eukaryotic cell. 
 The second version of the GFP translocation method involves split-GFP. The bacteria are 
made to express a fused protein consisting of an effector and GFP1-10, a non-fluorescent subunit 
of GFP. This conjugate is then translocated via the T3SS into a eukaryotic host cell that expresses 
GFP11. Upon interactions between GFP1-10 and GFP11, the molecule becomes fluorescent. T3SS 
activity can therefore be quantified as a function of fluorescence. This method has typically been 
used to indicate localization patterns of effectors within host cells. Given that this method does not 
rely on host cell enzymes for signal production, our initial  efforts in assay development began 
with a split-GFP system. 
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 Nature has been producing inhibitors of T3SS activity to protect itself from infection by 
bacterial pathogens, giving precedence for the effectiveness of T3SS inhibitors for abrogation of 
infection. Further development of T3SS inhibitors as therapeutics is ongoing, but results have so 
far indicated that this is a promising strategy. This dissertation describes the development of an 
assay for the identification and in vitro characterization of inhibitors of the T3SS in C. rodentium 
through the following aims: 
 Aim 1. Develop a screening assay that quantifies T3SS activity as a function of secreted 
protein or enzyme. This assay will not require eukaryotic cells to lend simplicity to the method 
and allow for easier replication of results. 
 Aim 2. Screen for inhibitors of the T3SS and identify natural products that are capable of 
inhibiting the T3SS. These compounds will be rationally chosen based on their known bioactivity 




 Media was purchased from Difco™ (LB broth), Amresco (SOB broth) and Gibco™ 
(DMEM without glucose). The antibiotic chloramphenicol was purchased from Fisher. Aurodox, 
piericidin A and fusaric acid were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). 
Carvacrol, thymol and trans-cinnamaldehyde were purchased from Tokyo Chemical Industry Co, 
Ltd. (Portland, OR). (-)-Epigallocatechin-3-gallate, oligomycin A and nosiheptide were purchased 
from Cayman Chemical Company (Ann Arbor, MI). Gallocatechin gallate, berberine chloride and 
trans-4-nitrocinnamaldehyde were purchased from Alfa Aesar (Haverhill, MA). trans-4-
Methoxycinnamaldehyde, ellagic acid and patulin were purchased from Acros Organics B.V.B.A. 
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(Fair Lawn, NJ). trans-4-Dimethylaminocinnamaldehyde was purchased from Chem-Impex Int’l, 
Inc. (Wood Dale, IL). Tannic acid, N-(β-ketocaproyl)-L-homoserine lactone, N-(p-coumaroyl)-L-
homoserine lactone, phloretin, 3-oxo-N-(2-oxocyclohexyl)-dodecanamide, N-(3-oxooctanoyl)-L-
homoserine lactone, and penicillic acid were purchased from Sigma-Aldrich (St. Louis, MO). 2-
Heptyl-3-hydroxy-4(1H)-quinolone was purchased from Chemodex (St. Gallen, Switzerland). 
Bergamottin was purchased from Honeywell Fluka™ (Morris Plains, NJ). Naringenin was 
purchased from Combi-Blocks, Inc. (San Diego, CA). Rotenone was purchased from Enzo Life 
Sciences, Inc. (Farmingdale, NY). Sanguinarine chloride was purchased from J&K Scientific 
(Beijing, China). Curvularin and harzianopyridone was purchased from AdipoGen Life Sciences 
(San Diego, CA). 
 
2.2.2 Cell lines  
 The cpg2 gene was amplified using polymerase chain reaction (PCR) with primers ALJ82 
(5’-cgctgcttctacactagggcggcagcttgtaggtatcgcaGCTCTGGCTCAGAAACGTGA-3’) and ALJ84 
(5’-TTACTTACCTGCACCCAGATCCA-3’), that were purchased from Life Technologies. The 
pBAD vector, purchased from Thermo Fisher Scientific, was amplified using PCR with primers 
ALJ89 (5’-ATCTGGGTGCAGGTAAGTAAGTTGCTCAGGTTTCACTTGTTTTCA-3’) and 
ALJ88 (5’- gccctagtgtagaagcagcgTTACTAATTCCATTAAGCATGGTTAATTCCTC-
CTGTTAGCCCAAA-3’) purchased from Invitrogen (Carlsbad, CA). The lowercase sequences 
indicate the EspF secretion signal that was incorporated via PCR. Amplification was performed 
using HS-Taq DNA polymerase (New England BioLabs®, Inc.). Amplified fragments were gel 
purified and the recombinant plasmid was assembled using the isothermal Gibson method on a 
T100 Thermal Cycler (Bio-Rad, Hercules, CA). C. rodentium DBS100 (ATCC 51459) cells were 
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made competent by washing 2x with ice cold 10% glycerol. 70 μL-aliquots of competent C. 
rodentium cells were transformed with the pBAD-EspF-CPG2 plasmid by electroporation using a 
BIORAD Micropulser™ on the E1 setting. Cells were immediately resuspended in preheated SOB 
media and incubated at 37 °C for one hour. 5 μL, 100 μL, and concentrated pellet samples of cells 
were spread on LB agar plates containing 30 μg/mL chloramphenicol and incubated overnight at 
37 °C. Transformants were confirmed by DNA sequencing using pBAD forward and reverse 
primers. 
 
2.2.3 Enzyme expression and lysate production  
 1 mL of overnight culture of  C. rodentium-EspF-CPG2 was added to 1 L LB media 
containing 30 μg/mL chloramphenicol and 1% arabinose (purchased from Alfa Aesar at 99% 
purity, resuspended in DI water and sterile filtered with a Gelman Laboratory Acrodisc® syringe 
filter, 0.2 μm) and grown overnight at 37 °C with shaking. Cells were pelleted by centrifugation 
at 4000 rpm for 20 minutes at 4 °C. Pellets were resuspended with 25 mL CPG2 buffer. Cells were 
lysed by sonication with a Fisherbrand™ Model 120 Sonic Dismembrator with the 1/8-inch probe. 
Lysate was centrifuged again to remove cellular debris before aspirating off the liquid layer. 
 
2.2.4 Synthesis of Glu-CyFur 
 The Glu-CyFur substrate was synthesized as previously described.372 The synthesis follows 
Scheme 1. This seven-step synthesis produced ~3 grams of material that were used for the 





Scheme 1. Synthesis of Glu-CyFur. 
 
 The synthesis of Glu-CyFur followed the previously published synthetic scheme.372 The 
synthesis involved the production of 4-(Boc-amino)benzaldehyde (26) and 3-cyano-2-
dicyanomethylene-4,5,5-trimethyl-2,5-dihydrofuran (24).373,374 24 and 26 were then coupled via 
condensation in the presence of ammonium acetate to give (E)-tert-butyl-4-(2-(4-cyano-5-
(dicyanomethylene)-2,2-dimethyl-2,5-dihydrofuran-3-yl)vinyl)phenylcarbamate (27).375 
Following acid-dissociation of the Boc protecting group, the aniline was activated for alkylation 
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with triphosgene, then alkylated with Boc-protected glutamate to give 29.372 Deprotection of 29 
gave Glu-CyFur (30). Products were confirmed by NMR or tracked by TLC. 
 
3-Cyano-2-dicyanomethylene-4,5,5-trimethyl-2,5-dihydrofuran (24). 3-Hydroxy-3-methyl-2-
butanone (1.03 mL) and malononitrile (1.63 mL) were mixed with 32 mL EtOH. Magnesium 
ethoxide (1.26 g) was added to the solution before heating at reflux overnight. The solution turned 
from light red to dark brown overnight. The solution was cooled to room temperature and 
concentrated by rotary evaporation, affording a dark brown sludge. The residue was suspended in 
dichloromethane and filtered to remove a dark solid. The filtrate was then concentrated again by 
rotary evaporation, yielding a dark red residue. This residue was washed with deionized water. 
The remaining residue was dissolved in heated ethanol and recrystallized to form a fluffy light 
solid (0.358 g, 20.5%). 1H NMR (400 MHz, CDCl3): δ 1.63 (6H, s), 2.36 (3H, s). 
 
4-(Boc-amino)benzyl alcohol (25). p-Aminobenzyl alcohol (543 mg) was dissolved in anhydrous 
dioxanes. DIPEA (0.8 mL) and di-tert-butyl dicarbonate (1 mL) were added to the solution, which 
was heated at reflux overnight. The solution was then cooled to room temperature and evaporated 
under vacuum. The residue was dissolved in ethyl acetate and washed with HCl (0.1 N) solution 
to remove unreacted starting material. The organic layer was then dried with magnesium sulfate 
and evaporated under vacuum to give 1.2 g. The crude product was carried forward without 
purification. 1H NMR: δ 1.55 (9H, s), 1.71 (1H, s), 4.66 (2H, s), 7.29 (1H, s), 7.32 (2H, d, J = 8.6), 




4-(Boc-amino)benzaldehyde (26). The crude product (25, 1 g) was dissolved in dry 
dichloromethane in a 20-dram vial. Manganese dioxide was added in excess (~4 equivalents). The 
reaction vessel was immersed in a sonicator (Bransonic B200 Ultrasonic Cleaner) which ran 
continuously. The sonication added kinetic energy and heat to the reaction. Reaction progress was 
monitored by thin layer chromatography (TLC) stained with vanillin. Once the starting material 
was fully converted to the aldehyde product, the mixture was filtered through celite and 
concentrated in vacuo. The residue was dissolved in ethyl acetate and the components were 
separated by silica gel chromatography (EtOAC:hexanes, 1:1, Rf = 0.5) before being evaporated 
in vacuo (0.98 g, 98%).  
 
(E)-tert-Butyl-4-(2-(4-cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-dihydrofuran-3-
yl)vinyl)phenylcarbamate (27). 24 (297.1 mg) and 26 (555 mg) were dissolved in 10 mL of a 
20% ethanol solution in dioxane. Once dissolved, ammonium acetate (250.9 mg) was added to the 
solution, which was set to stir overnight at room temperature. After 12 hours, the solution was 
diluted with deionized water (1:1) and the product was extracted 3 times with 15 mL EtOAc. The 
EtOAc was then washed with brine and dried over sodium sulfate and filtered. The filtrate was 
concentrated in vacuo and the product was purified by silica gel chromatography (EtOAc:hexanes, 
1:2, Rf = 0.25). The reddish yellow product were pooled and concentrated in vacuo (599.2 mg, 
quantitative yield). 1H NMR (400 MHz, CDCl3): δ 1.52 (6H, s), 1.53 (9H, s), 7.45 (1H, d, J = 8.6 
Hz), 7.53 (2H, d, J = 8.6 Hz), 7.71 (1H, d, J = 8.6 Hz), 7.82 (2H, d, J = 8.6). 
 
(E)-2-(4-(4-Aminostyryl)-3-cyano-5,5-dimethylfuran-2(5H)-ylidene)malononitrile (28). 27 
(599.2 mg) was dissolved in 40 mL of 20% TFA in dichloromethane. The solution was stirred for 
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dihydrofuran-3-yl)vinyl)phenyl)ureido)pentanedioate (29). 28 (171 mg) and pyridine (0.24 
mL) were added to dichloromethane (2.2 mL) and stirred on ice until cold. Triphosgene (1.32 mL) 
was added dropwise and the solution was stirred on ice for 1 hour. The solution was then 
concentrated in vacuo and the residue was diluted with triethylamine (0.92 mL). 31 (676.25 mg) 
was added to the solution and dissolved. The reaction stirred at room temperature for 1 hour  before 
being diluted in deionized water. The product was extracted 3 times with dichloromethane (1 mL). 
The organic layer was then washed with 1% HCl followed by a brine wash. The solution was dried 
over sodium sulfate and filtered before the volume was reduced in vacuo. The product was then 
separated on a silica gel column (EtOAc:hexanes, 1:1, Rf = 0.4). Collected 50 fractions. NMR 
confirmed the product in fraction 36. Fractions 31 to 45 were pooled and concentrated by rotary 
evaporation, yielding a bright red solid (139.6 mg, 42%). 1H NMR (300 MHz, CDCl3): δ 0.88 (2H, 
m), 1.46 (9H, s), 1.50 (9H, s), 1.81 (6H, d, J = 8.2 Hz), 1.99 (1H, m), 2.12 (1H, m), 2.39 (2H, m), 
4.41 (1H, m), 7.01 (1H, d, J = 16.2 Hz), 7.46 (1H, d, J = 8 Hz), 7.55 (4H, q, J = 8.6, J = 11.9), 7.70 
(1H, d, J = 8.5). 
 
Glu-CyFur (30). 29 (139.6 mg) was dissolved in 20% TFA in dichloromethane (2 mL) and set to 
stir at room temperature for 1 hour. The product was concentrated by rotary evaporation to give 




2.2.5 Qualitative Glu-CyFur concentration analysis 
 Cell lysate containing CPG2 was diluted 1:1 with CPG2 stability buffer (CPG2 buffer: 50 
mM Tris pH 7.4, 0.1 mM ZnSO4, 0.04% Tween 20). Glu-CyFur was added to the listed 
concentrations and DMSO concentration was normalized. As a control, Glu-CyFur was added 
directly to the CPG2 stability buffer to the listed concentration. After incubating at room 
temperature for 30 minutes, the photo was taken to document the degree of color change. 
 
2.2.6 Temperature stability testing 
 Cell lysate containing CPG2 was aliquoted into PCR tubes (0.1 mL each). The tubes were 
incubated at the listed temperatures in a T100 Thermal Cycler (Bio-Rad Laboratories, Hercules, 
CA) for 25 minutes before the temperatures were unified at 37 ˚C. Glu-CyFur was added to 50 μM 
and the solutions incubated at room temperature for 20 minutes. The absorbance at 570 nm was 
then recorded. 
 
2.2.7 Compound screening 
 An overnight culture of C. rodentium-EspF-CPG2 (grown in LB containing 30 μg/mL 
chloramphenicol) was diluted 1:100 in LB containing 30 μg/mL chloramphenicol and the test 
compound. After three hours, the cells were pelleted by centrifugation and resuspended to an 
absorbance measurement at 600 nm (OD600) of 0.75 in Dulbecco’s modified Eagle’s medium 
(DMEM) with 1% arabinose to initiate T3SS expression and CPG2 production. The DMEM also 
contained the compound or a vehicle control. After 6 hours incubation at 37 °C, cells were pelleted 
and supernatant was diluted 1:1 in buffer designed to aid in CPG2 activity (CPG2 buffer: 50 mM 
Tris pH 7.4, 0.1 mM ZnSO4, 0.04% Tween 20) in a Greiner Bio-one polypropylene black, F-
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shape, 384-well plate. Controls with vehicle or lacking arabinose were used. The substrate Glu-
CyFur (Figure 2B) was added to each well to a final concentration of 10 µM, and fluorescence was 
measured with a BMG Labtech CLARIOstar© Plus plate reader, where λex = 563 nm and λem = 
610 nm. As glutamate is cleaved by CPG2, fluorescence increases. 
 
2.2.8 Cytotoxicity screening 
 An overnight culture of C. rodentium was grown in LB media at 37 °C with shaking. The 
culture was diluted 1:100 in LB before compounds were added at the concentrations listed and 
vehicle was used as a control. 0.5-mL culture replicates of 5 were left to incubate for 6 hours in 
CytoOne 96-well flat bottom plates with the lid at 37 °C, with shaking in the BioTek Synergy HTX 
plate reader and incubator. Cell density was measured as OD600 once every hour with the BioTek 
Synergy HTX plate reader and incubator, beginning at the time of dilution. 
 
2.2.9 CPG2 direct inhibition analysis 
 These studies were conducted to ensure the compounds were not interfering with the ability 
of CPG2 to cleave Glu-CyFur. 1 mL of overnight culture of C. rodentium-EspF-CPG2 was added 
to 1-L LB media containing chloramphenicol and 1% arabinose and grown overnight at 37 °C with 
shaking. Cells were pelleted by centrifugation at 4000 rpm for 20 minutes at 4 °C. Pellets were 
resuspended with 25 mL CPG2 buffer. Cells were lysed by sonication with a Fisherbrand™ Model 
120 Sonic Dismembrator with the 1/8-inch probe. 50 μL of cell lysate containing CPG2 was 
transferred to a Greiner Bio-one Polypropylene black, F-shape, 384-well plate. Compound was 
added to the concentration listed, and vehicle was used as a control. Glu-CyFur was added to 10 
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µM with a Labcyte Echo550 acoustic liquid handler, and fluorescence was observed on a BMG 
Labtech CLARIOstar© Plus plate reader (λex = 563 nm and λem = 610 nm). 
 
2.2.10 Data analysis 
 The % inhibition was calculated from the rate of change in fluorescence compared to an 
uninhibited control using the following equation: 
 




Where m = slope, C = compound, and V = vehicle 
 
2.3 Split-GFP assay 
2.3.1 Rationale and assay design 
 In understanding the standards of the field of T3SS research, we sought to develop a 
screening assay for utilization in our lab. We initially drove to develop a solution-based screen 
involving bacterial cells that would secrete a detector molecule into the extracellular space for 
analysis. Ideally, we would be able to perform this assay in a plate format which would allow for 
the testing of multiple compounds at once. To begin our design, we chose to modify one of the 
simpler assays known in the field, the split-GFP reporter system. Our first modification would be 
maintaining the gene for GFP1-10 on a plasmid with a secretion tag. We chose the secretion tag 
from EspF, as that was reported as one of the most efficient tags for heterologous secretion in E. 
coli. We also chose to keep the gene on a plasmid so that we could have independent control of 
GFP1-10 production, separate from T3SS activation. This independent control of production 
allows us to separate expression of the LEE from expression of our reporter enzyme. since many 
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inhibitors function by decreasing LEE expression, we did not want to depend on LEE expression 
for production of GFP1-10.   
 The next major modification made involved developing an assay that was not reliant on 
eukaryotic host cells. Most of the assays developed for monitoring T3SS activity involve host 
functions to work. For example, CyaA changes levels of eukaryotic proteins as a quantifiable 
measure. The β-lactamase assay depends on eukaryotic esterases to uncage CCF2 before 
functioning properly. Interferences in these systems would result in a false positive reading and 
would be difficult to discern or troubleshoot. We therefore decided to develop a simple assay with 
hits that were easy to confirm by removing the dependence on eukaryotic cells. 
 We were also interested in developing an assay that provided both quantitative and 
qualitative results. Many of the inhibitors of the T3SS have unknown mechanisms of action, and 
the discovery of their molecular targets is more difficult than it is for traditional antibiotics. 
Following treatment of a cytotoxic compound, random mutations that result in antibiotic resistance 
allow for selective growth of resistant strains. The only bacteria that will grow are those cells that 
are resistant to the antibiotic. Inhibition of the T3SS does not result in the death of the bacteria, so 
we wanted a qualitative signal that would signify an active—or inhibited—T3SS. This would 
allow for the screening of random mutants for strains resistant to a T3SS inhibitor. While we are 
still making progress toward that project, this motivated us to use the split-GFP reporter method. 
 
2.3.2 Results and Discussion 
 The plasmid design and production were successfully completed by the laboratory 
technician Adam Johnson, MS. The gfp1-10 gene was amplified using primers designed with 
hanging complementary overlaps with plasmid pBAD. The primers also incorporated an N-
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terminal His6 tag. After PCR amplification of the plasmid and the gene of interest, the final 
plasmid was assembled using the Gibson method. The plasmid was introduced to C. rodentium 
DBS100 by electroporation and successful transformants were confirmed by nucleotide 
sequencing. Expression of GFP1-10 was confirmed by SDS-PAGE analysis and Western blotting 
using an anti-His antibody (Figure 18). 
 
 
Figure 18. GFP1-10 was produced and secreted by C. rodentium. Bacterial cells were 
incubated for 6 hours in DMEM with or without IPTG to induce GFP1-10 expression from 
the pBAD plasmid. After incubation, cells were pelleted, and 1 mL of the supernatant was 
concentrated by TCA precipitation. 2 μL of supernatant was loaded into each lane. After 
transferring to a nitrocellulose membrane, the protein was visualized with anti-His6 
primary antibody. 
 
 To perform this assay, C. rodentium-EspF-His-GFP1-10 was incubated in DMEM in the 
presence of screening compounds. DMEM activates the T3SS of C. rodentium. During this 
incubation, EspF-His-GFP1-10 production was initiated with IPTG. The cells were incubated until 
they reach the end of the log growth phase, typically after 6 hours. At that point, the cells were 
pelleted by centrifugation and the supernatant was aspirated off. GFP11 was added to the 
supernatant, and the fluorescent signal obtained correlated to the concentration of GFP1-10, which 
is dependent on T3SS activity. 
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 The assay was never successful, though we could confirm by Western blot that the 
supernatant contained GFP1-10 (Figure 18). We hypothesized that not enough GFP1-10 was being 
secreted into the dilute supernatant to produce a signal above the lower limit of quantification. One 
of the limits of this design is that protein is secreted and diluted into the extracellular space. The 
GFP1-10 system works well in situations where GFP concentrates at a particular location within a 
cell, but our design appeared to produce insufficient signal. We therefore decided to move into a 
different design involving a secreted enzyme. The enzyme would be capable of substrate turnover 
so that every secreted molecule would produce an amplified signal. 
 
2.4 CPG2 reporter assay 
2.4.1 Rational and design 
 Results from the split-GFP design were not promising for a solution-based screen. Previous 
work with split-GFP has been conducted within compartmentalized systems, such as translocation 
to and localization within a eukaryotic cell observed through fluorescence microscopy. We 
concluded that diffusion of the GFP subunits within solution gave too weak of a signal for 
quantification in our system. Since the two subunits had to interact to form the fluorescent GFP, a 
large quantity of GFP 1-10 must be secreted into the supernatant for the signal produced to reach 
the lower limit of quantification. We therefore concluded that altering our design to secrete an 
enzyme would be beneficial. We could then rely on the catalytic turnover of the secreted enzyme 
to produce an amplified signal. By measuring the relative rate of change of fluorescence over time, 
we could perform a comparative analysis based on the concentration of enzyme in the extracellular 
space. Since the concentration of enzyme is dependent on type III secretion, higher concentrations 
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of enzyme in the supernatant would indicate an active T3SS, while lower concentrations of enzyme 
would indicate inhibition of the T3SS. 
 Yount et al. reported the secretion of a zinc-dependent protease, carboxypeptidase G2 
(CPG2), from S. enterica.372 CPG2 was fused to the C-terminus of Salmonella effector SopE2 and 
expressed with an HA tag for visualization. The SopE2-CPG2-HA construct was expressed on a 
pWSK29 plasmid under the control of the native SopE2 promoter. The enzyme was successfully 
secreted and refolded in the supernatant, as indicated by enzymatic activity. This system has been 
used to screen for inhibitors of the Salmonella T3SS in a 96-well plate. We chose to adapt this 
method for the screening of E. coli and C. rodentium T3SS inhibitors. 
 CPG2 is a metalloprotease that specifically cleaves glutamate residues. The assay 
described by Yount et al. utilizes a CPG2-specific substrate, glutamate-modified 2-
dicyanomethylene-3-cyano-2,5-dihydrofuran (Glu-CyFur), which is fluorescent when cleaved by 
CPG2. Glu-CyFur has been characterized as an efficient CPG2 substrate (kcat = 0.25 ± 0.03 s
-1, KM 
= 1.87 ± 0.53 μM). When the glutamate residue on Glu-CyFur was replaced with aspartate, CPG2 
would not cleave the substrate. The synthesis of Glu-CyFur has been described previously 
(Scheme 1).  
 We have altered the design of the CPG2 reporter system for compatibility with the LEE-
encoded T3SS. We expressed CPG2 with the EspF N-terminal secretion tag, as reported 
previously. The EspF-CPG2 construct was expressed on a pBAD plasmid under the control of an 
arabinose-induced promoter rather than the LEE-encoded promoters (Figure 19). This independent 
control of expression allows observation of many mechanisms of T3SS inhibition. By having a 
consistently-expressed reporter enzyme, it is possible to observe any potential T3SS-mediated 
secretion. In contrast, studies have indicated that some promoter regions are not essential for all 
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T3SS-mediated expression and downregulation may decrease T3SS activity without inhibiting it 
entirely. If an inhibitor targeted the promoter region controlling CPG2 expression in our system, 
it may only inhibit CPG2 transcription rather than T3SS activity. By controlling CPG2 expression 
with a well-characterized promoter that is not related to the LEE, we can more definitively 
characterize any observed inhibition. 
 
 
Figure 19. A plasmid was constructed to produce CPG2 for the purpose of enzymatic 
cleavage of the Glu-CyFur substrate. A) The gene for CPG2 was tagged on the N-terminus 
with the secretion signal from effector EspF. Expression of EspF-CPG2 is under the control 
of an arabinose promoter. B) CPG2 cleaves the non-fluorescent, yellow substrate Glu-
CyFur (22), releasing fluorescent, purple compound, CyFur (23). 
 
 
Figure 20. C. rodentium was made to produce CPG2 with the N-terminal secretion tag 
from EspF. Protein production was induced with arabinose (ara) and the cells were 
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incubated for 6 hours before cells were pelleted and 1 mL of the supernatant was 
concentrated using TCA precipitation. 5 μL was loaded into each lane. 
 
 The initial design of the CPG2 reporter assay was typical of an EPEC screening assay in 
that it involved an incubation period with compounds, an incubation period to allow for optimal 
T3SS-mediated accumulation of enzyme in the supernatant, and a quantification step. In this 
scheme, the C. rodentium cells are incubated in DMEM with arabinose to initiate T3SS activity 
and CPG2 production. Any compounds being screened for inhibitory activity are also present at 
this stage to inhibit initiation of type III secretion. After six hours of incubation, the previously-
determined time for maximal effector accumulation, the bacteria are pelleted by centrifugation, 
and the supernatant is removed. The supernatant is then diluted 1:1 in a buffer specifically designed 
to aid in CPG2 folding and enzymatic activity. Glu-CyFur is added to the supernatant to a final 
concentration of 10 mM immediately before fluorescence measurement. Fluorescence is measured 
for approximately 10 minutes and the initial slope is quantified as a measure of T3SS activity. 
 
2.4.2 Assay optimization 
 Analysis of enzyme stability. CPG2-mediated cleavage of Glu-CyFur is visible to the 
naked eye (Figure 20). Uncleaved substrate is yellowish orange in appearance, and cleavage results 
in a purple color. The ease of observation allowed for qualitative analysis of enzymatic activity 
under different environmental conditions. For these initial studies, EspF-CPG2 was overexpressed 
in C. rodentium. The cells were washed and lysed by saponification in CPG2 buffer. This lysate 
was then used to confirm enzymatic activity of the tagged enzyme, test for pH stability, and analyze 
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a range of concentrations of Glu-CyFur for optimization of visual results. The tagged enzyme was 
found to be active with no changes in performance at pH between 7 and 1.5. 
 
 
Figure 21. Initial qualitative studies on enzyme production by C. rodentium. A) 500 μM 
Glu-CyFur in buffer or whole-cell lysate containing CPG2. B) Acid stability screening; 
whole-cell lysate containing CPG2 adjusted to pH = 1.5 before adding 500 μM Glu-CyFur. 
There is no observable change to CPG2 activity with pH. C) Visible color change for 
differing concentrations of Glu-CyFur. 
 
 Multiple concentrations of Glu-CyFur were analyzed for their appearance after cleavage 
by CPG2. Analysis of inhibition may be analyzed visually as well as quantified with fluorescence. 
In the initial stages of compound analysis, controls were analyzed visually in addition to 
quantifying the fluorescent signal to confirm the success of the attempt. These initial qualitative 
analyses aided in observational conclusions drawn from screening. We also analyzed the effect of 
temperature on the stability of CPG2. Cell lysate containing CPG2 was incubated at temperatures 
ranging from 37 ˚C to 55 ˚C before analyzing the resulting activity. The Glu-CyFur substrate may 
be analyzed by absorbance (at 570 nm) as well as fluorescence. We measured the absorbance at 
570 nm for the solutions after incubation at the listed temperatures (Table 3) and determined that, 
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while the resulting values differ greatly depending on temperature, the difference between the 
lysate of induced cells and uninduced cells was consistent.  
 
Table 3. CPG2 activity is affected by temperature. Cells were incubated with or without 
1% arabinose to induce CPG2 production. The cells were then lysed by sonication, 
resulting in a solution containing the active enzyme. The lysate was aliquoted (100 μL) 
into PCR tubes and incubated at the listed temperatures for 25 minutes before the 
temperature was unified to 37 ˚C. Glu-CyFur was added to 50 μM and the absorbance at 
570 nm was observed. 
 
 
 Quantification of signal. Since a version of this assay was previously published, much of 
the method was already established. Optimization studies for the CPG2 buffer contents and 
concentrations, Glu-CyFur concentrations, compound concentrations, and incubation times were 
all reported previously. The analyses we performed included the media for incubation and 
arabinose concentrations.  
We observed changes in the performance of the assay when the incubations were 
performed in LB vs DMEM (Figure 22). We initially hoped to perform the CPG2 expression and 
compound incubation during the logarithmic growth phase, as was done for the Salmonella CPG2 
reporter assay. Unfortunately, the signal we were able to obtain was much lower than expected. 
We then attempted the assay in DMEM. The results indicated that we were secreting more CPG2 
after DMEM incubation than after LB incubation. The C. rodentium T3SS is not activated in LB, 
37 38.2 40.3 43.9 48.1 51.2 53.5 55
+ 0.535 0.633 0.581 0.765 0.948 0.869 0.84 1.302





while switching to DMEM is well understood to be a T3SS activating strategy. In addition, glucose 
acts as an inhibitor of arabinose-induced expression. 
 
 
Figure 22. The media the cells are incubated in during CPG2 induction affects the amount 
of CPG2 secreted. DMEM incubation results in much higher CPG2 activity in the 
supernatant. 
 
 We analyzed the effects of the addition of glucose to the DMEM. Glucose (4.5 g/L) 
appeared to inhibit CPG2 expression entirely, while incubating the cells in DMEM that did not 
contain glucose with 1% arabinose increased the resultant signal (Figure 23). We chose to analyze 
4.5 g/L of glucose because that is glucose content of the LB media used. The expression of CPG2 
may not have been entirely inhibited in the initial LB study due to the growth of the bacteria in LB 
and the consumption of the glucose by the bacteria. Since the C. rodentium do not grow during the 








Figure 23. Glucose inhibits arabinose induction of CPG2. Adding 4.5 g/L glucose to the 
DMEM results in inhibited CPG2 secretion similar to the uninduced cells. 
 
 We analyzed the arabinose content and the effect it had on signal generation. The 
concentrations of arabinose tested were 1%, 5%, and 10% (wt/vol %) in DMEM with 
chloramphenicol. After a 6-hour incubation of C. rodentium harboring the EspF-CPG2 construct, 
the activity of secreted CPG2 was analyzed. The results indicated that the 5% arabinose 
concentration performed as well as the 10% samples. The uninhibited slope was slightly higher 
for the 5% arabinose samples. Our goal was to produce CPG2 at a slow rate to reduce the 
accumulation of folded enzyme in the cytosol before secretion, so we analyzed different conditions 





Figure 24. During the incubation period, arabinose is present to induce CPG2 production. 
At 1% arabinose, the signal produced is much lower than when arabinose is present at 5% 
or 10%. 
 
 The next condition we chose to optimize was the ratio of supernatant to CPG2 buffer. In 
the original publication of this method, the supernatant is diluted into a buffer specifically designed 
to aid in CPG2 performance. Since the enzyme must be linearized to pass through the T3SS and 
then refolded in the extracellular space, the presence of a buffer to aid in the refolding and 
enzymatic activity of the metalloprotease is justified. The reported buffer:supernatant ratio was 
90:10. We were interested in how changing the concentration of supernatant would affect signal, 
and if signal would be negatively impacted by increased concentrations of poorly-folded CPG2. 
We analyzed the change in signal produced when the buffer:supernatant ratio is adjusted to 50:50 
(Figure 24). With a larger proportion of the solution being supernatant, we found that we could get 
similar performance between 1% arabinose incubation and 5% arabinose incubation. With this 
improvement in signal, we moved forward with studies utilizing 1% arabinose during incubation 





Figure 25. The buffer:supernatant ratio used in analysis has a large effect on performance. 
When the ratio of buffer:supernatant is 90:10, the signal obtained in the presence of 1% 
arabinose is significantly lower than when 5% is present. That activity is regained if the 
buffer:supernatant ratio is changed to 50:50.  
 
 Once the reagents and conditions for the assay were optimized, we decided to test the 
sensitivity of our assay. Regacin is a known inhibitor of the C. rodentium T3SS.16 Regacin was 
originally discovered as a competitive inhibitor of transcriptional regulator RegA. Regacin 
interferes with the ability of RegA to bind to DNA by interacting with a  conserved DNA-binding 
motif on RegA. SDS-PAGE analysis of the secreted protein profiles of a RegA knockout compared 
to wt ± regacin indicated that altering RegA activity downregulated T3SS expression without 
showing cytotoxicity or inhibiting bacterial cell growth. Compared to the wt control, effectors 
EspA, EspB, EspD and Tir show decreased concentrations in the supernatant in the presence of 
regacin. Importantly, however, they are still visibly secreted and make up a majority of the 
secretome. This decrease in T3SS-mediated secretion still proved capable of abrogating 
colonization of mouse colons though the T3SS was not entirely inactive. 
 We were interested in using regacin as an example of a partial inhibitor of the T3SS to 
analyze the sensitivity of our assay. By growing C. rodentium-EspF-CPG2 in the presence of 400 
μM regacin (10-fold higher than the IC50 against RegA) and then incubating the bacteria in DMEM 
+ 1% arabinose and 400 μM regacin, we observed partial inhibition of CPG2 secretion (Figure 
26). At this concentration, RegA is fully inhibited, so transcription of T3SS-related genes is 
downregulated. We observed this downregulation clearly in our assay while still seeing the 





Figure 26. The CPG2 reporter assay can differentiate between partial and total inhibition. 
At 10X the IC50 concentration, regacin shows partial inhibition of the T3SS. Since regacin 
is only a partial inhibitor of type III secretion, these results indicate that our assay is 
sensitive enough to delineate partial and total inhibition. 
 
 After completing optimization studies and initial screening of inactive or partially inhibited 
T3SS, we began screening compounds. The compounds screened were chosen to analyze the 
relationship between T3SS activity and other cellular mechanisms, including epigenetic 
modification and quorum sensing. We also analyzed the known inhibitor EGCG and its analog 
gallocatechin gallate (GCG), which has not been analyzed previously. Some compounds, such as 
the SAs, inhibit the T3SSs of multiple organisms. For this reason, we screened known inhibitors 
of other T3SSs for their ability to inhibit in C. rodentium. 
 
2.5 Results and discussion 
2.5.1 Known E. coli T3SS inhibitors 
 Some compounds are known for their ability to inhibit the T3SS of E. coli, including 
aurodox, carvacrol, thymol, and EGCG. Aurodox was originally discovered as an antibiotic of 
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Gram-positive bacteria.330 Recently, it has been characterized as a T3SS inhibitor in C. rodentium 
capable of attenuating infection in mice.17 Studies on gene expression indicate that aurodox 
downregulates T3SS-related genes by an unknown mechanism.25 Those same studies indicate that 
aurodox decreases the expression of ler, a major activator of the T3SS by 25% compared to 
untreated cells. In total, 25 of the 41 LEE-encoded genes were downregulated by treatment with 
aurodox.  
 The consequence of this downregulation on the secretion of effectors is not known. The 
authors analyzed the secretion of effectors Tir and EspB/D, which are all downregulated in the 
presence of aurodox.25 They also analyzed the translocation of labeled effectors into mammalian 
cells, which requires the pore-forming activity of EspB/D. Because our assay does not depend on 
translocation into a host cell and does not measure the secretion of any particular effector, we are 
able to distinguish between the complete abolishment of secretion and downregulation of some 
effectors. 
 Our screen with aurodox indicate that, while the compound does decrease the amount of 
CPG2 secreted into the supernatant, some secretion still occurs at concentrations higher than the 
IC50 (Figure 27). We found that at 50 μM, secretion is inhibited to ~50%. The concentration-
dependent data corroborates the published results in that ler downregulation decreases T3SS 
activity to some extent.25 Importantly, the published data also showed that the structural proteins 
involved in the formation of the base of the T3SS are not downregulated. Our results indicate that 





Figure 27. Aurodox (3) partially inhibits type III secretion. A) Increasing concentrations 
of 3 results in decreases in secretion of CPG2. B) High concentrations of 3 (50 μM, 10x 
the IC50 as determined by hemolysis assays) results in ~50% inhibition of secretion. 3 
downregulates the expression of the major activator ler, without inhibiting secretion 
entirely. 
 
 Thymol and carvacrol are the principal compounds in thyme essential oil.376 Thyme has a 
long history of being used for medicinal and culinary purposes in the Mediterranean and 
surrounding regions.377 Their effects on EHEC virulence properties have also been explored.378 In 
that study, the ability of thymol and carvacrol to alter the expression of virulence-related genes 
was observed. Thymol and carvacrol both downregulated genes related to chemotaxis, motility, 
and the T3SS through an unknown mechanism. The expression levels of sepD and escC were 
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described to have changed between “-1 and -5-fold” indicating mild downregulation of these 
genes. In our studies with thymol and carvacrol, we could not find evidence of observable 




Figure 28. Carvacrol (32) and thymol (33) do not inhibit secretion of CPG2. A) Structures 
of 32 and 33. B) 32 did not appear to inhibit the secretion of CPG2 compared to the DMSO 
vehicle control at 50 μM. C) 33 did not inhibit the secretion of CPG2 at 50 μM. 
   
 EGCG is a major polyphenolic compound in green tea.337 It has been explored for potential 
therapeutic uses against a collection of diseases due to its anti-inflammatory activity and its 
reported histone deacetylase inhibitory properties.23,338–341,343 One study implicated EGCG as an 
inhibitor of the T3SS in multiple organisms, including E. coli, S. Typhimurium, and Y. 
pseudotuberculosis.18 In this study, inhibition by EGCG was characterized according to model 
assays for these organisms. EGCG was found to inhibit secretion of EspB in a concentration-
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dependent manner by ELISA. The hemolytic activity of E. coli was inhibited 80% by 50 μg/mL 
(109 μM) EGCG. Adherence to Hep-2 cells was inhibited by 65% at the same concentration.  
 We were interested in characterizing EGCG-dependent inhibition of the T3SS at lower 
concentrations (Figure 29). We also tested the EGCG epimer, gallocatechin gallate (GCG), for its 
ability to inhibit the T3SS in our assay. The compounds were initially screened at 100 μM and 25 
μM. EGCG and GCG inhibited secretion to approximately the same extent. Further analysis of 
EGCG displayed concentration-dependent inhibition of type III secretion with an IC50 of 
approximately 2.5 μM. No cytotoxicity was observed upon EGCG treatment up to 50 μM. EGCG 
was tested for inhibition of CPG2 directly, as inhibiting the enzyme would give similar results as 





    
 
Figure 29. Inhibition of the T3SS by (-)-epigallocatechin-3-gallate (EGCG, 9) and 
gallocatechin gallate (GCG, 35). A) Structures of 9 and 35. B) 9 and 35 were screened at 
the listed concentrations in the CPG2-reporter assay. DMSO was used as the vehicle 
control. 9 and 35 display ≥ 80% inhibition at 25 μM. C) 9 was screened at 2 μM, 10 μM, 
and 25 μM and displayed concentration-dependent inhibition of T3SS-mediated CPG2 
activity. D) 9 was screened for cytotoxicity against C. rodentium. 9 is not cytotoxic. E) 9 
does not inhibit CPG2 directly. 9 was added to cell lysate containing CPG2 to a final 
concentration of 50 μM, and CPG2 activity was comparable to the DMSO control. 
 
 Since the activity of the T3SS is usually measured by assays that rely on successful 
translocation of effectors into a host cell, every part of the T3SS must be functioning properly in 
order for activity to be observed. While this may be physiologically relevant, the ability to 
determine the mechanism of inhibition is entirely lost. We were able to show that partial 
downregulation of the expression of the LEE does not abolish secretion. Aurodox, thymol, and 
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carvacrol all have shown that they negatively regulate the expression of T3SS-related genes, but 
our assay indicates that they are not capable of inhibiting secretion entirely. 
 
2.5.2 Quorum sensing regulators 
 Some of the first work done to characterize the T3SS involved analyzing regulatory 
mechanisms of expression of the LEE.60,289,379 Expression of the T3SS-related genes has since 
been linked to major global regulators of E. coli as well as other adaptive virulence mechanisms, 
such as quorum sensing.379 Quorum sensing is a mechanism of regulation of gene expression in 
response to environmental chemical signals. These signaling molecules are indicative of cell 
density and increases in their concentrations result in alterations in expression patterns in genes 
related to antibiotic resistance, horizontal gene transfer, biofilm formation, and secretion systems. 
Quorum sensing is imperative for successful propagation of infection and evasion of antibiotic 
treatment. The links between quorum sensing and the T3SS, while understood, have not been 
explored in terms of identification of potential therapeutic targets. We chose several modulators 
of quorum sensing to analyze their effects on T3SS activity. These include analogs of trans-
cinnamaldehyde (36-39), ellagic acid (40), tannic acid (41), secreted quorum sensing signaling 
molecules L-homoserine lactone analogs (42-46), bergamottin (47), naringenin (48), penicillic 
acid (49), and patulin (50). 
 Tannic acid (41) is a well-known inhibitor of quorum sensing and it has been used as a 
positive control in screens for quorum sensing inhibitiors.380 Tannic acid and trans-
cinnamaldehyde (36) were identified as inhibitors of the AHL synthase production in 2014.23 In 
one study, we analyzed para-substituted analogs of trans-cinnamaldehyde. We were initially 
interested in examining the inhibitory activity of 36 in our CPG2 reporter assay. Our initial results 
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indicated that 36 does not inhibit CPG2 secretion. We screened analogs of 36 and found that para 
substitution with a dimethylamino group (39) results in 76.5% inhibition of type III secretion. 
Since these analogs have not been analyzed, it is unclear if there is a parallel pattern of inhibition 
in quorum sensing.  
 
 
Figure 30. Of the trans-cinnamaldehyde analogs studied, only 4-
(dimethylamino)cinnamaldehyde (39) shows inhibition in the CPG2 reporter assay. 
Compounds were screened at 50 μM. 
 
 We next analyzed ellagic acid (40) and tannic acid (41), which have the same mechanism 
of quorum sensing inhibition as 36, to see if we would observe comparable results. One previously 
published study compared the AHL-inhibitory abilities of tannic acid, EGCG, and ellagic acid, all 
polyphenolic compounds containing a gallic acid moiety.24 All three compounds indicated an 
ability to inhibit AHL signaling. We were interested in comparing their T3SS inhibitory activity. 
We initially screened 40 and 41 at 50 μM in our CPG2 reporter assay (Figure 31). We found that 
41 is a more potent inhibitor than 40 and decided to characterize this inhibition further. 41 shows 
concentration-dependent inhibition of T3SS-mediated CPG2 translocation with an IC50 of <1 μM. 
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Our results indicate that these polyphenolic compounds may inhibit the T3SS in a mechanism 
separate from their quorum sensing targets, since trans-cinnamaldehyde does not appear to inhibit 
the T3SS.  
 
Figure 31. A) Ellagic acid (40) and tannic acid (41) are polyphenols containing gallate. B) 
40 has an IC50 of approximately 50 μM. 41 inhibits T3SS activity almost entirely at that 
concentration. C) 41 inhibits the secretion of CPG2 in a concentration-dependent manner. 
 
 The best-characterized quorum sensing pathway involves the N-acylhomoserine lactones 
(AHL) autoinducers.381 AHLs are synthesized by AHL synthases, and consist of a homoserine 
lactone ring that is N-acylated. These molecules induce the expression of the biosynthetic 
mechanisms that result in their production, making them autoinducers. We analyzed a collection 
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of N-acylhomoserine lactones for their ability to overcome tannic acid inhibition of the T3SS 
(Figure 32). An initial screen was run to identify the effects of the AHLs independently (20 μM, 
Figure 32B). The compounds were then rescreened in the presence of tannic acid (Figure 32C). 
The C. rodentium cells harboring the pBAD-EspF-CPG2 plasmid were incubated in the presence 
of 1 μM tannic acid in addition to the listed AHL at 20 μM. DMSO was normalized and used as 
the vehicle control. 
 
 





  C 
 
Figure 32. N-acylhomoserine lactones (AHLs) and their ability to overcome tannic acid 
inhibition. A) Structures of the AHLs analyzed. B) AHLs were studied in the CPG2 
reporter assay for their effect on the T3SS. 42 and 43 appear to inhibit T3SS activity, so 
they were not carried forward to test their ability to overcome 41 inhibition. C) AHLs were 
analyzed in the CPG2 reporter assay in the presence of 1 μM 41. While 44 and 46 appear 
to overcome tannic acid inhibition to the extent of regaining control activity, 45 appears to 
enhance T3SS activity.  
 
 From the initial screen, it appeared that 42 and 43 inhibited T3SS activity.   We then 
rescreened 44-46 for their effect on tannic acid’s inhibitory activity. We observed that 44 and 46 
were able to overcome the inhibition to the same level as the DMSO control, while 45 appeared to 
increase T3SS activity significantly. These results indicate that tannic acid’s inhibition of the T3SS 
may be related to AHL signaling mechanisms in C. rodentium. The ability to overcome tannic acid 
inhibition indicates a competitive relationship between AHLs and the T3SS target of tannic acid 
that should be further analyzed. 
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 Bergamottin (47) and naringenin (48) are cytochrome p450 inhibitors derived from 
grapefruit juice (Figure 33). 47 has been indicated as an inhibitor of biofilm formation in EHEC 
O157:H7.382 48 is a flavonoid compound shown to inhibit the production of AHLs and decrease 
the expression of some quorum sensing-related genes in P. aeruginosa. Our screening of these 
compounds indicated that neither bergamottin nor naringenin act as inhibitors of the C. rodentium 
T3SS (Figure 33). 
 
 
Figure 33. Bergamottin and naringenin do not inhibit the T3SS at 50 μM. A) Structures of 
bergamottin (47) and naringenin (48). B) When 47 was analyzed in the CPG2 reporter 
assay at 50 μM, no inhibition was observed. C) 50 μM 48 did not inhibit T3SS-mediated 




 Penicillic acid (49) and patulin (50) are secondary metabolites produced by Penicillium 
spp. of fungi. Both compounds were found to downregulate the expression of QS-related genes in 
P. aeruginosa.383 Our results indicate that 49 and 50 are not inhibitors of the T3SS at 50 μM. 
 
 
Figure 34. Penicillic acid and patulin do not inhibit the T3SS at 50 μM. A) Structures of 
penicillic acid (49) and patulin (50). B) Compared to the DMSO vehicle control, 50 μM of 
49 or 50 does not inhibit T3SS-mediated secretion of CPG2. 
  
 Our screen of quorum sensing modulators revealed a correlation between polyphenolic 
compounds with gallic acid moieties as a structural class of T3SS inhibitors. Tannic acid (41) has 
a known mechanism of quorum sensing inhibition that it shares with trans-cinnamaldehyde (36). 
41 most likely has a separate mechanism of action as a T3SS inhibitor, since 36 does not share the 
same efficacy. It is possible that 41, EGCG (9), and ellagic acid (40) act through related 
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mechanisms given their structural similarities, but much more investigation is required to 
corroborate those claims. 
 
2.5.4 Inhibitors of the T3SS in other organisms 
 Inhibition of the T3SS can be performed through a multitude of pathways. Some inhibitors 
that have been characterized appear to foster the ability to inhibit the T3SS across different 
organisms. The mechanisms by which this is possible are not well understood, but a few known 
cases involve gene expression. These include the previously mentioned inhibitors SAs and EGCG. 
We used this knowledge, and the success of EGCG in our assay, as inspiration to analyze a 
collection of inhibitors of the T3SS of other organisms. These include piericidin A (51), rotenone 
(52), fusaric acid (53), sanguinarine chloride (54), and phloretin (55). 
 51 was originally discovered as an insecticide by bioactivity-guided fractionation of 
Streptomyces sp. 16-22 extract.384 In this study, it was noted that 51 did not appear toxic to Gram-
negative bacteria such as E. coli and Xanthomonas oryzae,384 though 51 was later characterized as 
an antibiotic against Gram-positive bacteria.385 51 targets NADH dehydrogenase within complex 
I (100% inhibition at 0.03 nmol compound per mg protein), a complex important in mitochondrial 
electron transport. A high throughput screen to discover new inhibitors of the Y. 
pseudotuberculosis T3SS revealed 51 as an inhibitor.5 SDS-PAGE analysis indicated that secretion 
of effector YopE was decreased by 65% at 71 μM compound. 51 was also shown to potently inhibit 
translocation of effector YopM (75% decrease at 71 μM) into Chinese hamster ovary (CHO) cells. 
The mechanism of inhibition by 51 is not entirely understood, though 51 decreases the assembly 
of needle structures while having no effect on expression of T3SS-related genes.386 Analysis of 
another Complex I inhibitor, 52, indicated that a separate T3SS target may be present.21 We 
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analyzed both 51 and 52 in the CPG2 reporter assay (Figure 35). Neither appear to act as inhibitors 
of the T3SS in C. rodentium. 
 
 
Figure 35. Piericidin A and rotenone do not inhibit the C. rodentium T3SS. A) Structures 
of piericidin A (51) and rotenone (52). B) Neither compound appears to inhibit the T3SS-
mediated secretion of CPG2. 
 
 53 is an inhibitor of the T3SS in S. enterica.387 The inhibitory effect of 53 cannot be 
overcome by overexpression of T3SS activator HilA. 53 also appears to have no effect on the 
transcription of T3SS-related genes or transcriptional pathways, so its mechanism of action is 






Figure 36. Fusaric acid does not inhibit the T3SS of C. rodentium. A) Structure of fusaric 
acid (53). B) At 50 μM, 53 does not inhibit T3SS-mediated secretion of CPG2. 
 
 54 is a T3SS inhibitor against S. Typhimurium.388 Overexpression of T3SS activator HilA 
overcomes the inhibitory effects of 54, indicating a possible mechanism of action. When we 




Figure 37. Sanguinarine chloride does not inhibit the T3SS of C. rodentium. A) Structure 
of sanguinarine chloride (54). B) At 50 μM, (54) does not inhibit the T3SS-mediated 




 55 is an apple-derived flavonoid. It has been implicated as an inhibitor of the expression 
of T3SS-related genes in the plant pathogen P. syringae.389 Research also implicates a mechanism 
of resistance to 55, and data suggest that phloretin induces the expression of a multidrug resistance 
efflux pump that rapidly transports it out of P. syringae. In addition, 55 has been characterized as 
an inhibitor of biofilm formation in EHEC.22 The mechanism in EHEC also appears to be a 
consequence of altered gene expression. This evidence notwithstanding, the ability of 55 to alter 
the expression of T3SS-related genes in E. coli or C. rodentium has not yet been explored. We 
sought to identify if the T3SS was inhibited by 55 in the CPG2 reporter assay. Our results indicate 
that the expression of the T3SS is not downregulated enough to see a decrease in secretion of 
CPG2 (Figure 38). 
 
 
Figure 38. Phloretin does not inhibit the T3SS. A) Structure of phloretin (55). B) At 50 
μM, 55 does not inhibit the T3SS-mediated secretion of CPG2. 
 
 Our assay was unable to recognize any inhibitory effects from compounds known to inhibit 
other T3SSs. This result is unsurprising, given the accumulation of genetic and structural 
differences between the injectosomes of unrelated organisms. Many of the inhibitors from this 
category that we tested have unknown mechanisms of T3SS inhibition, so the relatability from 




2.5.5 Natural product antibiotics 
 There are several examples of sublethal concentrations of antibiotics resulting in inhibition 
of the T3SS, including aurodox,17 piericidin,21 thymol,378 and carvacrol.378 These compounds were 
originally recognized for their antibiotic effects and were later characterized as inhibitors of the 
T3SS. Guided by this precedent, we screened natural product antibiotics for their potential to 
inhibit T3SS-mediated secretion of CPG2. These compounds include oligomycin A (56), 
nosiheptide (57), harzianopyridone (58), berberine chloride (59), and curvularin (60). 
 56 is an antifungal agent with activity against Aspergillus spp. and Penicillium spp.390 It 
was isolated from several species of Streptomyces, a bacterial component of soil.19,391,392 56 is an 
inhibitor of ATP synthase, attributing to its toxicity for multiple cell types.393 56 is one of nine 
compounds in the oligomycin family, all of which are substituted macrolide rings consisting of 
ketones.394 Unfortunately, 56 is almost insoluble in water and presents toxicity in mice, so its 
potential for use as a therapeutic is limited.395 Our study of 56 initially showed some evidence of 
inhibition of T3SS activity (Figure 39). At 50 μM, 56 appeared to inhibit T3SS-dependent 
secretion of CPG2. We also analyzed 56 for its cytotoxicity against C. rodentium at that 
concentration and found that 56 enhances cell growth. This is a characteristic of T3SS inhibitors 





Figure 39. Oligomycin A inhibits the T3SS of C. rodentium. A) Structure of oligomycin 
A (56). B) At 50 μM, 56 inhibits the T3SS. C) At 50 μM, the T3SS-mediated secretion of 
CPG2 is inhibited by 43 ± 5%. D) 56 is not cytotoxic to C. rodentium at 50 μM. 
 
 57 is a thiopeptide antibiotic with cytotoxicity toward Gram-positive bacteria including S. 
aureus and Clostridium difficile.396 Much of the study surrounding 57 for the last few decades has 
been focused on synthesizing it or optimizing a biosynthetic procedure for its production.397–401 57 
is an inhibitor of Ef-Tu, which is the same antibiotic target as 3.20 Interestingly, at 50 μM, 57 
appeared to inhibit T3SS-dependent secretion of CPG2 to a greater extent than 3 did. Studies on 
the cytotoxicity of 57 toward C. rodentium indicated that at 50 μM, the bacteria were viable. When 
the T3SS is active, bacterial growth rate naturally slows due to the consumption of resources 
resulting from production of the macromolecular needle structure. Inhibitors of the T3SS may 
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restore the growth rate in bacteria by redistributing resources.70 57 therefore represents the second 




Figure 40. 57 is an inhibitor of Ef-Tu and the T3SS. A) The structure of nosiheptide (57). 
B) At 50 μM, 57 inhibits T3SS-mediated secretion of CPG2 by 96 ± 1%. C) 57 increases 
the growth rate of C. rodentium. 
 
 58 is a secondary metabolite of the fungus Trichoderma.402 This compound has antifungal 
and antiviral activity.403,404 58 belongs to a structural group of compounds called atpenins, which 
inhibit mitochondrial complex II, or succinate-ubiquinone oxidoreductase.405 59 is an isolate from 
the plant Berberis vulgaris. It has proven effective for multiple conditions, including for the 
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treatment of Leishmaniasis,406 glioblastoma,407 cardiac dysfunction,408 and insulin resistance,409 
along with possessing anti-inflammatory activity. Further in vivo analysis also indicates that 59 is 
cytotoxic to some of the most prevalent strains of MRSA410 and oral Streptococci spp.411 60 is a 
lactone derived from Penicillium gilmanii fungus.412 60 is an inhibitor of TGF-β signaling related 
to angiogenesis.413 60 is also an antifungal agent, and the analog αβ-dehydrocurvularin possesses 
antibiotic activity towards S. aureus.414 58-60 were all screened in the CPG2 reporter assay. While 
none of them signified inhibition of the T3SS at 50 μM, 59 appears to activate the T3SS to some 
extent (Figure 41). 
 
 
Figure 41. 58-60 are cytotoxic to various organisms. A) Structures of harzianopyridone 
(58), berberine chloride (59), curvularin (60). B) 58 (50 μM) does not inhibit the T3SS. 59 
(50 μM) appears to enhance T3SS activity. C) 60 (50 μM) does not inhibit relative to a 




 The initial success of the antibiotic compounds oligomycin A and nosiheptide requires 
further investigation for analysis. The toxicity of oligomycin A in mice limits its ability to be 
studied in in vitro models of C. rodentium infection, though biochemical analysis of its role as an 
ATP synthase inhibitor may be helpful in determining its mechanism of T3SS antagonism. 
Nosiheptide shares an antibacterial target with aurodox in Ef-Tu. The correlation between Ef-Tu 
inhibition and T3SS moderation has not been identified, though this is the third known case of Ef-
Tu interactions coinciding with T3SS inhibition.17,20,351 Projects elucidating this relationship are 
currently under discussion for the future of our group. 
 
2.6 Conclusions and limitations 
 We have successfully developed a solution-based assay for the screening of T3SS 
inhibitors. Our C. rodentium construct secretes CPG2 into the supernatant to concentrations 
sufficient to produce a quantifiable signal. We have successfully screened a collection of 
compounds in the original large-volume format at 1 mL. Aurodox and regacin, partial inhibitors 
of LEE expression, presented as partial inhibitors, indicating that this assay is sensitive enough to 
decipher between varying degrees of activity. This assay was used to characterize the efficacy of 
inhibitor EGCG and its IC50 value was determined for the first time. In addition, the epimer GCG 
was determined as an inhibitor of T3SS activity as well. We identified structurally similar 
polyphenolic-gallate compounds tannic acid and ellagic acid as T3SS inhibitors for the first time 
as well. 
 Aurodox and nosiheptide are both recognized as antibiotics targeting EF-Tu, a moderator 
of protein production. Our CPG2-reporter assay recognizes both compounds as inhibitors of the 
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T3SS. The mechanism of inhibition of aurodox is related to downregulation of expression of the 
LEE. We have not identified the mechanism of action of nosiheptide. A small molecule SA analog 
was also identified as a potential binder of EF-Tu in pull-down analysis,351 and they recognized a 
downregulation of LEE expression with treatment of the compound. The authors did not 
acknowledge the potential connection between EF-Tu inhibition and downregulation of the LEE. 
 The future research for the May group involves elucidating the relationship between EF-
Tu interaction and T3SS activity. The EF-Tu mutations necessary for an aurodox-resistance 
phenotype are known. The May group intends to construct aurodox-resistant C. rodentium mutant 
strains through site-directed mutagenesis. These mutants will then be analyzed for changes in their 
T3SS activity in the presence of aurodox. If the mutants are resistant to the T3SS inhibitory 
functions of aurodox, the connection between EF-Tu inhibition and T3SS activity will be 
elucidated. If the mutants are not resistant, it will be confirmed that EF-Tu is not the molecular 
target for T3SS inhibition.  
 Another future project for the May group involves optimizing the plated format of the assay 
to allow for more rapid screening. While I have performed a screen of the epigenetics library in a 
96-well plate, the gain in fluorescence was very low for controls. The signal never exceeded 150 
RFU for any of the control wells, while a test-tube screen allows for gains by the thousands. 
Changes in incubation times and conditions may be necessary to produce better results. 
 Julia Hotinger, a PhD candidate in the May group, is developing an in vivo monitoring 
assay to study the potential protective effects of compounds against C. rodentium infection. This 
assay directly monitors damage to the colonic epithelium as a function of leakage into the 
bloodstream. Compounds that have been identified in the CPG2 reporter assay are currently being 




SCREENING CAMPAIGN FOR THE IDENTIFICTION OF INHIBITORS OF NOVEL 
BACTERIAL RIBOSOMAL PROCESSING PROTEASE PRP 
 
3.1 Introduction 
 In 2019, over 2.8 million cases of antibiotic-resistant infections occurred in the United 
States, resulting in ~35,000 deaths.415 Approximately 10,600 of these deaths are attributable to 
methicillin-resistant Staphylococcus aureus (MRSA), a Gram-positive bacterial pathogen 
responsible for skin infections, pneumonia, and sepsis. Since 2006, contractions of MRSA have 
been monitored by the National and State Healthcare-Associated Infections Report through the 
Centers for Disease Control and Prevention (CDC).416 Over the first decade of monitoring, the rate 
of hospital-acquired MRSA infections decreased due to vigilant implementation of protocols 
designed to improve patients’ protection from infection. These efforts notwithstanding, the overall 
rate MRSA infection remains high, with >323,000 cases reported in 2017.415 
 Many S. aureus strains have been identified as harboring antibiotic resistance genes. 
Clinical isolates have indicated strains that are resistant to the PhLOPSA antibiotics (Phenicols, 
Lincosamides, Oxazolidines, Pleuromutilins, and Streptogramin A),417 chlorohexidine,418 and 
vancomycin419 in addition to methicillin.420 Vancomycin-resistant S. aureus (VRSA) is growing 
in clinical importance as the therapeutic options for VRSA are limited.419 One strain of VRSA that 
was isolated was resistant to methicillin, teicoplanin, erythromycin, clindamycin, ciprofloxacin, 
gentamycin, and trimethoprim-sulfamethoxazole treatment.421 As this pathogen continues to 
acquire genes for antibiotic resistance, new antibiotics need to be developed as therapeutics to fight 
S. aureus infection. 
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 The bacterial ribosome is the target of many antibiotics currently on the market. These 
include macrolides, lincosamides, oxazolidinones, and tetracyclines.422 These compounds each 
block amino acid polymerization to proteins by interfering with ribosomal processing of 
aminoacyl-tRNA. The bacterial ribosome consists of a combination of ribosomal proteins and 
rRNA that form two subunits. These subunits are characterized by their sedimentation rate. The 
larger subunit is referred to as the 50S ribosomal subunit while the smaller is 30S. The complete 
ribosome is 70S. The 50S and 30S subunits come together to form the APE sites necessary for 
mRNA translation, with each subunit forming part of the sites. The 50S subunit contains the 
catalytic site of the ribosome, the peptidyl transferase center (PTC). The PTC is stabilized by the 
amino terminus of the ribosomal protein L27.423  
 It was recently discovered that an N-terminal extension on L27 is conserved in Firmicutes, 
including Staphylococcus, Bacillus, Listeria, Clostridium, and Streptococcus.424 This extension 
must be cleaved for proper assembly and function of the ribosome in these organisms, as an 
extension of L27 would result in steric hindrance capable of halting protein production. Phage-
related ribosomal protease (Prp) is responsible for cleavage of the N-terminal extension from the 
ribosomal protein L27.424 S. aureus L27 knockouts are nonviable in the presence of “pre-cleaved” 
L27 that lacked the N-terminal peptide extension or in the presence of “uncleavable” L27 
mutants.425  This indicates that the cleavage process performed by Prp is necessary for cell survival. 
The interaction between Prp and L27 is critical in ribosomal assembly and cleavage of the N-
terminal sequence of L27 by Prp is a requirement for a functional ribosome in bacteria that contain 




 Due to its recent discovery, Prp has never been targeted for inhibition. This means that 
resistance to Prp inhibitors is unlikely to have already occurred in nature. Deadly drug-resistant S. 
aureus, Streptococcus pneumoniae, and Clostridium difficile should be susceptible to Prp 
inhibition, similar to non-resistant strains. Any Prp inhibitor should be selective for a small subset 
of pathogenic bacteria because most bacteria do not encode Prp.424 In addition, those Firmicutes 
that do express the N-terminal L27 extension have varying sequences within the cleavage domain, 
so an inhibitor of Prp may be designed to selectively inhibit in one organism. This would result in 
less selective pressure is being exerted across all bacteria as a whole, which should slow the rate 
of formation of resistance, and cause fewer side effects from killing commensal bacteria.  
 Mutational studies exploring the importance of specific amino acids of the N-terminal L27 
extension have indicated that Prp presents substrate specificity. Mutations F8A and F9A resulted 
in an uncleavable protein. Unpublished work by Dr. Gail Christie and Dr. Darrell Peterson 
indicates that Q7A and Q7E are also uncleavable, while A10G and A10S can be cleaved by Prp. 
Since the cleavage site of Prp is between F9 and A10, these results indicate that the interactions 
between Prp and L27 that are important for cleavage exist primarily on the amino-terminal side of 
the cut site. This information may be implemented in design of specific L27 peptidomimetic 
inhibitors of Prp. 
 In this dissertation, we describe a high throughput screening campaign using a modified 
and miniaturized form of the fluorogenic assay previously developed. We also discuss the 
optimization of a new fluorogenic substrate and the subsequent screening of broad-spectrum 






 Prp was produced and isolated as described previously.424 Peptide substrate, consisting of 
fluorophore FITC or ABZ conjugated to the Prp-specific cleavage sequence of L27 and DNP 
quencher (FITC/ABZ-KLNLQFFASKK-DNP), was purchased from United Biosystems 
(Herndon, VA). The ApexScreen compound library was purchased from TimTec, Inc. (New Castle 
County, DE). Phenyl mercuric borate was sourced from Aldrich Chemical Company, Inc (St. 
Louis, MO). Methyl mercuric chloride was from Pfaltz & Bauer, Inc (Waterbury, CT). Mersalyl 
acid was sourced from Bios Laboratories, Inc (New Haven, CT). Ethylmercurylthiosalicylic acid 
was sourced from Fisher Scientific Company (Waltham, MA). Phenyl mercuric acetate, o-
chloromercuryl phenol, p-chloromercuribenzoic acid and phenylmercuric salicylate were sourced 
from K&K Laboratories, Inc (Plainview, NY). p-Acetoxymercurianiline was sourced from 
Polysciences, Inc (Warrington, PA). Dimercurial acetate was sourced from Anatrace Products, 
LLC (Maumee, OH). Thiomersal was sourced from Sigma Chemical Company (St. Louis, MO). 
Merbromin was sourced from ICN Pharmaceuticals, Inc. (Costa Mesa, CA). 
 
3.2.2 Screening assay 
  The peptide substrate was reconstituted in dimethyl sulfoxide (DMSO) to 1 mM, and its 
concentration was determined by measuring absorbance at 325 nm at 0.1 cm pathlength with a 
BioTek Synergy HTX plate reader. 20 µL aliquots were stored at -20 °C until use. The assay was 
performed with purified Prp, produced as previously described at 20 nM and peptide at a final 
concentration of 500 nM (FITC). Assays were performed in sodium phosphate buffer (50 mM, pH 
7) with 1.5 mM dithiothreitol (DTT) and 2.35 mM ethylenediaminetetraacetic acid (EDTA) and 
0.01% Tween 20.  
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 Assay buffer was dispensed into 1536-well plates (Fisherbrand 1536-well black flat-
bottom) with the MultidropTM Combi nL Reagent Dispenser (to 5 µL) before the addition of Prp 
to 21.4 nM using a Labcyte Echo550 acoustic liquid handler. Compounds being screened were 
then added to the desired concentration with a Labcyte Echo550 acoustic liquid handler before 
incubating at room temperature for 30 minutes. Peptide substrate was added to 0.5 µM 
immediately before monitoring fluorescence with a BMG Labtech CLARIOstar© Plus plate 
reader. When Prp cleaved the peptide, the quencher and FITC were released. The concentration of 
free fluorescent FITC was directly related to the intensity of the fluorescent signal (λex/λem = 488-
15/530-15 nm). Fluorescence was monitored for 45 minutes. 
 
3.2.3 Data analysis 
 The Z factor is a statistical parameter used for validation and evaluation of the quality of 
a high throughput screening (HTS) assay.426 To calculate the Z factor for this screening assay, 
the inhibitor mersalyl acid (MA) was screened at 0.1 mM using the procedure above. The % 
inhibition by MA was calculated from the rate of change in fluorescence compared to an 
uninhibited control using the following equation: 
 




Where m = slope, MA = mersalyl acid, and V = vehicle 
The % inhibition by MA and the vehicle control was then used to calculate the Z factor 
using the equation below.  






Where σ = standard deviation, μ = mean, MA = mersalyl acid, and V = vehicle 
 
3.2.4 Fluorescent interference assay 
 This experiment is performed to identify any non-specific interactions between the 
screening compounds and the substrate after cleavage. Assay buffer was dispensed into 1536-well 
plates (Fisherbrand 1536-well black flat-bottom) with the MultidropTM Combi nL Reagent 
Dispenser (to 5 µL) before the addition of compounds to the screening concentration with a 
Labcyte Echo550 acoustic liquid handler. A “pre-cleaved” version of the substrate (ABZ-
KLNLQFF) was then dispensed using a Labcyte Echo550 acoustic liquid handler to 1 μM. This 
compound is fluorescent, so any interference with the fluorescence of the substrate will be apparent 
by a decrease in the signal obtained in the presence of the compound. The fluorescence of the 
solution is measured for approximately 40 minutes with a BMG Labtech CLARIOstar© Plus plate 
reader (λex/λem = 320-15 nm/420-15 nm). 
 
3.3 Preliminary Studies 
 Assay miniaturization. The assay previously described involves a fluorophore/quencher 
system linked by the amino acid sequence for the L27 cleavage domain. The fluorophore was 2-
aminobenzoic acid (ABZ) and the quencher was dinitrophenyl (DNP). When these two domains 
are held in close proximity by the intact linker, the fluorogenic signal of ABZ is quenched by DNP. 
When the linker is cleaved by Prp, DNP and ABZ are separated and ABZ becomes fluorescent, 








Figure 42. A) Scheme of the fluorogenic assay. Prp cleaves the pre-fluorescent substrate 
and releases the fluorophore (FITC). B) Fluorescence increases over time as the substrate 
is being processed. The compound mersalyl acid was used as a positive control and inhibits 




 At the onset off this study, the assay as developed previously was performed in a volume 
of 60 μL. To conserve material and perform more rapid screening, lab member Adam Johnson 
miniaturized the assay to 5 μL. Upon initial screening in this smaller volume, the signal observed 
decreased significantly and could not be quantified accurately. He hypothesized that this issue may 
have come from protein adhesion to the walls of the wells. As volume decreases, the surface-to-
volume ratio increases. In any screening environment, some proteins adhere to the walls and the 
bottom of the wells. This adherence allows for the successful implementation of ELISA protocols 
and other solid phase assays that depend upon protein adherence. In this case, this solution-based 
assay requires that the enzyme and substrate be soluble and available in solution. To approach this 
problem, a small amount of a detergent was added to the assay buffer (0.01% Tween 20). This 
limited the adherence of the enzyme and substrate to the walls of the well and the signal was 
restored. I adopted this assay to screen a library of over 5000 compounds for their ability to inhibit 
Prp. 
 Optimization using FITC fluorophore. Once the high throughput screening campaign 
was underway, it became apparent that many of the compounds we screened were fluorescent at 
the same wavelength as ABZ. A few of the compounds we screened resulted in signals that were 
above the upper limit of quantification, so no meaningful data could be collected. We replaced the 
ABZ moiety in the assay substrate with a new fluorophore, fluorescein isothiocyanate (FITC). This 
fluorophore has higher excitation/emission wavelengths than ABZ (495 nm/519 nm rather than 
320 nm/420 nm). By screening the fluorescent compounds with this new fluorophore, we were 
able to collect meaningful data for all the compounds in the library. 
 The concentration of the ABZ-conjugated substrate was 1 μM for screening. This 
concentration gave ample signal while being low enough not to outcompete the compounds being 
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screened (~35 μM). When the new fluorophore was introduced, the signal obtained from the 
cleavage of 1 μM was above the upper limit of quantification (Figure 43). A lower concentration 
of the FITC-conjugated substrate was therefore used for screening (0.5 μM). This was the only 
significant change made to the screening protocol. 
 
 
Figure 43. The FITC-conjugated substrate gives a signal above the upper limit of 
quantification if screened at 1 μM. The signal is optimal at 0.5 μM since the signal does 
not exceed the quantitative limits of the instrument. 
 
3.4 Results and discussion 
3.4.1 Calculating the Z-factor 
 Mersalyl acid was screened at 100 µM using the FITC-conjugated substrate. Figure 44 
shows a representation of positive and negative control conditions for the fluorogenic cleavage 
assay. As Prp cleaved the 11-mer peptide, the quencher was released from the fluorophore and 
fluorescence increased. When an inhibitor was present, in this case mersalyl acid, Prp was 
incapable of cleaving the peptide and fluorescence did not increase. Using this data, the Z factor 





Figure 44. A) Structure of mersalyl acid (61). B) 61 inhibits Prp at 100 μM and was used 
as a positive control to calculate the Z factor (Z-factor = 0.67). 
 
3.4.2 ApexScreen 5040 library 
 The ApexScreen library consists of 5040 diverse structures. These compounds were 
initially screened in singlet using the ABZ-conjugated substrate (Appendix I). Any compounds 
fluorescent at the screening wavelength were rescreened using the FITC-conjugated substrate. 
None of the fluorescent compounds were ultimately inhibitors of Prp. Compounds that appeared 
to inhibit Prp after the initial screen were then screened in triplicate at lower concentrations to 
identify concentration-dependent inhibition. These compounds were also screened for fluorescent 
interference with ABZ-KLNLQFF fluorescent substrate. At this stage, most compounds were 
eliminated for either non-repeatable inhibition or for interference with the fluorescence of the 
substrate post-cleavage. One compound appeared to inhibit Prp (Figure 45). This compound is (E)-
4-(4-bromostyryl)pyridine. A post-doctoral fellow, John Saathoff, synthesized this compound as 





Figure 45. Analogs of the screening hit synthesized by John Saathoff. 
 
We were unable to recreate the inhibition seen in the plate screening. The bromo-
substituted compound 62 had no activity against Prp. The trifluoromethyl-substituted compound 
63 was a very weak inhibitor, but we were able to observe concentration-dependent inhibition 
(Figure 46). Because of the weak activity, the compound was abandoned. Ultimately, this library 
did not present any hits to pursue further. 
 
 
Figure 46. 63 exhibited concentration-dependent inhibition of Prp. 
 
3.4.3 Protease inhibitors 
  We screened a collection of broad-spectrum protease inhibitors (Figure 47) and other 
small-spectrum inhibitors. We were interested in exploring whether the active site of Prp would 
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be able to interact with these compounds. Ultimately, we found that none of these protease 
inhibitors included in the library were able to inhibit Prp. 
 The broad-spectrum inhibitors in this collection included peptides containing epoxides or 
aldehydes, where enzymatic activity would result in covalent linkage of the inhibitor to the 
protease. The compounds tested in this screen include CA-074Me (64), leupeptin (65), loxistatin 
acid (66), mg101 (67), E-64 (68), and aloxistatin (69, Figure 47).  
 
 
Figure 47. Structures of compounds analyzed for Prp inhibitory activity: CA-
074ME (64), leupeptin (65), loxistatin acid (66), mg101 (67), E64 (68), and 
aloxistatin (69).  





Figure 48. Fluorogenic cleavage data curves for the suicide inhibitors 64-69. 
 
 CA-074Me is a cell-membrane permeable analogue of CA-074 and acts as an irreversible 
cathepsin B inhibitor.427 Leupeptin, an isolate from Actinomycetes, was first implicated as an 
inhibitor of plasmin, trypsin, papain, and thrombokinase in 1969.428  Leupeptin was then 
discovered as an inhibitor of Leishmania donovani cysteine protease.429 E64 is an irreversible 
cysteine protease inhibitor.430 Loxistatin acid is a synthetic and cell permeable derivative of E-64, 
and irreversibly inhibits cysteine proteases cathepsins B, H, and L.430 Mg101 is a broad-spectrum, 
potent inhibitor of cysteine proteases including lysosomal cathepsins and calpains.431 Aloxistatin 
is also a broad-spectrum cysteine protease inhibitor that has blood platelet aggregation inhibitory 
properties.432 The collection of these compounds was selected for their range of specificity for 
protease targets. Our results indicate that none of these broad-spectrum antibiotics are capable of 
inhibiting Prp at 100 μM (Figure 48), which suggests that Prp has a high level of substrate 
specificity. Rational design of an L27 mimetic with a warhead capable of covalent modification 


































3.4.4 Mercurial compounds 
 We also screened a collection of organomercurial compounds (Figure 49). These 
compounds were analyzed in response to the discovery of the inhibitory ability of mersalyl acid. 
The compounds selected for screening were phenyl mercuric borate (70), methyl mercuric chloride 
(71), mersalyl acid (72), ethylmercurylthiosalicylic acid (73), phenyl mercuric acetate (74), p-
acetoxymercurianiline (75), o-chloromercuryl phenol (76), phenylmercuric salicylate (77), 
thiomersal (78), merbromin (79), and p-chloromercuribenzoic acid (80). Compounds were initially 
analyzed at 100 μM concentration in duplicate (Table 4) and those indicating high levels of 
inhibition (70-77, 80% inhibition or higher) were rescreened at 1 μM in triplicate. The percent 




Figure 49. Structures of organomercurials analyzed for Prp inhibitory activity: 
phenylmercuric borate (70), methylmercuric chloride (71), mersalyl acid (72), 
ethylmercurylthiosalicylic acid (73), phenylmercuric acetate (74), p-acetoxymercurianiline 
(75), o-chloromercuryl phenol (76), phenylmercuric salicylate (77), thiomersal (78), 




Table 4. Calculated inhibitory levels of 70-80. Compounds were screened in triplicate, so 
standard deviation cannot be calculated. 70-77 were rescreened at 1 μM but 78-80 were 

















Table 5. Inhibition data for compounds 70-77, which appear to inhibit Prp. Compounds 
were screened at 1 μM and DMSO concentration was normalized. 
Compound % Inhibition at 1 μM 
70 71 ± 17 
71 64 ±7 
Compound 
(100 μM) 
Slope % Inhib. 
70 Trial 1 -52 101 
70 Trial 2 -33 100 
71 Trial 1 -101 101 
71 Trial 2 -60 101 
72 Trial 1 -69 101 
72 Trial 2 -46 101 
73 Trial 1 -56 101 
73 Trial 2 -19 100 
74 Trial 1 89 99 
74 Trial 2 170 98 
75 Trial 1 210 96 
75 Trial 2 172 97 
76 Trial 1 158 98 
76 Trial 2 36 100 
77 Trial 1 1397 81 
77 Trial 2 1523 79 
78 Trial 1 7452 -1 
78 Trial 2 7212 3 
79 Trial 1 7014 6 
79 Trial 2 6905 7 
80 Trial 1 7062 5 
80 Trial 2 7459 -1 
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72 59 ± 5 
73 36 ± 1 
74 29 ± 6 
75 28 ± 2 
76 16 ± 2 
77 8 ± 3 
 
 Given the unusual inhibitory profile of Prp to traditional broad-spectrum protease 
inhibitors, we pursued other compounds capable of inhibition. Mercury is thiophilic,433 and we 
suspected that the active-site cysteine of Prp could be inhibited by certain commercially available 
organomercurials. Mersalyl is an organomercurial that has been used therapeutically as a 
diuretic434,435 and served as a positive control in the development of our HTS assay. 
Phenylmercuric borate (Merfen orange),436,437 mersalyl,434,435 phenylmercuric acetate,438,439 
thiomersal,440,441 and merbromin (Mercurochrome)437,442 have been used for their antiseptic 
properties in topical ointments. Phenylmercuric acetate is used as an antimicrobial in eyedrops and 
is used to combat ocular fungal pathogens in addition to its herbicidal functionality.439 Thiomersal 
(also known as thimerosal) was a preservative in vaccines meant to prevent fungal growth within 
the vials.440,441 The resulting controversy caused by thiomersal’s mercury content has become a 
popular topic for groups interested in adverse effects caused by vaccination. In recent redeeming 
research, the toxicity of thiomersal is being investigated for its potential as a cancer 
treatment.434,443–445 Thiomersal is capable of inducing apoptosis in multiple cancer cell types, 
including prostate,443 gastric,444 and oral cancers.445 This indicates the opportunity for further 
research into mercury-containing compounds as a strategy to target harmful cell types using their 
innate toxicity. Our research contributes to this trend by revealing the potential for 





 As a novel, never-drugged, essential enzyme for Firmicutes, Prp has high potential as an 
antibiotic target. Research into inhibiting Prp indicates that the active site cannot be targeted by 
known broad-spectrum protease inhibitors. This specificity notwithstanding, we have 
demonstrated that Prp can be inhibited by small-molecule organomercurial compounds. Because 
of the toxicity related to organomercurials, though, these compounds may not behave well as 
therapeutics, so other options must be explored. Given the specificity of the binding site of Prp, a 
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Table A1: Compounds in the ApexScreen 5040 Library and results of initial screen. 









1 C03 pyridine-2,6-dicarbohydrazide No 
1 D03 4,5-dichloroisothiazol-3-yl piperidyl ketone No 
1 E03 ethyl 5-(ethoxycarbonyl)-2-(2,2,7-trimethyl-3-thioxo(4-1,2-
dihydroquinolyliden e))-1,3-dithiolene-4-carboxylate 
No 
1 F03 ethyl 5-(ethoxycarbonyl)-2-(1,2,2-trimethyl-3-thioxo(4-1,2-
dihydroquinolyliden e))-1,3-dithiolene-4-carboxylate 
No 
1 G03 ethyl 5-(ethoxycarbonyl)-2-(1,2,2,6-tetramethyl-3-thioxo(4-1,2-
dihydroquinolyl idene))-1,3-dithiolene-4-carboxylate 
No 
1 H03 indeno[2,3-b]1,2,5-oxadiazolo[3,4-e]pyrazin-5-one No 
1 I03 ethyl 4-amino-1,2,5-oxadiazole-3-carboxylate No 
1 J03 6-[(1E)-2-(4-bromophenyl)vinyl]-5-nitropyrimidine-2,4-diol No 































































dimethyltetracyclo[8.7.0.0<2,7>. 0<11,15>]heptadec-14-yl acetate 
No 
1 C05 morpholin-4-yl(phenylamino)methane-1-thione No 
1 D05 2-(4-nitropyrazol-3-yl)propane-1,3-dial No 
1 E05 2-(4-nitropyrazolyl)acetic acid No 
1 F05 diethyl 2,3-diacetylbutane-1,4-dioate No 
1 G05 1-(1-methylvinyl)-3-hydrobenzimidazol-2-one No 
1 H05 4-pyrrolylphenol No 





























1 C06 amino(4-methylquinazolin-2-yl)carboxamidine No 
1 D06 amino(6-methoxy-4-methylquinazolin-2-yl)carboxamidine OFF-SCALE 











































1 C07 5-[(2,4-dichlorophenyl)methylene]-2-thioxo-1,3-diazolidin-4-one No 
1 D07 quinoxaline-2,3-diol No 
1 E07 dibenzo[f,h]phenanthro[9,10-b]quinoxaline No 
1 F07 (2E)-3-(N-cyclohexylcarbamoyl)prop-2-enoic acid No 
1 G07 4-(hydrazinoiminomethyl)-1,2,5-oxadiazole-3-ylamine No 
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1 H07 6-(4-nitrophenyl)-1,3,5-triazine-2,4-diamine Yes 
1 I07 2-furyl-N-(1,2,4-triazol-4-yl)carboxamide Yes 
1 J07 2-((1E)-2-nitrovinyl)thiophene No 
1 K07 ethyl 4-methyl-4-nitropentanoate No 
1 L07 4-(amino(hydroxyimino)methyl)-1,2,5-oxadiazole-3-ylamine No 
1 M07 1-(9-anthryl)-2-nitroethan-1-ol No 
1 N07 4-[(3-bromophenyl)methylene]-2-phenyl-1,3-oxazolin-5-one No 




1 P07 amino(4,8-dimethylquinazolin-2-yl)carboxamidine No 
1 A08 amino(8-methoxy-4-methylquinazolin-2-yl)carboxamidine OFF-SCALE 






























1 L08 1-(3-amino-2,4,6-tribromophenyl)pyrrolidin-2-one No 





























1 H09 ethyl 2-(2-thienylcarbonylamino)-4,5,6,7,8-
pentahydrocyclohepta[2,1-b]thiophen e-3-carboxylate 
No 
1 I09 3-chlorobenzo[b]thiophen-2-yl indolinyl ketone No 







1 M09 ethyl 2-(cyclopropylcarbonylamino)-4,5,6,7,8-
pentahydrocyclohepta[2,1-b]thioph ene-3-carboxylate 
No 

















1 D10 ethyl (3E)-4-[(5,6-dimethyl-4-oxo(3-hydrothiopheno[2,3-
d]pyrimidin-2-yl))amino ]-3-methyl-4-azabut-3-enoate 
No 




1 G10 2-methyl-5-[(trifluoromethyl)sulfonyl]benzothiazole No 























(methylpiperidyl)ethane, i odide, iodide 
No 
1 P10 2-(1-methyl-3-(2-pyridyl)piperidyl)-1-[(6-methyl-6-
azabicyclo[4.4.0]dec-2-yl)m ethoxy]ethane, iodide, iodide 
No 
1 A11 1-((1E)-2-(1,3-thiazol-2-yl)-2-azavinyl)naphthalen-2-ol No 












1 H11 2-[3-(3,5-dimethylphenyl)-2-methylpropyl]benzimidazole YES 
1 I11 1,2-dibenzimidazol-2-ylethane-1,2-diol No 
1 J11 3-[4-(2-carboxyethyl)imidazolyl]propanoic acid No 
1 K11 5-(2-methylthioethyl)-3-prop-2-enylimidazolidin-4-one No 
1 L11 2-methoxy-1-(5-methylthio(1,3,4-oxadiazol-2-yl))benzene No 
1 M11 5-(2,4-dichlorophenyl)-2-propylthio-1,3,4-oxadiazole No 
1 N11 5-(2,4-dichlorophenyl)-2-(phenylmethylthio)-1,3,4-oxadiazole No 




















1 G12 9-methoxy-2,2-dimethyl-6-hydro-2H-pyrano[5,6-c]quinolin-5-one No 
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1 H12 9-methyl-3-oxa-9-azatricyclo[3.3.1.0<2,4>]non-7-yl 3-hydroxy-2-









1 K12 7,8-dioxabicyclo[3.2.1]oct-3-en-2-one YES 
1 L12 2-amino-4,5,6-trihydrocyclopenta[1,2-b]thiophene-3-carbonitrile No 
1 M12 5-(2,5-dichlorophenyl)furan-2-carbaldehyde No 
1 N12 5-amino-4-chloro-2-phenyl-2-hydropyridazin-3-one No 
1 O12 ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate No 
1 P12 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide No 
1 A13 1-methylpyrazole-5-carboxylic acid No 
1 B13 pyrazole-3-carboxylic acid No 
1 C13 4-nitropyrazole-3-carboxylic acid No 
1 D13 ethyl 2-amino-4-methyl-1,3-thiazole-5-carboxylate No 
1 E13 methyl 2-amino-6-(tert-butyl)-4,5,6,7-
tetrahydrobenzo[b]thiophene-3-carboxylat e 
No 
1 F13 ethyl 2-(2-amino-1,3-thiazol-4-yl)acetate No 


















1 N13 5-[(4-chlorophenyl)methylthio]-1,3,4-thiadiazole-2-ylamine No 
1 O13 5-(diphenylmethylthio)-1-methyl-1,2,3,4-tetraazole No 
1 P13 2-[(2,4-dinitrophenyl)amino]ethan-1-ol No 
1 A14 2-[(5-nitro-8-quinolyl)amino]ethan-1-ol No 
1 B14 (2-aminoethyl)(2,4-dinitrophenyl)amine No 
1 C14 (4-amino(1,2,5-oxadiazol-3-yl))-N-(2-aminoethyl)carboxamide No 
1 D14 (3-aminopropyl)(4-nitrophenyl)amine No 




1 G14 (2,2-diethoxyethyl)- No 
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1 H14 N-methyl-N-(pyridin-4-ylmethyl)morpholine-2-carboxamide No 




1 K14 2-({2-[(4-chloro-2-nitrophenyl)amino]ethyl}amino)ethan-1-ol No 
1 L14 2-({2-[(2-chloro-4-nitrophenyl)amino]ethyl}amino)ethan-1-ol No 
1 M14 2-({2-[(2,4-dinitrophenyl)amino]ethyl}amino)ethan-1-ol No 
1 N14 2-[(2,4-dinitrophenyl)amino]-2-methylpropan-1-ol No 
1 O14 (2-chloro-5-nitrophenyl)pyrrolidine No 
1 P14 4-(5-chloro-2-nitrophenyl)morpholine No 
1 A15 5-morpholin-4-yl-2-nitrophenylamine No 




1 D15 2-nitro-5-piperazinylphenylamine No 
1 E15 1-(2-chloro-4-nitrophenyl)-4-methylpiperazine No 




1 H15 1-(2,4-dinitrophenyl)-3-methylpiperazine No 
1 I15 3,5-dimethyl-1-(5-nitro(8-quinolyl))piperazine No 
1 J15 5-chloro-2-nitrophenylhydrazine No 
1 K15 2-[(5-chloro-2-nitrophenyl)amino]ethan-1-ol No 




1 N15 (adamantanylethyl)(5-chloro-2-nitrophenyl)amine No 
1 O15 2-(5-chloro-2-nitrophenylthio)ethan-1-ol No 












1 F16 ethyl 5-(2-amino-3-cyano-7-methyl-5-oxo-4H-pyrano[3,2-
c]pyran-4-yl)furan-2-car boxylate 
No 

















1 L16 2,3-bis(4-methylpiperazinyl)quinoxaline No 

















thiazolidin-3-yl}bu tanoic acid 
No 
1 D17 2-[5-(1-methyl-2-oxobenzo[d]azolin-3-ylidene)-4-oxo-2-thioxo-

















1 J17 N-adamantanyl-2-(4-bromo-5-methyl-3-nitropyrazolyl)acetamide No 
1 K17 4-nitrophenyl 3-(trifluoromethyl)piperidinesulfonate No 
1 L17 2,4,6-trimethylphenyl [(4-morpholin-4-ylphenyl)amino]sulfonate No 







































1 K18 {[4-(3-chlorophenyl)piperazinyl]methyl}benzotriazole No 




1 N18 1-(4-fluorophenyl)-2-quinolylethan-1-one, bromide No 
1 O18 3-acetyl-1-[2-(4-fluorophenyl)-2-oxoethyl]pyridine, bromide No 




1 B19 [(4-aminophenyl)sulfonyl](5-ethyl(1,3,4-thiadiazol-2-yl))amine No 
1 C19 [(4-aminophenyl)sulfonyl](2,6-dimethoxypyrimidin-4-yl)amine No 
1 D19 [(4-aminophenyl)sulfonyl](6-chloropyridazin-3-yl)amine No 
1 E19 2-(1,2,2,2-tetrafluoroethyl)benzimidazole No 





thiazol-5-yl}ethan- 1-ol, chloride, chloride 
No 
1 I19 1-[(3,5-dimethylpiperidyl)sulfonyl]-4-chlorobenzene No 
1 J19 1,4-dichloro-2-[(3-methylpiperidyl)sulfonyl]benzene No 
1 K19 1-[(4-methoxyphenyl)sulfonyl]-3,5-dimethylpiperidine No 







1 O19 3-(1,2,3,4-tetrahydroquinolyl)benzo[d]1,2-thiazole-1,1-dione No 
1 P19 ethyl 2-[(1,1-dioxobenzo[d]1,2-thiazol-3-yl)phenylamino]acetate No 
1 A20 5-chloro-7-[(4-methylpiperazinyl)methyl]quinolin-8-ol No 






1 D20 4-(2,4-dichlorophenoxy)-N-(1,2,4-triazol-4-yl)butanamide No 
1 E20 1,3-bisbenzyl-2-(4-fluorophenyl)imidazolidine No 
1 F20 4,5-diphenyl-2-(3-pyridyl)imidazole No 




1 I20 1-[(2-chlorophenyl)methyl]-2-(methylsulfonyl)benzimidazole No 
1 J20 [(2,5-dichlorophenyl)sulfonyl](3-pyridylmethyl)amine No 
1 K20 1-(diphenylmethyl)-4-(phenylsulfonyl)piperazine No 




1 N20 1-(6-azabicyclo[4.4.0]dec-2-yl)azolidine-2,5-dione No 
1 O20 7,11-diazatricyclo[7.3.1.0<2,7>]trideca-2,4-dien-6-one No 
1 P20 3-imidazolylbutanoic acid No 
1 A21 3-(2-methylimidazolyl)propanoic acid No 
1 B21 4-[3-(3-carboxypropyl)-2-oxo-3-hydrobenzimidazolyl]butanoic 
acid 
No 
1 C21 5,6,11,12-tetrahydropyridazino[1,2-b]phthalazine-1,4-dione No 
1 D21 6-morpholin-4-yl-4-(phenylamino)-1,3,5-triazin-2-ol No 
1 E21 methyl 4,5-dinitropyrazole-3-carboxylate No 
1 F21 3-(4-nitropyrazolyl)-1H-benzo[b]1,4-diazepine No 
1 G21 5,7-dimethyl-3-nitro-8-hydro-3-pyrazolino[2,3-a]pyrimidin-2-one No 






1 J21 ethyl 1-acetylpiperidine-4-carboxylate No 
1 K21 7-nitro-5-(pyrrolidinylmethyl)quinolin-8-ol No 
1 L21 5-[(4-methylpiperazinyl)methyl]-7-nitroquinolin-8-ol No 
1 M21 5-[(cyclohexylmethylamino)methyl]-7-nitroquinolin-8-ol No 
1 N21 7-methoxy-4,5-dihydrobenzo[e]benzothiazole-2-ylamine No 
1 O21 2-(1-bromo-2-5,6,7,8-tetrahydronaphthyloxy)acetohydrazide No 



























1 K22 2-(4-ethylphenyl)-4-hydroimidazo[1,2-a]pyridine No 







1 O22 3-[2-(3-sulfopropylthio)benzothiazol-3-yl]propanesulfonic acid No 
1 P22 di4-methoxy-2-nitrophenyl disulfide No 
Plate Well IUPAC NAME Inhibitor 
Y/N 
2 A03 dibenzo[c,e]1,2-dithiane-3,8-diamine No 
2 B03 3-(2-methylbenzothiazol-3-yl)propanesulfonic acid No 
2 C03 5-oxo-1-(4-sulfophenyl)-2-pyrazoline-3-carboxylic acid No 
2 D03 2-methyl-6-nitrobenzothiazole No 
2 E03 2-methyl-5-nitrobenzo[c]azoline-1,3-dione No 
2 F03 antipyrine No 
2 G03 7-methyl-2-methylthio-4-hydro-1,2,4-triazolo[1,5-a]pyrimidin-5-ol No 
2 H03 1-phenyl-1,2,3,4-tetraazole-5-thiol No 




2 K03 adenosine No 
2 L03 (1E)-1-(3,4-dichlorophenyl)-2-indol-3-yl-1-azaethene No 
2 M03 4-(cyclohexylideneazamethyl)-1,2,4-triazole No 
2 N03 bis(methylethoxy)[(4-methoxyphenyl)amino]phosphino-1-one No 
2 O03 1-morpholin-4-ylbutane-1,3-dione No 
2 P03 (1E)-2-indol-3-yl-1-(3-pyridyl)-1-azaethene No 
2 A04 2-((1E)-2-(1,3-thiazol-2-yl)-2-azavinyl)-4-bromophenol No 
2 B04 (3E)-4-(2-hydroxynaphthyl)-3-azabut-3-en-1-ol No 




2 E04 2-[(1E)-2-(4-iodophenyl)-2-azavinyl]-4-nitrophenol No 










2 I04 ethyl 2-methyl-6-(4-nitropyrazolyl)-8-hydropyrazolo[1,5-
a]pyrimidine-3-carboxy late 
No 
2 J04 methyl (2Z)-2-cyano-3-(1-methylpyrrol-2-yl)prop-2-enoate No 
2 K04 1,2,3,4-tetrahydroquinolyl xanthen-9-yl ketone No 











2 P04 ethyl 2-amino-5-oxo-4-(2-thienyl)-4H-6,7,8-trihydrochromene-3-
carboxylate 
No 

























2 J05 2-chloro-4-oxo-5-hydropyridino[1,2-a]pyrimidine-3-carbaldehyde No 
2 K05 4-iodo-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one No 
2 L05 2-bromobenzo[b]benzo[b]thiophene No 
2 M05 4-(4-iodophenyl)-1-nitrobenzene No 
2 N05 1-[1,2-dibromo-2-(4-bromophenyl)ethyl]-2-bromobenzene No 
2 O05 2,3-dimethylquinoxaline No 
2 P05 2,3-diphenylquinoxaline No 
2 A06 2H,6H-azolino[3',4'-1,2]benzo[4,5-c]azolidine-1,3,5,7-tetraone No 
2 B06 4-bromo-1-[1-(4-bromophenyl)-2,2,2-trichloroethyl]benzene No 
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2 F06 2,3-bis(3-iodophenyl)quinoxaline No 
2 G06 2,3-bis(4-bromophenyl)quinoxaline No 
2 H06 2-(2-phenylethynyl)benzo[b]benzo[b]thiophene No 
2 I06 2-chloroquinoline-3-carbaldehyde No 
2 J06 2-methoxy-5-(vinylsulfonyl)phenylamine No 
2 K06 2-amino-3-bromo-5-nitrobenzenecarbonitrile No 
2 L06 2-chloro-4-nitrophenylamine No 
2 M06 6-bromo-2-chloro-4-nitrophenylamine No 
2 N06 2,6-dibromo-4-nitrophenylamine No 
2 O06 N-[6-(acetylamino)hexyl]acetamide No 
2 P06 2,7-diiodofluoren-9-one No 
2 A07 3,4-diacetylhexane-2,5-dione No 
2 B07 3,5-bis(dimethylamino)-2-[(phenylamino)thioxomethyl]phenol No 






2 E07 2-ethyl-6-methoxy-2,5-dimethyl-2H-3,4,5,6-tetrahydropyran No 
2 F07 6,6-diethylthiohexane-1,2,3,4,5-pentaol No 
2 G07 8-ethoxy-3-ethyl-8-methyl-2,7,9-trioxabicyclo[4.3.0]nonane No 
2 H07 2-((1E)-2-(2-furyl)-1-azavinyl)-5-nitrophenol No 
2 I07 2-((1E)-2-(2-furyl)-1-azavinyl)-4-nitrophenol No 
2 J07 5-[(1E)-2-(3,4-dichlorophenyl)-2-azavinyl]-2-bromofuran No 
2 K07 5-[(1E)-2-(3,4-dichlorophenyl)-2-azavinyl]-2-iodofuran No 
2 L07 3-[(1E)-2-(3,4-dichlorophenyl)-2-azavinyl]-2-chloroquinoline No 










2 A08 2-[(1E)-2-(4-iodophenyl)-2-azavinyl]-4-bromophenol No 
2 B08 2-[(1E)-2-(2,5-dimethoxyphenyl)-2-azavinyl]-4-bromophenol No 
2 C08 2-[(1E)-2-(2,5-dichlorophenyl)-2-azavinyl]-4-bromophenol No 
2 D08 2-[(1E)-2-(3,5-dichlorophenyl)-2-azavinyl]-4-bromophenol No 
2 E08 2-[(1E)-2-(4-chlorophenyl)-2-azavinyl]thiophene No 
2 F08 2-[(1E)-2-(2-hydroxy-4-nitrophenyl)-2-azavinyl]-4-bromophenol No 
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2 P08 2-[(1E)-2-(4-nitrophenyl)-2-azavinyl]-4,6-dibromophenol No 
2 A09 3-[(1E)-2-(4-bromophenyl)-2-azavinyl]-2-chloroquinoline No 
2 B09 3-[(1E)-2-(2,5-dichlorophenyl)-2-azavinyl]-2-chloroquinoline No 
2 C09 2-[(1E)-2-(2,4-dichlorophenyl)-2-azavinyl]-4,6-dibromophenol No 
2 D09 2-[(1E)-2-(5-chloro(2-pyridyl))-2-azavinyl]-4,6-dibromophenol No 
2 E09 2-[(1E)-2-(2,5-dichlorophenyl)-2-azavinyl]-4,6-dibromophenol No 
2 F09 2-[(1E)-2-(3,4-dichlorophenyl)-2-azavinyl]-4,6-dibromophenol No 
2 G09 2-[(1E)-2-(3,5-dichlorophenyl)-2-azavinyl]-4,6-dibromophenol No 
2 H09 2-[(1E)-2-(3,5-dimethylphenyl)-2-azavinyl]-4,6-dibromophenol No 




2 K09 1-[(1E)-2-(5-chloro(2-pyridyl))-2-azavinyl]naphthalen-2-ol No 
2 L09 6-[(1E)-2-(5-chloro(2-pyridyl))-2-azavinyl]-2-bromo-4-nitrophenol No 
2 M09 2-[(1E)-2-(5-chloro(2-pyridyl))-2-azavinyl]-4-bromophenol No 
2 N09 2-((1E)-2-naphthyl-1-azavinyl)-5-chloropyridine No 
2 O09 2-[(1E)-2-(4-fluorophenyl)-1-azavinyl]-5-chloropyridine No 
2 P09 2-[(1E)-2-(4-chlorophenyl)-1-azavinyl]-5-chloropyridine No 




2 C10 2-((1E)-2-(2-pyridyl)-2-azavinyl)-4,6-dichlorophenol No 
2 D10 2-[(1E)-2-(2,5-dimethoxyphenyl)-2-azavinyl]-4,6-dichlorophenol No 
2 E10 2-[(1E)-2-(2,5-dichlorophenyl)-2-azavinyl]-4,6-dichlorophenol No 
2 F10 2-[(1E)-2-(3,5-dichlorophenyl)-2-azavinyl]-4,6-dichlorophenol No 




2 I10 2-[(1E)-2-(4-fluorophenyl)-2-azavinyl]-4,6-dichlorophenol No 
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2 J10 1-((1E)-2-(2-pyridyl)-2-azavinyl)naphthalen-2-ol No 
2 K10 2-[(1E)-2-(2-chlorophenyl)-1-azavinyl]-5-chloropyridine No 
2 L10 2-((1E)-2-(2-pyridyl)-2-azavinyl)-4-bromophenol No 
2 M10 2-[(1E)-2-(2,5-dichlorophenyl)-2-azavinyl]thiophene No 
2 N10 2-[(1E)-2-(2,4-dichlorophenyl)-2-azavinyl]thiophene No 
2 O10 2-((1E)-2-(1,3-thiazol-2-yl)-2-azavinyl)-4,6-dibromophenol No 
2 P10 2-((1E)-2-(2-pyridyl)-2-azavinyl)-4,6-dibromophenol No 
2 A11 4-chloro-1-[(3-methylpiperidyl)sulfonyl]benzene No 
2 B11 1-chloro-4-{[4-(4-fluorophenyl)piperazinyl]sulfonyl}benzene No 
2 C11 [(4-chlorophenyl)sulfonyl](2,4,5-trichlorophenyl)amine No 
2 D11 4-chloro-1-(1,2,3,4-tetrahydroquinolylsulfonyl)benzene No 
2 E11 4-chloro-1-[(4-methylpiperidyl)sulfonyl]benzene No 
2 F11 (2,5-dimethoxyphenyl)[(4-chlorophenyl)sulfonyl]amine No 
2 G11 (3-chloro-4-fluorophenyl)[(4-chlorophenyl)sulfonyl]amine YES 
2 H11 [(4-chlorophenyl)sulfonyl]cycloheptylamine YES 
2 I11 4-chloro-1-(indolinylsulfonyl)benzene No 
2 J11 (3,5-dichlorophenyl)[(4-chlorophenyl)sulfonyl]amine YES 
2 K11 N,N-bis(cyanomethyl)-2-thienylcarboxamide No 
2 L11 1-bromo-4-{[4-(4-nitrophenyl)piperazinyl]sulfonyl}benzene No 
2 M11 [(4-bromophenyl)sulfonyl](2-furylmethyl)amine No 
2 N11 1-(azaperhydroepinylsulfonyl)-4-bromobenzene No 
2 O11 4-bromo-1-[(3-methylpiperidyl)sulfonyl]benzene No 
2 P11 1-bromo-4-[(4-methylpiperazinyl)sulfonyl]benzene No 
2 A12 [(4-bromophenyl)sulfonyl](oxolan-2-ylmethyl)amine No 
2 B12 1,4-dichloro-2-{[4-(4-nitrophenyl)piperazinyl]sulfonyl}benzene No 
2 C12 [(2,5-dichlorophenyl)sulfonyl](2-methoxyethyl)amine No 
2 D12 1,4-dichloro-2-(2-1,2,3,4-tetrahydroisoquinolylsulfonyl)benzene No 
2 E12 [(2,5-dichlorophenyl)sulfonyl](2,5-dimethoxyphenyl)amine No 
2 F12 1-phenyl-4-(phenylsulfonyl)piperazine No 
2 G12 (2,4-dinitrophenyl)(phenylsulfonyl)amine No 
2 H12 (4-bromophenyl)(phenylsulfonyl)amine YES 
2 I12 diphenyl(phenylsulfonyl)amine No 
2 J12 (4-chlorophenyl)[(4-fluorophenyl)sulfonyl]amine No 
2 K12 (4-bromophenyl)[(4-fluorophenyl)sulfonyl]amine No 
2 L12 4-fluoro-1-[(4-phenylpiperazinyl)sulfonyl]benzene No 
2 M12 (3,4-dichlorophenyl)[(4-fluorophenyl)sulfonyl]amine No 
2 N12 1-fluoro-4-{[4-(4-nitrophenyl)piperazinyl]sulfonyl}benzene No 
2 O12 benzothiazol-2-yl[(4-methoxyphenyl)sulfonyl]amine No 
2 P12 2-[(4-methoxyphenyl)sulfonyl]-1,2,3,4-tetrahydroisoquinoline No 
2 A13 cycloheptyl[(4-methoxyphenyl)sulfonyl]amine No 
2 B13 [(4-methoxyphenyl)sulfonyl](2,4,5-trichlorophenyl)amine No 
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2 C13 1-(morpholin-4-ylsulfonyl)-4-nitrobenzene No 
2 D13 cycloheptyl[(4-nitrophenyl)sulfonyl]amine No 
2 E13 benzothiazol-2-yl[(4-nitrophenyl)sulfonyl]amine No 
2 F13 1-(benzimidazolylsulfonyl)-4-nitrobenzene No 



























2 O13 tert-butyl 6-amino-5-(ethoxycarbonyl)-8-oxo-2-propylspiro[4H-
pyran-4,3'-indoli ne]-3-carboxylate 
No 
2 P13 methylethyl 6-amino-5-(ethoxycarbonyl)-8-oxo-2-propylspiro[4H-
pyran-4,3'-indol ine]-3-carboxylate 
No 












2 E14 methyl 2-amino-11-bromo-5-[(2-methoxyethyl)oxycarbonyl]-6-
methyl-8-oxospiro[4H -pyran-4,3'-indoline]-3-carboxylate 
No 
2 F14 ethyl 2-amino-11-bromo-5-[(2-methoxyethyl)oxycarbonyl]-6-
methyl-8-oxospiro[4H- pyran-4,3'-indoline]-3-carboxylate 
No 
2 G14 methylethyl 2-amino-5-[(2-methoxyethyl)oxycarbonyl]-6-methyl-
8-oxospiro[4H-pyr an-4,3'-indoline]-3-carboxylate 
No 























































































































2 M16 7-phenylpyridino[2',3'-4,5]thiopheno[2,3-b]pyridine-2,4-diol No 













2 C17 3-((1E)-3-phenyl-2-azaprop-1-enyl)-4-phenyl-1,4-thiazine No 





















2 J17 N-[1-(2-bromoethyl)-2-oxoindolin-3-yl]acetamide No 
2 K17 (6-methoxy-2-hydrobenzo[b]furan-3-ylidene)azamethyl 2-
chloroacetate 
No 










2 P17 4-(dimethylamino)-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one No 
2 A18 4,5-diacetyloxy-6-(acetyloxymethyl)-2-prop-2-enyloxy-2H-








2 D18 2-(acetylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic 
acid 
No 
2 E18 4-indol-3-ylbutanoic acid No 
2 F18 2,15-dimethyl-14-oxotetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-















2 K18 10-methylacridine-3,6-diamine, chloride, chloride No 
2 L18 [6-chloro-4-(ethylamino)(1,3,5-triazin-2-yl)]ethylamine No 
2 M18 4-methylphenyl di4-methylphenyl phosphate No 






2 P18 1-[4,6-bis(2-chloroethoxy)(1,3,5-triazin-2-yloxy)]-2-chloroethane No 
2 A19 1-acetyl-4-[2-oxo-1-(3-oxoisobenzofuranylidene)propyl]benzene No 




















2 I19 2-(hydroxyimino)-3-methylhydroquinoxaline No 
2 J19 indolo[2,3-e]1,2,3,4-tetraazolo[1,5-b]1,2,4-triazine No 



















2 B20 1-cyclohexylthio-2-(1,3-dithiolan-2-yl)-4-nitrobenzene No 




2 E20 4-((1E)-2-(2-thienyl)-1-azavinyl)phenyl 4-chlorobenzenesulfonate No 




2 H20 acridine-3,6-diamine No 






2 K20 1-chloro-2-(morpholin-4-ylsulfonyl)-4-nitrobenzene No 
2 L20 5-chloro-7-nitroquinolin-8-ol No 
2 M20 methyl(phenylsulfonyl)-8-quinolylamine No 
2 N20 5-chlorobenzothiazole-2-thiol No 
2 O20 acenaphthen-5-yl(methylsulfonyl)amine No 




2 B21 (4-chloro-2-nitrophenyl)cyclohexylamine No 
2 C21 1,4-bis(4-chloro-2-nitrophenyl)piperazine No 








2 H21 4-(4-bromophenyl)-2-morpholin-4-yl-1,3-thiazole No 
2 I21 1-(4-nitrophenyl)pyrrolidin-2-one No 




2 L21 1-(morpholin-4-ylmethyl)-4-phenyl-1,2,3,4-tetraazoline-5-thione No 
2 M21 4,5,6,7-tetrahydrobenzothiazole-2-ylamine No 
2 N21 2-chloro-1-indolinylethan-1-one No 
2 O21 methyl 7-(methoxycarbonyl)-2,6-dimethylfurano[2',3'-
5,4]benzo[b]furan-3-carbox ylate 
No 







2 C22 6-methyl-3-(phenyldiazenyl)-2-pyridylamine No 
2 D22 2-pyridyl-1-(2-thienyl)ethan-1-one, iodide No 
2 E22 8-bromopurine-6-ylamine No 
2 F22 3-chloro-4-morpholin-4-ylphenylamine No 
2 G22 [3,4-diacetyloxy-5-(6-hydroxypurin-9-yl)oxolan-2-yl]methyl 
acetate 
No 







2 K22 5-hexyl-2,3-diphenyl-1,2,3,4-tetraazole, chloride No 









2 O22 1-(tert-butyl)-5-nitrobenzimidazole No 
2 P22 (2-oxo-2-(2-thienyl)ethyl)thiocarbonitrile No 
Plate Well IUPAC NAME Inhibitor 
Y/N 
3 A03 5-undecyl-1,3,4-thiadiazole-2-ylamine No 
3 B03 3,4-diphenyl-1-(piperidylmethyl)-1,2,4-triazoline-5-thione No 
3 C03 2-[(2,6-dichlorophenyl)methylthio]benzoxazole No 
3 D03 2-amino-6-(aminocarbonylamino)hexanoic acid No 
3 E03 5-phenyl-4-benzyl-1,2,4-triazole-3-thiol No 
3 F03 (2-chloroethyl)(phenylsulfonyl)amine No 
3 G03 purine-2,6-diamine No 




3 J03 4,7-dimethylpyridino[3,2-h]quinoline, oxamethane No 
3 K03 5-nitro-3-hydrobenzimidazol-2-one No 
3 L03 2-(2-amino-6-oxohydropurin-9-yl)-4-phenylcarbonyloxy-5-
(phenylcarbonyloxymethy l)oxolan-3-yl benzoate 
No 
3 M03 bis(5-chloro-3-methyl-1-phenylpyrazol-4-yl)diazene No 
3 N03 2,2-dimethyl-5-nitrobenzo[d]1,3-dioxolene No 
3 O03 5-(2-phenylethyl)-4-benzyl-1,2,4-triazole-3-thiol No 
3 P03 1-(phenylsulfonyl)pyrrolidine-2-carboxylic acid No 
3 A04 1-phenylbenzimidazole-2-thiol No 




3 D04 2-ethylthiobenzimidazole No 
3 E04 5-acetyl-2-amino-4-methyl-1,3-thiazole No 
3 F04 4-[(2-methylpiperidyl)sulfonyl]phenylamine No 




3 I04 4-((1Z)-2-nitrovinyl)-1,2-dimethoxybenzene No 
3 J04 4-phenyl-5-(phenoxymethyl)-1,2,4-triazole-3-thiol No 
3 K04 2-chloro-N-(2-furylmethyl)acetamide No 
3 L04 di2-nitro-4-(trifluoromethyl)phenyl disulfide No 
3 M04 (methylsulfonyl)indoline No 
3 N04 5-(phenoxymethyl)-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
3 O04 4-benzoxazol-2-yl-2,6-dichlorophenylamine No 
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3 P04 2,6-dibromo-4-(6-methylbenzothiazol-2-yl)phenylamine No 
3 A05 [5-(2,4-dichlorophenyl)-2-furyl]methan-1-ol No 
3 B05 methyl 2-amino-4-methyl-1,3-thiazole-5-carboxylate No 
3 C05 3-(1,3-oxazolino[4,5-b]pyridin-2-yl)phenylamine No 
3 D05 3-(5,7-dimethylbenzoxazol-2-yl)-4-chlorophenylamine No 
3 E05 3-benzoxazol-2-yl-4-chlorophenylamine No 
3 F05 4-chloro-3-(5-chlorobenzoxazol-2-yl)phenylamine No 
3 G05 5-(5,7-dimethylbenzoxazol-2-yl)-2-methylphenylamine No 
3 H05 2-methyl-5-(5-methylbenzoxazol-2-yl)phenylamine No 
3 I05 2-methyl-5-(6-methylbenzoxazol-2-yl)phenylamine No 
3 J05 4-(5-chlorobenzoxazol-2-yl)phenylamine No 
3 K05 2-(4-chlorophenyl)benzoxazole-5-ylamine No 
3 L05 2-(2,4-dichlorophenyl)benzoxazole-5-ylamine No 
3 M05 2-(2,5-dichlorophenyl)benzoxazole-5-ylamine No 
3 N05 2-(3,4-dichlorophenyl)benzoxazole-5-ylamine No 
3 O05 2-(5-bromo-2-chlorophenyl)benzoxazole-5-ylamine No 
3 P05 2-naphthylbenzoxazole-5-ylamine YES 
3 A06 2-phenyl-2-hydrobenzotriazole-5-ylamine No 
3 B06 2-(4-methoxyphenyl)-2-hydrobenzotriazole-5-ylamine No 
3 C06 2-(4-ethoxyphenyl)-2-hydrobenzotriazole-5-ylamine No 
3 D06 2-(3-chlorophenyl)-2-hydrobenzotriazole-5-ylamine No 
3 E06 2-(4-chlorophenyl)-2-hydrobenzotriazole-5-ylamine No 
3 F06 4-amino-2-(5-chlorobenzoxazol-2-yl)phenol No 
3 G06 2-(4-phenylphenyl)benzoxazole-5-ylamine No 
3 H06 2-(4-fluorophenyl)-2-hydrobenzotriazole-5-ylamine No 
3 I06 2-(4-bromophenyl)-2-hydrobenzotriazole-5-ylamine No 
3 J06 2-naphthyl-2-hydrobenzotriazole-5-ylamine No 
3 K06 2-(3,5-dichloro-4-methoxyphenyl)benzoxazole-5-ylamine No 
3 L06 2-chloro-N-(5-ethyl(1,3,4-thiadiazol-2-yl))acetamide No 




3 O06 (4-bromophenyl)[(4-chlorophenyl)sulfonyl]amine No 
3 P06 benzothiazol-2-yl[(4-chlorophenyl)sulfonyl]amine No 
3 A07 1-[3-(dimethylamino)prop-1-ynyl]cyclohexan-1-ol No 
3 B07 4-(diethylamino)-1,1-diphenylbut-2-yn-1-ol No 
3 C07 (2-(1,3-dioxolan-4-ylidene)ethyl)diethylmethylamine, iodide No 
3 D07 4-[2-(methylpiperidyl)ethylidene]-1,3-dioxolane, iodide No 






















3 M07 (1E)-1-acridin-9-yl-2-phenyl-1-azaethene No 
3 N07 2-((1E)-2-phenyl-1-azavinyl)-1,3-thiazole No 
3 O07 2-[(1E)-2-(4-chlorophenyl)-1-azavinyl]-1,3-thiazole No 
3 P07 2-((1E)-2-(2-furyl)-1-azavinyl)-4-phenyl-1,3-thiazole No 
3 A08 2-((1E)-2-(2-furyl)-1-azavinyl)-1,3-thiazole No 
3 B08 [4-((1E)-2-(1,3-thiazol-2-yl)-2-azavinyl)phenyl]dimethylamine No 







3 F08 5-(2-furylmethylene)-1,3-dihydropyrimidine-2,4,6-trione No 
3 G08 2-[2-(diethylamino)-isopropyl]benzo[c]azoline-1,3-dione YES 





























3 C09 methyl 4-(6-bromo(2H-benzo[d]1,3-dioxolan-5-yl))-2,7,7-
trimethyl-5-oxo-1,4,6,7 ,8-pentahydroquinoline-3-carboxylate 
No 
3 D09 methylethyl 4-(6-bromo(2H-benzo[d]1,3-dioxolan-5-yl))-2-methyl-
5-oxo-1,4,6,7,8 -pentahydroquinoline-3-carboxylate 
No 
3 E09 cyclohexyl 2,7,7-trimethyl-5-oxo-4-(3,4,5-trimethoxyphenyl)-
1,4,6,7,8-pentahyd roquinoline-3-carboxylate 
No 
3 F09 2-methoxyethyl 4-(6-bromo(2H-benzo[d]1,3-dioxolen-5-yl))-2,7,7-
trimethyl-5-oxo -1,4,6,7,8-pentahydroquinoline-3-carboxylate 
No 
3 G09 4-(3-iodophenyl)-1,3,4-trihydrobenzo[h]quinolin-2-one No 






3 J09 ethyl 4-methyl-2-oxo-6-(2-thienyl)-1,3,6-trihydropyrimidine-5-
carboxylate 
No 
3 K09 4-(4-iodophenyl)-1,3,4-trihydrobenzo[h]quinolin-2-one No 







3 O09 4-(chloromethyl)-1-[4-(chloromethyl)phenylthio]benzene No 




3 B10 [(dimethylamino)sulfonyl](3-nitrophenyl)amine No 
3 C10 1-morpholin-4-yl-2-(morpholin-4-ylsulfonyl)-4-nitrobenzene No 
3 D10 1-(2,4-dinitrophenyl)-5-ethoxy-3-methylpyrazole No 
3 E10 3,7-dibromobenzo[b]benzo[b]thiophene No 
3 F10 5-nitrospiro[benzo[d]1,3-dioxolene-2,1'-cyclopentane] No 
3 G10 3-methylthio-4,5-diphenyl-1,2,4-triazole No 




3 J10 2-methoxydibenzo[b,e]thiin-10-one No 
3 K10 (cyclohexylamino)(2-pyridylamino)methane-1-thione No 
3 L10 3-phenyl-4-hydroisoxazol-5-one No 
3 M10 3-(4-decyloxyphenyl)-4-prop-2-enyl-1,2,4-triazoline-5-thione No 
3 N10 1-(3-fluorophenyl)-4,4,6-trimethyl-1,3,4-trihydropyridine-2-thione No 
3 O10 5-[3,5-bis(trifluoromethoxy)phenyl]furan-2-carbaldehyde No 
3 P10 5,6,7,8,10-pentahydroacridin-9-one No 









3 D11 methylbeta-carboline No 
3 E11 4-oxopyran-2,6-dicarboxylic acid No 
3 F11 [5-(4-amino-2-oxohydropyrimidinyl)-3,4-dihydroxyoxolan-2-
yl]methyl dihydrogen phosphate, sodium salt, sodium salt 
No 
3 G11 2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl 
dihydrogen phosph ate 
No 
3 H11 [5-(2,4-dioxo(1,3-dihydropyrimidinyl))-3,4-dihydroxyoxolan-2-








3 K11 4-(1,3-thiazol-2-yldiazenyl)benzene-1,3-diol No 
3 L11 [5-(4-amino-2-oxohydropyrimidinyl)-3,4-dihydroxyoxolan-2-
yl]methyl dihydrogen phosphate 
No 
3 M11 [5-(4-amino-2-oxohydropyrimidinyl)-3-hydroxyoxolan-2-













(phenylcarbonyloxy methyl)oxolan-3-yl benzoate 
No 
3 B12 [3,4-diacetyloxy-5-(2,4-dioxo(1,3-dihydropyrimidinyl))oxolan-2-














3 G12 3-phenyl-2-thioxo-1,3-diazolidin-4-one No 
3 H12 3-(5,6-dimethylbenzoxazol-2-yl)-4-chlorophenylamine No 
3 I12 2-(3-iodophenyl)benzoxazole-5-ylamine No 
3 J12 2-(4-iodophenyl)benzoxazole-5-ylamine No 
3 K12 2-[4-(tert-butyl)phenyl]benzoxazole-5-ylamine No 
3 L12 4-(5,7-dichlorobenzoxazol-2-yl)phenylamine YES 
3 M12 2-((1E)-2-nitroprop-1-enyl)thiophene No 
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3 N12 4-iodo-2,5-dioctyloxybenzaldehyde No 







3 B13 methylethyl (2Z)-3-(2-bromo(3-thienyl))-2-cyanoprop-2-enoate No 







































































































































3 A16 2,6-diamino-4-(3-pyridyl)-4H-chromene-3-carbonitrile, chloride No 




































































3 J17 3,5-diaminothiopheno[3,2-b]thiophene-2,6-dicarbonitrile No 
3 K17 4-methyl-6-(3-pyridyl)-2-thioxohydropyridine-3-carbonitrile No 
3 L17 [(3,5-dimethoxyphenyl)methylene]methane-1,1-dicarbonitrile No 











































































3 G19 2-(4-bromo-5-methyl-3-nitropyrazolyl)acetic acid No 
3 H19 2-(3,5-dimethyl-4-nitropyrazolyl)acetic acid No 
3 I19 methyl 5-(methoxycarbonyl)-2,6-
dioxotricyclo[3.3.1.1<3,7>]decanecarboxylate 
No 









3 M19 4-[(2-furylmethyl)amino]-3-hydroxythiolane-1,1-dione No 
3 N19 ethyl 6-methyl-2-[(methylsulfonyl)amino]-4,5,6,7-
tetrahydrobenzo[b]thiophene-3 -carboxylate 
No 






3 A20 2-methylpropyl 6-(6-bromo(2H-benzo[d]1,3-dioxolan-5-yl))-3,4-
dimethyl-2-oxo-1, 3,6-trihydropyrimidine-5-carboxylate 
No 

































3 M20 prop-2-enyl 6-(6-bromo(2H-benzo[d]1,3-dioxolan-5-yl))-3-ethyl-4-
methyl-2-oxo-1 ,3,6-trihydropyrimidine-5-carboxylate 
No 









3 A21 4-phenyl-2-hydrophthalazin-1-one No 
3 B21 4-phenyl-2-(2-phenylethyl)-2-hydrophthalazin-1-one No 
3 C21 7-nitro-2-(2-thienyl)benzo[d]1,3-oxazin-4-one No 
3 D21 ethyl 6-methyl-2-(2-morpholin-4-ylacetylamino)-4,5,6,7-
tetrahydrobenzo[b]thiop hene-3-carboxylate 
No 
3 E21 ethyl 2-(2-azaperhydroepinylacetylamino)-4,5,6-
trihydrocyclopenta[2,1-b]thioph ene-3-carboxylate 
No 
3 F21 ethyl 6-methyl-2-(2-piperidylacetylamino)-4,5,6,7-
tetrahydrobenzo[b]thiophene- 3-carboxylate 
No 
3 G21 ethyl 2-(2-morpholin-4-ylacetylamino)-4,5,6-
trihydrocyclopenta[2,1-b]thiophene -3-carboxylate 
YES 
3 H21 ethyl 2-(2-morpholin-4-ylacetylamino)-4,5,6,7-
tetrahydrobenzo[b]thiophene-3-ca rboxylate 
No 
3 I21 6-(2-furyl)-1-phenylpyrazolo[5,4-d]1,3-oxazin-4-one No 
3 J21 ethyl 2-(adamantanylcarbonylamino)-3-(ethoxycarbonyl)-4,5,6,7-
tetrahydrothioph eno[2,3-c]pyridine-6-carboxylate 
No 
3 K21 ethyl 3-(ethoxycarbonyl)-2-(propanoylamino)-4,5,6,7-
tetrahydrothiopheno[2,3-c] pyridine-6-carboxylate 
No 
3 L21 ethyl 3-(ethoxycarbonyl)-2-(2-thienylcarbonylamino)-4,5,6,7-
tetrahydrothiophen o[2,3-c]pyridine-6-carboxylate 
No 








3 O21 ethyl 3-(ethoxycarbonyl)-2-(2,2,2-trifluoroacetylamino)-4,5,6,7-
tetrahydrothio pheno[2,3-c]pyridine-6-carboxylate 
No 





















3 G22 2-phenylbenzo[d]1,3-oxazin-4-one No 
3 H22 3-amino-2-phenyl-3-hydroquinazolin-4-one No 
3 I22 2-(2-fluorophenyl)benzo[d]1,3-oxazin-4-one No 
3 J22 2-(2-pyridyl)benzo[d]1,3-oxazin-4-one No 
3 K22 2-(2-furyl)-3-hydroquinazolin-4-one No 
3 L22 2-(2-furyl)-3-phenyl-3-hydroquinazolin-4-one No 
3 M22 3-amino-2-(2-furyl)-3-hydroquinazolin-4-one No 






3 P22 3-phenyl-2-(trifluoromethyl)-3-hydroquinazolin-4-one No 
Plate Well IUPAC NAME Inhibitor 
Y/N 
4 A03 2-methyl-3-(2-pyridyl)-3-hydroquinazolin-4-one No 










































4 P03 1-(4-bromophenyl)-2-(3-bromopyridyl)ethan-1-one, bromide No 
4 A04 2-(2-amino-4-methylpyridyl)-1-(4-bromophenyl)ethan-1-one, 
bromide 
No 
4 B04 1-(4-bromophenyl)-2-pyridylethan-1-one, bromide No 
4 C04 2-(hydroxymethyl)-1-[(4-methylphenyl)sulfonyl]pyrrolidine No 













4 I04 [((1E)-2-(2-furyl)-1-azaprop-1-enyl)amino]aminomethane-1-thione No 
4 J04 [((1E)-2-(2-thienyl)-1-azaprop-1-enyl)amino]aminomethane-1-thione No 










4 O04 6-[(1E)-2-(3,5-dichlorophenyl)-2-azavinyl]-4-bromo-2-nitrophenol No 
4 P04 6-[(1E)-2-(2,5-dichlorophenyl)-2-azavinyl]-4-bromo-2-nitrophenol No 
4 A05 6-[(1E)-2-(4-nitrophenyl)-2-azavinyl]-4-bromo-2-nitrophenol No 
4 B05 6-[(1E)-2-(4-bromophenyl)-2-azavinyl]-4-bromo-2-nitrophenol No 
4 C05 6-[(1E)-2-(4-iodophenyl)-2-azavinyl]-4-bromo-2-nitrophenol No 




















































































4 D07 ethyl 2-(4-morpholin-4-yl-1,2,5-thiadiazol-3-yloxy)acetate No 
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4 E07 4-morpholin-4-yl-1,2,5-thiadiazol-3-ol No 
4 F07 3-chloro-4-morpholin-4-yl-1,2,5-thiadiazole No 
4 G07 3-(4-amino(1,2,5-oxadiazol-3-yl))-2-imino-1,3-thiazolidin-4-one No 
4 H07 2-imino-3-(1,3-thiazol-2-yl)-1,3-thiazolidin-4-one YES 
4 I07 6-methyl-4H,8H-1,2,5-oxadiazolo[3,4-b]1,4-diazepin-5-one No 




4 L07 oxolan-2-ylmethyl 6-(6-bromo(2H-benzo[d]1,3-dioxolen-5-yl))-4-
methyl-2-oxo-1,3 ,6-trihydropyrimidine-5-carboxylate 
No 
4 M07 methylpropyl 3a,8b-dihydroxy-2-methyl-4-oxoindano[2,1-d]2-
pyrroline-3-carboxyl ate 
No 
4 N07 pentyl 6-(6-bromo(2H-benzo[d]1,3-dioxolen-5-yl))-4-methyl-2-oxo-
1,3,6-trihydro pyrimidine-5-carboxylate 
No 
4 O07 cyclopentyl 2-methyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-
pentahydroquinoline-3-carbo xylate 
No 
4 P07 2-methoxyethyl 2,7,7-trimethyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-
pentahydroquinoli ne-3-carboxylate 
No 
4 A08 cyclohexyl 2,7,7-trimethyl-5-oxo-4-(4-pyridyl)-1,4,6,7,8-
pentahydroquinoline-3 -carboxylate 
No 
4 B08 methylethyl 2-methyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-
pentahydroquinoline-3-carbo xylate 
No 
4 C08 methylethyl 2,7,7-trimethyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-
pentahydroquinoline- 3-carboxylate 
No 
4 D08 2-phenoxyethyl 3-methyl-4H-benzo[e]1,4-thiazine-2-carboxylate No 
4 E08 cyclohexyl 2,7,7-trimethyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-
pentahydroquinoline-3 -carboxylate 
No 
4 F08 propyl 4-(6-bromo(2H-benzo[d]1,3-dioxolan-5-yl))-2,7,7-trimethyl-
5-oxo-1,4,6,7 ,8-pentahydroquinoline-3-carboxylate 
No 




4 H08 (6-azabicyclo[4.4.0]dec-2-yl)methan-1-ol No 
4 I08 ethyl 6-(4-nitropyrazol-3-yl)-8-hydropyrazolo[1,5-a]pyrimidine-3-
carboxylate 
No 





























































4 O09 2-(3-benzimidazol-2-ylpropyl)benzimidazole No 
4 P09 2-methyl-1,3-dinonylimidazole, bromide YES 
4 A10 2-benzimidazol-2-ylethanenitrile No 
4 B10 5,6-dimethyl-1,3-dinonylbenzimidazole, bromide YES 
4 C10 3,7-dimethyl-1-nonyl-1,3,7-trihydropurine-2,6-dione No 
4 D10 1-nonyl-2-[3-(1-nonylbenzimidazol-2-yl)propyl]benzimidazole No 
























4 M10 6-phenyl-2-thioxo-4-(trifluoromethyl)hydropyridine-3-carbonitrile No 
4 N10 6-(2-thienyl)-2-thioxo-4-(trifluoromethyl)pyran-3-carbonitrile No 
4 O10 6-chloro-3-hydrobenzoxazol-2-one No 
4 P10 4,5-dihydroxynaphthalene-2,7-disulfonic acid No 
4 A11 2-cyclopent-2-enylpropanedioic acid No 




4 D11 4-{[4-(2-aminoethyl)piperazinyl]methyl}-3,5-bis(tert-butyl)phenol No 
4 E11 3,3,5,5-tetramethylmorpholine No 
4 F11 2,3,3-trimethyl-3H-pyrrolo[3,2-h]quinoline No 




















4 O11 tert-butyl 6-amino-5-cyano-10-methylspiro[4H-pyrano[2,3-
c]pyrazole-4,4'-piperi dine]-3-carboxylate 
No 




imidazolino[1,2-b]3-pyrazo lin-6-one, bromide 
No 
4 B12 (2S)-4-oxo-1-(1,1,2,2-tetramethyl-1-silapropyl)azetidine-2-carboxylic 
acid 
No 
4 C12 3,4-bis(diphenylmethyl)-1,2,5-oxadiazol-2-ol No 
4 D12 4-(5,7-dimethylbenzoxazol-2-yl)phenylamine No 






4 G12 (benzimidazol-2-ylmethoxy)benzene No 
4 H12 4-(hydroxyimino)-3-methyl-1-phenyl-1,2-diazolin-5-one No 
4 I12 2,3,4,7,3a-pentahydrobenzimidazole-2-carboxylic acid, hydrate, 
hydrate 
No 
4 J12 methyl quinoline-2-carboxylate No 
4 K12 6-???-2,3-dihydrophthalazine-1,4-dione No 
4 L12 5-(3-fluorophenyl)-4-phenyl-1,2,4-triazole-3-thiol No 











4 B13 5-(4-nitrophenyl)-1H-1,2,4-triazole-3-thiol No 
4 C13 spiro[3H-benzo[e]1,3-oxazaperhydroine-2,1'-cyclohexane]-4-one No 
4 D13 spiro[1,2,3,5,6,7,8-heptahydroquinazoline-2,1'-cyclohexane]-4-one No 
4 E13 4-amino-3-ethyl-2-thioxo-1,3-thiazoline-5-carboxamide No 
4 F13 5-ethoxy-3-methyl-1-(4-nitrophenyl)pyrazole No 
4 G13 4-(4-nitrophenyl)-1,3-dioxan-5-ol No 
4 H13 1,3,5-trihydrofurano[3,4-d]pyrimidine-2,4,7-trione No 
4 I13 2-(4-chlorophenyl)-5-methyl-5-pentyl-1,2,4-triazolidine-3-thione No 







4 M13 4-(1,3-dithiolan-2-yl)-1-methoxy-2-nitrobenzene No 
4 N13 2-(1,3-dithiolan-2-yl)-1-(2-furylmethylthio)-4-nitrobenzene No 
4 O13 cyclododecylideneazamethyl 4-fluorobenzoate No 
4 P13 N-(3,5-dichlorophenyl)-2-(1-methylimidazol-2-ylthio)acetamide No 
4 A14 1-(4-fluorophenyl)azolidine-2,5-dione No 
4 B14 1-(2,4-difluorophenyl)azolidine-2,5-dione No 
4 C14 N-(4-fluorophenyl)-2-(1-methylimidazol-2-ylthio)acetamide No 
4 D14 N-(4-fluorophenyl)-2-(4-methyl(1,2,4-triazol-3-ylthio))acetamide No 




4 G14 3-(2,5-difluorophenyl)-2-methyl-3-hydroquinazolin-4-one YES 
4 H14 (benzotriazolylmethyl)(2,3,4-trifluorophenyl)amine No 






4 K14 N-(2,5-difluorophenyl)-2-(4-methyl(1,2,4-triazol-3-ylthio))acetamide No 







4 O14 2-((1E)-2-phenylvinyl)benzo[d]1,3-oxazin-4-one No 
4 P14 3-amino-2-(2-thienyl)-3-hydroquinazolin-4-one No 
4 A15 2-[3-(trifluoromethyl)phenyl]benzo[d]1,3-oxazin-4-one No 
4 B15 (benzotriazolylmethyl)(3,4-dichlorophenyl)amine No 
4 C15 5-(5-bromo(2-thienyl))-2-(4-chlorophenyl)-1,3-thiazole No 








octahydrophenanthren ecarboxylic acid 
No 







4 K15 5-[(1E)-2-(4-morpholin-4-ylphenyl)-2-azavinyl]-2-nitrothiophene No 







4 O15 1-(4-chlorophenyl)-4-hydroimidazo[1,5-a]pyridine No 








4 D16 [5-(2,4-dichlorophenyl)-2-thioxo-1,3,4-oxadiazolin-3-yl]methan-1-ol No 








2-carboxyl ic acid 
No 







4 L16 2-(4-bromophenyl)-3-(4-methoxyphenyl)-1,3-oxazolidine-4-thione No 
4 M16 2-(4-bromophenyl)-3-phenyl-1,3-oxazolidine-4-thione No 
4 N16 2,3-bis(4-bromophenyl)-1,3-oxazolidine-4-thione No 
4 O16 (3-pyridylmethyl)(2-thienylsulfonyl)amine No 




















4 H17 3-methyl-6-nitro-3-hydroquinazolin-4-one No 
4 I17 ethyl 2-amino-5-(N,N-diethylcarbamoyl)-4-methylthiophene-3-
carboxylate 
No 
4 J17 adamantanyl-N-(2-hydroxyethyl)carboxamide No 
4 K17 1-(cyclohexylideneazamethoxy)-4-nitrobenzene No 
4 L17 1-(methylsulfonyl)-5-nitroindoline No 
4 M17 8-nitro-1,2,3,4-tetrahydrobenzo[d]benzo[1,2-b]furan No 
4 N17 2-amino-4,5-dimethylthiophene-3-carboxamide No 
4 O17 (4-methoxyphenyl)purin-6-ylamine No 
4 P17 methyl 1-(2-furylmethyl)-2-methyl-5-oxo-2-pyrroline-3-carboxylate No 
4 A18 1,4-bis(methylsulfonyl)piperazin-2-one No 
4 B18 4-[(4-bromophenyl)methylene]-3-(2-fluorophenyl)isoxazol-5-one No 




4 E18 4-[(2,4-dichlorophenyl)methylene]-3-(4-bromophenyl)isoxazol-5-one No 
4 F18 4-((2E)-3-phenylprop-2-enylidene)-3-(4-bromophenyl)isoxazol-5-one No 






4 I18 4-[(2,4-dichlorophenyl)methylene]-3-(3-iodophenyl)isoxazol-5-one No 
4 J18 4-((2E)-3-phenylprop-2-enylidene)-3-(3-iodophenyl)isoxazol-5-one No 
4 K18 3-(2,4-dichlorophenyl)-4-[(2-bromophenyl)methylene]isoxazol-5-one No 




4 N18 3-(2-fluorophenyl)-4-[(2-fluorophenyl)methylene]isoxazol-5-one No 
4 O18 4-[(3-bromophenyl)methylene]-3-(2-fluorophenyl)isoxazol-5-one No 
4 P18 3-(4-nitrophenyl)-4-(3-pyridylmethylene)isoxazol-5-one No 




4 C19 4-((2E)-3-phenylprop-2-enylidene)-3-(2-thienyl)isoxazol-5-one No 




4 F19 4-(2-furylmethylene)-3-(2-thienyl)isoxazol-5-one No 
4 G19 3-(4-chloro-3-nitrophenyl)-4-(3-pyridylmethylene)isoxazol-5-one No 
4 H19 4-[(2,4-dichlorophenyl)methylene]-3-naphthylisoxazol-5-one No 




4 K19 3-phenyl-4-(piperidylmethylene)isoxazol-5-one No 
4 L19 3-(2-furyl)-4-(2-furylmethylene)isoxazol-5-one No 


















4 E20 5-ethyl-2-ethylthiothiophene-3-carboxylic acid No 









4 I20 2,3-bis(ethylsulfonyl)thiophene No 
4 J20 2,4-dinitro-1-(2-thienylthio)benzene No 
4 K20 2,5-bis(ethylsulfonyl)thiophene No 
4 L20 2,5-bis(methylsulfonyl)thiophene No 




4 O20 2-ethyl-5-ethylthio-4-formylthiophene-3-carboxylic acid No 
4 P20 5-methyl-2-(methylsulfonyl)thiophene-3-carboxylic acid, hydrate No 
4 A21 5-methyl-2-methylthiothiophene-3-carboxamide No 
4 B21 2-acetyl-5-methylthiothiophene No 
4 C21 (hydroxyimino)(5-methyl-2-methylthio(3-thienyl))methane No 
4 D21 5-ethyl-3-ethylthiothiophene-2-carboxylic acid No 
4 E21 3-((hydroxyimino)methyl)-5-methyl-2-(methylsulfonyl)thiophene No 
4 F21 5-ethylthiopheno[2,3-b]thiophene-2-carboxylic acid No 
4 G21 [4-(hydroxymethyl)-2,5-dimethylthio-3-thienyl]methan-1-ol No 
4 H21 [(5-ethyl-2-ethylthio-3-thienyl)methylene]methane-1,1-dicarbonitrile No 
4 I21 5-(4-nitrophenyl)-3-(3-pyridyl)-1,2,4-oxadiazole No 
4 J21 5-(4-bromophenyl)-3-(3-pyridyl)-1,2,4-oxadiazole No 










4 O21 ethyl (2Z)-3-{[4-(acetylamino)(1,2,5-oxadiazol-3-yl)]amino}but-2-
enoate 
No 



























































5 F03 2,6-diamino-4-(2,5-diethoxyphenyl)-4H-thiin-3,5-dicarbonitrile No 
5 G03 ethyl 6-amino-5-cyano-2-methyl-4-(2,4,6-trimethyl-3,5-
dinitrophenyl)-4H-pyran- 3-carboxylate 
No 


























5 B04 3-amino-7-hydroxy-8aH-chromene-4-carbonitrile No 
5 C04 N-(3,4-dichlorophenyl)(cyclohexylamino)carboxamide No 
5 D04 [(5-methyl-2-thienyl)methylene]methane-1,1-dicarbonitrile No 
5 E04 methyl (2E)-2-cyano-3-(5-methyl(2-thienyl))prop-2-enoate No 
5 F04 [(5-ethyl-2-thienyl)methylene]methane-1,1-dicarbonitrile No 




5 I04 ethyl 4-(4-bromo(2-thienyl))-2,7,7-trimethyl-5-oxo-1,4,6,7,8-
pentahydroquinoli ne-3-carboxylate 
No 










5 N04 2-(acetylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide No 




5 A05 methyl (2E)-2-cyano-3-(5-ethyl(2-thienyl))prop-2-enoate No 
5 B05 ethyl (2E)-3-(5-butyl-4-nitro(2-thienyl))-2-cyanoprop-2-enoate No 
5 C05 methyl (2E)-3-(5-butyl-4-nitro(2-thienyl))-2-cyanoprop-2-enoate No 
5 D05 5-methyl-3-nitropyrazole-4-carboxylic acid No 
5 E05 4-bromo-5-methyl-1,3-dinitropyrazole No 




5 H05 ethyl (2E)-3-(4-bromo(2-thienyl))-2-cyanoprop-2-enoate No 
5 I05 5-bromothiophene-2-carboxylic acid No 





5 L05 (2E)-2-(aminothioxomethyl)-3-(5-bromo(2-thienyl))prop-2-enenitrile No 
5 M05 1-(2,5-dimethyl(3-thienyl))-2-chloroethan-1-one No 
















5 D06 (2Z)-3-(2,6-dichlorophenyl)-2-(2-pyridyl)prop-2-enenitrile No 
5 E06 7-chloro-1-cyclopropyl-6-fluoro-4-oxohydroquinoline-3-carboxylic 
acid 
No 
5 F06 3,4,5,6-tetraphenyl-7-(phenylcarbonyl)-3H,6H-azocin-2-one No 
































5 B07 2-methoxy-4,6-diphenylpyridine-3-carbonitrile OFFSCALE 







5 F07 ethyl 3,5-dimethyl-4-(2-methylpropyl)pyrrole-2-carboxylate No 



























































5 L08 3-amino-1-phenyl-1,2,4-triazoline-5-thione No 
5 M08 N-(5-ethylthio(1,3,4-thiadiazol-2-yl))hexyloxycarboxamide No 
5 N08 5-methylthio-1-phenyl-1,2,4-triazole-3-ylamine No 
5 O08 5-octylthio-1-phenyl-1,2,4-triazole-3-ylamine No 
5 P08 bis(4-methyl-2-pyridyl)diazene No 




5 C09 3-(methoxy(hydroxyphosphoryl))propanohydrazide No 









5 G09 bis(2-chloro-3-pyridyl)diazene No 
5 H09 bis(5-bromo-2-pyridyl)diazene No 
5 I09 3-(tert-butyl)-5,6-dimethyl-1,3-dihydropyrimidine-2,4-dione No 
5 J09 methyl 4-amino-3,5,6-trichloropyridine-2-carboxylate No 
5 K09 (4,6-dichloro(1,3,5-triazin-2-yl))methylamine No 
5 L09 N-benzimidazol-2-ylmethoxycarboxamide No 
5 M09 9-hydroxyfluorene-9-carboxylic acid No 
5 N09 (3-(hydroxyimino)-1,1-dimethylbutyl)dimethoxyphosphino-1-one No 
5 O09 benzylpurin-6-ylamine No 
5 P09 [(dibutoxycarbonyl)methoxy]-N-(3,4-dichlorophenyl)carboxamide No 
5 A10 3-benzimidazol-2-ylpropan-1-ol No 
5 B10 2-chloro-N-(2-pyridyl)acetamide No 
5 C10 2-chloro-N-pyrimidin-2-ylacetamide No 
5 D10 ethyl 4-amino-2-methylthio-1,3-thiazole-5-carboxylate No 





















5 L10 4-oxohydroquinoline-3-carboxylic acid No 
5 M10 N,N-diethyl(4-oxo(3-hydroquinolyl))carboxamide No 
5 N10 3-(piperidylcarbonyl)hydroquinolin-4-one No 
5 O10 N-butyl(2-oxoimidazolidinyl)carboxamide No 
5 P10 (2-oxoimidazolidinyl)-N,N-dipropylcarboxamide No 
5 A11 N-(tert-butyl)-N-(2-cyanoethyl)(2-oxoimidazolidinyl)carboxamide No 
5 B11 N-cyclohexyl(2-oxoimidazolidinyl)carboxamide No 
5 C11 N-(3-chlorophenyl)(2-oxoimidazolidinyl)carboxamide No 
5 D11 N-(3,4-dichlorophenyl)(2-oxoimidazolidinyl)carboxamide No 
5 E11 N-(2,4-dichlorophenyl)(2-oxoimidazolidinyl)carboxamide No 










5 J11 N-(4-amino(1,2,5-oxadiazol-3-yl))-2-naphthylthioacetamide No 






































5 I12 4-[(2,4-dichlorophenyl)methylene]-3-phenylisoxazol-5-one No 
5 J12 4-[(5-bromo(2-thienyl))methylene]-3-phenylisoxazol-5-one YES 
















5 A13 (2Z)-2-cyano-3-(5-methyl(2-furyl))prop-2-enamide No 






5 D13 (2Z)-2-(aminothioxomethyl)-3-(5-methyl(2-furyl))prop-2-enenitrile No 
5 E13 methyl (2Z)-2-cyano-3-(5-methyl(2-furyl))prop-2-enoate No 








5 J13 4-[(4-fluorophenyl)methylene]-3-phenylisoxazol-5-one No 
5 K13 4-[(1-methylpyrrol-2-yl)methylene]-3-phenylisoxazol-5-one No 
5 L13 3-phenyl-4-(3-pyridylmethylene)isoxazol-5-one No 
5 M13 ethyl (2Z)-2-cyano-3-(1-methylpyrrol-2-yl)prop-2-enoate No 




5 P13 (2Z)-2-cyano-3-(1-methylpyrrol-2-yl)prop-2-enamide No 




























































5 G15 2,6-diamino-4-(5-methyl(2-thienyl))-4H-thiin-3,5-dicarbonitrile No 







5 K15 methyl 6-amino-5-cyano-2-methyl-4-(2-thienyl)-4H-pyran-3-
carboxylate 
No 
5 L15 methyl 6-amino-5-cyano-4-(5-ethyl(2-thienyl))-2-methyl-4H-pyran-
3-carboxylate 
No 
5 M15 methyl 6-amino-4-(4-bromo-5-methyl(2-thienyl))-5-cyano-2-methyl-
4H-pyran-3-car boxylate 
YES 
5 N15 methyl 6-amino-4-(4-bromo-5-ethyl(2-thienyl))-5-cyano-2-methyl-
4H-pyran-3-carb oxylate 
No 
5 O15 ethyl 6-amino-5-cyano-2-methyl-4-(5-methyl(2-thienyl))-4H-pyran-
3-carboxylate 
No 





























5 I16 ethyl 6-amino-4-(4-bromo-5-methyl(2-thienyl))-5-cyano-2-methyl-
4H-pyran-3-carb oxylate 
No 



























5 C17 methyl 2,7,7-trimethyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-
pentahydroquinoline-3-car boxylate 
No 
5 D17 methyl 4-(5-ethyl(2-thienyl))-2,7,7-trimethyl-5-oxo-1,4,6,7,8-
pentahydroquinol ine-3-carboxylate 
No 
5 E17 methyl 4-(4-bromo-5-methyl(2-thienyl))-2,7,7-trimethyl-5-oxo-
1,4,6,7,8-pentahy droquinoline-3-carboxylate 
No 
5 F17 methyl 4-(4-bromo-5-ethyl(2-thienyl))-2,7,7-trimethyl-5-oxo-
1,4,6,7,8-pentahyd roquinoline-3-carboxylate 
No 
5 G17 ethyl 2,7,7-trimethyl-4-(5-methyl(2-thienyl))-5-oxo-1,4,6,7,8-
pentahydroquinol ine-3-carboxylate 
No 
5 H17 ethyl 4-(5-ethyl(2-thienyl))-2,7,7-trimethyl-5-oxo-1,4,6,7,8-
pentahydroquinoli ne-3-carboxylate 
No 
5 I17 ethyl 4-(4-bromo-5-methyl(2-thienyl))-2,7,7-trimethyl-5-oxo-
1,4,6,7,8-pentahyd roquinoline-3-carboxylate 
No 
5 J17 ethyl 4-(4-bromo-5-ethyl(2-thienyl))-2,7,7-trimethyl-5-oxo-1,4,6,7,8-
pentahydr oquinoline-3-carboxylate 
No 
5 K17 ethyl 2,7,7-trimethyl-4-(5-methyl-4-nitro(2-thienyl))-5-oxo-1,4,6,7,8-
pentahyd roquinoline-3-carboxylate 
No 
5 L17 methyl 2-methyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-pentahydroquinoline-
3-carboxylat e 
No 





5 N17 methyl 4-(4-bromo-5-ethyl(2-thienyl))-2-methyl-5-oxo-1,4,6,7,8-
pentahydroquino line-3-carboxylate 
No 
5 O17 methyl 2-methyl-4-(5-methyl-4-nitro(2-thienyl))-5-oxo-1,4,6,7,8-
pentahydroquin oline-3-carboxylate 
No 
5 P17 ethyl 2-methyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-pentahydroquinoline-3-
carboxylate 
No 
5 A18 ethyl 2-methyl-4-(5-methyl(2-thienyl))-5-oxo-1,4,6,7,8-
pentahydroquinoline-3-c arboxylate 
No 
5 B18 ethyl 4-(5-ethyl(2-thienyl))-2-methyl-5-oxo-1,4,6,7,8-
pentahydroquinoline-3-ca rboxylate 
No 
5 C18 ethyl 4-(4-bromo-5-methyl(2-thienyl))-2-methyl-5-oxo-1,4,6,7,8-
pentahydroquino line-3-carboxylate 
No 
5 D18 ethyl 4-(4-bromo-5-ethyl(2-thienyl))-2-methyl-5-oxo-1,4,6,7,8-
pentahydroquinol ine-3-carboxylate 
No 
5 E18 ethyl 2-amino-4-(4-bromo-5-methyl(2-thienyl))-5-oxo-4H-6,7,8-
trihydrochromene- 3-carboxylate 
No 




































5 B19 (2Z)-2-(aminothioxomethyl)-3-(2-thienyl)prop-2-enenitrile No 
5 C19 (2Z)-2-(aminothioxomethyl)-3-(5-methyl(2-thienyl))prop-2-enenitrile No 
5 D19 (2Z)-2-cyano-3-(5-methyl(2-thienyl))prop-2-enamide No 
5 E19 methylethyl (2Z)-2-cyano-3-(5-ethyl(2-thienyl))prop-2-enoate No 
5 F19 (2Z)-2-(aminothioxomethyl)-3-(5-ethyl(2-thienyl))prop-2-enenitrile No 
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5 G19 (2Z)-2-cyano-3-(5-ethyl(2-thienyl))prop-2-enamide No 






5 J19 (2Z)-3-(4-bromo-5-methyl(2-thienyl))-2-cyanoprop-2-enamide No 
5 K19 methyl (2Z)-3-(4-bromo-5-ethyl(2-thienyl))-2-cyanoprop-2-enoate No 
5 L19 ethyl (2Z)-3-(4-bromo-5-ethyl(2-thienyl))-2-cyanoprop-2-enoate No 






5 O19 (2Z)-3-(4-bromo-5-ethyl(2-thienyl))-2-cyanoprop-2-enamide No 
5 P19 ethyl (2Z)-2-cyano-3-(5-methyl-4-nitro(2-thienyl))prop-2-enoate No 






5 C20 (2Z)-2-cyano-3-(5-methyl-4-nitro(2-thienyl))prop-2-enamide No 
5 D20 [(5-methyl-4-nitro-2-thienyl)methylene]methane-1,1-dicarbonitrile No 
5 E20 methyl (2Z)-2-cyano-3-(5-ethyl-4-nitro(2-thienyl))prop-2-enoate No 














5 L20 4-(4-bromophenyl)-2-(phenylazamethylene)-1,3-thiazoline No 
5 M20 5-(4-methoxyphenyl)-1,3-thiazolin-2-imine No 
5 N20 4-(2H,3H-benzo[3,4-e]1,4-dioxin-6-yl)-1,3-thiazolin-2-imine, 
bromide 
No 
5 O20 4-(2,4,6-trimethylphenyl)-1,3-thiazolin-2-imine, bromide No 
5 P20 2-{2-[(1,1-dioxobenzo[d]1,2-thiazolin-3-yl)amino]ethoxy}ethyl 5-
oxo-1-phenylpy rrolidine-3-carboxylate 
No 
5 A21 N-methyl-N-phenyl-2-(pyrrolidinylthioxomethylthio)acetamide No 
5 B21 [2-(4-amino(1,2,5-oxadiazol-3-yloxy))ethyl]phenylamine No 
5 C21 4-(5,6-dimethylbenzoxazol-2-yl)phenylamine No 
5 D21 2-(2-chloro-5-iodophenyl)benzoxazole-5-ylamine No 






5 G21 5-(2-chlorophenyl)-1H-1,2,4-triazole-3-thiol No 
5 H21 5-(3-methylbutyl)-1,3,4-thiadiazole-2-ylamine No 
5 I21 4-(nitromethyl)-2-hydrophthalazin-1-one No 
5 J21 3,4-dimethoxybenzenesulfonamide No 
5 K21 5-methylthio-1-phenyl-1,2,3,4-tetraazole No 
5 L21 adamantanylmethylamine, chloride No 
5 M21 6-hydroxy-1,4-dimethyl-2-oxohydropyridine-3-carbonitrile No 
5 N21 5-phenyl-1,3,4-oxadiazole-2-ylamine No 
5 O21 benzimidazol-2-ylphenylmethan-1-ol No 
5 P21 3-[(3-chlorophenyl)azamethylene]-1H-benzo[d]azolidin-2-one No 
5 A22 (2,4-dinitrophenyl)methylamine No 
5 B22 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-ylamine No 
5 C22 (2,4-dinitrophenyl)piperidine No 
5 D22 3,3,6,6-tetramethyl-2,3,4,5,6,7-hexahydroacridine-1,8-dione No 
5 E22 methoxy-N-(1,3-thiazol-2-yl)carboxamide No 
5 F22 9-(4-pyridylmethyl)acridine No 
5 G22 1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinoline No 
5 H22 di6-nitrobenzothiazol-2-yl disulfide No 
5 I22 [(4-iodophenyl)amino](methylamino)methane-1-thione No 
5 J22 (methylamino)morpholin-4-ylmethane-1-thione No 
5 K22 1-(1H,3H-naphtho[1,2-e]1,3-oxazin-2-yl)-2-ethoxybenzene No 




5 N22 cyclohexyl-N-(1,3-thiazol-2-yl)carboxamide No 
5 O22 amino-N-[(4-aminophenyl)sulfonyl]amide, hydrate No 
5 P22 benzo[b]furan-2-carboxylic acid No 
Plate Well IUPAC NAME Inhibitor 
Y/N 
6 A03 2-acetyl-3,6-dimethyl-7-oxo-1,3-thiazolino[3,2-b]1,2,4-triazine No 


















6 H03 5-[5-((hydroxyimino)methyl)-2-furyl]-2H-benzo[c]azoline-1,3-dione No 
6 I03 4-(2-thienyl)-2-hydrophthalazin-1-one No 
6 J03 4-amino-3-prop-2-enyl-2-thioxo-1,3-thiazoline-5-carboxamide No 
















6 A04 1,3-dimethyl-5-nitro-3-hydrobenzimidazol-2-one No 
6 B04 (indol-3-ylmethyl)dimethylamine No 
6 C04 7-methoxy-1-methyl-3,4-dihydrobeta-carboline No 
6 D04 4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene No 
6 E04 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxychromen-4-one, 
oxamethane, oxam ethane, oxamethane 
No 
6 F04 (phenylamino)-N-(1,2,3-thiadiazol-5-yl)carboxamide YES 
6 G04 2-(2-benzoxazol-2-ylthioethylthio)benzoxazole No 
6 H04 1,1,2-triphenylethane-1,2-diol No 
6 I04 hydroxy-2-pyridylmethanesulfonic acid No 
6 J04 4-nitroquinolin-1-ol No 




6 M04 2-amino-3-(oxyphosphinyloxyphosphinyl)propanoic acid No 
6 N04 3,4,5,6-tetrahydroxy-2H-3,4,5,6-tetrahydropyran-2-carboxylic acid No 




6 A05 3-(pyrrolylmethyl)pyridine No 
6 B05 2-methyl-4,9,10-trihydrobenzo[d]1,3-oxazolo[5,4-a][7]annulen-4-ol No 
6 C05 methyl 2-oxopyran-5-carboxylate No 
6 D05 1H-1,2,3-triazole-4,5-dicarboxylic acid No 
6 E05 N-(4-methyl-1,3-thiazol-2-yl)acetamide No 
6 F05 (3S,4S,2R,5R)-3,4-bis(phenylmethoxy)-5-
[(phenylmethoxy)methyl]oxolan-2-yl 4-ni trobenzoate 
No 
6 G05 2H-naphtho[2,3-c]azoline-1,3-dione No 
6 H05 (4S)-2-[(4S)-4-benzyl(1,3-oxazolin-2-yl)]-4-benzyl-1,3-oxazoline No 
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6 I05 N-((3S)-5-oxo(3-2,3,4-trihydrofuryl))(phenylmethoxy)carboxamide No 
6 J05 2-(6-chloropurin-9-yl)-2H-3,4,5,6-tetrahydropyran No 




6 M05 1,5-diaminoanthracene-9,10-dione No 
6 N05 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline No 





6 A06 indeno[2,3-e]1,2,3,4-tetraazolo[1,5-b]1,2,4-triazin-10-one No 
6 B06 2-[(4-hydroxy-3-methylphenyl)(3-methyl-4-oxocyclohexa-2,5-
dienylidene)methyl]b enzenesulfonic acid 
No 










6 G06 3-phenyl-2-(phenylazamethylene)-1,3-thiazolidin-4-one No 




6 J06 ethyl 2-(acetylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxylate 
No 
6 K06 5-[(4-methylphenyl)methylthio]-1,3,4-thiadiazole-2-ylamine No 
6 L06 2H,3H-benzo[3,4-e]1,4-dioxan-6-yl(2-naphthylsulfonyl)amine No 
6 M06 2-furyl-N-{[(methylamino)thioxomethyl]amino}carboxamide No 
6 N06 4-chloro-1-(methylsulfonyl)benzene No 
6 O06 N-(2-hydroxyethyl)-N'-(2-hydroxyethyl)propane-1,3-diamide No 
6 P06 amino(4-chlorophenyl)[(4-chlorophenyl)azamethylene]-1-ol No 
6 A07 (4-hydroxy-3-methoxyphenyl)thiocarbonitrile No 
6 B07 3-hydroxy-3-(2-oxocyclohexyl)indolin-2-one No 
6 C07 4-[(2,5-dimethoxyphenyl)sulfonyl]morpholine No 
6 D07 (3-nitrophenyl)pyrrolidine No 
6 E07 adamantanyl-N-(2-hydroxypropyl)carboxamide No 
6 F07 1-bromo-4-(methylsulfonyl)benzene No 
6 G07 2-(3-nitrophenyl)isoindoline No 
6 H07 2-(acetylamino)-3-methylpentanoic acid No 






6 K07 1-chloro-4-(ethylsulfonyl)benzene No 
6 L07 1-(3-nitrophenyl)pyrrole-2-carbaldehyde No 
6 M07 4-(5,5-dimethyl-1,3-dioxan-2-yl)phenol No 
6 N07 methyl 2-cyano-2-(2-oxo(1H-benzo[d]azolidin-3-ylidene))acetate No 
6 O07 3-{[(4-chlorophenyl)sulfonyl](2-cyanoethyl)amino}propanenitrile No 
6 P07 5-amino-2-[(4-aminophenyl)amino]benzenesulfonic acid No 
6 A08 (methylamino)(phenylamino)methane-1-thione No 
6 B08 [(4-chlorophenyl)amino](methylamino)methane-1-thione No 
6 C08 [(4-bromophenyl)amino](methylamino)methane-1-thione No 
6 D08 (2E)-3-(2,4-dichlorophenyl)-2-(4-chlorophenyl)prop-2-enenitrile No 
6 E08 [(4-bromophenyl)amino](ethylamino)methane-1-thione No 
6 F08 (ethylamino)[(4-iodophenyl)amino]methane-1-thione No 
6 G08 (ethylamino)[(4-fluorophenyl)amino]methane-1-thione No 
6 H08 (ethylamino)morpholin-4-ylmethane-1-thione No 
6 I08 [(3-methoxyphenyl)amino](methylamino)methane-1-thione No 
6 J08 [(4-methoxyphenyl)amino](methylamino)methane-1-thione No 
6 K08 [(4-fluorophenyl)amino](methylamino)methane-1-thione No 
6 L08 (methylamino)piperidylmethane-1-thione No 
6 M08 [(2-chlorophenyl)amino](phenylamino)methane-1-thione No 
6 N08 [(4-fluorophenyl)amino](phenylamino)methane-1-thione YES 
6 O08 [(tert-butyl)amino](phenylamino)methane-1-thione No 




6 B09 3-butoxy-1-piperidylpropan-2-ol No 
6 C09 3-butoxy-1-pyrrolidinylpropan-2-ol No 
6 D09 4-amino-3-(5-aminobenzimidazol-2-yl)phenol No 
6 E09 1-morpholin-4-yl-2-(3-pyridyl)ethane-1-thione No 
6 F09 1-azaperhydroepinyl-3-phenoxypropan-2-ol No 







6 J09 N-(4-nitrophenyl)-2-(1,3-thiazolin-2-ylthio)acetamide No 
6 K09 3-hydroxy-3-(2-oxopropyl)indolin-2-one No 
6 L09 3-nitro-5,6,7,8,9-pentahydro-4aH-carbazole No 
6 M09 3,6-bis(3,5-dimethylpyrazolyl)-1,2,4,5-tetraazine No 




6 P09 bis(4-phenyl-1,2,5-oxadiazol-3-yl)diazene No 
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6 D10 dimethyl[4-(5-methyl-5-nitro(1,3-dioxan-2-yl))phenyl]amine No 
6 E10 3,9-bis(2-bromophenyl)-2,4,8,10-tetraoxaspiro[5.5]undecane No 
6 F10 ethyl 5-amino-4-cyano-3-methylthiophene-2-carboxylate No 
6 G10 ethyl 5-(acetylamino)-4-cyano-3-methylthiophene-2-carboxylate YES 
6 H10 ethyl 5-(acetylamino)-4-cyano-3-methylthiophene-2-carboxylate, 
potassium salt 
YES 






















6 A11 (3-chloroquinoxalin-2-yl)(phenylsulfonyl)amine No 
6 B11 (3-morpholin-4-ylquinoxalin-2-yl)(phenylsulfonyl)amine No 
6 C11 indolo[2,3-b]quinoxaline No 
6 D11 2-fluoroindolo[2,3-b]quinoxaline No 
6 E11 5-acetyl-2-fluoroindolo[2,3-b]quinoxaline No 
6 F11 3,7-dibromoindolo[2,3-b]pyridino[3,2-e]pyrazine No 
6 G11 2-methylindolo[2,3-b]quinoxaline No 
6 H11 5-(2-hydroxy-1,3-dioxo-2-hydrocyclopenta[3,4-a]benzen-2-yl)-1,3,5-





6 J11 2-(2-furylmethylene)cyclopenta[1,2-a]benzene-1,3-dione No 
6 K11 2-[(5-methyl-2-furyl)methylene]cyclopenta[1,2-a]benzene-1,3-dione No 
6 L11 2-(4-quinolylmethylene)cyclopenta[1,2-a]benzene-1,3-dione No 
6 M11 2-(indol-3-ylmethylene)cyclopenta[1,2-a]benzene-1,3-dione No 
6 N11 3-(indol-3-ylmethylene)benzo[b]pyran-2,4-dione YES 
6 O11 11-phenylindeno[2,3-e]indeno[3,2-b]pyridine-10,12-dione No 
6 P11 11-(3-bromophenyl)indeno[2,3-e]indeno[3,2-b]pyridine-10,12-dione No 






6 C12 1,2,5-oxadiazolo[3,4-b]pyrazine-5,6-diamine No 
6 D12 ethyl 2-amino-4-methyl-5-(piperidylcarbonyl)thiophene-3-
carboxylate 
No 
6 E12 ethyl 3a,8b-dihydroxy-2-methyl-4-oxoindano[2,1-d]2-pyrroline-3-
carboxylate 
No 
6 F12 ethyl 2-amino-4-methyl-5-(morpholin-4-ylcarbonyl)thiophene-3-
carboxylate 
No 
6 G12 methyl 7-(2H-benzo[3,4-d]1,3-dioxolan-5-yl)-5-methyl-3-oxo-4,7-
dihydro-2H-1,3- thiazolidino[3,2-a]pyrimidine-6-carboxylate 
No 












6 L12 (4R)-2-(4-oxochromen-3-yl)-1,3-thiazolidine-4-carboxylic acid No 







6 P12 4-(5-bromo-2-fluorophenyl)-1,3,4-trihydrobenzo[h]quinolin-2-one No 
6 A13 ({2-[dithiocarboxy(2-thienylmethyl)amino]ethyl}(2-
thienylmethyl)amino)methaned ithioic acid, sodium salt, sodium salt 
No 
6 B13 2-[(tert-butyl)sulfonyl]-1,3-dibromo-5-methylbenzene No 
6 C13 [(2,6-dibromo-4-methylphenyl)sulfonyl]diethylamine No 
6 D13 2,2,6,6-tetramethyl-3-(2-thienylmethylene)azaperhydroin-4-one No 
















6 K13 3-[(tert-butyl)sulfonyl]-2-(methylsulfonyl)thiophene No 
6 L13 2-(2-aminophenylthio)-5-(ethylsulfonyl)-3-nitrothiophene No 
6 M13 2,5-bis(tert-butylthio)thiophene No 
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6 P13 4-bromo-2-(4-bromo(2-thienyl))thiophene No 
6 A14 6-butylthio-2-phenyl-4-hydroimidazo[1,2-a]pyridine, bromide No 
6 B14 5-[1-methyl-1-benzylpyrrolidin-2-yl]-2-pyridylamine, iodide No 
6 C14 (tert-butoxy)-N-(5-methyl(2-thienyl))carboxamide No 







6 G14 1,2,3,9,9a-pentahydrocyclopenta[2,1-b]quinolin-3-ol, chloride No 





6 J14 3,7-diacetyloxy-2-(3,4-diacetyloxyphenyl)-4-oxochromen-5-yl 
acetate 
No 





6 M14 (2S)-5,7-dihydroxy-2-phenylchroman-4-one YES 
6 N14 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one YES 














6 D15 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one No 
6 E15 xanthen-9-one No 
6 F15 7,8-dihydroxy-6-methoxychromen-2-one No 
6 G15 7-hydroxy-6-methoxy-3-(2-oxochromen-7-yloxy)chromen-2-one No 






























6 A16 1-(3-hydroxyphenyl)-2-(methylamino)ethan-1-ol No 
6 B16 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine No 
6 C16 [(4-aminophenyl)sulfonyl](5-methylisoxazol-3-yl)amine No 



























14-yl)-2-o xoethyl propanoate 
No 
6 N16 1,3-dimethyl-1,3,7-trihydropurine-2,6-dione No 
6 O16 (2S)-2-[(4-{[(2-amino-4-oxohydropteridin-6-










6 B17 2-(2-methyl-5-nitroimidazolyl)ethan-1-ol No 
6 C17 1-(ethylsulfonyl)-2-(2-methyl-5-nitroimidazolyl)ethane No 
6 D17 [(2-amino-3,5-dibromophenyl)methyl]cyclohexylmethylamine No 
6 E17 (2S,5R,6R)-6-(2-amino-2-phenylacetylamino)-3,3-dimethyl-7-oxo-4-
thia-1-azabicy clo[3.2.0]heptane-2-carboxylic acid 
No 
6 F17 7-acetyloxy-6-methoxy-2-oxochromen-8-yl acetate No 










6 K17 ((7aS,1R)perhydropyrrolizinyl)methyl 2,3-dihydroxy-2-
(methylethyl)butanoate 
No 
6 L17 (7S,7aS)-7-hydroxy-3,5,6,7,7a-pentahydropyrrolizinyl 2-hydroxy-3-
methoxy-2-(me thylethyl)butanoate 
No 
6 M17 4-hydroxy-1-methyl-2-oxohydropyridine-3-carbonitrile No 
6 N17 4-methoxy-1-methyl-2-oxohydropyridine-3-carbonitrile No 
6 O17 3-cyano-1-methyl-2-oxo-4-hydropyridyl acetate No 
6 P17 4-{(1E)-2-[3-(trifluoromethyl)phenyl]-2-azavinyl}phenyl 
methylsulfonate 
No 
















6 G18 methyl 4-(methoxycarbonyl)-3-methyl-5-(2,2,3,3,4,4,5,5,5-
nonafluoropentanoylam ino)thiophene-2-carboxylate 
No 
6 H18 ethyl 5-(N,N-diethylcarbamoyl)-2-(2,2,3,3,4,4,4-
heptafluorobutanoylamino)-4-me thylthiophene-3-carboxylate 
No 







6 K18 2-amino-3-(2,5-difluorophenyl)propanoic acid No 
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6 N18 2-[5-(carbamoylmethylthio)-1,3,4-thiadiazol-2-ylthio]acetamide No 
6 O18 2-(8-quinolylthio)acetamide No 











6 E19 N-butyl-2-(4-nitropyrazolyl)acetamide No 
6 F19 1-[(2,4-dichlorophenyl)methyl]-3-nitro-1,2,4-triazole No 




























6 C20 2,5-di(2-thienyl)-1,3-thiazolo[5,4-d]1,3-thiazole No 
6 D20 2,5-bis(4-fluorophenyl)-1,3-thiazolo[5,4-d]1,3-thiazole No 
6 E20 2,5-bis(4-chlorophenyl)-1,3-thiazolo[5,4-d]1,3-thiazole No 
































































6 J21 2-[3-(carboxymethyl)adamantanyl]acetic acid No 
6 K21 4-phenyl-2-(4-phenyl(2-pyridyl))pyridine No 
6 L21 1-cyclohexylazoline-2,5-dione No 
6 M21 3-amino-2-thioxo-1,3-thiazolidin-4-one No 
6 N21 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one No 





6 P21 (2R)-2-amino-3-methyl-3-sulfanylbutanoic acid No 
6 A22 2-methylbenzo[d]1,3-oxazin-4-one No 








6 F22 2-[5-(2-furylmethylene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic 
acid 
No 
6 G22 3-amino-3-thioxo-2-(triphenylylidene)propanenitrile No 
6 H22 4-((1E)-3-cyclohexylthio-3-oxoprop-1-enyl)benzenecarbonitrile No 
6 I22 4-((1E)-2-(2-thienyl)-1-azavinyl)phenyl 4-fluorobenzenesulfonate No 
6 J22 4-((1E)-2-(2-thienyl)-1-azavinyl)phenyl 2,5-
dichlorobenzenesulfonate 
No 
6 K22 (2E)-3-(2-chlorophenyl)-2-phenylprop-2-enenitrile No 
6 L22 (2E)-3-naphthyl-2-phenylprop-2-enenitrile No 
6 M22 (2Z)-2-(4-bromophenyl)-3-naphthylprop-2-enenitrile No 




6 P22 3-(4-chlorophenyl)-5-fluoren-9-ylthio-4-benzyl-1,2,4-triazole No 





7 B03 2,5-bis((2E)-3-phenylprop-2-enylthio)-1,3,4-thiadiazole No 
















7 I03 3-hydroxy-1-methyl-3-(5-methyl-2-oxocyclohexyl)indolin-2-one No 
7 J03 5,7-dibutyl-2-phenyl-8-hydropyrazolo[1,5-a]pyrimidine No 
7 K03 3-[(4-hydroxyphenyl)diazenyl]-5-(methylsulfonyl)-1H-1,2,4-triazole No 












7 P03 (dimethylamino)bis(2-phenylhydrazino)phosphino-1-one No 
7 A04 3-{[(4-chlorophenyl)methylthio]methyl}-1,2,4-triazolin-5-one No 
7 B04 5-[(2-chlorophenyl)methylthio]-1,3,4-thiadiazole-2-thiol No 
7 C04 5-(3,4-dimethoxyphenyl)-1,3,4-oxadiazole-2-thiol No 
7 D04 5-(naphthylmethyl)-1,3,4-oxadiazole-2-thiol No 
7 E04 4-(4-fluorophenyl)-1,3-thiazole-2-thiol No 
7 F04 [2-(5-methyl(2-furyl))-2-oxoethyl]thiocarbonitrile No 
7 G04 5,6-dimethyl-4-phenyl-1,3,4-thiadiazine-2-thiol YES 
7 H04 11-{[(dimethylamino)sulfonyl]amino}undecanoic acid YES 
7 I04 1,1,1-trichloro-3-(1-methylbenzimidazol-2-yl)propan-2-ol No 
7 J04 5-(2-furyl)-4-methyl-1,2,4-triazole-3-thiol No 







7 N04 6-methyl-1H-1,2,4-triazolino[4,5-b]1,2,4-triazin-7-one No 
7 O04 (2Z)-2-methyl-3-[(6-methyl-5-oxo(4H-1,2,4-triazin-3-yl))amino]-3-
azaprop-2-eno ic acid 
No 
7 P04 2-[4-(methylethyl)phenyl]-1,3-thiazolidine-4-carboxylic acid No 
7 A05 2-(3,5-dioxo-2H,4H-1,2,4-triazin-6-ylthio)ethyl hydroxysulfonate No 
7 B05 2-(3,5-dioxo-2H,4H-1,2,4-triazin-6-ylthio)ethanenitrile No 
7 C05 3-(4-methoxyphenoxy)-4-oxochromen-7-yl 2,2-dimethylpropanoate No 
7 D05 4-benzothiazol-2-ylthiobutanoic acid No 






7 G05 2,5-dioxoazolidinyl 6-(1,3-dioxobenzo[c]azolidin-2-yl)hexanoate No 
7 H05 2-[((1E)-1-methyl-3-oxobut-1-enyl)amino]propanoic acid No 
7 I05 5-bromo-1-methylbenzo[d]azoline-2,3-dione No 
7 J05 2-(cyclohexylamino)-3-hydropyrimidin-4-one No 
7 K05 5-{[2-(dimethylamino)ethyl]amino}-6-methyl-2H-1,2,4-triazin-3-one No 
7 L05 2,5-dioxoazolidinyl 2-(1,3-dioxobenzo[c]azolidin-2-yl)-3-
methylbutanoate 
No 
7 M05 6-(phenylmethylthio)-5-thioxo-2H,4H-1,2,4-triazin-3-one No 






7 P05 1-(2,4-dichlorophenyl)-3,4-dichloroazoline-2,5-dione No 
7 A06 1-(2,5-dichlorophenyl)-3,4-dichloroazoline-2,5-dione No 
7 B06 1-(3,4-dichlorophenyl)-3,4-dichloroazoline-2,5-dione No 
7 C06 1-(3,4-dichlorophenyl)azoline-2,5-dione No 
7 D06 3-methyl-2-(quinazolin-4-ylamino)butanoic acid No 
7 E06 6,6-dihydroxy-1,3,6-trihydropyrimidine-2,4,5-trione No 
7 F06 1-(4-chlorophenyl)-3,4-dimethylpyrano[5,6-d]pyrazol-6-one No 
7 G06 4-(6-chloropyridazin-3-yl)morpholine No 
7 H06 1,3,7-trimethyl-8-pyrrolidinyl-1,3,7-trihydropurine-2,6-dione No 
7 I06 2-[2-(4-chlorophenoxy)ethylthio]pyrimidine-4,6-diamine No 
7 J06 2-butylthio-6-methylhydropyrimidin-4-one No 
7 K06 2-(6-methyl-4-oxohydropyrimidin-2-ylthio)acetamide No 
7 L06 [imino(phenylamino)methyl]phenylamine No 




7 O06 5-[(2,4-dichlorophenoxy)methyl](2-furyl) 4-bromopyrazolyl ketone No 
7 P06 5-[(2,5-dichlorophenoxy)methyl]furan-2-carbohydrazide No 
7 A07 5-[(4-iodophenoxy)methyl](2-furyl) pyrrolidinyl ketone No 
7 B07 4-(2-furylcarbonyl)piperazinyl 5-(indan-5-yloxymethyl)(2-furyl) 
ketone 
No 







7 F07 N-cyclooctyl[5-(indan-5-yloxymethyl)(2-furyl)]carboxamide No 
7 G07 6-bromo-2-(5-chloro(2-thienyl))quinoline-4-carboxylic acid YES 
7 H07 5-[(4-fluorophenoxy)methyl]furan-2-carbohydrazide No 
7 I07 6-bromo-2-(2-furyl)quinoline-4-carboxylic acid YES 




7 L07 6-bromo-2-(5-methyl(2-thienyl))quinoline-4-carboxylic acid No 
7 M07 6-bromo-2-(4-ethylphenyl)quinoline-4-carboxylic acid No 
7 N07 2-(2-chlorophenyl)quinoline-4-carboxylic acid No 
7 O07 2-(2-thienylsulfonyl)thiophene No 
7 P07 ethyl 2-(4-methyl-1,3-thiazol-2-ylthio)acetate No 
7 A08 2-{[methyl(2-thienylmethyl)amino]thioxomethylthio}ethan-1-ol No 
7 B08 2-(phenylsulfonyl)thiophene No 
7 C08 3-(phenylsulfonyl)thiophene No 
7 D08 2-(tert-butylthio)-1,3-dibromobenzene No 
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7 E08 3-(tert-butylthio)thiophene-2,5-dicarboxylic acid No 
7 F08 1-methoxy-4-(2-thienylthio)benzene No 
7 G08 8-bromo-1,2,3,4,10-pentahydropyridino[1,2-a]benzimidazole No 
7 H08 5-ethylthio-2-(5-ethylthio(2-thienyl)thio)thiophene No 
7 I08 (2-thienylmethyl){2-[(2-thienylmethyl)amino]ethyl}amine No 
7 J08 5-(tert-butylthio)-2-(2,4-dinitrophenylthio)thiophene No 
7 K08 2,5-bis(2,2,6,6-tetramethyl-4-1,2,5,6-tetrahydropyridyl)thiophene No 
7 L08 (N-cyclohexylcarbamoyl)methyl acetate No 
















7 C09 4-methyl-1-(4,5,6,7-tetrahydroindolylethoxy)benzene No 
7 D09 1-(ethynylcyclohexyloxy)-1-(2-phenylpyrrolyl)ethane No 
7 E09 1-[(2-(2-thienyl)pyrrolyl)ethoxy]prop-2-yne No 
7 F09 1-[(2-phenylpyrrolyl)ethoxy]prop-2-yne No 
7 G09 [(4-chlorophenyl)sulfonyl](2,2,2-trichloro-1-hydroxyethyl)amine No 
7 H09 (phenylsulfonyl)(2,2,2-trichloro-1-hydroxyethyl)amine No 
7 I09 (phenylsulfonyl)(2,2,2-trichloro-1-methoxyethyl)amine No 
7 J09 2-amino-4-propyl-1,3-thiazine-6-thione No 




7 M09 2,2-dimethyl-3H-benzo[e]1,3-oxazin-4-one No 
7 N09 1-(methylethoxy)-1-(2-phenylpyrrolyl)ethane No 
7 O09 diethyl{4-[(2-phenylpyrrolyl)ethoxy]but-2-ynyl}amine No 
7 P09 (2Z)-4-hydroxy-4-methyl-3-pyrazolylpent-2-enenitrile No 
7 A10 2-amino-4-phenyl-1,3-thiazine-6-thione No 
7 B10 4-(2,2-dichlorovinyl)-1,3-thiazole-2-ylamine No 
7 C10 6-(2,2-dichlorovinyl)-4-methylpyran-2-one No 
7 D10 6-(2,2-dichlorovinyl)-4-ethyl-3-methylpyran-2-one No 
7 E10 4-chloro-2-{[(4-methylphenyl)sulfonyl]ethyl}benzenisocyanide No 




7 H10 N-(5-methyl(1,3,4-thiadiazol-2-yl))-2-thienylcarboxamide No 
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7 I10 [(4-chlorophenyl)sulfonyl](6-methoxybenzothiazol-2-yl)amine No 




7 L10 1-(3,5-dichlorophenyl)azoline-2,5-dione No 
7 M10 5-(dimethylamino)-6-methylpyrimidine-2,4-diol No 
7 N10 (2E)-3-[N-(1,3-dioxobenzo[c]azolin-2-yl)carbamoyl]prop-2-enoic 
acid 
No 
7 O10 ethyl (2E)-3-(N-(1,3-thiazol-2-yl)carbamoyl)prop-2-enoate No 






7 B11 ethyl (2E)-3-[N-(2-cyclohex-1-enylethyl)carbamoyl]prop-2-enoate No 
7 C11 bisbenzylhydroxylamine No 
7 D11 3-(4-pyridyl)-4,5-dihydro-2H-benzo[g]indazole, methanesulfonic 
acid 
No 
7 E11 2-phenylbenzoxazole No 











7 J11 1-(2-phenyl-1,2,3-triazol-4-yl)butane-1,2,3,4-tetraol No 
7 K11 3-chlorobenzo[b]thiophen-2-yl 4-methylpiperazinyl ketone No 













































7 M12 6-chloro-2-(4-fluorophenyl)-4-hydroimidazo[1,2-a]pyridine No 




7 P12 4-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)butanoic acid No 
7 A13 5-[(3-methyl(2-thienyl))methylene]-2-piperidyl-1,3-thiazolin-4-one No 


















7 J13 8-methyl-2-(4-methylphenyl)-4-hydroimidazo[1,2-a]pyridine No 
7 K13 7-(4-methoxyphenyl)-2-oxobenzo[3,4-d]1,3-oxathiolan-5-yl (2E)-3-
(4-methoxyphen yl)prop-2-enoate 
No 
7 L13 methyl 4-methyl-2-oxo-6-(2-thienyl)-1,3,6-trihydropyrimidine-5-
carboxylate 
No 




















7 D14 5-[(oxolan-2-ylmethyl)amino]-2-phenyl-1,3-oxazole-4-carbonitrile OFFSCALE 




























7 O14 5-(2H-chromen-3-ylmethylene)-2-morpholin-4-yl-1,3-thiazolin-4-one No 







7 C15 3-(2H-chromen-3-yl)(2Z)-2-cyano-N-prop-2-enylprop-2-enamide No 
7 D15 7-(4-methoxyphenyl)-2-oxobenzo[3,4-d]1,3-oxathiolen-5-yl 3,4,5-
trimethoxybenzo ate 
No 



































7 P15 2-(methylethyl)-5-morpholin-4-yl-1,3-oxazole-4-carbonitrile No 
7 A16 prop-2-enyl 4-methyl-2-(2-thienylcarbonylamino)-1,3-thiazole-5-
carboxylate 
No 
7 B16 prop-2-enyl 2-(2-furylcarbonylamino)-4-methyl-1,3-thiazole-5-
carboxylate 
No 
7 C16 2-methoxyethyl 6-cyclohex-3-enyl-4-methyl-2-oxo-1,3,6-
trihydropyrimidine-5-car boxylate 
No 






7 F16 ethyl 4-methyl-6-(3-methyl(2-thienyl))-2-oxo-1,3,6-
trihydropyrimidine-5-carbox ylate 
No 
7 G16 ethyl 4-methyl-6-(5-methyl(2-furyl))-2-oxo-1,3,6-trihydropyrimidine-
5-carboxyl ate 
No 
7 H16 methylethyl 6-cyclohex-3-enyl-4-methyl-2-oxo-1,3,6-
trihydropyrimidine-5-carbox ylate 
No 
7 I16 methylethyl 4-methyl-6-(5-methyl(2-furyl))-2-oxo-1,3,6-
trihydropyrimidine-5-ca rboxylate 
No 















7 N16 6,8-dichloro-2-nitro-9,10-dihydrophenanthrene-9-carbonitrile No 
7 O16 1,4-dichloro-6-nitro-9,10-dihydrophenanthrene-9-carbonitrile No 
7 P16 1-(4-bromophenyl)-2-phenylpropane-1,3-dicarbonitrile No 
7 A17 1-(4-bromophenyl)-2-(4-chlorophenyl)propane-1,3-dicarbonitrile No 
7 B17 6-bromo-2,3-dimethoxy-9,10-dihydrophenanthrene-9-carbonitrile YES 
7 C17 7-methoxy-2-nitro-9,10-dihydrophenanthrene-9-carbonitrile No 







7 G17 5-[(4-iodophenoxy)methyl]furan-2-carboxylic acid No 
7 H17 5-(indan-5-yloxymethyl)furan-2-carboxylic acid No 




7 K17 2,4,6-tris[(4-fluorophenyl)methylthio]-1,3,5-triazine No 
7 L17 5-(3-chlorophenyl)-3-(2-naphthyl)-1-phenyl-2-pyrazoline No 








7 A18 8-ethoxy-3,10-dihydrobenzo[g]pteridine-2,4-dione No 
7 B18 5-((2E)-3-phenylprop-2-enylidene)-2-thioxo-1,3-thiazolidin-4-one No 















7 J18 1-(2-naphthylsulfonyl)-4-(4-nitro-3-pyrrolidinylphenyl)piperazine No 









7 N18 1-(2-naphthylsulfonyl)-4-(4-nitro-3-piperidylphenyl)piperazine No 
7 O18 4-(3-morpholin-4-yl-4-nitrophenyl)-1-(2-naphthylsulfonyl)piperazine No 




7 B19 {3-[(4-chloro-2-nitrophenyl)amino]propyl}(methylsulfonyl)amine No 
7 C19 2-[(8-nitro-5-quinolyl)amino]ethan-1-ol No 










7 H19 (hydroxyimino)(4-methylphenyl)methylamine No 







7 L19 N-benzothiazol-2-yl(3-chlorobenzo[b]thiophen-2-yl)carboxamide No 
7 M19 5-(3-methoxyphenyl)-1,3,4-oxadiazole-2-thiol No 
7 N19 4-[(5-(2-furyl)-1,3,4-oxadiazol-2-ylthio)methyl]benzoic acid No 
7 O19 2-cyano-2-(1-methyl-2-oxobenzo[d]azolin-3-ylidene)acetamide No 
7 P19 1-[(3,4-dichlorophenyl)sulfonyl]pyrrolidine-2-carboxylic acid No 







7 D20 2-methyl-5-[(2,4,6-trimethylphenyl)methylthio]-1,3,4-thiadiazole No 













7 J20 N'-(2-cyclohex-1-enylethyl)-N-cyclohexylethane-1,2-diamide No 






7 M20 N-(2-cyclohex-1-enylethyl)-N'-(2-methoxyethyl)ethane-1,2-diamide No 
7 N20 phenyl(4-phenyl-5-sulfanyl(1,2,4-triazol-3-yl))methan-1-ol No 
7 O20 2-[(3-methyl(2-furyl))carbonylamino]-4-methylthiobutanoic acid No 
7 P20 4-(benzoxazol-2-ylthiomethyl)-3-chlorobenzenecarbonitrile No 
7 A21 4-(4,6-dimethylpyrimidin-2-ylthio)-3,5-dinitrobenzoic acid, 
azamethane 
No 
7 B21 1-(4-fluorophenoxy)-4-nitro-2-(trifluoromethyl)benzene No 
7 C21 dimethyl[(2-methylthiobenzothiazol-6-yl)sulfonyl]amine No 
7 D21 3-chloro-4-(2-pyridylthiomethyl)benzenecarbonitrile No 
7 E21 5-(2-methyl(3-furyl))-4-phenyl-1,2,4-triazole-3-thiol No 




7 H21 1,3-dinitro-2-(4-phenylimidazol-2-ylthio)-5-(trifluoromethyl)benzene No 




7 K21 2-[(4-phenylpiperidyl)sulfonyl]dibenzo[b,d]furan No 
7 L21 2,5-bis[4-(tert-butyl)phenyl]-1,3-thiazolo[5,4-d]1,3-thiazole No 
7 M21 2-{[1-(2-phenylethyl)benzimidazol-2-yl]methylthio}benzoxazole No 



























7 H22 2-(4-methylphenyl)-1-thia-3,4-diazaspiro[4.5]dec-2-ene No 
7 I22 4-methoxy-1-[5-(4-methylphenyl)(1,3,4-thiadiazolin-2-yl)]benzene No 









7 M22 2-[5-(4-methylphenyl)-1,3,4-thiadiazolin-2-yl]thiophene No 
7 N22 3-ethyl-5-hydroxy-5-(trifluoromethyl)(2-pyrazolinyl) 4-pyridyl 
ketone 
No 
7 O22 3-benzyl-2-thioxo-1,3-thiazolino[4,5-d]pyrimidin-7-ol No 
7 P22 N-benzo[3,4-b]benzo[d]furan-3-ylmorpholin-4-ylcarboxamide No 
Plate Well IUPAC NAME Inhibitor 
Y/N 








8 E03 8-nitro-5-(1-phenyl(1,2,3,4-tetraazol-5-ylthio))quinoline No 
8 F03 1-methyl-5-methylthio-3-(4-nitrophenyl)-1,2,4-triazole No 
8 G03 N-[(1,1-dioxobenzo[d]1,2-thiazol-3-yl)amino]-2-naphthylacetamide No 
8 H03 1-[5-(4-methylphenyl)-1,3,4-thiadiazolin-2-yl]pentane-1,2,3,4-tetraol No 




8 K03 2,6-dimethyl-4-(4-pyridyl)hepta-1,6-dien-4-ylamine No 
8 L03 4-(2,6-diprop-2-enyl-2-1,2,5,6-tetrahydropyridyl)hepta-1,6-dien-4-ol No 
8 M03 2,6-bis(2-methylprop-2-enyl)-1-benzyl-1,2,5,6-tetrahydropyridine No 




8 P03 (2S,6R)-2,6-bis(2-methylprop-2-enyl)-1,2,5,6-tetrahydropyridine No 
8 A04 (2S,6S)-1-acetyl-2,6-diprop-2-enyl-1,2,5,6-tetrahydropyridine No 






8 D04 (2E)-4-indolinyl-4-oxobut-2-enoic acid No 
8 E04 (2E)-3-{N-[3-(methoxycarbonyl)(4,5,6,7-tetrahydrobenzo[b]thiophen-
2-yl)]carbam oyl}prop-2-enoic acid 
No 
8 F04 (2S,6S)-1-acetyl-4-methyl-2,6-diprop-2-enyl-1,2,5,6-tetrahydropyridine No 




8 I04 N-[4-(indolinylsulfonyl)phenyl](phenylamino)carboxamide No 
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8 L04 2-(3-quinolyl)quinoline No 














8 C05 methyl 2-(propanoylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxylate 
YES 
8 D05 3-[N-(2,6-dimethoxypyrimidin-4-yl)carbamoyl]propanoic acid No 

















8 L05 naphthalene-2,3-diamine No 
8 M05 3-amino-2-thioxo-1,3-dihydroquinazolin-4-one No 
8 N05 5-[(tert-butyl)sulfonyl]thiophene-2-carboxylic acid No 
8 O05 (tert-butylthio)naphthalene No 
8 P05 2,5-bis[(tert-butyl)sulfonyl]thiophene No 
8 A06 (2-thienylmethyl){4-[(2-thienylmethyl)amino]phenyl}amine No 
8 B06 5-(ethylsulfonyl)-2-(2-naphthylamino)-3-nitrothiophene No 
8 C06 methyl 2-(4-bromo-5-methyl-3-nitropyrazolyl)acetate No 
8 D06 2-(4-chloro-5-methyl-3-nitropyrazolyl)acetamide No 
8 E06 ethyl 2-(3,5-dimethyl-4-nitropyrazolyl)acetate No 
8 F06 2-(5-methyl-3-nitropyrazolyl)acetic acid No 
8 G06 2-(2-thienylthio)butanedioic acid No 
8 H06 5-(tert-butylthio)thiophene-2-carboxylic acid No 
8 I06 6-bromo-2-phenyl-4-hydroimidazo[1,2-a]pyridine No 
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8 J06 2-[(2,5-dimethoxyphenyl)sulfonyl]-1,4-dimethoxybenzene No 
8 K06 4-[(3,4-dimethoxyphenyl)sulfonyl]-1,2-dimethoxybenzene No 
8 L06 2-[(2,5-dimethoxyphenyl)sulfonyl]-3,6-dimethoxybenzoic acid No 














8 C07 (2E)-3-[N-(2-oxoazaperhydroepin-3-yl)carbamoyl]prop-2-enoic acid No 




8 F07 3-(4,5-diphenylimidazolyl)-1-phenothiazin-10-ylpropan-2-ol No 
8 G07 ethyl (6-oxo-5,11,4b-trihydro-12H,4bH-benzo[e]quinazolino[1,2-c]1,3-
oxazin-5-y loxy)formate 
No 




8 J07 (4-methyl(1,2,5-oxadiazol-3-yl))(phenylsulfonyl)amine No 
8 K07 3-(2-benzothiazol-2-ylthioethoxy)-1-methoxybenzene No 
8 L07 6-methyl-2-(trifluoromethyl)benzimidazole No 
8 M07 1-methyl-2-(phenylmethylthio)benzimidazole No 










8 B08 prop-2-enyl 4-{5-[(5-oxo-2-thioxo-1,3-diazolidin-4-ylidene)methyl]-2-
furyl}ben zoate 
No 
8 C08 2-amino-7-methyl-4-hydro-1,2,4-triazolo[1,5-a]pyrimidin-5-ol No 
8 D08 1-(3,4-dichlorophenyl)-4-(methylethylidene)-1,2-diazolidine-3,5-dione No 
8 E08 2-[(2-phenoxyethyl)sulfonyl]benzimidazole No 
























8 N08 2-methoxy-1-{2-[2-(methylethylthio)benzimidazolyl]ethoxy}benzene No 
8 O08 2-[1-benzylbenzimidazol-2-ylthio]ethan-1-ol No 
8 P08 2-{2-[2-(2-fluorophenoxy)ethylthio]benzimidazolyl}ethan-1-ol No 
8 A09 2-(benzimidazol-2-ylmethylthio)-1-phenylbenzimidazole No 
8 B09 4-methyl-1-(2-purin-6-ylthioethoxy)benzene No 
8 C09 [2-(6-bromobenzimidazol-2-ylthio)ethoxy]benzene No 
8 D09 N-(2-furylmethyl)-2-[2-(trifluoromethyl)benzimidazolyl]acetamide No 
8 E09 2-oxo-2-(4-phenylphenyl)ethyl 1,2,3-trihydrocyclopenta[2,1-
b]quinoline-9-carbo xylate 
No 
8 F09 (2Z)-2-(aminothioxomethyl)-3-(4-pyridyl)prop-2-enenitrile No 
8 G09 ethyl (2E)-2-cyano-3-(1-methylimidazol-2-yl)prop-2-enoate No 
8 H09 methyl (2E)-2-cyano-3-(1-methylimidazol-2-yl)prop-2-enoate No 
8 I09 ethyl 4-(5-ethyl(2-thienyl))-2,7,7-trimethyl-5-oxo-4H-6,7,8-
trihydrochromene-3 -carboxylate 
No 
8 J09 ethyl 2-amino-4-(4-bromo-5-ethyl(2-thienyl))-7,7-dimethyl-5-oxo-4H-
6,7,8-trihy drochromene-3-carboxylate 
No 
8 K09 2,6-diamino-4-(2,4,6-triethylphenyl)-4H-thiin-3,5-dicarbonitrile No 






































8 J10 ((2E)-3-phenylprop-2-enyl)piperazine No 
8 K10 6-amino-5-fluoro-3-hydropyrimidin-2-one YES 
8 L10 (2E)-3-dodecylthioprop-2-enoic acid No 
8 M10 1-ethylthio-2-(3-propyl-2-(2-thienyl)pyrrolyl)ethane No 
8 N10 2,2,2-trifluoro-1-(5-(2-thienyl)pyrrol-2-yl)ethan-1-one No 
8 O10 2-(2-(4,5,6,7-tetrahydroindolyl)ethylthio)acetamide No 
8 P10 2-(hydroxymethyl)-5-[(3-nitrophenyl)amino]oxolane-3,4-diol No 
8 A11 4-(benzo[f]benzimidazol-2-ylmethyl)morpholine No 

































8 O11 3-{[(2,4-dichlorophenyl)methyl]sulfonyl}-1H-1,2,4-triazole-5-ylamine No 
8 P11 2-[(4-phenylpiperazinyl)sulfonyl]dibenzo[b,d]furan No 
8 A12 spiro[2,3-dihydroperimidine-2,1'-cycloheptane] No 
8 B12 (6Z,4E)-7-amino-3,3,4-trimethyl-7-(4-methylphenyl)-5,6-diazahepta-




8 C12 N-{[(cyclohexylamino)thioxomethyl]amino}-2-thienylcarboxamide No 
8 D12 1-[(1E)-2-(1-hexyl(2-pyridyl))vinyl]-2,3,4-trimethoxybenzene, iodide No 
8 E12 3-[5-(5-bromo-2-oxo(1H-benzo[d]azolidin-3-ylidene))-4-oxo-2-thioxo-









8 H12 5-methyl-5-(4-methylphenyl)-1,3-diazolidine-2,4-dione No 


























8 C13 7-hydroxy-3-(4-methoxyphenoxy)chromen-4-one No 
8 D13 7,9-dibromo-5-hydro-3H,4H-pyridino[2,1-c]1,2,4-thiadiazine-2,2-dione No 
8 E13 5-{[(2-imino-4-methyl-1,3-thiazolin-5-
ylidene)azamethyl]amino}benzene-1,3-dica rboxylic acid 
No 
8 F13 3-amino-2-methyl-3-hydroquinazolin-4-one No 




1,3-thiazolid in-3-yl]hexanoic acid 
No 









8 L13 N-(2-furylmethyl)morpholin-4-ylcarboxamide YES 
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8 O13 2-({2-[4-(tert-butyl)phenyl]quinazolin-4-yl}amino)ethan-1-ol No 




8 B14 (4-(2-hydrobenzotriazol-2-yl)phenyl)(methylethyl)amine No 
8 C14 2-{4-[(methylethyl)amino]phenyl}-2-hydrobenzotriazol-1-ol No 
























8 N14 (dicyclohexylamino)(butylamino)methane-1-thione No 
8 O14 (dicyclohexylamino)(cyclohexylamino)methane-1-thione No 
8 P14 (dicyclohexylamino)[(1,1-dimethylhexyl)amino]methane-1-thione No 
8 A15 bis(cyclohexylamino)methane-1-thione No 
8 B15 2-[6-(2-hydroxyphenyl)-2-phenylpyrimidin-4-yl]phenol No 
8 C15 2-(2,6-diphenylpyrimidin-4-yl)phenol No 
8 D15 2-(4,6-diphenylpyrimidin-2-yl)phenol No 
8 E15 (butylamino)morpholin-4-ylmethane-1-thione No 
8 F15 (diethylamino)(cyclohexylamino)methane-1-thione No 
8 G15 3-benzothiazol-2-ylthiopropanenitrile No 
8 H15 11-chlorotricyclo[6.2.1.0<2,7>]undeca-2(7),3,5-trien-9-yl 
(diethylamino)sulfon ate 
No 
8 I15 2,6-bis(tert-butyl)-4-[(dimethylamino)methyl]phenol No 
8 J15 N-(4-oxo-2-thioxo-1,3-dihydroquinazolin-3-yl)acetamide No 
8 K15 1-(2-imino-1,3-thiazino[3,2-a]benzimidazol-4-yl)cyclohexan-1-ol No 
8 L15 4-(1-hydroxy-isopropyl)-1,3-thiazino[3,2-a]benzimidazol-2-one YES 
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8 M15 2-chloro-4-nitroimidazole No 
8 N15 (2S)-6-{[(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]amino}-2-
[(fluoren-9-ylm ethoxy)carbonylamino]hexanoic acid 
No 
8 O15 (3S)-3-[(fluoren-9-ylmethoxy)carbonylamino]-3-(prop-2-
enyloxycarbonyl)propanoi c acid 
No 



































8 M16 3,6-bis(2-furylmethylene)-1,4-diazaperhydroine-2,5-dione No 
8 N16 7-bromopyridino[2,3-b]pyrazine-2,3-diol No 
8 O16 5,6-diamino-3-hydrobenzimidazol-2-one No 
8 P16 3-amino-1-phenylpyrazol-5-ol No 










8 E17 1,6-dibromonaphthalen-2-ol No 



















8 M17 (4-bromophenyl)(methylsulfonyl)amine No 
8 N17 [4-(dimethylamino)phenyl]morpholin-4-ylmethane-1-thione No 
8 O17 (2R)-3-(tert-butoxy)-2-[(fluoren-9-ylmethoxy)carbonylamino]propanoic 
acid 
No 
8 P17 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one No 










8 E18 1-[(2,5-dimethoxyphenyl)(2-hydroxynaphthyl)methyl]naphthalen-2-ol No 




8 H18 phenyl 4,4,6,8-tetramethyl-1-thioxo(4,5-dihydro-1,2-dithioleno[5,4-
c]quinolin- 5-yl) ketone 
No 






















8 A19 [(2,5-dimethyl-3-thienyl)methylene]methane-1,1-dicarbonitrile No 
8 B19 methyl (2E)-3-(2,5-dimethyl(3-thienyl))-2-cyanoprop-2-enoate No 
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8 C19 (2E)-3-(2,5-dimethyl(3-thienyl))-2-cyanoprop-2-enamide No 
8 D19 ethyl (2E)-3-(2,5-dimethyl(3-thienyl))-2-cyanoprop-2-enoate No 
8 E19 methylethyl (2E)-3-(2,5-dimethyl(3-thienyl))-2-cyanoprop-2-enoate No 
8 F19 [(2-ethylthio-5-methyl-3-furyl)methylene]methane-1,1-dicarbonitrile No 
8 G19 N-(4-bromo-2-fluorophenyl)[(methylpropyl)amino]carboxamide No 
8 H19 N-(2-chloro(3-pyridyl))[(3-fluorophenyl)amino]carboxamide YES 
8 I19 N-(2-chloro(3-pyridyl))[(4-chlorophenyl)amino]carboxamide No 
8 J19 [(4-fluorophenyl)amino]-N-(1,3,4-thiadiazol-2-yl)carboxamide No 
8 K19 N-(2-chloro(3-pyridyl))[(4-fluorophenyl)amino]carboxamide No 
8 L19 [(4-fluorophenyl)amino]-N-(5-methylisoxazol-3-yl)carboxamide No 
8 M19 [(2-nitrophenyl)amino]-N-(1,3,4-thiadiazol-2-yl)carboxamide No 
8 N19 [(tert-butyl)amino]-N-(2-chloro(3-pyridyl))carboxamide No 
8 O19 [(tert-butyl)amino]-N-(5-methylisoxazol-3-yl)carboxamide No 
8 P19 [(tert-butyl)amino]-N-(1,3,4-thiadiazol-2-yl)carboxamide No 
8 A20 [(tert-butyl)amino]-N-(4-methyl(1,3-thiazol-2-yl))carboxamide No 
8 B20 [(3-chlorophenyl)amino]-N-(4-methoxyphenyl)carboxamide No 












8 I20 2,6-diamino-4-(4-bromo(2-thienyl))-4H-pyran-3,5-dicarbonitrile No 
8 J20 [3-(chloromethyl)-2,4,6-trimethylphenyl](hydroxyimino)methane No 
8 K20 5-benzo[b]thiophen-2-yl-1,3,4-oxathiazolin-2-one No 




8 N20 phenyl-N-(2-(1,3-thiazolin-2-ylthio)acetyl)carboxamide No 
8 O20 1-(2-phenoxyacetyl)imidazolidin-2-one No 
8 P20 N-[2-(3-methylthio(1,2,4-thiadiazol-5-ylthio))acetyl]benzamide No 
8 A21 (5-bromo(2-furyl))-N-(4-iodophenyl)carboxamide No 






8 D21 methyl 2-(2-pyrimidin-2-ylthioacetylamino)-4,5,6-
trihydrocyclopenta[2,1-b]thio phene-3-carboxylate 
No 













8 J21 cyclopentylideneazamethyl 3-chlorobenzo[b]thiophene-2-carboxylate No 








8 O21 ethyl 4-amino-2-hydroxy-1,2,5-oxadiazole-3-carboxylate No 
8 P21 2-(3-bromo-4-fluorophenyl)-1,3-thiazolidine-4-carboxylic acid No 
8 A22 2-(2-furyl)-1,3-thiazolidine-4-carboxylic acid No 
8 B22 2-cyclohex-3-enyl-1,3-thiazolidine-4-carboxylic acid No 
8 C22 2-(4-fluorophenyl)-1,3-thiazolidine-4-carboxylic acid No 
8 D22 2-(2,4-difluorophenyl)-1,3-thiazolidine-4-carboxylic acid No 
8 E22 2-[2-(trifluoromethyl)phenyl]-1,3-thiazolidine-4-carboxylic acid No 













8 K22 4-(4-???-5-methyl-1,2,3-triazolyl)-1,2,5-oxadiazole-3-ylamine No 










8 P22 ethyl 2-(2-(1,3-thiazolin-2-ylthio)acetylamino)-4,5,6-
trihydrocyclopenta[2,1-b ]thiophene-3-carboxylate 
No 








9 B03 5-bromo(2-furyl) indolinyl ketone No 
9 C03 N-cycloheptylcyclopropylcarboxamide No 
9 D03 N-(2,4-dibromophenyl)-2,2-dichloroacetamide No 
9 E03 4-(2,4-dinitrophenyl)-1,4-diazabicyclo[4.3.0]nonane No 
9 F03 N-[(1,3-dimethylpyrazol-4-yl)methyl](5-bromo(2-furyl))carboxamide No 
9 G03 N-(4-bromo-2-fluorophenyl)-2-(1,3-thiazolin-2-ylthio)acetamide No 




9 J03 (4-nitropyrazolyl)-N-prop-2-enylcarboxamide No 
9 K03 (4-chloropyrazolyl)-N-ethylcarboxamide No 
9 L03 methyl 4-bromo-3,5-dimethylpyrazolecarboxylate No 
9 M03 (ethylamino)(3-methylpyrazolyl)methane-1-thione No 
9 N03 4,6-dimethylbenzothiazole-2-ylamine No 
9 O03 2-cyano-N-(2-furylmethyl)acetamide No 
9 P03 4-chlorophenyl 2-oxopyran-5-carboxylate No 
9 A04 N-(2,4-dioxo(1,3-dihydropyrimidin-5-yl))-2,2-dimethylpropanamide No 














9 H04 1-[6-(2,5-dioxoazolidinyl)hexyl]azolidine-2,5-dione No 
9 I04 2-(3-fluorophenyl)benzo[d]1,3-oxazin-4-one No 
9 J04 6-bromo-2-(3-fluorophenyl)benzo[d]1,3-oxazin-4-one No 




9 M04 (4,6-dimethylpyrimidin-2-yl)[2-benzyl-1-azabut-1-enyl]amine No 
9 N04 (4,6-dimethylpyrimidin-2-yl)(2-phenyl-1-azapent-1-enyl)amine No 
9 O04 4,6-dimethylpyrimidine-2-ylhydrazine No 
9 P04 5-(4-fluorophenyl)pyrazole-4-carbaldehyde No 
9 A05 9-ethylcarbazole-3-ylamine No 












































9 D06 5-(morpholin-4-ylsulfonyl)-3-hydrobenzimidazol-2-one No 






9 G06 N-adamantanyl[1-(phenylsulfonyl)pyrrolidin-2-yl]carboxamide No 
9 H06 5-nitro-2-(4-pyridyl)benzimidazole No 
9 I06 4-amino-1,2,5-oxadiazole-3-carboxylic acid No 














9 O06 (4-fluorophenyl)({4-[(phenylsulfonyl)amino]phenyl}sulfonyl)amine No 
9 P06 3-(2-hydroxyethyl)-2-thioxo-1,3-dihydroquinazolin-4-one No 
9 A07 2-(2-oxopropylthio)-3-hydroquinazolin-4-one No 
9 B07 1-(adamantanylcarbonyl)imidazolidin-2-one No 
9 C07 1-[(4-methylphenyl)methyl]-3-nitro-1,2,4-triazole No 
9 D07 1-[(2,6-dichlorophenyl)methyl]-3-nitro-1,2,4-triazole No 
9 E07 4-[(4-nitroimidazolyl)methyl]benzenecarbonitrile No 
















9 L07 N-[6-(methylsulfonyl)benzothiazol-2-yl]-2-morpholin-4-ylacetamide No 

































9 H08 N-(cyclohexylcarbonylamino)octanamide No 
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9 I08 N-benzothiazol-2-yl(1-methylpyrazol-5-yl)carboxamide No 















9 P08 4-bromopyrazolyl 2-chloro-4,5-difluorophenyl ketone No 
9 A09 4-chloro-3,5-dimethylpyrazolyl 1-methylpyrazol-3-yl ketone No 
9 B09 3,5-dimethylpyrazolyl 1-methyl-4-nitropyrazol-3-yl ketone No 
9 C09 1-methyl-4-nitropyrazol-3-yl pyrazolyl ketone No 













9 I09 [(diethylamino)amino](cyclohexylamino)methane-1-thione No 
9 J09 (cyclohexylamino)(2-phenylhydrazino)methane-1-thione No 
9 K09 2,4,6-tris(tert-butyl)phenol No 
9 L09 1-[(2,5-dioxoazolinyl)disulfanyl]azoline-2,5-dione No 




9 O09 [(dibutylamino)amino](phenylamino)methane-1-thione No 
9 P09 2,6-bis(tert-butyl)-4-[3,5-bis(tert-butyl)-4-hydroxyphenyl]phenol No 







9 D10 2,6-bis{[3,5-bis(tert-butyl)-4-hydroxyphenyl]methyl}-4-ethylphenol No 
9 E10 1-(2-hydroxynaphthylthio)naphthalen-2-ol No 



























9 O10 methyl 2,3,5,6-tetrafluoro-4-{[2,3,5,6-tetrafluoro-4-
(methoxycarbonyl)phenyl]s ulfonyl}benzoate 
No 













9 E11 2-(3-amino-1H-1,2,4-triazol-5-yl)acetic acid No 
9 F11 2-(5-amino-1,2,3,4-tetraazolyl)acetic acid No 





thiazolidin-3 -yl)]-4-methylthiobutanoic acid 
No 
9 J11 2-[5-(5-bromo-2-oxo(1H-benzo[d]azolin-3-ylidene))-4-oxo-2-











9 N11 [4-((1E)-2-benzothiazol-2-ylvinyl)phenyl]dimethylamine No 
9 O11 1-chloroanthracene-9,10-dione No 
9 P11 1,5-dichloroanthracene-9,10-dione No 
9 A12 1-hydroxy-3,11-dioxa-7,9-diazatricyclo[4.3.1.1<2,5>]undecan-8-one No 
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9 B12 (6-methyl-6-azabicyclo[4.4.0]dec-2-yl)methyl 2-methoxyacetate, 
iodide 
No 
9 C12 quinoxaline-6-carboxylic acid No 
9 D12 ethyl 2-(2-furylcarbonylamino)-4-methyl-5-
(pyrrolidinylcarbonyl)thiophene-3-ca rboxylate 
No 

















9 L12 {[4-(4-bromophenoxy)phenyl]sulfonyl}piperidine No 













































9 L13 (4,6-dimethylpyrimidin-2-yl)[imino(naphthylamino)methyl]amine YES 





































9 J14 4-phenylphenyl 4,4,6-trimethyl-1-thioxo(4,5-dihydro-1,2-



























9 D15 indolinyl 2-thienyl ketone No 
9 E15 2-(1,3-dioxobenzo[c]azolin-2-yl)-N-(1,2,4-triazol-4-yl)propanamide No 
9 F15 3-ethyl-6,8-dimethyl-4-methylene-1,3-dihydroquinazolin-2-one No 








9 K15 1-phenyl-3-(2-pyridylthio)azolidine-2,5-dione No 
9 L15 11-(2-furyl)-2,3,4,5,11-pentahydroindeno[3,2-b]quinoline-1,10-dione No 
9 M15 3-methoxy-2-thioxo-1,3-dihydroquinazolin-4-one No 
9 N15 3-(phenylmethoxy)-2-(phenylmethylthio)-3-hydroquinazolin-4-one No 




9 A16 1-methyl-3-phenyl-2-thioxo-1,3-dihydroquinazolin-4-one No 
9 B16 3-phenyl-2-sulfanyl-3-hydroquinazolin-4-one No 
9 C16 3-phenyl-2-prop-2-ynylthio-3-hydroquinazolin-4-one No 




9 F16 N-butyl{2-[(cyclohexylamino)thioxomethylthio]ethoxy}carboxamide No 







9 J16 methyl 3-bromo-2-oxopyran-5-carboxylate No 
9 K16 4-phenyl-4,10-dihydro-1,2,3,4-tetraazolo[1,5-a]quinazolin-5-one YES 
9 L16 (1Z)-3,3-dichloro-1-phenyl-2-piperidyl-1-azaprop-1-ene No 
9 M16 2-methylthio-5,6,7-trihydrocyclopenta[2,1-b]pyridine-3-carbonitrile OFFSCALE 
9 N16 (1E)-2-(2-chloro-5-nitrophenyl)-1-(4-iodophenyl)-1-azaethene No 
9 O16 4-hydroxyquinoline-2-carboxylic acid No 








9 C17 2-(hydroxyimino)-1,2-diphenylethan-1-ol No 
9 D17 [(5-morpholin-4-yl-2-furyl)methylene]methane-1,1-dicarbonitrile No 
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9 E17 4-[(2,4-dinitrophenyl)amino]phenol No 





9 H17 2-((1S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethan-1-ol YES 
9 I17 3-hydroisoindolylamine YES 










9 N17 methyl 4-aminopyrazole-3-carboxylate No 




9 A18 3-(2-furyl)-4-methyl-1-(piperidylmethyl)-1,2,4-triazoline-5-thione No 
9 B18 spiro[1,2,3-trihydroquinazoline-2,3'-indoline]-4,12-dione No 
9 C18 2-(acetylamino)-N-cyclopropyl-3-indol-3-ylpropanamide No 
9 D18 2-(2-oxopropyl)-2-hydrobenzo[d]isothiazole-1,1,3-trione No 






9 G18 3-hydroxy-3-(2-oxocyclooctyl)indolin-2-one YES 
9 H18 6-methyl-2-[(2,4,6-trimethylphenyl)methylthio]pyrimidin-4-ol YES 
9 I18 indol-3-ylmethoxy-2-thienylmethane YES 
9 J18 4,6-dimethyl-5-nitro-2-oxohydropyridine-3-carbonitrile No 
9 K18 3-[(4-fluorophenyl)methylthio]-1,2,4-thiadiazole-5-ylamine No 
9 L18 3-quinazolin-4-ylthiopropanoic acid No 
9 M18 pyrrolidinyl 2-sulfanylbenzothiazol-5-yl ketone No 
9 N18 N-butyl-N'-(3-imidazolylpropyl)ethane-1,2-diamide No 
9 O18 6-(6-bromo(2H-benzo[d]1,3-dioxolan-5-yl))-5-nitropiperidin-2-one No 
9 P18 ethyl 2-(1H-1,2,3,4-tetraazol-5-yl)acetate No 
9 A19 2-(2,5-dimethoxyphenyl)-3-hydroxychromen-4-one No 
9 B19 (phenylsulfonyl)(2,2,6,6-tetramethyl(4-piperidyl))amine No 









9 F19 6-chloro-3-hydroxy-2-(2-thienyl)chromen-4-one No 
9 G19 4-hydroxy-3-[(4-methylpiperidyl)methyl]chromen-2-one No 
9 H19 3-[(2-chlorophenyl)methylthio]-1,2,4-thiadiazole-5-ylamine YES 
9 I19 5-amino-1,2-dimethylimidazole-4-carboxamide No 
9 J19 1-acetyl-3-(4-pyridyl)-4-oxa-1,2-diazaspiro[4.6]undec-2-ene No 
9 K19 6,7-dimethoxy-4-methylchromen-2-one No 
9 L19 1,2,3,4,6,11-hexahydrobenzimidazolo[2,1-b]quinazolin-12-one No 
9 M19 3-oxo-2H,4H-benzo[e]1,4-oxazaperhydroine-6-carboxylic acid No 
9 N19 2-(5,7-dichloro-2-methylindol-3-yl)ethylamine No 
9 O19 (1R,6R)-5-azabicyclo[4.4.0]decan-2-one No 
9 P19 2-(adamantanylamino)ethan-1-ol No 
9 A20 1H-1,2,4-triazol-3-yl-N-(2-morpholin-4-ylethyl)carboxamide No 










9 F20 methoxy-N-[5-(morpholin-4-ylmethyl)(1,3-thiazol-2-yl)]carboxamide No 




9 I20 6-(6-chloro(2H-benzo[d]1,3-dioxolan-5-yl))-5-nitropiperidin-2-one No 
9 J20 [(4-aminophenyl)sulfonyl]phenylamine No 
9 K20 ethyl 2-cyano-3,3-disulfanylprop-2-enoate No 
9 L20 (2R)-2-amino-3-indol-3-ylpropanoic acid No 
9 M20 5-(1,2-dihydroxyethyl)-3,4-dihydroxy-5-hydrofuran-2-one No 
9 N20 N-[(4-aminophenyl)sulfonyl]acetamide, oxamethane, sodium salt No 
9 O20 N-(1,3-dioxobenzo[c]azolin-2-yl)methoxycarboxamide No 
9 P20 (3,4-dimethoxyphenyl)(1-methylimidazol-2-yl)methan-1-ol No 







9 D21 2,4-dichloro-5-sulfamoylbenzoic acid No 
9 E21 2,4,6-triphenoxy-1,3,5-triazine No 
9 F21 3-(3-oxohydroisobenzofuranyl)-3-hydroisobenzofuran-1-one YES 
9 G21 9-methoxyfurano[3,2-g]chromen-2-one No 
9 H21 5-bromo-2,4-dimethoxybenzaldehyde YES 









9 L21 2-bromo-2-nitropropane-1,3-diol No 
9 M21 2-(phenylmethylthio)-1,2,3-trihydroquinazolin-4-one No 
9 N21 methyl 2-(4-oxo-3-prop-2-enyl-3-hydroquinazolin-2-ylthio)acetate No 







9 B22 2-(2,3-dihydroperimidin-2-yl)-1,4-dimethoxybenzene No 
9 C22 3-(1,2,3,4-tetraazolyl)propanoic acid No 
9 D22 5-bromo-1-(2-naphthylsulfonyl)indoline No 
9 E22 7-(phenylcarbonyl)-2H,4H,5H-benzo[f]1,4-oxazepin-3-one No 
9 F22 3-aminohydropyridin-2-one No 
9 G22 3-(2-cyclohexylthiobenzimidazolyl)propan-1-ol No 
9 H22 8-quinazolin-4-ylthiopurine-6-ylamine No 
9 I22 2-(3-cyanoindolyl)-N-(2-indol-3-ylethyl)acetamide No 
9 J22 4-(2-benzimidazol-2-ylthioethoxy)-1-(methylpropoxy)benzene No 
9 K22 1-cyclohexyl-2-(phenylmethylthio)benzimidazole No 
9 L22 1-chloro-4-[2-(1-cyclohexylbenzimidazol-2-ylthio)ethoxy]benzene No 







9 P22 {2-[(4-chloro-2-nitrophenyl)amino]ethyl}(methylsulfonyl)amine No 












10 E03 [(4-methylphenyl)sulfonyl]-1,2,4-triazol-4-ylamine No 
10 F03 cyclopentyl[(4-methylphenyl)sulfonyl]amine No 
10 G03 (phenylsulfonyl)pyrimidin-2-ylamine No 
10 H03 (phenylsulfonyl)-1,2,4-triazol-4-ylamine No 
10 I03 benzothiazol-2-yl(phenylsulfonyl)amine No 
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10 J03 (phenylsulfonyl)indoline No 
10 K03 2-methylpiperidyl 2-thienyl ketone No 
10 L03 1-(2-hydroxyethyl)-4-(phenylsulfonyl)piperazine No 
10 M03 [(4-methoxyphenyl)sulfonyl]dimethylamine No 
10 N03 1-(2-hydroxyethyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine No 
10 O03 [(4-fluorophenyl)sulfonyl]phenylamine No 
10 P03 bisbenzyl(methylsulfonyl)amine No 
10 A04 N-cyclohexyl-N-ethyl-2-thienylcarboxamide No 
10 B04 ethyl 4-(2-thienylcarbonyl)piperazinecarboxylate No 
10 C04 N-[3-(diethylamino)propyl]-2-thienylcarboxamide No 
10 D04 3,5-dimethylpiperidyl 2-thienyl ketone No 
10 E04 N-cycloheptyl-2-thienylcarboxamide No 
10 F04 (2-methoxyethyl)(phenylsulfonyl)amine No 
10 G04 2-[(cyanomethyl)(phenylsulfonyl)amino]ethanenitrile No 
10 H04 2-[(phenylsulfonyl)amino]ethanenitrile No 
10 I04 (2-methylpropyl)(phenylsulfonyl)amine No 
10 J04 (phenylsulfonyl)(2-pyridylmethyl)amine No 
10 K04 benzyl(phenylsulfonyl)-2-pyridylamine No 
10 L04 (oxolan-2-ylmethyl)(phenylsulfonyl)amine No 
10 M04 [3-(diethylamino)propyl][(4-chlorophenyl)sulfonyl]amine No 
10 N04 2-{[(4-chlorophenyl)sulfonyl](cyanomethyl)amino}ethanenitrile No 
10 O04 (3-imidazolylpropyl)[(4-methylphenyl)sulfonyl]amine No 
10 P04 cyclohexyl(2-hydroxyethyl)[(4-methoxyphenyl)sulfonyl]amine No 
10 A05 [(4-methoxyphenyl)sulfonyl]diprop-2-enylamine No 
10 B05 [(4-methoxyphenyl)sulfonyl](2-pyridylmethyl)amine No 
10 C05 cyclohexylethyl[(2,4,6-trimethylphenyl)sulfonyl]amine No 
10 D05 pentyl[(2,4,6-trimethylphenyl)sulfonyl]amine No 
10 E05 2-{(cyanomethyl)[(2,4,6-trimethylphenyl)sulfonyl]amino}ethanenitrile No 
10 F05 2-{[(2,4,6-trimethylphenyl)sulfonyl]amino}ethanenitrile No 
10 G05 (2-methylpropyl)[(2,4,6-trimethylphenyl)sulfonyl]amine No 
10 H05 (methylpropyl)[(2,4,6-trimethylphenyl)sulfonyl]amine No 
10 I05 [(4-fluorophenyl)sulfonyl]methylphenylamine No 
10 J05 cyclohexylethyl[(4-fluorophenyl)sulfonyl]amine No 
10 K05 [(4-fluorophenyl)sulfonyl](3-methoxypropyl)amine No 
10 L05 dibutyl[(4-fluorophenyl)sulfonyl]amine No 
10 M05 [(4-fluorophenyl)sulfonyl]diprop-2-enylamine No 
10 N05 2-{(cyanomethyl)[(4-fluorophenyl)sulfonyl]amino}ethanenitrile No 
10 O05 [(4-fluorophenyl)sulfonyl]benzyl-2-pyridylamine No 
10 P05 cycloheptyl[(4-fluorophenyl)sulfonyl]amine No 
10 A06 [(2,5-dichlorophenyl)sulfonyl](3-methoxypropyl)amine No 
10 B06 [(2,5-dichlorophenyl)sulfonyl]diprop-2-enylamine No 
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10 C06 2-{[(2,5-dichlorophenyl)sulfonyl](cyanomethyl)amino} 
ethanenitrile 
No 
10 D06 2-{[(2,5-dichlorophenyl)sulfonyl]amino}ethanenitrile No 
10 E06 [(2,5-dichlorophenyl)sulfonyl]propylamine No 
10 F06 [(2,5-dichlorophenyl)sulfonyl](methylpropyl)amine No 
10 G06 [(2,5-dichlorophenyl)sulfonyl](3-imidazolylpropyl)amine No 
10 H06 [2-chloro-5-(trifluoromethyl)phenyl](methylsulfonyl)amine No 
10 I06 (2,5-dichlorophenyl)(methylsulfonyl)amine No 
10 J06 (2,3-dichlorophenyl)(methylsulfonyl)amine No 
10 K06 (2,4-dichlorophenyl)(methylsulfonyl)amine No 
10 L06 (5-chloro-2-methoxyphenyl)(methylsulfonyl)amine No 
10 M06 (2,4-dimethoxyphenyl)(methylsulfonyl)amine No 
10 N06 (4-chloro-2,5-dimethoxyphenyl)(methylsulfonyl)amine No 
10 O06 1-(4-fluorophenyl)-4-(methylsulfonyl)piperazine No 
10 P06 dibutyl(methylsulfonyl)amine No 
10 A07 2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinoline No 
10 B07 (tert-butyl)[(4-methoxyphenyl)sulfonyl]amine No 




10 E07 butyl[(4-fluorophenyl)sulfonyl]amine No 
10 F07 [(4-fluorophenyl)sulfonyl]hexylamine No 
10 G07 4-chloro-1-[(2-ethylpiperidyl)sulfonyl]benzene No 
10 H07 1-[(4-methoxyphenyl)sulfonyl]-1,2,3,4-tetrahydroquinoline No 
10 I07 [(4-methoxyphenyl)sulfonyl]indoline No 
10 J07 (4-pyridylmethyl)[(2,4,6-trimethylphenyl)sulfonyl]amine No 
10 K07 1-[(2,4,6-trimethylphenyl)sulfonyl]-1,2,3,4-tetrahydroquinoline YES 
10 L07 [(2,4,6-trimethylphenyl)sulfonyl]indoline No 
10 M07 1-[(2-ethylpiperidyl)sulfonyl]-4-fluorobenzene No 
10 N07 1,4-dichloro-2-[(2-ethylpiperidyl)sulfonyl]benzene No 
10 O07 1-(methylsulfonyl)-1,2,3,4-tetrahydroquinoline No 
10 P07 ethyl 1-(methylsulfonyl)piperidine-4-carboxylate No 
10 A08 methyl(methylsulfonyl)benzylamine No 
10 B08 N-[3-(dimethylamino)propyl]-2-thienylcarboxamide No 
10 C08 [3-(dimethylamino)propyl][(4-chlorophenyl)sulfonyl]amine No 
10 D08 [3-(dimethylamino)propyl][(2,4,6-trimethylphenyl)sulfonyl]amine No 
10 E08 (3-fluorophenyl)[(4-fluorophenyl)sulfonyl]amine No 
10 F08 benzothiazol-2-yl[(4-fluorophenyl)sulfonyl]amine No 
10 G08 [(4-fluorophenyl)sulfonyl]pyrimidin-2-ylamine No 
10 H08 [(2,5-dichlorophenyl)sulfonyl](6-methyl(2-pyridyl))amine No 
10 I08 [(2,5-dichlorophenyl)sulfonyl][3-(dimethylamino)propyl]amine No 
10 J08 [(2,5-dichlorophenyl)sulfonyl]-3-pyridylamine No 
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10 K08 [(2,5-dichlorophenyl)sulfonyl]-2-pyridylamine No 
10 L08 (2,4-difluorophenyl)(methylsulfonyl)amine No 
10 M08 N-cyclohexyl-N-ethyl-2-methylpropanamide No 
10 N08 N-[3-(diethylamino)propyl]-2-methylpropanamide No 
10 O08 1-azaperhydroepinyl-2-methylpropan-1-one YES 
10 P08 N-cyclohexyl-2-methyl-N-methylpropanamide No 




10 C09 [benzylsulfonyl]diprop-2-enylamine No 
10 D09 4-benzyl-1-[benzylsulfonyl]piperidine No 
10 E09 cyclohexylmethyl[benzylsulfonyl]amine No 
10 F09 benzothiazol-2-yl[benzylsulfonyl]amine No 
10 G09 [benzylsulfonyl]-1,2,4-triazol-4-ylamine No 
10 H09 2-{[(4-bromophenyl)sulfonyl](cyanomethyl)amino}ethanenitrile No 
10 I09 2-{[(4-bromophenyl)sulfonyl]amino}ethanenitrile No 
10 J09 [(4-bromophenyl)sulfonyl]-4-pyridylamine No 
10 K09 [(4-bromophenyl)sulfonyl]-3-pyridylamine No 
10 L09 2-furyl-N-(4-iodophenyl)carboxamide No 
10 M09 N,N-bis(cyanomethyl)-2-furylcarboxamide No 
10 N09 3,5-dimethylpiperidyl 2-furyl ketone No 
10 O09 2-furyl-N-heptylcarboxamide No 
10 P09 2,6-dimethylmorpholin-4-yl 2-furyl ketone No 







10 D10 N,N-bis(cyanomethyl)xanthen-9-ylcarboxamide No 
10 E10 N-cyclopentylxanthen-9-ylcarboxamide No 
10 F10 N-methylxanthen-9-ylcarboxamide No 
10 G10 4-methylpiperazinyl xanthen-9-yl ketone No 
10 H10 ethyl 4-(morpholin-4-ylcarbonyl)piperazinecarboxylate No 
10 I10 N-(3-methoxypropyl)morpholin-4-ylcarboxamide No 
10 J10 3,5-dimethylpiperidyl morpholin-4-yl ketone No 
10 K10 N-cycloheptylmorpholin-4-ylcarboxamide No 
10 L10 azaperhydroepinyl morpholin-4-yl ketone No 
10 M10 N,N-diethylmorpholin-4-ylcarboxamide No 
10 N10 indolinyl morpholin-4-yl ketone No 
10 O10 ethyl 1-(morpholin-4-ylcarbonyl)piperidine-4-carboxylate No 
10 P10 2-methylpiperidyl morpholin-4-yl ketone No 
10 A11 2,6-dimethylmorpholin-4-yl morpholin-4-yl ketone No 
10 B11 ethyl 2-(3,5-dimethylpiperidyl)-2-oxoacetate No 
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10 C11 ethyl 2-(2,6-dimethylmorpholin-4-yl)-2-oxoacetate No 
10 D11 ethyl (N-(1,2,4-triazol-4-yl)carbamoyl)formate No 
10 E11 2-ethyl-N,N-diprop-2-enylhexanamide No 
10 F11 N,N-bis(cyanomethyl)-2-ethylhexanamide No 
10 G11 2-ethyl-N-(oxolan-2-ylmethyl)hexanamide No 
10 H11 N-(tert-butyl)-2-ethylhexanamide No 




10 K11 N,N-dipropyl-N',N'-dipropylethane-1,2-diamide No 
10 L11 1,2-diindolinylethane-1,2-dione No 
10 M11 ethyl 1-{2-[4-(ethoxycarbonyl)piperidyl]-2-oxoacetyl}piperidine-4-
carboxylate 
No 
10 N11 [(4-bromophenyl)sulfonyl](5-chloro(2-pyridyl))amine No 
10 O11 N-(5-chloro(2-pyridyl))xanthen-9-ylcarboxamide No 
10 P11 N-[4-(dimethylamino)phenyl]morpholin-4-ylcarboxamide No 
10 A12 4-({[(4-chlorophenyl)sulfonyl]amino}methyl)benzenesulfonamide No 
10 B12 [(4-chlorophenyl)sulfonyl](methylbutyl)amine No 
10 C12 (methylbutyl)[(2,4,6-trimethylphenyl)sulfonyl]amine No 
10 D12 [(4-bromophenyl)sulfonyl](methylbutyl)amine No 
10 E12 N-(methylbutyl)morpholin-4-ylcarboxamide No 
10 F12 5,6-dimethylbenzimidazolyl morpholin-4-yl ketone No 
10 G12 [(4-fluorophenyl)sulfonyl](3-methylbutyl)amine No 
10 H12 [(2,5-dichlorophenyl)sulfonyl](3-methylbutyl)amine No 
10 I12 (3-methylbutyl)(methylsulfonyl)amine No 
10 J12 [(4-bromophenyl)sulfonyl](3-methylbutyl)amine No 
10 K12 dimethyl[(4-phenylpiperazinyl)sulfonyl]amine No 
10 L12 N-[3-(dimethylamino)propyl]-2-(2-thienyl)acetamide No 
10 M12 [(dimethylamino)sulfonyl](oxolan-2-ylmethyl)amine No 
10 N12 2-methyl-N-(oxolan-2-ylmethyl)butanamide No 
10 O12 2-methyl-N-(oxolan-2-ylmethyl)pentanamide No 
10 P12 [(dimethylamino)sulfonyl](methylethyl)benzylamine No 
10 A13 (3,4-dichlorophenyl)[(dimethylamino)sulfonyl]amine No 
10 B13 N-hexyl-2-(2-thienyl)acetamide No 
10 C13 [(hexylamino)sulfonyl]dimethylamine No 
10 D13 N-cyclopentyl-2-(2-thienyl)acetamide No 
10 E13 2-methyl-N-(1,3-thiazol-2-yl)butanamide No 
10 F13 dimethyl{[4-benzylpiperidyl]sulfonyl}amine No 
10 G13 [(dimethylamino)sulfonyl](4-bromophenyl)amine No 
10 H13 N,N-diprop-2-enyl-2-(2-thienyl)acetamide No 
10 I13 [(dimethylamino)sulfonyl](phenylethyl)amine No 
10 J13 3-methyl-N-pentylbutanamide No 
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10 K13 [(dimethylamino)sulfonyl](4-ethoxyphenyl)amine No 
10 L13 [(dimethylamino)sulfonyl]methylphenylamine No 
10 M13 N,N-diethyl-2-(2-thienyl)acetamide No 
10 N13 N-cycloheptyl-2-(2-thienyl)acetamide No 
10 O13 N-cycloheptyl-3-methylbutanamide No 
10 P13 N-cycloheptyl-2-methylpentanamide No 
10 A14 [(dimethylamino)sulfonyl](5-chloro-2-methoxyphenyl)amine No 
10 B14 ethyl 1-[(dimethylamino)sulfonyl]piperidine-4-carboxylate No 
10 C14 ethyl 1-(3-methylbutanoyl)piperidine-4-carboxylate No 
10 D14 [(dimethylamino)sulfonyl][(4-methoxyphenyl)methyl]amine No 
10 E14 [(dimethylamino)sulfonyl]benzylamine No 
10 F14 [(dimethylamino)sulfonyl][(4-methylphenyl)methyl]amine No 
10 G14 1-azaperhydroepinyl-2-methylbutan-1-one No 
10 H14 N-(3-imidazolylpropyl)-2-(2-thienyl)acetamide No 




10 K14 N,N-dibutyl-2-(2-thienyl)acetamide No 
10 L14 [(dimethylamino)sulfonyl]ethylphenylamine No 
10 M14 dimethyl{[(methylpropyl)amino]sulfonyl}amine No 
10 N14 dimethyl(piperidylsulfonyl)amine No 
10 O14 [(dimethylamino)sulfonyl][4-(methylethyl)phenyl]amine No 
10 P14 ethyl 2-(2-methylpentanoylamino)acetate No 
10 A15 N-(2-methoxy-isopropyl)-2-thienylcarboxamide No 















10 I15 ethyl 1-(methylsulfonyl)piperidine-3-carboxylate No 




10 L15 methyl 1-(2-furylcarbonyl)piperidine-4-carboxylate No 
10 M15 ethyl 1-[2-(1,3-dimethyl-2,6-dioxo-1,3,7-trihydropurin-7-
yl)acetyl]piperidine- 3-carboxylate 
No 
10 N15 ethyl 1-(morpholin-4-ylcarbonyl)piperidine-3-carboxylate No 
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10 O15 ethyl [N-(5-methyl-1,3,4-thiadiazol-2-yl)carbamoyl]formate No 
10 P15 ethyl [N-(5-methylisoxazol-3-yl)carbamoyl]formate No 
10 A16 ethyl 2-[3-(ethoxycarbonyl)piperidyl]-2-oxoacetate No 
10 B16 2-ethyl-N-(2-methoxy-isopropyl)hexanamide No 
10 C16 N-(2-methoxy-isopropyl)-2-(2-thienyl)acetamide No 
10 D16 N-(ethylpropyl)-2-(2-thienyl)acetamide No 
10 E16 ethyl 2-[2-(3,3-dimethylbutanoylamino)-1,3-thiazol-4-yl]acetate No 
10 F16 ethyl 1-(3,3-dimethylbutanoyl)piperidine-3-carboxylate No 
10 G16 methyl 1-(3,3-dimethylbutanoyl)piperidine-4-carboxylate No 








10 L16 methyl 1-(2-methylbutanoyl)piperidine-4-carboxylate No 






10 O16 4-chloro-1-methylpyrazole-3-carboxylic acid No 
10 P16 4-chloro-1-methylpyrazole-5-carboxylic acid No 
10 A17 1-methyl-3-(trifluoromethyl)pyrazole-5-carboxylic acid No 
10 B17 5-methyl-7-(trifluoromethyl)-8-hydropyrazolo[1,5-a]pyrimidine-3-
carboxylic aci d 
No 
10 C17 8-hydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid No 
10 D17 N,N-diprop-2-enylxanthen-9-ylcarboxamide No 
10 E17 N-(2-morpholin-4-ylethyl)-2-(2-thienyl)acetamide No 
10 F17 (4-iodophenyl)(2-naphthylsulfonyl)amine No 
10 G17 7-nitrobenzo[c]1,2,5-oxadiazole-4-ylamine No 
10 H17 ethyl 5-(aminomethyl)furan-2-carboxylate No 
10 I17 methyl 2-{3-[(3-oxo-1,3-thiazolidino[3,2-a]benzimidazol-2-
ylidene)methyl]indol yl}acetate 
No 
10 J17 4-morpholin-4-yl-1-nitro-2-(2-pyridylthio)benzene No 
10 K17 6-[(4-fluoronaphthyl)methylthio]purine No 
10 L17 4-(1,3-dithiolan-2-yl)-6-methoxy-2-nitrophenol No 
10 M17 2-[(2H-benzo[3,4-d]1,3-dioxolan-5-ylamino)methyl]-4-bromophenol No 
10 N17 (5S,2R,3R,4R)-3,5-diacetyloxy-6-bromo-2-(methoxycarbonyl)-2H-
3,4,5,6-tetrahydr opyran-4-yl acetate 
No 
10 O17 3,5-dibromopyridine No 
10 P17 2,4,6-trimethoxybenzaldehyde No 
10 A18 5-bromothiophene-2-carbaldehyde No 
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10 B18 diethyl 2-(2-cyanoethyl)propane-1,3-dioate No 
10 C18 2-[(carboxymethylthio)thioxomethylthio]acetic acid No 
10 D18 ((4S,5S)-2-methyl-5-phenyl(1,3-oxazolin-4-yl))methoxymethane No 
10 E18 diethyl (2E)-2,3-dicyanobut-2-ene-1,4-dioate No 
10 F18 4-chloro-2,6-dinitrophenylamine No 
10 G18 chloro[(4-methylphenyl)sulfonyl]methane No 
10 H18 methyl 4,6-dimethoxyindole-2-carboxylate No 
10 I18 (2S,3R,6R)-2-(acetyloxymethyl)-6-ethoxy-2H-3,6-dihydropyran-3-yl 
acetate 
No 
10 J18 (2Z)-3-[(ethoxycarbonyl)methoxy]-2-pyrazol-3-yl-3-azaprop-2-enoic 
acid 
No 
10 K18 5-bromo-3-nitro-4H-1,2,4-triazole No 
10 L18 spiro[4-imidazolino[4,5-b]pyridine-2,1'-cyclohexane] No 
10 M18 5-bromo-6-methyl-1,3-dihydropyrimidine-2,4-dione No 







10 A19 6-methoxybenzothiazole-2-carbonitrile No 
10 B19 1-ethyl-4-oxohydro-7H-1,3-dioxoleno[4,5-g]cinnoline-3-carboxylic 
acid 
No 





yl)-4-methylhex -4-enoic acid 
No 
10 F19 (2S,3S,4S,6S,5R)-3,4,5-trihydroxy-6-(4-methyl-2-oxochromen-7-
yloxy)-2H-3,4,5,6 -tetrahydropyran-2-carboxylic acid 
No 
10 G19 1-(2,3,4,5,6-pentafluorophenyl)azoline-2,5-dione YES 
10 H19 2-(2-thienyl)-2H,3H-benzo[e]1,3-oxazin-4-one No 
10 I19 7-chloro-3-phenyl-1,3-thiazolino[4,5-d]pyrimidine-2-thione No 
10 J19 3-phenyl-2-thioxo-1,3-thiazolino[4,5-d]pyrimidin-7-ol No 
10 K19 5-butyl-2,3-diphenyl-1,2,3,4-tetraazole, bromide No 
10 L19 3-(4-nitrophenyl)-2,5-diphenyl-1,2,3,4-tetraazole, bromide No 

















10 D20 5-(hydroxyimino)indeno[3,2-b]pyridine No 
10 E20 2-piperidyl-5-(2-pyridylmethylene)-1,3-thiazolin-4-one No 
10 F20 1-[(2,5-dichlorophenyl)sulfonyl]pyrrolidine-2-carboxylic acid No 
10 G20 N-{5-[(4-methylpiperidyl)methyl]-1,3-thiazol-2-yl}acetamide No 






10 J20 methylthio(3,4,5-trimethoxyphenyl)methanimine, iodide No 
10 K20 5-(indol-3-ylmethyl)-1,3,4-thiadiazole-2-ylamine No 
10 L20 3-(nonylsulfonyl)-1H-1,2,4-triazole-5-ylamine No 











10 B21 5-[(4-fluorophenyl)methylthio]-2-(phenylmethylthio)-1,3,4-thiadiazole No 







10 F21 2,2-dimethyl-6-hydro-2H-pyrano[5,6-c]quinolin-5-one No 
10 G21 4-(chlorodifluoromethoxy)phenylamine No 










10 L21 6-chloro-3-hydroxy-2-(3-pyridyl)chromen-4-one No 




10 O21 (2,4-dinitrophenyl)-1,3-thiazol-2-ylamine No 
10 P21 2-[(5-nitro-2-furyl)methylene]cyclopenta[1,2-a]benzene-1,3-dione No 
10 A22 2,5-bis(4-methylphenyl)-8-hydropyrazolo[1,5-a]pyrimidine-7-ylamine No 
10 B22 2-fluoren-9-ylthiobenzothiazole No 
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10 E22 8-benzimidazol-2-ylthio-1,3,7-trimethyl-1,3,7-trihydropurine-2,6-dione No 







10 I22 4-methyl-3-(phenoxymethyl)-1-xanthen-9-yl-1,2,4-triazoline-5-thione No 




10 L22 2-(1-methylbenzimidazol-2-ylthio)-5-nitropyridine No 
10 M22 4-[(4-methylthiophenyl)methylene]-3-phenylisoxazol-5-one No 
10 N22 3-nitro-5H-benzimidazolo[2,1-b]benzo[d]1,3-thiazine No 
10 O22 5-methyl-5-nitrospiro[1,3-dioxane-2,3'-indoline]-8-one No 
10 P22 3-acetyl-1-(2-cyclohex-1-enylethyl)-5-hydroxy-2-methylindole No 
Plate Well IUPAC NAME Inhibitor 
Y/N 
11 A03 2-methylpyrano[3,2-c]chromene-4,5-dione No 
11 B03 N-cyclopropyl(4-oxo(3-hydrophthalazinyl))carboxamide No 






11 E03 7-[2-(3-nitro-1,2,4-triazolyl)ethoxy]chromen-2-one No 










11 J03 5-[(3,5-dimethoxyphenyl)methylene]-2-thioxo-1,3-thiazolidin-4-one No 



















11 B04 3-[2-(1,1-dioxobenzo[d]1,2-thiazolin-3-yl)hydrazino]propanenitrile No 
11 C04 1-(4-nitrophenyl)pyrrole-2-carbaldehyde No 
11 D04 2-[(4,6-dipiperidyl-1,3,5-triazin-2-yl)amino]ethan-1-ol No 




11 G04 1-(2,4-dinitrophenyl)-3,5-dimethylpyrazole No 
11 H04 1,3-bis(hydroxymethyl)-5-methoxy-3-hydrobenzimidazol-2-one YES 
11 I04 4-[4-((1E)-2-(2-furyl)-1-azavinyl)phenyl]morpholine No 





































11 H05 2-(2-methylthiobenzimidazolyl)acetamide No 
11 I05 pyrrolidinyl-2-thienylmethane-1-thione No 
11 J05 2-[2-(phenylmethylthio)quinazolin-4-ylthio]acetic acid YES 
11 K05 (hydroxyimino)(4-morpholin-4-ylphenyl)methane No 
11 L05 2-quinazolin-4-ylthiopropanoic acid No 


















11 C06 2-(2,5-dimethylpyrrolyl)-4-methyl-5-propylthiophene-3-carbonitrile No 
11 D06 8-[(2-chlorophenyl)methylthio]purine-6-ylamine No 
11 E06 2-(6-aminopurin-8-ylthio)-N-(4-methoxyphenyl)acetamide No 
11 F06 2-(2-cyclohexylthiobenzimidazolyl)acetamide No 
11 G06 1-(tert-butyl)-4-[2-(2-methylquinazolin-4-ylthio)ethoxy]benzene No 
11 H06 morpholin-4-yl(4-nitrophenyl)methane-1-thione No 
11 I06 (4-iodophenyl)[(3-nitrophenyl)sulfonyl]amine No 
11 J06 (phenylsulfonyl)-3-pyridylamine No 
11 K06 (2,4-dinitrophenyl)benzotriazole No 




1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetat e 
No 
11 N06 2-amino-4-(3,4-dimethylphenyl)-5-methylthiophene-3-carbonitrile No 
11 O06 2-amino-4-[4-(2-methylpropyl)phenyl]thiophene-3-carbonitrile No 
11 P06 2-amino-5-methyl-4-[4-(methylethyl)phenyl]thiophene-3-carbonitrile No 
11 A07 2-amino-4-(2,4-dichlorophenyl)thiophene-3-carbonitrile No 
11 B07 2-amino-5-methyl-4-(4-propylphenyl)thiophene-3-carbonitrile No 
11 C07 2-amino-4-(2,5-dimethylphenyl)thiophene-3-carbonitrile No 
11 D07 2-amino-4-(4-phenylphenyl)thiophene-3-carbonitrile No 
11 E07 2-amino-4-(4-butylphenyl)thiophene-3-carbonitrile No 
11 F07 [(1-ethylpyrazol-4-yl)methyl]methylamine No 
11 G07 4-[4-nitro-2-(trifluoromethyl)phenyl]morpholine No 










11 L07 2-furyl-N-(5-methyl(1,3,4-thiadiazol-2-yl))carboxamide No 






11 O07 ethyl 4-(2-furylcarbonyl)piperazinecarboxylate No 














11 F08 3-(carboxymethyl)indole-2-carboxylic acid No 
11 G08 4-benzotriazolyl-5-(4-fluorophenoxy)benzene-1,2-dicarbonitrile No 
11 H08 1-(2-hydroxypropyl)-4,6-dimethyl-2-oxohydropyridine-3-carbonitrile No 




11 K08 (2R,6R)-2,6-diaminoheptanedioic acid No 










11 P08 1-(methylethyl)-5-oxopyrrolidine-3-carboxylic acid No 
11 A09 2-methyl-4-hydro-2H,3H-1,3-thiazolidino[2,3-b]quinazolin-5-one No 




11 D09 {1-[(2-fluorophenyl)methyl]benzimidazol-2-yl}phenylmethan-1-ol No 
11 E09 N-(tert-butyl)-2-(3-nitro(1,2,4-triazolyl))acetamide No 
11 F09 (3-aminophenyl)[(dimethylamino)sulfonyl]amine No 
11 G09 N-(2-methyl-5-oxochromeno[3,4-c]pyridin-4-yl)propanamide No 




11 J09 4,6-dimethyl-2-oxopyran-5-carboxylic acid No 















11 P09 1-(diphenylmethyl)-1,3-dihydropyrimidine-2,4-dione No 







11 D10 methyl 5-(methoxycarbonyl)-1,2,6-trimethyl-4-(2-thienyl)-1,4-
dihydropyridine-3 -carboxylate 
No 



























11 N10 oxolan-2-ylmethyl 4-(5-bromo-2-methoxyphenyl)-2-methyl-5-oxo-
1,4,6,7,8-pentahy droquinoline-3-carboxylate 
No 






11 A11 cyclohexyl 2-methyl-4-(5-methyl(2-furyl))-5-oxo-1,4,6,7,8-
pentahydroquinoline- 3-carboxylate 
No 






11 D11 2-ethylthioethyl 2-methyl-5-oxo-4-(3-thienyl)-1,4,6,7,8-
pentahydroquinoline-3- carboxylate 
No 














11 I11 methyl 2-methyl-5-oxo-4,7-di(2-thienyl)-1,4,6,7,8-
pentahydroquinoline-3-carbox ylate 
YES 






11 L11 methoxy(2-methylindol-3-yl)-2-thienylmethane No 




11 O11 6-(2-bromo-3,4,5-trimethoxyphenyl)-5-nitropiperidin-2-one No 
11 P11 methylethyl 4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,3,6-
trihydropyrimid ine-5-carboxylate 
No 
11 A12 ethyl 5-(ethoxycarbonyl)-1,2,6-trimethyl-4-(3-thienyl)-1,4-
dihydropyridine-3-c arboxylate 
No 
11 B12 ethyl 6-acetyl-2-amino-4,5,6,7-tetrahydrothiopheno[2,3-c]pyridine-3-
carboxylat e 
No 
11 C12 2-ethylthioethyl 2-methyl-5-oxo-4-(4-oxochromen-3-yl)-1,4,6,7,8-
pentahydroquin oline-3-carboxylate 
No 
11 D12 2-ethoxyethyl 2-methyl-5-oxo-4-(4-oxochromen-3-yl)-1,4,6,7,8-
pentahydroquinoli ne-3-carboxylate 
No 
11 E12 propyl 2,7,7-trimethyl-4-(5-methyl(2-furyl))-5-oxo-1,4,6,7,8-
pentahydroquinoli ne-3-carboxylate 
No 
11 F12 methylethyl 2,7,7-trimethyl-4-(6-methyl-4-oxochromen-3-yl)-5-oxo-
1,4,6,7,8-pen tahydroquinoline-3-carboxylate 
No 
11 G12 oxolan-2-ylmethyl 2-methyl-4-(5-methyl(2-furyl))-5-oxo-1,4,6,7,8-
pentahydroqui noline-3-carboxylate 
No 
11 H12 2-ethoxyethyl 2-methyl-5-oxo-4-(2-thienyl)-1,4,6,7,8-
pentahydroquinoline-3-car boxylate 
No 
11 I12 2-methylpropyl 2-methyl-5-oxo-4-(3-thienyl)-1,4,6,7,8-
pentahydroquinoline-3-ca rboxylate 
No 
11 J12 methyl 5-(methoxycarbonyl)-1-methyl-4-(2-thienyl)-1,4-
dihydropyridine-3-carbox ylate 
No 
11 K12 2-ethylthioethyl 2-methyl-4-(5-methyl(2-furyl))-5-oxo-1,4,6,7,8-
pentahydroquin oline-3-carboxylate 
No 












11 O12 methyl 4-(6-bromo(2H-benzo[d]1,3-dioxolan-5-yl))-5-
(methoxycarbonyl)-1-methyl- 1,4-dihydropyridine-3-carboxylate 
No 
11 P12 methyl 4-(6-chloro(2H-benzo[d]1,3-dioxolan-5-yl))-5-
(methoxycarbonyl)-1-methyl -1,4-dihydropyridine-3-carboxylate 
No 
11 A13 methyl 4-(6-chloro-4-oxochromen-3-yl)-2-methyl-5-oxo-1,4,6,7,8-
pentahydroquino line-3-carboxylate 
No 
11 B13 N-(4-fluorophenyl)-2-pyrimidin-2-ylthioacetamide No 
11 C13 ((4S,1R,2R)bicyclo[2.2.1]hept-2-yl)[(4-chlorophenyl)sulfonyl]amine No 




























11 N13 [1-(3-chlorophenyl)-2,5-dimethylpyrrol-3-yl](hydroxyimino)methane No 
11 O13 2-{3-[(3-oxo-1,3-thiazolidino[3,2-a]benzimidazol-2-































11 I14 ethyl 2-{2,4-dioxo-5-[(5-pyrrolidinyl(2-furyl))methylene]-1,3-
thiazolidin-3-yl }acetate 
No 







































11 G15 (2E)-2-benzimidazol-2-yl-3-(5-chloro(2-thienyl))prop-2-enenitrile No 
















11 N15 N-pyrimidin-2-yl-2-thienylcarboxamide No 
11 O15 2-(4-bromophenoxy)-N-(oxolan-2-ylmethyl)acetamide No 
11 P15 2-(2,4-dichlorophenoxy)-N-(oxolan-2-ylmethyl)acetamide No 
11 A16 ethyl 2-[2-(2-furylcarbonylamino)-1,3-thiazol-4-yl]acetate No 
11 B16 adamantanyl-N-(2-morpholin-4-ylethyl)carboxamide No 
11 C16 [(4-chlorophenyl)sulfonyl]-4-pyridylamine No 







































11 C17 2-(4-chlorophenylthio)-N-(oxolan-2-ylmethyl)propanamide No 
11 D17 2-(4-chlorophenylthio)-N-[2-(2-furylmethylthio)ethyl]acetamide No 
11 E17 [(3,4-dimethoxyphenyl)sulfonyl](2-phenylthioethyl)amine No 




11 H17 [(4-fluorophenyl)sulfonyl](2-pyridylmethyl)amine No 












































triene-5-carbo xylic acid 
No 
11 I18 methyl 2-(acetylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxylate 
No 
11 J18 2-(1-cyclohexyl-1,2,3,4-tetraazol-5-ylthio)propanoic acid No 




11 M18 5-(3-oxohydroisobenzofuran-5-yl)furan-2-carbaldehyde No 
11 N18 1-acetyl-4-[2-(6-aminopurin-8-ylthio)ethoxy]benzene No 








11 C19 1-nitro-4-piperazinyl-2-(2-pyridylthio)benzene No 
11 D19 4-methyl-5-(2-phenylethyl)-1,2,4-triazole-3-thiol No 
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11 E19 2-[2-(phenylmethylthio)benzimidazolyl]ethan-1-ol No 
11 F19 4-(2-nitro-5-piperidylphenyl)morpholine No 
11 G19 (8-nitro-5-quinolyl)piperazine No 
11 H19 cyclopropyl(2-nitro-5-piperazinylphenyl)amine No 
11 I19 2-(4-methyl(1,2,4-triazol-3-ylthio))-1-nitro-4-pyrrolidinylbenzene No 
11 J19 cyclopropyl[5-(4-methylpiperazinyl)-2-nitrophenyl]amine No 
11 K19 4-[3-(cyclopropylamino)-4-nitrophenyl]piperazinyl 2-furyl ketone No 
11 L19 2-methyl-4-nitro-5-pyrrolidinylphenylamine No 
11 M19 (5-chloro-2-nitrophenyl)(2-furylmethyl)amine No 
11 N19 (2-furylmethyl)(2-nitro-5-pyrrolidinylphenyl)amine No 
11 O19 (2-furylmethyl)(5-morpholin-4-yl-2-nitrophenyl)amine No 
11 P19 2-ethoxy-1-nitro-4-pyrrolidinylbenzene No 
11 A20 [5-(2,6-dimethylmorpholin-4-yl)-2-nitrophenyl]cyclopropylamine No 
11 B20 [3-(3,5-dimethylpyrazolyl)-4-nitrophenyl]piperazine No 













11 H20 4-[5-(3-methylpiperazinyl)-2-nitrophenyl]morpholine No 
11 I20 2-{[5-(3-methylpiperazinyl)-2-nitrophenyl]amino}ethan-1-ol No 
11 J20 [4-nitro-2-(trifluoromethyl)phenyl]pyrrolidine YES 
11 K20 [2-nitro-4-(trifluoromethyl)phenyl]pyrrolidine YES 
11 L20 (3-morpholin-4-ylpropyl)(5-nitro(8-quinolyl))amine No 
11 M20 (5-chloro-2-nitrophenyl)(3-morpholin-4-ylpropyl)amine No 
11 N20 (3-morpholin-4-ylpropyl)(8-nitro(5-quinolyl))amine No 
11 O20 (3-morpholin-4-ylpropyl)(2-nitro-5-pyrrolidinylphenyl)amine No 
11 P20 (5-morpholin-4-yl-2-nitrophenyl)(3-morpholin-4-ylpropyl)amine No 
11 A21 (adamantanylethyl)(2-nitro-5-piperazinylphenyl)amine No 
11 B21 [2-nitro-4-(trifluoromethyl)phenyl]piperazine No 
11 C21 [2-(4-fluorophenoxy)ethyl](5-morpholin-4-yl-2-nitrophenyl)amine No 
11 D21 [2-(ethylamino)ethyl](5-nitro(8-quinolyl))amine No 
11 E21 4-methyl-1-[5-(4-methylpiperazinyl)-2-nitrophenyl]piperazine No 
11 F21 4-(2-furyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxamide No 
11 G21 1-[2-(2-methoxyphenoxy)ethyl]indole-3-carbaldehyde No 
11 H21 1-[2-(2-fluorophenoxy)ethyl]indole-3-carbaldehyde No 
11 I21 1-[2-(2-chlorophenoxy)ethyl]indole-3-carbaldehyde No 






11 L21 [4-(2,5-dimethylpyrrolyl)-2-nitrophenyl]cyclopentylamine No 
11 M21 8-[2-(2-fluorophenoxy)ethylthio]purine-6-ylamine No 
11 N21 8-[2-(2-methylphenoxy)ethylthio]purine-6-ylamine No 
11 O21 8-[2-(4-methylphenoxy)ethylthio]purine-6-ylamine No 




11 B22 1-methyl-2-[(6-nitrobenzimidazol-2-yl)methylthio]benzimidazole No 
11 C22 2-(benzimidazol-2-ylmethylthio)-1-methylbenzimidazole No 
11 D22 2-{[1-benzylbenzimidazol-2-yl]methylthio}-1-propylbenzimidazole No 
11 E22 3-(4,6-dimethylpyrimidin-2-ylthio)propanoic acid No 
11 F22 2-(2-benzoxazol-2-ylthioethoxy)-1-methoxybenzene No 
11 G22 2-(2-benzoxazol-2-ylthioethoxy)-1-fluorobenzene No 
11 H22 4-(2-benzoxazol-2-ylthioethoxy)-1-chlorobenzene No 
11 I22 4-(2-benzoxazol-2-ylthioethoxy)-1-methoxybenzene No 
11 J22 2-{[1-benzylbenzimidazol-2-yl]methylthio}benzoxazole No 
11 K22 3-(2-methylquinazolin-4-ylthio)propanoic acid No 




11 N22 2-(1-cyclohexyl-1,2,3,4-tetraazol-5-ylthio)acetamide No 
11 O22 2-[(6-nitrobenzimidazol-2-yl)methylthio]benzothiazole No 
11 P22 4-[2-(6-bromobenzimidazol-2-ylthio)ethoxy]-1-chlorobenzene No 
Plate Well IUPAC NAME Inhibitor 
Y/N 
12 A03 2-[2-(6-bromobenzimidazol-2-ylthio)ethoxy]-1-fluorobenzene No 
12 B03 2-[2-(trifluoromethyl)benzimidazolyl]acetic acid No 
12 C03 cyclopropyl(2-nitro-5-pyrrolidinylphenyl)amine No 
12 D03 3-(3-bromophenyl)-5,7-dimethyl-8-hydropyrazolo[1,5-a]pyrimidine No 
12 E03 1,2-dimethoxy-4-(2-morpholin-4-yl(1,3-thiazol-4-yl))benzene No 
12 F03 5-(hydroxymethyl)quinolin-8-ol No 
12 G03 methyl 2-amino-5-methylthiophene-3-carboxylate No 
12 H03 1,2-dihydroxyanthracene-9,10-dione No 
12 I03 1,2,4-trihydroxyanthracene-9,10-dione No 
12 J03 3,4-dihydroxy-9,10-dioxoanthracene-2-sulfonic acid, sodium salt No 
12 K03 2-phenylbenzo[h]chromen-4-one YES 
12 L03 5-hydroxy-2-(3-hydroxyphenyl)chromen-4-one No 
12 M03 7-hydroxy-2-(3-hydroxyphenyl)chromen-4-one No 
12 N03 7-hydroxy-2-(4-methoxyphenyl)chromen-4-one No 
12 O03 adamantanyl-N-[3-(dimethylamino)propyl]carboxamide No 
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12 B04 1-[(4-methoxyphenyl)sulfonyl]-4-methylpiperazine No 
12 C04 [(4-fluorophenyl)sulfonyl]-3-pyridylamine No 
12 D04 2H-benzo[3,4-d]1,3-dioxolan-5-yl[(4-chlorophenyl)sulfonyl]amine No 
12 E04 (3,5-dichlorophenyl)(2-thienylsulfonyl)amine No 











12 K04 5-((1E)-2-naphthylvinyl)-2-(2-chlorophenyl)-1,3,4-oxadiazole No 




12 N04 5-(diphenylmethyl)-2-(2-bromophenyl)-1,3,4-oxadiazole No 
12 O04 5-(5-bromo(2-furyl))-2-phenyl-1,3,4-oxadiazole No 
12 P04 5-[(1E)-2-(4-fluorophenyl)vinyl]-2-phenyl-1,3,4-oxadiazole No 
12 A05 5-(2,4-dichlorophenyl)-2-(4-fluorophenyl)-1,3,4-oxadiazole No 
12 B05 5-(2,4-dichlorophenyl)-2-(3,5-dinitrophenyl)-1,3,4-oxadiazole No 
12 C05 5-((1E)-2-naphthylvinyl)-2-(2,4-dichlorophenyl)-1,3,4-oxadiazole No 
12 D05 5-((1E)-2-(2-furyl)vinyl)-2-(2,4-dichlorophenyl)-1,3,4-oxadiazole No 







12 H05 2-(2,4-dichlorophenyl)-5-(2-methyl(3-furyl))-1,3,4-oxadiazole No 
12 I05 (7R,7aR)-3-(acetyloxymethyl)-7-amino-6-oxo-2H,7H-azetidino[2,1-
b]1,3-thiazine- 4-carboxylic acid 
No 
12 J05 (2S,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-






















yl))methyl]amino}phenyl)carbonyl amino]pentanedioic acid, hydrate 
No 
12 C06 5-(amidinoamino)-2-(aminocarbonylamino)pentanoic acid No 
12 D06 4-hydroxy-2-methoxy-5-(phenylcarbonyl)benzenesulfonic acid No 
12 E06 2-hydroxy-3-indol-3-ylpropanoic acid No 




12 H06 (2S)-2-amino-3-(1-methylindol-3-yl)propanoic acid No 
12 I06 di2,4-dihydroxyphenyl ketone No 
12 J06 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol, hydrate No 































12 G07 1-methyl-3-(2-methylpropyl)-1,3,7-trihydropurine-2,6-dione No 
12 H07 9,10-dimethoxy-5,6-dihydro-2H-1,3-dioxolano[4,5-

















12 N07 1-[(1E)-2-(1-hexyl(2-pyridyl))vinyl]-2,4-dimethoxybenzene, iodide No 
12 O07 5-[(1E)-2-(1-hexyl(2-pyridyl))vinyl]-2H-benzo[d]1,3-dioxolane, 
iodide 
No 
12 P07 methyl 2-[(2,5-dichlorophenyl)sulfonyloxy]-5-iodobenzoate No 
12 A08 2-[(2-hydroxyethyl)amino]-N-(4-iodophenyl)acetamide No 
12 B08 3,6-dichloro-2-methylbenzo[b]thiole-1,1-dione No 
12 C08 5-[4-(benzotriazolylmethyl)piperazinyl]-2H-benzo[d]1,3-dioxolene No 
12 D08 4,6-bis(4-chlorophenyl)-1,3,6-trihydropyrimidin-2-one No 
12 E08 4-ethyl-5-(4-fluorophenyl)-1,2,4-triazole-3-thiol No 
12 F08 4-phenyl-5-(2-thienyl)-1,2,4-triazole-3-thiol No 




12 I08 2-[4-(4-fluorophenyl)piperazinyl]-N-(2,4,5-trifluorophenyl)acetamide No 
12 J08 2,4,6-tri(2-pyridyl)-1,3,5-triazine No 
12 K08 3,3-bis(3-chloro-4-hydroxyphenyl)benzo[c]1,2-oxathiolene-1,1-dione No 
12 L08 2,5-dioxoazolidinyl (2,5-dioxoazolidinyloxy)formate No 
12 M08 2,5-dioxoazolidinyl (phenylmethoxy)formate No 
12 N08 2,5-dioxoazolidinyl (fluoren-9-ylmethoxy)formate No 












a]benzimidazol-3- yl) phenyl ketone 
No 
12 D09 5-(1,2,3,4-tetraazolyl)-3-hydroisobenzofuran-1-one No 






















12 M09 1-[3-(2-chlorophenoxy)propyl]indole-3-carbonitrile No 












12 D10 [4-bromo-5-(4-chlorophenylthio)(2-furyl)](hydroxyimino)methane No 
12 E10 3-(3-bromophenyl)-4-ethyl-1,2,4-triazoline-5-thione No 
12 F10 3-(3-bromophenyl)-1,2,4-triazoline-5-thione No 
12 G10 2-(2,4-dihydroxyphenyl)chromen-4-one No 
12 H10 3,6-dimethoxy-2-phenylchromen-4-one No 
12 I10 3-hydroxy-2-(3-hydroxyphenyl)chromen-4-one No 
12 J10 3,6-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one YES 
12 K10 7,8-dihydroxy-2-(2-hydroxyphenyl)chromen-4-one No 
12 L10 7,8-dihydroxy-2-(3-hydroxyphenyl)chromen-4-one No 
12 M10 2-(3,4-dihydroxyphenyl)-3-hydroxychromen-4-one No 
12 N10 2-naphthyl[(phenanthridin-6-ylmethylthio)methyl]amine No 
12 O10 4-{[4-(4-bromophenoxy)phenyl]sulfonyl}morpholine No 
12 P10 phenyl(xanthen-9-ylamino)methane-1-thione No 










12 E11 4-(1H-1,2,3,4-tetraazol-5-yl)-1,2,5-oxadiazole-3-ylamine No 
12 F11 1-(4-bromophenyl)-1,2-diazolidine-3,5-dione No 




12 I11 2-(4-methyl(1,2,4-triazol-3-ylthio))-1-nitro-4-piperidylbenzene No 
12 J11 2-[2-(3-methoxyphenoxy)ethylthio]hydroquinazolin-4-one No 










12 O11 4-nitro-5-[(oxolan-2-ylmethyl)amino]benzene-1,2-dicarbonitrile No 
12 P11 4,5-diaminobenzene-1,2-dicarbonitrile No 
12 A12 4-(4-quinoxalin-2-ylphenoxy)benzene-1,2-dicarbonitrile No 










12 F12 1-adamantanyl-4-nitropyrazole-3-carboxylic acid No 
12 G12 2-[3-(4-chloro-5-methyl-3-nitropyrazolyl)adamantanyl]acetic acid No 
12 H12 5-(2-thienyl)-7-(trifluoromethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]1,3-
diazaperhydro ine-2-carboxylic acid 
No 
12 I12 5-methyl-7-(1,1,2,2,2-pentafluoroethyl)-4H,5H,6H,7H-pyrazolo[1,5-





12 K12 2-[(3-methyl-4-nitropyrazol-5-yl)sulfinyl]acetic acid No 







12 O12 2,4,5-trichlorophenyl (tert-butoxy)formate No 
12 P12 6-[(6-hydroxy-2-naphthyl)disulfanyl]naphthalen-2-ol No 
12 A13 5-bromo-3-fluoro-2-methoxy-1-nitrobenzene No 
12 B13 2-methoxy-4-nitrophenol, potassium salt, hydrate No 
12 C13 2-[(3,4-dihydroxyphenyl)(3-hydroxy-4-oxocyclohexa-2,5-














12 G13 4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol No 




12 J13 2-amino-4-bromophenol No 






12 M13 7,8-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one No 
12 N13 (3S,4aS,5aS,4R,14aR)-3-hydroxy-1,2,3,4,5,11,14,14a,4a,5a-






12 P13 (1R)(6-methoxy(4-quinolyl))(5-vinylquinuclidin-2-yl)methan-1-ol No 
12 A14 (4bS,1R,10aR,4aR)-1,4a-dimethyl-7-(methylethyl)-



































12 K14 (1S)-4-quinolyl(5-vinylquinuclidin-2-yl)methan-1-ol No 
12 L14 (3aS,2R,3R,9aR)-2-(hydroxymethyl)-6-imino-9-hydro-2H,3H-
oxolano[2,3-d]pyrimidi no[2,1-b]1,3-oxazolidin-3-ol, chloride 
No 
12 M14 (2Z,4E)-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-enyl)-3-
methylpenta-2,4-d ienoic acid 
No 
12 N14 3-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy](1S,3R,4R,5R)-































12 G15 2,3,3-trihydroxy-2-(2,3,3-trihydroxy-1-oxoindan-2-yl)indan-1-one No 
12 H15 (2E)-3-(3-bromo-4-fluorophenyl)prop-2-enoic acid No 




12 K15 3-indol-3-yl-2-oxopropanoic acid No 







































12 K16 2-chloro-N-(4-fluorophenyl)acetamide No 
12 L16 N-(2,6-dichlorophenyl)-2-chloroacetamide No 
12 M16 2-chloro-N-(2-chloro(3-pyridyl))acetamide No 
12 N16 N,N-diethyl(3-methyl-4-oxo(3-hydrophthalazinyl))carboxamide No 
12 O16 N-cyclohexyl(3-methyl-4-oxo(3-hydrophthalazinyl))carboxamide No 
12 P16 (3-methyl-4-oxo(3-hydrophthalazinyl))-N-prop-2-enylcarboxamide No 
12 A17 2H,3H-benzo[e]1,4-dioxin-6-yl(5-nitro(2-pyridyl))amine No 
12 B17 N-(tert-butyl)-2-(2-methylindol-3-yl)-2-oxoacetamide No 
12 C17 1-indol-3-yl-2-morpholin-4-ylethane-1,2-dione No 
12 D17 N,N-diethyl-2-(1-methylindol-3-yl)-2-oxoacetamide No 
12 E17 N-cyclopropyl-2-(2-methylindol-3-yl)-2-oxoacetamide No 




12 H17 4-(benzothiazol-2-ylthiomethyl)hydroquinolin-2-one No 








a]benzimidazol -3-yl) phenyl ketone 
No 
12 M17 5-phenyl-3-(3-pyridylmethylthio)-1,2,4-triazole-4-ylamine No 








12 B18 5,8-dimethoxy-4-methylhydroquinolin-2-one No 




12 E18 (4-oxo(3-hydrophthalazinyl))-N-prop-2-enylcarboxamide No 




12 H18 4-{[4-(4-(1,2,3,4-tetraazolyl)phenyl)phenyl]sulfonyl}morpholine No 
12 I18 5-chloro-2-[(4-phenylpiperazinyl)sulfonyl]thiophene No 










12 N18 methyl 2-{1-[(methoxycarbonyl)methyl]-2,4-dioxo-1,3-
dihydroquinazolin-3-yl}ace tate 
No 











12 D19 2,4,6-trimethyl-3-(1,2,3,4-tetraazolyl)benzenesulfonamide No 
12 E19 7-methyl-3-oxo-2H,4H-benzo[e]1,4-oxazine-6-sulfonamide No 
12 F19 1-acetylindoline-5-sulfonamide No 
12 G19 1-(methylsulfonyl)indoline-5-carboxamide No 
12 H19 5-(2-furyl)-3-(morpholin-4-ylmethyl)-1,3,4-oxadiazoline-2-thione No 
12 I19 5-(2-furyl)-3-(piperidylmethyl)-1,3,4-oxadiazoline-2-thione No 
12 J19 6-(piperidylsulfonyl)-2H,4H-benzo[e]1,4-oxazin-3-one No 







12 N19 5-((1E)-2-nitroprop-1-enyl)-2H-benzo[d]1,3-dioxolene No 







12 B20 3-(diphenylmethyl)-4-methyl-1,2,4-triazoline-5-thione No 







12 F20 5-adamantanyl-4-prop-2-enyl-1,2,4-triazole-3-thiol No 




12 I20 3-(4-methyl-5-methylthio-1,2,4-triazol-3-yl)naphthalen-2-ol No 
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12 J20 [5-(3-hydroxypropyl)-4-phenyl(1,2,4-triazol-3-yl)]thiocarboxylic acid No 











12 P20 2-[(2-chloro-4,5-difluorophenyl)methylthio]-6-ethoxybenzothiazole No 


























































diol, bromi de 
No 
12 F22 5-[3-(2-pyridyl)-6-(5-sulfo(2-furyl))-1,2,4-triazin-5-yl]furan-2-
sulfonic acid , sodium salt, sodium salt 
No 




























Plate Well IUPAC NAME Inhibitor 
Y/N 
13 A03 5-{[5-cyano-2-hydroxy-1-(2-hydroxyethyl)-4-methyl-6-oxo-3-
hydropyridyl]diazeny l}-4H-1,2,4-triazole-3-carboxylic acid 
No 
13 B03 4-chloro-3-{[5-cyano-2-hydroxy-1-(2-hydroxyethyl)-4-methyl-6-
oxo(3-hydropyridy l)]diazenyl}benzenesulfonic acid 
No 














13 I03 2-oxoindoline-3-carbaldehyde No 
13 J03 6,8-dibromo-11,13,13-trimethylspiro[2H-chromene-2,2'-indoline] YES 
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13 K03 3-(2-ethylisoxazol-5-yl)benzenesulfonic acid No 
























yl]methyl dihydr ogen phosphate, sodium salt, sodium salt 
No 
13 F04 [(3S,2R,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl 
dihydrogen phosp hate 
No 
13 G04 [(3S,2R,5R)-5-(2-amino-6-oxohydropurin-9-yl)-3-hydroxyoxolan-2-
yl]methyl dihyd rogen phosphate, sodium salt 
No 
13 H04 [(3S,2R,5R)-3-acetyloxy-5-(5-methyl-2,4-dioxo(1,3-

























(hydroxymethyl)oxo lan-3-yl dihydrogen phosphate 
No 
13 A05 [(3S,2R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-













































2,5-dienylid ene)methyl]-2-hydroxy-3-methylbenzoic acid 
No 
13 A06 4-nitro-1,2,5-oxadiazole-3-ylamine No 
13 B06 2,6-bis(tert-butyl)-4-sulfanylphenol No 







13 F06 bis[4-(dimethylamino)phenyl]phenylmethan-1-ol No 
13 G06 5-[(3-carboxy-4-hydroxyphenyl)(3-carboxy-4-oxocyclohexa-2,5-
dienylidene)methyl ]-2-hydroxybenzoic acid, N 
No 
13 H06 3,4,10,6a-tetrahydroxy-7,6a-dihydroindeno[2,1-c]chroman-9-one No 
13 I06 2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione No 
13 J06 2-[(3,4-dihydroxyphenyl)(3-hydroxy-4-oxocyclohexa-2,5-














dienylidene)methyl ]-2-hydroxybenzoic acid 
No 
13 O06 (4-{bis[4-(dimethylamino)phenyl]methyl}phenyl)dimethylamine No 
13 P06 5-[(3-carboxy-5-methyl-4-oxocyclohexa-2,5-dienylidene)(2-


















13 F07 5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one No 
13 G07 1-methyl-3,4-dihydrobeta-carbolin-7-ol No 



















































ene- 5-carboxylic acid 
No 
13 J08 4,10-dioxatricyclo[5.2.1.0<2,6>]decane-3,5-dione No 
13 K08 1,2,3,4-tetrahydroisoquinolylmethylamine No 
13 L08 1H-indazol-6-yl[(4-aminophenyl)sulfonyl]amine No 
13 M08 4,5-dihydroxybenzene-1,3-disulfonic acid, sodium salt, sodium salt, 
hydrate 
No 




13 P08 3-[(1E)-2-(4-nitrophenyl)-1-azavinyl]-4H-1,2,4-triazole No 
13 A09 3-benzo[3,4-b]benzo[d]furan-3-yl-3-hydroquinazolin-4-one No 
13 B09 N-(2-furylmethyl)-N'-(3-morpholin-4-ylpropyl)ethane-1,2-diamide No 
13 C09 8-chloro-1,3-dinitrodibenzo[b,f]oxepin No 
13 D09 amino-N-(1-phenylbenzimidazol-5-yl)amide No 
13 E09 2-(dimethoxymethyl)-2-methyl-1,2,3-trihydroquinazolin-4-one No 










13 J09 3-(morpholin-4-ylsulfonyl)phenylamine No 
13 K09 4-(4-methyl-1,2,4-triazol-3-yl)phenylamine No 
13 L09 methyl 4-(aminomethyl)-5-ethylfuran-2-carboxylate No 
13 M09 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol, chloride No 







13 A10 8-(3,4-dichlorophenoxy)-5-methoxy-2,4-dimethylquinoline No 
13 B10 5-methoxy-2-phenoxyphenylamine No 
13 C10 2-(3,4-dichlorophenoxy)-5-methoxyphenylamine No 







13 G10 5,6-dimethoxy-11-methylspiro[indane-2,1'-isoindoline] No 
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13 H10 2,3-dioxo-1H-benzo[d]azoline-5-sulfonic acid, sodium salt, hydrate No 
13 I10 (7-amino-8-methylphenothiazin-3-ylidene)dimethylamine, chloride No 
13 J10 7-(diethylylidene)-3,4-dihydroxyphenoxazinecarboxamide, chloride No 
13 K10 1-((1E)-2-nitrovinyl)-2-(trifluoromethyl)benzene No 
13 L10 [(4,5-dimethoxy-2-nitrophenyl)methyl]thiocarboxamidine, bromide No 
13 M10 2-(2,3-dimethoxyphenyl)-6-methoxychromen-4-one No 
13 N10 4-formylbenzene-1,3-disulfonic acid No 
13 O10 (7R,7aR)-3-(acetyloxymethyl)-6-oxo-7-(2-(4-pyridylthio)acetylamino)-
2H,7H-azet idino[2,1-b]1,3-thiazine-4-carboxylic acid, sodium salt 
No 
13 P10 (1R)((5S)-5-ethylquinuclidin-2-yl)(6-ethoxy(4-quinolyl))methan-1-ol No 
13 A11 4-[3-(2-pyridyl)-5-(5-sulfo(2-furyl))-1,2,4-triazin-6-yl]furan-2-sulfonic 
acid 
No 















13 H11 2-amino-4,5-dimethoxyphenyl 6,7-dimethoxyisoquinolyl ketone No 












13 N11 9-chloro-5,6,7,8-tetrahydroacridine No 
13 O11 4-chloro-2-methylquinoline No 
13 P11 [2-(hydroxymethyl)-4-oxa-1-azaspiro[4.5]dec-2-yl]methan-1-ol No 
13 A12 2-(phenylmethylthio)benzimidazole No 
13 B12 adamantanyl-N-(1,3-thiazol-2-yl)carboxamide No 
13 C12 4-(4-nitrophenyl)morpholine No 
13 D12 1-(2-naphthylsulfonyl)pyrrolidine-2-carbohydrazide No 
13 E12 ethyl 2-(acetylamino)-5-{[5-(acetylamino)-4-(ethoxycarbonyl)-3-
methyl(2-thieny l)]disulfanyl}-4-methylthiophene-3-carboxylate 
No 






13 H12 ethyl 2-amino-6-methyl-4,5,6,7-tetrahydrothiopheno[2,3-c]pyridine-3-
carboxylat e 
No 








13 M12 3-(hydroxymethyl)-5,5-dimethyl-1,3-diazolidine-2,4-dione No 
13 N12 3-(di???methyl)thiolane-1,1-dione No 
13 O12 ethyl 6-bromo-2-oxochromene-3-carboxylate No 
13 P12 ethyl 2-(2-chloroacetylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxylat e 
No 
13 A13 1-(3-ethyl-3-hydrobenzothiazol-2-ylidene)acetone No 
13 B13 ((1Z)-1-morpholin-4-yl-2-phenyl-2-azavinyl)phenylamine No 
13 C13 [4-(hydroxymethyl)-2-(phenoxymethyl)-1,3-oxazolin-4-yl]methan-1-ol No 




13 F13 1-(4,5-dimethyl(1,2,4-triazol-3-ylthio))-2-chloro-4-nitrobenzene No 
13 G13 6-iodo-3-hydroquinazolin-4-one No 
13 H13 1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetraazole No 
13 I13 1-[(2-chlorophenyl)methyl]-2-methylthiobenzimidazole No 
13 J13 1-acetylpyrrolidine-2-carboxylic acid No 
13 K13 3-methyl-1,3-dihydroquinazoline-2,4-dione No 




13 N13 1,4-dimethyl-1,4-dihydroquinoxaline-2,3-dione No 
13 O13 4,5-bisbenzyl-1,2,4-triazole-3-thiol No 
13 P13 3,6-dibromo-1-nitrocarbazole No 
13 A14 3-nitroquinoline-2,4-diol No 
13 B14 2-(2-methylpyridyl)-1-phenylethan-1-one, chloride No 
13 C14 4-amino-3-chlorothiolane-1,1-dione No 
13 D14 4-hydroxy-3-{[(2-phenylethyl)amino]methyl}chromen-2-one No 
13 E14 4-chloro-5-phenyl-3-(trifluoromethyl)pyrazole No 
13 F14 1-(4-nitrophenyl)-5-(trifluoromethyl)pyrazole-4-carboxylic acid No 
13 G14 4-chloro-5-methyl-3-(trifluoromethyl)pyrazole YES 
13 H14 4-[3-(trifluoromethyl)pyrazolyl]phenylamine No 
13 I14 2-amino-3-pyrrolo[2,3-b]pyridin-3-ylpropanoic acid No 
13 J14 4-[(3-carboxy-4-oxonaphthylidene)phenylmethyl]-1-




13 K14 (2S)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid No 
13 L14 7-methyl-1H-indazole-5-ylamine No 














13 B15 6-(2-chloroacetyl)-3-hydrobenzoxazol-2-one No 




13 E15 6-methyl-2,3,4-trihydrobeta-carbolin-1-one No 
13 F15 3-amino-1-(3-methylpiperidyl)propan-2-ol No 
13 G15 2-(2,3-dioxobenzo[d]azolidinyl)acetic acid No 
13 H15 3-[(ethylpropyl)amino]benzo[d]1,2-thiazoline-1,1-dione No 





13 K15 3-nitro-4-pyrrolidinylbenzaldehyde No 
13 L15 3-nitro-4-phenylthiobenzaldehyde No 
13 M15 5-prop-2-ynylthio-1,3,4-thiadiazole-2-ylamine No 
13 N15 2-(2-indol-3-ylacetylamino)butanedioic acid No 




13 A16 2-(aminocarbonylamino)-3-indol-3-ylpropanoic acid No 




13 D16 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one No 
13 E16 2-(4,6-dimethylpyrimidin-2-ylthio)acetic acid, hydrate No 
13 F16 (2S,1R)-2-(2-thienylcarbonyl)cyclohexanecarboxylic acid No 

















13 K16 amino[(4-aminophenyl)sulfonyl]carboxamidine No 
13 L16 2-(4-chlorophenyl)-1-(2,4,6-trihydroxyphenyl)ethan-1-one No 
13 M16 2-amino-7-methyl-4-hydro-1,3,4-thiadiazolino[3,2-a]pyrimidin-5-one No 
13 N16 5-bromo-7-methyl-1H-indazole No 
13 O16 3,5-dimethyladamantanylamine No 




13 B17 3,3-bis(4-hydroxyphenyl)benzo[c]1,2-oxathiolene-1,1-dione No 
13 C17 ethyl (2E)-2-[(3-methylphenyl)carbonylamino]-3-(4-nitrocyclopenta-
1,3-dienyl)p rop-2-enoate 
No 
13 D17 2-bromo-3-methoxypyridine No 











13 I17 [2-(4-chlorophenylthio)ethyl](methylsulfonyl)amine No 



















13 A18 [(4-aminophenyl)sulfonyl]methylamine No 
13 B18 (2S)-1-((2S)-3-acetylthio-2-methylpropanoyl)pyrrolidine-2-carboxylic 
acid 
No 
13 C18 5-phenyl-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
13 D18 [(4-methyl-5-methylthio-1,2,4-triazol-3-yl)methoxy]benzene No 
13 E18 5-(2-bromophenyl)-4-methyl-1,2,4-triazole-3-thiol No 
13 F18 3-(4-prop-2-enyl-5-sulfanyl-1,2,4-triazol-3-yl)naphthalen-2-ol No 






13 I18 3-{2-[(2,4-dinitrophenyl)amino]ethyl}-1,3-oxazolidin-2-one No 
13 J18 7-chloro-4-methoxyquinoline No 
13 K18 6-nitro-1,4-dihydroquinoxaline-2,3-dione No 
13 L18 [2,6-dinitro-4-(trifluoromethyl)phenyl]imidazole No 
13 M18 5-(methylsulfonyl)-1-phenyl-1,2,3,4-tetraazole No 
13 N18 4-methyl-5-phenyl-1,2,4-triazole-3-thiol No 
13 O18 5-(3-chloro-4-methylphenyl)-4-methyl-1,2,4-triazole-3-thiol No 
13 P18 5-(4-methoxyphenyl)-4-methyl-1,2,4-triazole-3-thiol No 
13 A19 4-methyl-5-benzyl-1,2,4-triazole-3-thiol No 




13 D19 5-(2-chloro-4-methylphenyl)-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
13 E19 2,6,7-trihydroxy-9-methylxanthen-3-one No 
13 F19 1-(4-chlorophenyl)-2-(6-methoxyquinolyl)ethan-1-one, bromide No 
13 G19 2-(2-chloro-4-nitroimidazolyl)acetamide No 
13 H19 2-chloro-1-[(2-chloro-4-nitroimidazolyl)methyl]-4-nitroimidazole No 
13 I19 2-chloro-4-nitro-1-[(4-nitrophenyl)methyl]imidazole No 







13 M19 4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazole-3-ylamine No 
13 N19 5-nitro-3-hydrobenzimidazole-2-thione No 
13 O19 (2S)-2-[(tert-butoxy)carbonylamino]-3-imidazol-4-ylpropanoic acid No 
13 P19 (1R)(6-methoxy(4-quinolyl))[1-benzyl-5-vinylquinuclidin-2-yl]methan-
1-ol, chlo ride 
No 
13 A20 5-phenyl-2-(4-pyridyl)-1,3-oxazole No 
13 B20 3,5-diamino-6-chloropyrazine-2-carboxamide No 
13 C20 4-amino-2,3,5,6-tetrafluorobenzamide No 






















13 L20 ethyl 2-hydrazino-4-methyl-1,3-thiazole-5-carboxylate No 
13 M20 adamantanyl 4-(2-pyridyl)piperazinyl ketone No 
13 N20 ethyl 2-(5-hydroxy-3-methylpyrazolyl)-4-methyl-1,3-thiazole-5-
carboxylate 
No 
13 O20 ethyl 2-[4-(2-furylmethylene)-3-methyl-5-oxo(1,2-diazolinyl)]-4-
methyl-1,3-thi azole-5-carboxylate 
No 
13 P20 ethyl 4-methyl-2-{3-methyl-4-[(5-methyl(2-furyl))methylene]-5-
oxo(1,2-diazolin yl)}-1,3-thiazole-5-carboxylate 
No 
13 A21 ethyl 4-methyl-2-{3-methyl-4-[(5-methyl(2-thienyl))methylene]-5-
oxo(1,2-diazol inyl)}-1,3-thiazole-5-carboxylate 
No 
13 B21 ethyl 2-{4-[(5-ethyl(2-thienyl))methylene]-3-methyl-5-oxo(1,2-
diazolinyl)}-4-m ethyl-1,3-thiazole-5-carboxylate 
No 
13 C21 ethyl 4-methyl-2-[3-methyl-5-oxo-4-(2-thienylmethylene)(1,2-
diazolinyl)]-1,3-t hiazole-5-carboxylate 
No 




13 E21 2-(5-bromo-2,3-dioxobenzo[d]azolidinyl)acetic acid No 
13 F21 1-(chloromethyl)-4-nitropyrazole No 
13 G21 2-(2-chloro-4-nitroimidazolyl)acetic acid No 
13 H21 1-[(5-bromo-2-thienyl)sulfonyl]pyrrolidine-2-carboxylic acid No 
13 I21 2-(5-bromo-2,3-dioxobenzo[d]azolidinyl)propanoic acid No 
13 J21 2H,4H-benzo[e]1,3-dioxin-6-ylamine No 
13 K21 1-(chloromethyl)-3-nitropyrazole No 
13 L21 5-bromo-7-methyl-1H-benzo[d]azolidine-2,3-dione No 
13 M21 methyl 6-methoxybenzothiazole-2-carboxylate No 
13 N21 2-(2,3-dioxobenzo[d]azolidinyl)propanoic acid No 
13 O21 N-(2,6-dimethoxypyrimidin-4-yl)-3-(1,2,3,4-tetraazolyl)propanamide No 
13 P21 N-[3,5-bis(trifluoromethyl)phenyl]-3-(1,2,3,4-tetraazolyl)propanamide No 













13 F22 methylethyl 3-[N-(2,6-dimethoxypyrimidin-4-yl)carbamoyl]propanoate No 
13 G22 N-(4-methyl(1,3-thiazol-2-yl))(1-methylpyrazol-5-yl)carboxamide No 
13 H22 N-(2,4-dichlorophenyl)tricyclo[4.3.0.0<3,9>]non-7-ylcarboxamide No 
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13 M22 4-(3,5-di(1,2,3-thiadiazol-4-yl)phenyl)-1,2,3-thiadiazole No 
13 N22 4-hydroxy-3-iodo-5-methoxybenzaldehyde No 




Plate Well IUPAC NAME Inhibitor 
Y/N 
14 A03 3-(3,5-dimethoxyphenyl)-1H-1,2,4-triazole-5-ylamine No 
14 B03 6-bromo-4-oxochromene-2-carboxylic acid No 
14 C03 7-methoxy-2-oxochromene-3-carbonitrile No 
14 D03 6-methyl-2-(3-methylphenyl)chromen-4-one No 
14 E03 4-hydroxy-6-methoxychromen-2-one No 
14 F03 3-acetyl-2-oxo-3-hydrobenzoxazole No 




14 I03 methyl 4-hydroxy-1,1-dioxo-2H-benzo[e]1,2-thiazine-3-carboxylate No 
14 J03 methyl 4-hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazine-3-
carboxylate 
No 
14 K03 methyl 4-methyl-6-(2-thienyl)-2-thioxo-1,3,6-trihydropyrimidine-5-
carboxylate 
No 
14 L03 ethyl 4-methyl-6-(5-methyl(2-thienyl))-2-oxo-1,3,6-
trihydropyrimidine-5-carbox ylate 
YES 
14 M03 ethyl 6-(2,5-dimethyl(3-thienyl))-4-methyl-2-oxo-1,3,6-
trihydropyrimidine-5-ca rboxylate 
No 































14 I04 (1-cyclohexyl-5-oxopyrrolidin-3-yl)-N-(4-iodophenyl)carboxamide YES 







14 M04 5-bromo-1-methylindolin-2-one No 
14 N04 3-(3,4-dichlorophenyl)pyrazole-4-carbaldehyde No 




14 A05 6-(indolinylsulfonyl)-2-methylthiobenzothiazole No 
14 B05 4-quinoxalin-2-ylphenol No 










14 G05 [4-(4-pyridylmethyl)phenyl](pyrrolidinylsulfonyl)amine No 


















14 P05 4-pyridino[4,3-e]pyrazin-3-ylphenol No 
















14 G06 1-[(3,4-dichlorophenyl)sulfonyl]pyrrolidin-2-yl piperidyl ketone No 
14 H06 1-adamantanyl-2-benzothiazol-2-ylthioethan-1-one No 
14 I06 3-(4-fluorophenyl)-2-sulfanyl-3-hydroquinazolin-4-one No 







14 M06 (2H,3H-benzo[3,4-e]1,4-dioxin-6-ylsulfonyl)cyclohexylamine No 












14 D07 4-ethyl-1-(morpholin-4-ylmethyl)-3-phenyl-1,2,4-triazoline-5-thione No 




14 G07 [(3,4-dimethoxyphenyl)sulfonyl](6-methoxy(3-pyridyl))amine No 










14 L07 4-fluoro-1-[(4-pyrimidin-2-ylpiperazinyl)sulfonyl]benzene No 




14 O07 2-chloro-5-{[4-(4-nitrophenyl)piperazinyl]sulfonyl}thiophene No 
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14 P07 2-chloro-5-(piperidylsulfonyl)thiophene No 
14 A08 N-adamantanyl(4-phenylpiperazinyl)carboxamide No 
14 B08 methyl 5-(methoxycarbonyl)-2,6-dimethyl-4-(2-thienyl)pyridine-3-
carboxylate 
No 




14 E08 4-piperidyl-1-(2-thienylcarbonyl)piperidine-4-carboxamide No 










14 J08 (dibenzo[b,d]furan-2-ylsulfonyl)(6-methoxy(3-pyridyl))amine No 
14 K08 (fluoren-2-ylsulfonyl)(6-methoxy(3-pyridyl))amine No 
































14 J09 cyclohexyl[(2-ethoxy-5-(1,2,3,4-tetraazolyl)phenyl)sulfonyl]amine No 




14 M09 [3,5-bis(trifluoromethyl)phenyl][(5-chloro(2-thienyl))sulfonyl]amine No 













14 C10 5-chlorothiopheno[3,2-b]pyridine-3-carbaldehyde No 
14 D10 [(1-acetylindolin-5-yl)amino]-N-adamantanylcarboxamide No 
14 E10 1-acetyl-5-{[(tert-butyl)amino]sulfonyl}indoline No 
14 F10 1-acetyl-5-[(cyclopropylamino)sulfonyl]indoline No 
14 G10 1-acetyl-5-(indolinylsulfonyl)indoline No 
14 H10 1-acetyl-5-[(diethylamino)sulfonyl]indoline No 
14 I10 1-acetyl-5-(morpholin-4-ylsulfonyl)indoline No 
14 J10 6,7-dimethoxy-2-oxo-1,3,4-trihydroquinoline-4-carboxylic acid No 
14 K10 2-thienyl-N-(2-(2-thienyl)ethyl)carboxamide No 
14 L10 (2-naphthylsulfonyl)(2-(2-thienyl)ethyl)amine No 
14 M10 N-adamantanyl[(4-pyridylmethyl)amino]carboxamide No 
14 N10 N-cyclopropyl[1-(methylsulfonyl)indolin-5-yl]carboxamide No 
































14 M11 N-acenaphthen-5-yl(1-methyl-5-oxopyrrolidin-3-yl)carboxamide No 












14 B12 5-aminoquinolin-8-ol No 
14 C12 2-amino-5,5-dimethyl-4,5,6-trihydrobenzothiazol-7-one No 
14 D12 2-methylbenzo[g]benzothiazole No 




14 G12 methyl 2-amino-5-propylthiophene-3-carboxylate No 
14 H12 methyl 2-amino-5-(methylethyl)thiophene-3-carboxylate No 
14 I12 4-chloro-1-[(4-fluorophenoxy)methyl]pyrazole-3-carboxylic acid No 
14 J12 3-bromo-6-fluorochromen-4-one No 
14 K12 5-aminoindole-3-carboxamide YES 
14 L12 2-(2,7-bis{[bis(carboxymethyl)amino]methyl}-6-hydroxy-3-
oxoxanthen-9-yl)benzoi c acid 
No 
14 M12 (2S,6R,9R)-9-phenyl-7-oxa-1-azabicyclo[4.3.0]nonane-2-carbonitrile No 
14 N12 4-amino-6-(tert-butyl)-1-methyl-1,3,5-triazin-2-one No 
14 O12 5-hydroxy-2-phenylchromen-4-one No 
14 P12 7-(dimethylamino)phenothiazin-3-one No 
14 A13 2-{(carboxymethyl)[(7-hydroxy-4-methyl-2-oxochromen-8-
yl)methyl]amino}acetic a cid 
No 
14 B13 ethyl 4-methyl-6-(5-methyl(2-thienyl))-2-thioxo-1,3,6-
trihydropyrimidine-5-car boxylate 
No 




14 D13 methyl 4-[(2,5-dichlorophenylthio)methyl]-6-(2,4-dimethylphenyl)-
2-oxo-1,3,6-t rihydropyrimidine-5-carboxylate 
No 






14 G13 methyl (2E)-2-cyano-3-{4-[(1-methyl(1,2,3,4-tetraazol-5-
ylthio))methyl](2-thie nyl)}prop-2-enoate 
YES 





























14 A14 ethyl 2-(2,2-dimethylpropanoylamino)-4-methyl-1,3-thiazole-5-
carboxylate 
No 
14 B14 ethyl 4-methyl-2-(propanoylamino)-1,3-thiazole-5-carboxylate No 




















































































14 A16 4-[(1Z)-1-ethyl-2-(4-hydroxyphenyl)but-1-enyl]phenol No 
14 B16 5-((1E)-4-amino-2-azabut-1-enyl)-3-iodo-2-methoxyphenol No 
14 C16 3-[N-(4,5-dimethyl-1,3-thiazol-2-yl)carbamoyl]propanoic acid No 
14 D16 2-methylpropyl 5-(N-(2H-benzo[3,4-d]1,3-dioxolen-5-
yl)carbamoyl)-3-hydroxypyrr olidinecarboxylate 
No 
14 E16 2-methylpropyl 3-hydroxy-5-[N-(4-
iodophenyl)carbamoyl]pyrrolidinecarboxylate 
No 
14 F16 2-methylpropyl 3-hydroxy-5-[N-(4-iodo-2,6-
dimethylphenyl)carbamoyl]pyrrolidine carboxylate 
No 
14 G16 tert-butyl 2-[N-(4-iodo-2-
methylphenyl)carbamoyl]pyrrolidinecarboxylate 
No 
14 H16 N-(4-iodophenyl)[1-(2-thienylcarbonyl)pyrrolidin-2-yl]carboxamide No 
14 I16 2-methylpropyl 2-[N-(4-
chlorophenyl)carbamoyl]pyrrolidinecarboxylate 
No 

















14 O16 3-chloro-4,6-diphenylpyridazine No 
14 P16 2-(5-amino(1,3,4-thiadiazol-2-ylthio))-1-pyrrolidinylethan-1-one No 
14 A17 4-(3-methylpyrazolyl)phenylamine No 
















14 H17 1-[4-(chlorosulfonyl)phenyl]pyrrolidin-2-one YES 
14 I17 methyl 1,5-dimethylpyrazole-3-carboxylate No 
14 J17 2-(2-bromoethyl)benzo[c]azoline-1,3-dione No 
14 K17 4,5-diphenyl-1,3-oxazole-2-thiol No 
14 L17 1,2,4-triazino[5,6-b]indole-3-thiol No 
14 M17 1,2,4-triazino[5,6-b]indole-3-ylhydrazine No 
14 N17 [(4-aminophenyl)sulfonyl](3,4-dimethylisoxazol-5-yl)amine No 
14 O17 [(4-aminophenyl)sulfonyl]pyrimidin-2-ylamine No 
14 P17 5-amino-3-nitrophenol No 
14 A18 4,6-dimethylpyrimidine-2-thiol, chloride No 




14 D18 ethyl 4-methyl-2-[(methylsulfonyl)amino]-1,3-thiazole-5-carboxylate No 
14 E18 ethyl 2-(2-ethylbutanoylamino)-4-methyl-1,3-thiazole-5-carboxylate No 
14 F18 ethyl 4-methyl-2-(pentanoylamino)-1,3-thiazole-5-carboxylate No 



















14 N18 3-[(4-chlorophenyl)phenylmethylthio]-1,2,4-thiadiazole-5-ylamine No 
329 
 
14 O18 2-(2-piperazinylethyl)benzo[c]azolidine-1,3-dione No 




14 B19 2-[(fluoren-9-ylmethoxy)carbonylamino]indane-2-carboxylic acid No 
14 C19 1-[(fluoren-9-ylmethoxy)carbonylamino]indanecarboxylic acid No 
14 D19 2-[(fluoren-9-ylmethoxy)carbonylamino]-1,2,3,4-
tetrahydronaphthalene-2-carboxy lic acid 
No 
14 E19 (2S,3S)-2-[(fluoren-9-ylmethoxy)carbonylamino]-3-methylpentanoic 
acid 
No 
14 F19 7-hydroxyphenoxazin-3-one No 
14 G19 7-hydroxyphenoxazin-3-one No 
14 H19 (2S)azetidine-2-carboxylic acid No 
14 I19 (5R,6R)-4-chloro-5,6-dihydroxycyclohexa-1,3-dienecarboxylic acid No 
14 J19 3-chloro-1H-indazole No 
14 K19 histidine, chloride, hydrate No 
14 L19 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carbaldehyde No 
14 M19 6-methyl-2-(methylethyl)pyrimidin-4-ol No 
14 N19 2-(5-hydroxyindol-3-yl)acetic acid No 
14 O19 2-(5-methylpyrazol-3-yl)acetic acid No 
14 P19 2,8-bis(2,4-dihydroxyphenyl)-7-hydroxyphenoxazin-3-one No 
14 A20 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one No 
14 B20 4,6-bis(1-cyclohexyl(1,2,3,4-tetraazol-5-yl)thio)-5-nitropyrimidine No 




14 E20 [(2,5-dimethoxy-3,4,6-trimethylphenyl)sulfonyl]piperidine No 
14 F20 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one, hydrate, 
hydrate 
No 
14 G20 1-nitro-3-(trifluoromethyl)dibenzo[b,e]1,4-dioxin No 
14 H20 N-(2-adamantanyloxypropyl)cyclopropylcarboxamide No 
14 I20 1-acetyl-5-{[(2-oxo(3-3,4,5-trihydrothienyl))amino]sulfonyl}indoline No 
14 J20 2-chloro-4-nitro-1-(2-pyridylthio)benzene No 
14 K20 1-cyclohexyl-5-[(4-nitrophenyl)methylthio]-1,2,3,4-tetraazole No 
14 L20 5-methyl-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
14 M20 5-(3,4-dimethoxyphenyl)-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
14 N20 5-[4-(tert-butyl)phenyl]-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
14 O20 5-(4-methoxyphenyl)-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
14 P20 5-(2-phenylethyl)-4-prop-2-enyl-1,2,4-triazole-3-thiol No 
14 A21 5-(2,4-dichlorophenyl)-4-prop-2-enyl-1,2,4-triazole-3-thiol No 






14 D21 3-imino-3-indolinyl-2-azaprop-1-ene-1,1-diamine, chloride No 
14 E21 (2-nitrophenyl)imidazole No 
14 F21 3-methyl-1-(4-nitrophenyl)pyrazole No 
14 G21 2-(hydroxyimino)adamantane No 
14 H21 [(1-methylbenzimidazol-2-yl)methoxy]benzene No 
14 I21 6-nitroquinoxaline No 
14 J21 6-methyl-2,3,4,9-tetrahydro-4aH-carbazol-1-one No 
14 K21 4-ethyl-5-(4-methylphenyl)-1,2,4-triazole-3-thiol No 
14 L21 4-cyclohexyl-5-benzyl-1,2,4-triazole-3-thiol No 
14 M21 7,8-dimethoxy-4-methylchromen-2-one No 
14 N21 phenyl 5-chloro-2-oxo-3-hydrobenzoxazole-3-carboxylate No 
14 O21 7-methoxy-4-methylchromen-2-one No 
14 P21 4-(4-chloro-2-nitrophenyl)morpholine No 
14 A22 1-cyclohexyl-5-oxopyrrolidine-3-carboxylic acid No 
14 B22 5-({2-[(4-carboxy-5-methyl(2-furyl))methylthio]ethylthio}methyl)-2-
methylfuran -3-carboxylic acid 
No 
14 C22 N-(1,3-thiazol-2-yl)-2-thienylcarboxamide No 












14 J22 (adamantanylmethyl)(3-nitro(2-pyridyl))amine No 
14 K22 3-(2-furylmethylthio)-1-indolinylacetone No 
14 L22 adamantan-2-yl(3-nitro(2-pyridyl))amine No 







14 P22 5-[(diethylamino)sulfonyl]-1,3-diethyl-3-hydrobenzimidazol-2-one No 
Plate Well IUPAC NAME Inhibitor 
Y/N 
15 A03 N-adamantanyl(4-pyrimidin-2-ylpiperazinyl)carboxamide No 
15 B03 3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methylthio]thiolane-1,1-dione No 
15 C03 (3-nitro(2-pyridyl))(2-(2-thienyl)ethyl)amine No 
15 D03 N-(1-oxo(3-hydroisobenzofuran-5-yl))-2-quinolylcarboxamide No 
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15 G03 5-bromo-3-hydroxy-3-(2-oxo-2-(2-thienyl)ethyl)indolin-2-one No 
15 H03 3-(2-(2-furyl)-2-oxoethyl)-3-hydroxy-1-methylindolin-2-one No 
15 I03 6-hydroxy-2-[(4-phenylpiperazinyl)methyl]-2-hydropyridazin-3-one No 




15 L03 {[4-(2-fluorophenyl)piperazinyl]methyl}benzimidazole No 
15 M03 3-methylthio-1,2,4-thiadiazole-5-ylamine No 
15 N03 1-indolinyl-2-(4-methyl(1,2,4-triazol-3-ylthio))ethan-1-one No 
15 O03 1-(2-thienylsulfonyl)pyrrolidine-2-carboxylic acid No 




15 B04 1,3-bis[(4-chlorophenyl)methyl]-2-(4-pyridyl)imidazolidine No 
15 C04 3-hydroxyadamantanecarboxylic acid No 
15 D04 1,3-dimethyl-5-(piperidylsulfonyl)-3-hydrobenzimidazol-2-one No 
15 E04 (fluoren-2-ylsulfonyl)(2-phenoxyethyl)amine No 











15 K04 2-methyl-5-(morpholin-4-ylmethyl)furan-3-carboxylic acid No 
15 L04 5-[(2-bromophenyl)methylthio]-1,3,4-thiadiazole-2-ylamine No 
15 M04 3-methyl-1-(morpholin-4-ylmethyl)-3-hydrobenzimidazole-2-thione No 
15 N04 N-cyclohexyl-2-(5-methyl(1,3,4-thiadiazol-2-ylthio))acetamide No 
15 O04 2-(benzimidazol-2-ylmethylthio)-4-phenylimidazole No 
15 P04 [(dimethylamino)sulfonyl]fluoren-2-ylamine No 
15 A05 5-adamantanyl-4-methyl-1,2,4-triazole-3-thiol No 




15 D05 1-(morpholin-4-ylmethyl)-3-benzyl-4-imidazoline-2-thione No 
15 E05 2-[(dibenzo[b,d]furan-2-ylsulfonyl)methylamino]acetic acid No 














15 L05 2-(ethylsulfonyl)-1-(2-pyridylmethyl)benzimidazole No 







15 P05 4-morpholin-4-yl-3-(morpholin-4-ylsulfonyl)phenylamine No 
15 A06 5-bromo-1,4-dimethoxy-2-nitrobenzene No 
15 B06 4-fluoro-1-(pyrrolidinylsulfonyl)benzene No 







15 F06 5-(2-furyl)-4-phenyl-1,2,4-triazole-3-thiol No 
15 G06 4-methyl-1,3-thiazole-5-carboxylic acid No 
15 H06 5-chloro-2-morpholin-4-ylphenylamine No 












15 O06 [4-(methylamino)phenyl]thiocarbonitrile No 
15 P06 2-(4-chlorophenyl)-4-(4-nitrophenyl)-1,3-dioxolane No 
15 A07 4-(2,4-dichlorophenyl)-2-morpholin-4-yl-1,3-thiazole No 








15 E07 (2-methoxydibenzo[b,d]furan-3-yl)(pyrrolidinylsulfonyl)amine No 






15 H07 7-nitro-2-(pyrrolidinylsulfonyl)dibenzo[b,d]furan No 
15 I07 5-(isoxazol-3-ylmethylthio)-3-methyl-4-phenyl-1,2,4-triazole No 
15 J07 1-indol-3-yl-2-pyrrolidinylethane-1,2-dione No 
15 K07 3-[methyl(4-phenyl(1,3-thiazol-2-yl))amino]thiolane-1,1-dione No 















15 B08 N-cyclohexyl-2-thienylcarboxamide No 




15 E08 1-(4-fluorophenyl)-4-(pyrrolidinylcarbonyl)pyrrolidin-2-one No 
15 F08 (5-chloro(2-pyridyl))(ethylsulfonyl)amine No 




15 I08 4-(dibenzo[b,d]furan-2-ylsulfonyl)-2,6-dimethylmorpholine No 




15 L08 8-imidazolyl-1,3,7-trimethyl-1,3,7-trihydropurine-2,6-dione No 
15 M08 (1,4-dioxan-2-ylmethyl)methylamine No 
15 N08 4-phenyl-1,2,5-oxadiazole-3-ylamine No 
15 O08 2-amino-1-(3-hydroxyphenyl)ethan-1-ol No 
15 P08 N-(6-hydroxypurin-2-yl)acetamide YES 
15 A09 2-methylnaphthalene-1,4-dione No 
15 B09 (2S)-3-indol-3-yl-2-(methylamino)propanoic acid No 


















15 H09 2-(2-pyridylmethylthio)benzothiazole YES 
15 I09 (5-bromo(2-pyridyl))[benzylsulfonyl]amine YES 
15 J09 (5-bromo(2-pyridyl))(methylsulfonyl)amine YES 












dihydroxyphenyl)propano ic acid 
No 
15 P09 2-(2,5-dioxo-3-3,4-dihydrofuryl)acetic acid No 
15 A10 1-methyl-4-nitroimidazole No 
15 B10 3-(3-pyridyl)-1H-1,2,4-triazole-5-ylamine No 
15 C10 6-methoxycyclohexane-1,2,3,4,5-pentaol No 
15 D10 (1S,5S,2R)-5-methyl-2-(methylethyl)cyclohexan-1-ol No 





15 G10 (2S,1R,5R)-5-methyl-2-(methylethyl)cyclohexyl (2R)-2-
hydroxypropanoate 
No 



























15 P10 6-bromo-2-(3-methylphenyl)chromen-4-one No 

















15 F11 7-methoxy-1-methylbeta-carboline No 
15 G11 (4S,3R,5R)-3,4,5-trihydroxycyclohex-1-enecarboxylic acid YES 
15 H11 (2S)-2-amino-5-(aminocarbonylamino)pentanoic acid YES 
15 I11 2-methoxy-4-prop-2-enylphenol No 
15 J11 3-((2S)-1-methylpyrrolidin-2-yl)pyridine YES 
15 K11 (1S,5S)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one YES 
15 L11 3,7,11,15-tetramethylhexadec-1-en-3-ol YES 
15 M11 5,7-dihydroxy-2-phenylchromen-4-one No 
15 N11 3,7-dimethyloct-6-en-1-ol No 


























15 H12 (4bS,9aR)indano[2,1-c]chroman-1,2,6,7,9a-pentaol YES 
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15 I12 3,7-dimethyl-1,3,7-trihydropurine-2,6-dione No 
15 J12 arginine No 
15 K12 7-[(5S,2R,3R,4R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)(2H-
3,4,5,6-tetrahydropy ran-2-yl)]-3,5,6,8-tetrahydroxy-1-methyl-9,10-
dioxoanthracene-2-carboxylic aci d 
YES 
15 L12 (2S)-5-oxopyrrolidine-2-carboxylic acid YES 
15 M12 isosafrole No 
15 N12 6-methyl-2-phenylchromen-4-one No 








15 C13 1,1-bis(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile No 











15 I13 2,7-dinitrofluorene YES 
15 J13 4-nitropyrazole-3-carboxamide No 











































































































15 P15 6H,11H,5aH-benzo[b]chromeno[2,3-e]1,4-diazepin-13-one No 
15 A16 (4-methyl-5-sulfanyl(1,2,4-triazol-3-yl))phenylmethan-1-ol No 
15 B16 di7-chloro(4-quinolyl) disulfide No 
15 C16 1,3,6-trimethyl-5-nitro-1,3-dihydropyrimidine-2,4-dione No 
15 D16 morpholin-4-yl 3,4,5-trimethoxyphenyl ketone No 
15 E16 3-prop-2-enyl-2-sulfanyl-3-hydroquinazolin-4-one No 
15 F16 4-cyclohexyl-5-phenyl-1,2,4-triazole-3-thiol No 
15 G16 5,6-dimethylbenzimidazole-2-thiol No 
15 H16 ethyl (2Z)-2-cyano-3-(2-furyl)prop-2-enoate YES 
15 I16 1-(methylsulfonyl)-6,8-dinitro-1,2,3,4-tetrahydroquinoline No 
15 J16 5-chloro-1,3-dimethyl-6-nitro-3-hydrobenzimidazol-2-one No 
15 K16 phenazine-2,5,10-triol No 
15 L16 benzo[a]phenazine-7,12-diol No 
15 M16 5-phenyl-1H-1,2,4-triazole-3-thiol No 


















15 F17 (adamantanylmethyl)[(5-bromo(2-thienyl))sulfonyl]methylamine No 




















15 M17 1,3-dimethyl-1,3,5-trihydrofurano[3,4-d]pyrimidine-2,4,7-trione No 
15 N17 2-(trifluoromethyl)benzimidazole-5-ylamine No 




15 A18 [(4-fluoren-9-ylpiperazinyl)sulfonyl]dimethylamine No 
15 B18 (adamantanylmethyl)[(dimethylamino)sulfonyl]methylamine No 
15 C18 (2-methyl(3-furyl))-N-(5-propyl(1,3,4-thiadiazol-2-yl))carboxamide No 
15 D18 N-(1-carbamoyl-3-methylbutyl)cyclopentylcarboxamide No 
15 E18 benzo[b]thiophen-2-yl-N-(oxolan-2-ylmethyl)carboxamide No 




15 H18 6-methoxy-2H-benzo[d]1,3-dioxolene-5-ylamine No 
















15 O18 (1S,9R)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene No 



















15 F19 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman-6-yl 
acetate 
No 




















15 N19 1-ethyl-6-fluoro-4-oxo-7-piperazinylhydroquinoline-3-carboxylic 
acid 
No 
15 O19 6-fluoro-4-oxochromene-3-carboxylic acid No 
15 P19 4-(indolinylcarbonyl)-1-methylpyrrolidin-2-one No 







15 D20 2-adamantanyl-N-[5-(tert-butyl)(1,3,4-thiadiazol-2-yl)]acetamide No 
15 E20 1-adamantanylbenzimidazole-2-thiol No 





























15 P20 1-[(3,5-dimethylphenyl)amino]ethene-1,2,2-tricarbonitrile No 
15 A21 2-fluoro-5H-dibenzo[c,f]azepine-6,11-dione No 
15 B21 2H-benzo[d]1,3-dioxolen-5-yl(methylsulfonyl)amine No 
15 C21 2-(1-phenylpyrazol-4-yl)ethylamine No 
15 D21 1-(3-(3-pyridyl)-1,2,4-oxadiazol-5-yl)ethylamine No 
15 E21 5-oxo-1-(oxolan-2-ylmethyl)pyrrolidine-3-carboxylic acid No 
15 F21 3-methyl-4-oxo-5,6,7-trihydroindole-2-carboxylic acid YES 
15 G21 3,3-bis(4-hydroxyphenyl)-3-hydroisobenzofuran-1-one YES 
15 H21 5,7-dihydroxy-4-propylchromen-2-one YES 
15 I21 2-phenyl-6-hydro-1,2,3-triazolo[4,5-d]pyrimidin-7-one No 
15 J21 4-pyrrolidinyl-3-(trifluoromethyl)phenylamine YES 










15 O21 3-hydroxy-3-(2-oxocycloheptyl)indolin-2-one No 




15 B22 N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)acetamide No 
15 C22 2-benzimidazol-2-yl-3-methylbut-2-enenitrile No 




15 F22 2H-1,2,3,4-tetraazol-5-yl[(2,6-dichlorophenyl)methyl]amine No 
































16 B03 3-methylisoxazole-5-carboxylic acid No 
16 C03 6-methylthiopurine No 










16 H03 2-imidazol-5-ylethylamine No 
16 I03 3-indolinylpropylamine No 
16 J03 4-(4-methylpiperazinyl)butylamine YES 
16 K03 1-(piperidylmethyl)cyclohexylamine No 
16 L03 2-methyl-1-(4-methylpiperazinyl)prop-2-ylamine No 
16 M03 1-methyl-2,7-diazabicyclo[5.3.0]decan-8-one No 
16 N03 (3-propylisoxazol-5-yl)methylamine No 
16 O03 phenyl-3-pyridylmethylamine No 
16 P03 (5-chlorobenzimidazol-2-yl)methylamine No 
16 A04 2-[3-(aminomethyl)piperidyl]ethan-1-ol No 
16 B04 2-methyl-1-(2-(4-piperidyl)ethyl)imidazole No 
16 C04 4-imidazolylbutylamine No 
16 D04 4-[(methylamino)methyl]quinolin-2-ol No 
16 E04 2-(4-piperidylmethoxy)pyridine No 
16 F04 (isochromanylmethyl)methylamine No 
16 G04 2-(1-methylbenzimidazol-2-yl)ethylamine No 
16 H04 1-ethylbenzimidazole-2-ylamine No 
16 I04 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid No 
16 J04 1-methyl-6-oxo-1,4,5-trihydropyridazine-3-carboxylic acid No 
16 K04 1,1-dioxothiolane-3-carboxylic acid No 
16 L04 [(5-bromo(2-thienyl))sulfonyl](2-cyclohex-2-enylethyl)amine No 
16 M04 3,6-dihydroxy-2-(3-hydroxyphenyl)chromen-4-one No 
16 N04 (3-methyl-1H-1,2,4-triazol-5-yl)methylamine No 
16 O04 (3,5-dimethylphenyl)[(5-bromo(2-thienyl))sulfonyl]amine No 
16 P04 leucine No 
16 A05 (2R)-2-aminopentanedioic acid No 
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16 B05 (2R)-2-amino-3-(carboxymethylthio)propanoic acid No 











16 F05 2-sulfanylpyrimidin-4-ol No 
16 G05 2-[N-(adamantanylmethyl)-2-thienylcarbonylamino]ethyl 
thiophene-2-carboxylate 
No 









16 K05 2-adamantanyl-5-(2-pyridylmethylthio)-1,3,4-oxadiazole No 







































16 M06 2-(3-bromophenyl)-5-(isoxazol-3-ylmethylthio)-1,3,4-oxadiazole No 
16 N06 5,7-dichloro-2-(isoxazol-3-ylmethylthio)-6-methylbenzoxazole No 







16 B07 adamantanyl 4-(2-thienylcarbonyl)piperazinyl ketone No 
















16 I07 adamantanyl 4-(methylsulfonyl)piperazinyl ketone No 
16 J07 adamantanyl 4-[(5-bromo(2-thienyl))sulfonyl]piperazinyl ketone No 
16 K07 N-(adamantanylmethyl)(5-oxopyrrolidin-2-yl)carboxamide No 












4-(3-pyridylcarbon yloxy)oxolan-3-yl pyridine-3-carboxylate 
No 
16 B08 2-[(1E,3E)-5-(3-ethyl(3-hydrobenzothiazol-2-ylidene))penta-1,3-






16 D08 2-propylpentanamide No 
16 E08 (2S,6R)-4,8-dioxabicyclo[3.3.0]octane-2,6-diol No 
16 F08 (4R)-1,3-thiazolidine-4-carboxylic acid No 

































2-oxoethyl ace tate 
No 
16 O08 3-(4-phenylpiperazinyl)propane-1,2-diol No 





























































diiodophenyl]propanoic aci d 
No 
16 P09 4-(2-fluorophenyl)-1-(piperidylsulfonyl)piperazine No 
16 A10 naphthyl(piperidylsulfonyl)amine No 























16 K10 2-octylcyclopropanecarboxylic acid No 
16 L10 2-(2H-3,4,5,6-tetrahydropyran-2-yl)acetic acid No 
16 M10 6-aminohexanoic acid No 
347 
 
16 N10 2-aminobutanedioic acid No 
16 O10 (2S)-2-amino-5-[(aminothioxomethyl)amino]pentanoic acid No 
16 P10 2-(trimethylamino)ethyl acetate, chloride No 
16 A11 [5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl 
hydrogen (phosphonooxy) (hydroxyphosphoryl) phosphate 
No 
16 B11 3-{[(2R)-2-((4R,8R)-4,8,12-trimethyltridecyl)-2,5,7,8-
tetramethylchroman-6-yl] oxycarbonyl}propanoic acid 
No 
16 C11 (4R)-2-oxo-1,3-thiazolidine-4-carboxylic acid No 










16 H11 3-(5-fluorobenzimidazol-2-yl)propylamine No 
16 I11 3-cyclohexylisoxazole-5-carboxylic acid No 
16 J11 ethyl 5-(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-
carboxylate 
No 




16 M11 1,3,4-trimethylpyrazolo[5,4-d]pyrimidine No 
16 N11 4-(methoxymethyl)-6-methylpyrazolo[5,4-b]pyridine-3-ylamine No 













16 D12 methyl 5-bromobenzo[d]furan-2-carboxylate No 
16 E12 dibenzo[b,f]azepine-5-carboxamide No 
16 F12 fluoren-9-ylpiperazine No 










16 K12 (adamantanylmethyl)methyl(piperidylsulfonyl)amine No 
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16 L12 1-[(5-bromo-2-thienyl)sulfonyl]pyrrolidin-2-one No 
16 M12 (4-fluorophenyl)(isoxazol-3-ylmethyl)(methylsulfonyl)amine No 
16 N12 2,5-bis(3-pyridylmethylthio)-1,3,4-thiadiazole No 
16 O12 5-(1,2,3,4-tetraazolyl)-2H-benzo[d]1,3-dioxolene No 
16 P12 2,3-bis(isoxazol-3-ylmethylthio)quinoxaline No 







16 D13 1,3-bis(isoxazol-3-ylmethyl)-3-hydrobenzimidazol-2-one No 
16 E13 2-(isoxazol-3-ylmethylthio)-5,6-dimethoxybenzimidazole No 
































16 B14 (2S)pyrrolidine-2-carboxamide No 
16 C14 1-[(4-chlorophenyl)methyl]cyclopropylamine No 
16 D14 3-[4-(2-hydroxyethyl)piperazinyl]propanoic acid No 
16 E14 tert-butyl 2-(aminomethyl)piperidinecarboxylate No 
16 F14 tert-butyl 3-(aminomethyl)piperidinecarboxylate No 
16 G14 1-propylpyrazole-4-carboxylic acid No 
16 H14 5-oxotricyclo[2.2.1.0<2,6>]heptane-3-carboxylic acid No 
16 I14 3-benzimidazol-2-ylchromen-2-one No 






16 L14 N-(4-chlorophenyl)[(oxolan-2-ylmethyl)amino]carboxamide No 
16 M14 (4,6-dimethylpyrimidin-2-yl)(4-morpholin-4-ylphenyl)amine No 
16 N14 2-(2-(2-furyl)-4-oxochromen-6-yloxy)ethanenitrile No 

















16 F15 2,6,8-trimethyl-3-(morpholin-4-ylmethyl)quinolin-4-ol No 
16 G15 3-[(diethylamino)methyl]-2,6-dimethylquinolin-4-ol No 
16 H15 5,9-dimethoxy-2-methylfurano[3,2-g]chromen-4-one No 
16 I15 6-amino-5-methyl-3-hydropyrimidin-2-one No 
16 J15 4-[(2S,1R)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol No 
16 K15 ???-N-(1,3-thiazol-2-yl)carboxamide No 
16 L15 1-(4-bromophenyl)-4-methylpyrazol-3-ol No 




16 O15 (4-chlorophenyl)-2-furyl(hydroxyimino)methane No 




16 B16 1,2,7-trihydrobenzo[a]4aH-carbazole No 
16 C16 2-(4-fluorophenyl)quinoxaline No 
16 D16 (hydroxyimino)(1-methylimidazol-2-yl)(4-nitrophenyl)methane No 




16 G16 3,9-di(2-furyl)-2,4,8,10-tetraoxaspiro[5.5]undecane No 




16 J16 4,5-dimethyl-1,3-dioxolen-2-one No 
16 K16 2,3-dimethyl-1-phenyl-3-pyrazoline-5-thione No 
16 L16 2-(3,5-diiodo-4-oxohydropyridyl)acetic acid No 
16 M16 1,3-bis[(4-nitrophenyl)methyl]imidazole No 
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16 A17 ethyl(2-thienylcyclohexyl)amine No 
16 B17 1-phenylimidazole-2-thiol No 




16 E17 1-(2H-benzo[3,4-d]1,3-dioxolen-5-yl)-4-imidazoline-2-thione No 




























Table A2. Results from the secondary screen for concentration-dependent inhibition of Prp. 
Plate Well Inhibitor 
Y/N 
Plate Well Inhibitor 
Y/N 
Plate Well Inhibitor 
Y/N 
1 A08 YES 1 I07 NO 2 H14 NO 
1 D06 YES 1 I13 NO 2 J20 NO 
1 I04 NO 1 K12 NO 2 G11 NO 
1 G16 NO 1 K16 NO 2 G16 NO 
1 H07 NO 1 L04 NO 2 H11 NO 
1 H10 NO 1 L10 NO 2 H12 NO 
1 H11 NO 1 M13 NO 2 H13 NO 
1 H16 NO 2 H19 NO 2 H17 NO 
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Plate Well Inhibitor 
Y/N 
Plate Well Inhibitor 
Y/N 
Plate Well Inhibitor 
Y/N 
2 H18 NO 6 I14 NO 9 M16 NO 
2 J11 NO 6 K04 NO 9 D14 NO 
3 P05 NO 6 M14 NO 9 F21 NO 
3 G08 NO 6 N08 NO 9 G17 NO 
3 P08 NO 6 O13 NO 9 G18 NO 
3 L12 NO 6 N10 NO 9 H14 NO 
3 I09 NO 6 N11 NO 9 H17 NO 
3 P11 NO 6 N12 NO 9 H18 NO 
3 G18 NO 6 N13 NO 9 H19 NO 
3 G12 NO 6 N14 NO 9 H21 NO 
4 B10 YES 6 N15 NO 9 I15 NO 
4 G10 NO 6 O10 NO 9 I17 NO 
4 G14 NO 6 P14 NO 9 I18 NO 
4 H07 NO 7 D14 NO 9 J11 NO 
4 H10 NO 7 N06 NO 9 J17 NO 
4 H18 NO 7 B17 YES 9 K12 NO 
4 L10 NO 7 G04 NO 9 K16 NO 
4 P09 NO 7 G07 YES 9 L13 NO 
5 A07 YES 7 H04 NO 9 L14 NO 
5 A12 YES 7 I07 NO 9 M08 NO 
5 B07 NO 7 K12 NO 9 N07 NO 
5 E07 YES 8 A10 YES 9 O07 NO 
5 E12 NO 8 M09 NO 10 G19 NO 
5 I14 NO 8 J03 NO 10 I16 NO 
5 M18 NO 8 J04 NO 10 J21 NO 
5 P11 NO 8 B17 NO 10 K07 NO 
5 D07 NO 8 C05 NO 10 O08 NO 
5 G05 NO 8 G13 NO 11 L13 NO 
5 H06 NO 8 H16 NO 11 L12 NO 
5 J04 NO 8 H19 NO 11 L10 NO 
5 J10 NO 8 J12 NO 11 K21 NO 
5 J12 NO 8 J17 NO 11 K20 NO 
5 M15 NO 8 K10 NO 11 J20 NO 
6 C19 YES 8 K18 NO 11 H04 NO 
6 D16 NO 8 L13 NO 11 H03 NO 
6 F04 NO 8 L15 NO 11 I10 NO 
6 G10 NO 8 N3 NO 11 I11 NO 




Plate Well Inhibitor 
Y/N 
Plate Well Inhibitor 
Y/N 
12 J05 NO 15 H19 NO 
12 J07 NO 15 H21 NO 
12 J10 NO 15 I09 NO 
12 K03 NO 15 I10 YES 
13 G12 NO 15 I13 NO 
13 G05 NO 15 I14 NO 
13 G11 NO 15 I15 NO 
13 G14 NO 15 J05 NO 
13 G17 NO 15 J09 NO 
13 H04 NO 15 J11 NO 
13 J03 NO 15 J15 NO 
13 J04 NO 15 J17 NO 
13 P03 NO 15 J18 NO 
14 G13 NO 15 J21 NO 
14 G14 NO 15 K11 NO 
14 G18 NO 15 K12 NO 
14 H17 NO 15 K13 NO 
14 I04 NO 15 K14 NO 
14 K04 NO 15 K15 NO 
14 K11 NO 15 K17 NO 
14 K12 NO 15 K20 NO 
14 L03 NO 15 K21 NO 
14 L05 NO 15 L10 NO 
15 F21 NO 15 L11 NO 
15 G11 NO 15 L12 NO 
15 G14 NO 15 L13 NO 
15 G17 NO 15 L14 NO 
15 G18 NO 15 L15 NO 
15 G21 NO 15 P08 NO 
15 H09 NO 15 P18 NO 
15 H11 NO 16 A14 NO 
15 H12 NO 16 F13 YES 
15 H13 NO 16 J03 NO 





Table A3. Third screen of compounds and interference assay. Compounds were tested in triplicate 
at concentrations (μM) 30, 25, 20, 15, 10, 8, 6, 4, 3, 2, 1, and 0.5. Most compounds were either 
eliminated because the initial inhibition could not be reproduced at these concentrations (marked 
NO). Others were eliminated for interfering with fluorescence from the cleaved peptide (marked 
INT). One compound (highlighted) appeared to inhibit Prp in a concentration-dependent manner. 




1 A08 NO NO 
1 D06 NO NO 
4 B10 NO NO 
5 A07 NO NO 
5 A12 NO NO 
5 E07 NO NO 
6 C19 NO NO 
7 B17 NO NO 
7 G07 NO NO 
8 A10 NO NO 
8 P09 NO NO 
15 I10 YES YES 
16 F13 YES NO 
 
